Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation by Takeda, A. et al.
	 	
	
 
This is the published version 
 
Takeda, A., Cooper, K., Bird, A., Baxter, L., Frampton, G.K., 
Gospodarevskaya, E., Welch, K. and Bryant, J. 2010, Recombinant human 
growth hormone for the treatment of growth disorders in children: a 
systematic review and economic evaluation, NIHR Health Technology 
Assessment Programme 
 
 
 
 
 
 
 
Available from Deakin Research Online 
 
http://hdl.handle.net/10536/DRO/DU:30064292	
	
	
	
	 	
	
	
	
Reproduced with the kind permission of the copyright owner 
	
 
 
 
 
 
Copyright: 2010, NIHR Health Technology Assessment Programme 
Health Technology Assessment 2010; Vol. 14: No. 42 
 
 
 
 
 
 
 
 
 
 
 
 
Recombinant human growth hormone 
for the treatment of growth disorders 
in children: a systematic review and 
economic evaluation 
A Takeda, K Cooper, A Bird, L Baxter, 
GK Frampton, E Gospodarevskaya, K Welch 
and J Bryant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
September 2010 
10.3310/hta14420 
 
 
 
 
Health Technology Assessment 
NIHR HTA programme 
www.hta.ac.uk 
Copyright notice 
2010-09-17 01:18:51 
-------------------------------------------- 
© 2010 Queen's Printer and Controller of HMSO 
HTA reports may be freely reproduced for the 
purposes of private research and study and 
may be included in professional journals 
provided that suitable acknowledgement is 
made and the reproduction is not associated 
with any form of advertising Violations should 
be reported to hta@hta.ac.uk 
Applications for commercial reproduction should 
      
     
    
   
 
 
 
 
 
HTA 
 
 
 
How to obtain copies of this and other HTA programme reports 
An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for 
personal use from the HTA website (www.hta.ac.uk).A fully searchable DVD is also available (see below). 
Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both 
public and private sector purchasers from our despatch agents. 
Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is 
£2 per issue and for the rest of the world £3 per issue. 
How to order: 
– fax (with credit card details) 
– post (with credit card details or cheque) 
– phone during office hours (credit card only). 
 
Additionally the HTA website allows you to either print out your order or download a blank order form. 
 
Contact details are as follows: 
Synergie UK (HTA Department) 
Digital House,The Loddon Centre 
Wade Road 
Basingstoke 
Hants RG24 8QW 
 
 
Email: orders@hta.ac.uk 
Tel: 0845 812 4000 – ask for ‘HTA Payment Services’ 
(out-of-hours answer-phone service) 
 
Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header 
 
Payment methods 
Paying by cheque 
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton 
and drawn on a bank with a UK address. 
Paying by credit card 
You can order using your credit card by phone, fax or post. 
 
Subscriptions 
NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for 
each volume (normally comprising 40–50 titles).The commercial subscription rate is £400 per volume 
(addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for 
details. Subscriptions can be purchased only for the current or forthcoming volume. 
 
How do I get a copy of HTA on DVD? 
Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free 
of charge worldwide. 
 
 
The website also provides information about the HTA programme and lists the membership of the various 
committees. 
 
 
 
 
Recombinant human growth hormone 
for the treatment of growth disorders 
in children: a systematic review and 
economic evaluation 
A Takeda, K Cooper, A Bird, L Baxter, 
GK Frampton, E Gospodarevskaya, K Welch 
and J Bryant* 
 
Southampton Health Technology Assessments Centre (SHTAC), 
Southampton, UK 
 
*Corresponding author 
 
Declared competing interests of authors: none 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published September 2010 
DOI: 10.3310/hta14420 
 
 
 
This report should be referenced as follows: 
 
Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, et al. 
Recombinant human growth hormone for the treatment of growth disorders in children: a 
systematic review and economic evaluation. Health Technol Assess 2010;14(42). 
 
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, 
Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch) and Current 
Contents/Clinical Medicine. 
T 
NIHR Health Technology Assessment programme 
he Health Technology Assessment (HTA) programme, part of the National Institute for Health 
Research (NIHR), was set up in 1993. It produces high-quality research information on the 
effectiveness, costs and broader impact of health technologies for those who use, manage and provide care 
in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent 
and treat disease, and improve rehabilitation and long-term care. 
The research findings from the HTA programme directly influence decision-making bodies such as the 
National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee 
(NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they 
form a key component of the ‘National Knowledge Service’. 
The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three 
routes to the start of projects. 
First is the commissioned route. Suggestions for research are actively sought from people working in the 
NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS 
trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service 
users). The HTA programme then commissions the research by competitive tender. 
Second, the HTA programme provides grants for clinical trials for researchers who identify research 
questions. These are assessed for importance to patients and the NHS, and scientific rigour. 
Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme 
commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together 
evidence on the value of specific technologies. 
Some HTA research projects, including TARs, may take only months, others need several years. They 
can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, 
undertaking a trial, or other research collecting new data to answer a research problem. 
The final reports from HTA projects are peer reviewed by a number of independent expert referees before 
publication in the widely read journal series Health Technology Assessment. 
Criteria for inclusion in the HTA journal series 
Reports are published in the HTA journal series if (1) they have resulted from work for the HTA 
programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and 
editors. 
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal 
and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication 
of the review by others. 
The research reported in this issue of the journal was commissioned and funded by the HTA programme 
on behalf of NICE as project number 08/51/01. The protocol was agreed in September 2008. 
The assessment report began editorial review in August 2009 and was accepted for publication 
in February 2010. The authors have been wholly responsible for all data collection, analysis and 
interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the 
accuracy of the authors’ report and would like to thank the referees for their constructive comments on 
the draft document. However, they do not accept liability for damages or losses arising from material 
published in this report. 
The views expressed in this publication are those of the authors and not necessarily those of the HTA 
programme or the Department of Health. 
Editor-in-Chief: Professor Tom Walley CBE 
Series Editors: Dr Martin Ashton-Key, Dr Aileen Clarke, Professor Chris Hyde, 
Dr Tom Marshall, Dr John Powell, Dr Rob Riemsma and Professor Ken Stein 
Editorial Contact: edit@southampton.ac.uk 
ISSN 1366-5278 
© 2010 Queen’s Printer and Controller of HMSO 
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www.publicationethics.org/). 
This journal may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. 
Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of 
Southampton Science Park, Southampton SO16 7NS, UK. 
Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA. 
Printed on acid-free paper in the UK by Henry Ling Ltd, The Dorset Press, Dorchester. T 
Health Technology Assessment 2010; Vol. 14: No. 42 DOI: 10.3310/hta14420 
 
 
 
 
 
 
 
 
 
 
Abstract 
Recombinant human growth hormone for the 
treatment of growth disorders in children: a 
systematic review and economic evaluation 
A Takeda, K Cooper, A Bird, L Baxter, GK Frampton, 
E Gospodarevskaya, K Welch and J Bryant* 
Southampton Health Technology Assessments Centre (SHTAC), Southampton, UK 
 
*Corresponding author 
 
Background: Recombinant human growth hormone 
(rhGH) is licensed for short stature associated with 
growth hormone deficiency (GHD), Turner syndrome 
(TS), Prader–Willi syndrome (PWS), chronic renal 
insufficiency (CRI), short stature homeobox-containing 
gene deficiency (SHOX-D) and being born small for 
gestational age (SGA). 
Objectives: To assess the clinical effectiveness and 
cost-effectiveness of rhGH compared with treatment 
strategies without rhGH for children with GHD, TS, 
PWS, CRI, SHOX-D and those born SGA. 
Data sources: The systematic review used a 
priori methods. Key databases were searched (e.g. 
MEDLINE, EMBASE, NHS Economic Evaluation 
Database and eight others) for relevant studies from 
their inception to June 2009. A decision-analytical 
model was developed to determine cost-effectiveness 
in the UK. 
Study selection: Two reviewers assessed titles and 
abstracts of studies identified by the search strategy, 
obtained the full text of relevant papers, and screened 
them against inclusion criteria. 
Study appraisal: Data from included studies were 
extracted by one reviewer and checked by a second. 
Quality of included studies was assessed using standard 
criteria, applied by one reviewer and checked by a 
second. Clinical effectiveness studies were synthesised 
through a narrative review. 
Results: Twenty-eight randomised controlled 
trials (RCTs) in 34 publications were included in the 
systematic review. GHD: Children in the rhGH group 
grew 2.7 cm/year faster than untreated children and 
had a statistically significantly higher height standard 
deviation score (HtSDS) after 1 year: –2.3 ± 0.45 
versus –2.8 ± 0.45. TS: In one study, treated girls 
grew 9.3 cm more than untreated girls. In a study of 
younger children, the difference was 7.6 cm after 2 
years. HtSDS values were statistically significantly 
higher in treated girls. PWS: Infants receiving rhGH 
for 1 year grew significantly taller (6.2 cm more) than 
those untreated. Two studies reported a statistically 
significant difference in HtSDS in favour of rhGH. 
CRI: rhGH-treated children in a 1-year study grew an 
average of 3.6 cm more than untreated children. HtSDS 
was statistically significantly higher in treated children 
in two studies. SGA: Criteria were amended to include 
children of 3+ years with no catch-up growth, with 
no reference to mid-parental height. Only one of the 
RCTs used the licensed dose; the others used higher 
doses. Adult height (AH) was approximately 4 cm 
higher in rhGH-treated patients in the one study 
to report this outcome, and AH-gain SDS was also 
statistically significantly higher in this group. Mean 
HtSDS was higher in treated than untreated patients 
in four other studies (significant in two). SHOX-D: 
After 2 years’ treatment, children were approximately 
6 cm taller than the control group and HtSDS was 
statistically significantly higher in treated children. The 
incremental cost per quality adjusted life-year (QALY) 
estimates of rhGH compared with no treatment were: 
£23,196 for GHD, £39,460 for TS, £135,311 for PWS, 
£39,273 for CRI, £33,079 for SGA and £40,531 for 
SHOX-D. The probability of treatment of each of the 
conditions being cost-effective at £30,000 was: 95% for 
GHD, 19% for TS, 1% for PWS, 16% for CRI, 38% for 
SGA and 15% for SHOX-D. 
Limitations: Generally poorly reported studies, 
some of short duration. 
Conclusions: Statistically significantly larger HtSDS 
values were reported for rhGH-treated children with 
GHD, TS, PWS, CRI, SGA and SHOX-D. rhGH- 
3 
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treated children with PWS also showed statistically 
significant improvements in body composition 
measures. Only treatment of GHD would be 
considered cost-effective at a willingness-to-pay 
threshold of £20,000–30,000 per QALY gained. This 
analysis suggests future research should include studies 
of longer than 2 years reporting near-final height or 
final adult height. 
iv 
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continued 
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QoL- 
AGHDAUTILITY 
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RCT randomised controlled trial 
rhGH recombinant human growth 
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SAR-SR Social Adjustment Scale-self 
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Executive summary 
 
 
Background 
Recombinant  human  growth  hormone  (rhGH) 
is licensed for short stature that is associated 
with growth hormone deficiency (GHD), Turner 
syndrome (TS), Prader–Willi syndrome (PWS), 
chronic renal insufficiency (CRI), short stature 
homeobox-containing gene deficiency (SHOX-D) 
and being born small for gestational age (SGA). 
The National Institute for Health and Clinical 
Excellence (NICE) guidance currently recommends 
rhGH treatment for children with GHD, TS, PWS 
or CRI, but does not cover SGA or SHOX-D. 
 
 
Objectives 
 
The aim of this report was to assess the clinical 
effectiveness and cost-effectiveness of rhGH 
compared with treatment strategies without rhGH 
for children with GHD, TS, PWS, CRI, SHOX-D 
and those born SGA. The report extends the 
previous review by actively searching for studies 
that report growth outcomes, body composition, 
biochemical markers or quality of life (QoL). 
 
 
Methods 
Data sources 
The systematic review of clinical effectiveness 
used a priori methods that are described in the 
research protocol. We searched key databases (e.g. 
MEDLINE, EMBASE, NHS Economic Evaluation 
Database and eight others) for relevant studies 
from their inception to June 2009, limiting to 
the English language. Relevant conferences, 
bibliographies of included papers, our expert 
advisory group and manufacturers’ submissions 
(MSs) to NICE were also consulted to identify any 
additional published or unpublished references. 
We developed an economic model using the best 
available evidence to determine cost-effectiveness 
in the UK. 
 
Study selection 
Two reviewers assessed titles and abstracts of 
studies identified by the search strategy, obtained 
the full text of relevant papers, and screened 
them against the inclusion criteria as defined in 
the research protocol. Any differences in opinion 
throughout the process were resolved through 
discussion. 
 
Key inclusion criteria were: 
 
• patients children with GHD, TS, PWS, CRI, 
SHOX-D or born SGA 
• treatment  rhGH 
• comparator treatment strategies without 
somatropin 
• outcomes height, height standard deviation 
score (HtSDS), growth velocity (GV) and SDS, 
body composition, biochemical markers, QoL, 
adverse events (AEs) 
• study type  randomised controlled trials (RCTs), 
systematic reviews. 
 
Data extraction and quality 
assessment 
Data from included studies were extracted by one 
reviewer and checked by a second. The quality 
of included studies was assessed using standard 
criteria. Criteria were applied by one reviewer and 
checked by a second, with differences in opinion 
resolved by discussion and involvement of a third 
reviewer where necessary. 
 
Data synthesis 
Clinical effectiveness studies were synthesised 
through a narrative review, with tabulation of 
results of included studies. Meta-analysis was not 
appropriate due to heterogeneity of study design 
and  participants. 
 
Economic model 
A decision-analytical model was developed  
to estimate the cost-effectiveness of rhGH 
treatment compared with no treatment for a 
cohort of children with GHD, TS, PWS, SGA, 
CRI and SHOX-D. The model was based upon 
that developed in a previous Health Technology 
Assessment (HTA) report but was extended by 
including QoL factors. The perspective of the 
xi 
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xii 
analysis was that of the UK NHS and Personal 
Social Services (PSS). The model was informed 
by a systematic search of the literature to 
identify parameters on the natural history and 
epidemiology of the indicated conditions, health- 
related quality of life (HRQoL) and costs. The 
model estimated the lifetime costs and benefits of 
rhGH with discount rates of 3.5%. The intervention 
effect in terms of improvement of HtSDS was 
derived from the systematic review of effectiveness. 
The outcome of the economic evaluation is  
reported as cost per quality-adjusted life-year 
(QALY) gained and cost per centimetre gained. 
 
 
Results 
Number and quality of studies 
Of the 674 references identified, 560 were excluded 
on inspection of their titles and abstracts. The full 
papers of 114 references were retrieved, of which  
28 RCTs in 34 publications were included in the 
systematic review of clinical effectiveness. Overall, 
the studies were generally poorly reported and 
some were of short duration. 
 
Summary of benefits and risks 
None of the studies reported QoL measures, and 
reporting of AEs was limited. Only one of the 
included studies reported adult height (AH). 
 
Growth hormone deficiency 
(one RCT) 
Children in the rhGH group grew 2.7 cm/year 
faster than children in the untreated group and 
had a statistically significantly higher HtSDS after 
1 year: –2.3 ± 0.45 versus –2.8 ± 0.45. 
 
Turner syndrome (six RCTs) 
Girls in one study grew an average of 9.3 cm 
more than untreated girls. In a study of younger 
children, the difference was 7.6 cm after 2 years. 
HtSDS values were statistically significantly higher 
in treated than in untreated girls. 
 
Prader–Willi (eight RCTs) 
Infants who received rhGH for 1 year grew 
significantly taller (6.2 cm more) than those in the 
untreated group in the only study to report change 
in height. Two studies reported a statistically 
significant difference in HtSDS in favour of rhGH. 
rhGH-treated patients had statistically significantly 
higher lean body mass (LBM) and lower body fat 
than untreated patients in three studies. Effects on 
body mass index (BMI) were mixed. 
 
Chronic renal insufficiency (six 
RCTs) 
Recombinant human growth hormone-treated 
children in a 1-year study grew an average of 
3.6 cm more than untreated children. HtSDS was 
statistically significantly higher in treated than in 
untreated children in two studies. 
 
Small for gestational age (six 
RCTs) 
No RCTs met the original inclusion criteria for  
the review, so these were amended to include 
children from the age of 3 years with no catch-up 
growth, with no reference to mid-parental height. 
Only one out of the six included RCTs used the 
licensed dose; the others used doses two or three 
times higher. AH was approximately 4 cm higher 
in rhGH-treated people in the only study to report 
this outcome. AH-gain SDS was also statistically 
significantly higher in this study’s rhGH group. 
Mean HtSDS was higher in treated than untreated 
patients in four other studies, significantly so in two 
of these. 
 
SHOX deficiency (one RCT) 
After 2 years of treatment, children were 
approximately 6 cm taller than the control group 
and HtSDS was statistically significantly higher in 
treated than in untreated patients. 
 
Summary of cost-effectiveness 
The systematic review of published economic 
evaluations identified two North American studies 
for children with TS and GHD and no studies 
conducted in the UK. The results of the two 
identified studies produced two very different 
estimates of cost-effectiveness, largely due to the 
choice of utility estimates and assumptions on 
effectiveness. 
 
The systematic review of QoL identified only six 
studies, mostly of poor methodological quality and 
for small numbers of individuals. One reasonable 
study was found for GHD. An additional study 
was found, which estimated QoL utilities in the 
general adult population according to height,  
using the Health Survey for England. These studies 
suggested that there is likely to be a small gain in 
utility from rhGH. 
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Six of the seven manufacturers submitted evidence 
to be considered for this review. Five out of the 
six manufacturers collaborated and submitted 
essentially the same electronic model. The model 
developed was based upon the previous HTA 
report but was extended to consider longer-term 
outcomes in order to estimate cost-effectiveness in 
terms of QALYs. In the manufacturers’ base case, 
the cost-effectiveness results for all conditions were 
less than £30,000 per QALY gained. 
 
From the model we developed for this review, the 
incremental cost per QALY estimates of rhGH 
compared to no treatment were: £23,196 for GHD, 
£39,460 for TS, £135,311 for PWS, £39,273 for 
CRI, £33,079 for SGA and £40,531 for SHOX-D. 
A further analysis was run for PWS, which included 
a lifelong improvement in body composition 
of 1.8 BMI and an associated additional utility 
of 0.031. Under these assumptions, the cost- 
effectiveness of PWS reduced to £54,800 per QALY 
gained. 
 
The effects of a range of parameter values for 
the economic model were evaluated in sensitivity 
analyses. The model results were found to be most 
sensitive to the discount rate used. All conditions, 
except PWS, were cost-effective for a willingness- 
to-pay threshold of £30,000 per QALY when the 
previous NICE discount rates of 6% for costs and 
1.5% for benefits were used. The model results are 
also sensitive to treatment start age and length, 
compliance and utility gain. The probability 
sensitivity analysis (PSA) estimated the probability 
of each of the conditions to be cost-effective at 
£30,000 to be: 95% for GHD, 19% for TS, 1%  
for PWS, 16% for CRI, 38% for SGA and 15% for 
SHOX-D. 
 
 
Discussion 
 
The systematic review was restricted to RCTs 
because these provide the highest level of evidence 
for clinical effectiveness. However, very few of 
these reported either final height (FH) or QoL as 
outcome measures, most were only 1 or 2 years in 
length, and some had very few participants. We  
did not identify any RCTs that met the original 
inclusion criteria for children born SGA, so these 
had to be amended. Only one of the included 
trials used the licensed dose, so results from the 
other five could overstate the effectiveness of rhGH 
treatment for this patient group. 
 
The QoL gains were highest for individuals with 
lower starting heights; for those with starting 
height of less than < –2 HtSDS the QoL gain 
was minimal. For example, those with PWS had 
a starting height of –2 HtSDS, and so for this 
group of patients the health gain (in terms of 
height) is small; therefore, rhGH treatment has 
high  incremental  cost-effectiveness  ratio  (ICER) 
values compared with no treatment. Patients with 
PWS may experience an improvement in body 
composition due to rhGH treatment, and this is 
often the point of treatment rather than gain in 
height, but this was difficult to quantify, especially 
in the long term. 
 
The cost-effectiveness results in the current report 
varied from those in the MS and the previous 
HTA report. The incremental costs reported are 
generally consistent between the three models. 
In general, the results, presented in terms of 
centimetres gained, are more favourable in the 
current analyses than in those in the previous HTA 
report. The ICERs in the MS are considerably more 
favourable than the current analysis, due to higher 
estimates of utility gain. 
 
The current analysis has not considered other 
benefits in addition to height gain within the 
model, apart from as a scenario analysis for PWS. 
The base case does not include possible benefits 
from changes in body composition, such as 
reduced risk of diabetes or cardiovascular disease, 
which may result in increases in life expectancy. 
At this stage, these health gains would be purely 
speculative due to lack of data, and it is not  
possible to quantify them. It is also possible that 
there may be additional psychological benefits such 
as improved self-esteem. 
 
 
Conclusions 
 
The included studies reported statistically 
significantly larger HtSDS values for rhGH- 
treated children than untreated children with 
GHD, TS, PWS, CRI, SGA and SHOX-D. 
rhGH-treated children with PWS also showed 
statistically significant improvements in body 
composition measures compared with controls.  
The cost-effectiveness estimates from our model 
vary between conditions. Only GHD would be 
considered cost-effective according to a willingness- 
to-pay  threshold  of  £20,000–30,000  per  QALY 
gained. TS, CRI, SGA and SHOX-D have 
ICERs between £33,000 and £40,500 per QALY 
gained. PWS has an ICER of between £55,000 
and £135,000 per QALY gained, depending on 
assumptions. 
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Executive summary 
 
 
 
 
 
 
Key research priorities 
• Longer studies beyond 2 years, reporting near- 
FH or final AH. 
• A standardised QoL assessment specifically 
designed for children and adults, to be used in 
future RCTs and QoL studies. 
• Good-quality trials of rhGH in children born 
SGA, where the children included and the dose 
administered match the licensing criteria. 
• Good-quality studies of the long-term effects 
of rhGH on body composition, psychological 
benefits, long-term morbidities (such as 
diabetes or cardiovascular disease) and life 
expectancy, particularly for individuals with 
PWS. 
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Chapter 1 
Background 
 
 
Description of health 
problem 
The first part of the chapter (see sections Growth 
hormone deficiency to Small for gestational age) 
describes the health problem individually for the 
different conditions covered in this review, in terms 
of their aetiology and epidemiology. The second 
part of the chapter (see sections Impact of health 
problem to Current usage in the NHS) covers the 
impact of the health problems and measurement of 
disease for all the conditions combined. 
 
Growth hormone deficiency 
Growth hormone deficiency (GHD) occurs when 
the pituitary gland fails to produce sufficient levels 
of growth hormone (GH). 
 
There is some debate about the diagnostic criteria 
for GHD: the diagnosis of GHD includes short 
stature, growth velocity (GV) below the 25th 
percentile for at least 1 year, and delayed bone 
age.1  Rosenfeld2  suggests other criteria: height 
> 3 standard deviations (SDs) below the mean, 
< –2 SD to –3 SD for age and deceleration in 
growth (such as GV < 25th percentile for age), 
GV < 5th percentile where there is no other 
explanation, a predisposing condition along with 
growth deceleration or other signs of pituitary 
dysfunction. Juul and colleagues3 found ‘large 
heterogeneity in the current practice of diagnosis 
and treatment of childhood GHD’. Their survey 
of European paediatricians found that the cut-off 
points of GH peak response used for diagnosis of 
deficiency clustered around 10 ng/ml or 20 mU/l. 
 
The primary goals of recombinant human growth 
hormone (rhGH) treatment for children with 
GHD are to normalise height during childhood, 
for the treated child to reach a ‘normal’ adult 
height (AH) as defined by the parental target and 
for mature somatic development to be reached 
around age 25.4  The British Society for Paediatric 
Endocrinology and Diabetes (BSPED) recommends 
3- or 6-monthly growth monitoring, annual insulin- 
like growth factor-1 (IGF-1)/ insulin-like growth 
factor building protein-3 (IGFBP-3) monitoring, 
and compliance assessment at each appointment.5 
Aetiology, pathology and prognosis 
Growth hormone deficiency can be caused 
by a variety of factors, but in many cases the 
cause is unknown. In some children, failure or 
reduction in GH secretion is congenital, and  
may be accompanied by other pituitary hormone 
deficiencies. In others, GHD is acquired as a result 
of trauma (either at birth or later in childhood), 
histiocytic infiltration (build up of tissue cells), 
lymphoma or leukaemia, tumours involving the 
pituitary gland or hypothalamus or following 
radiotherapy.6 Untreated patients have a final 
height (FH) of 134–146 cm in males and 128– 
134 cm in females.1 
 
Incidence and prevalence 
The UK Child Growth Foundation estimates  
that GHD of unknown origin occurs in about 
one in every 3800 births,7  but reliable figures are 
difficult to obtain for GHD that is associated with 
radiotherapy and other causes. Figures from a 
study in Belgium8 indicate an overall prevalence  
of GHD of 1 in 5600. The origin of GHD was 
stated to be unknown in 41% of the patients in  
this Belgian study, congenital in 20% and acquired 
in 35%.8 While the authors of this study state that 
these yearly numbers have remained similar across 
the 16 years of the study, these were not collected 
as part of a formal screening study, and, as a result, 
the study authors believe that this figure is an 
underestimation.8 
 
A Danish study calculated incidence rates of 
childhood-onset growth hormone deficiency (CO- 
GHD), based on 1823 patients incident during 
1980–99. The average incidences per 100,000 
population were calculated to be 2.58 [95% 
confidence interval (CI) 2.3 to 2.88] for males, 
and 1.70 (95% CI 1.48 to 196) for females. The 
differences between the sexes was statistically 
significant (p < 0.001).9  Other sources suggest that 
the disorder is two to three times more common 
in boys than in girls.7 A hereditary factor may be 
identified in some children; about 3% of children 
with GHD also have an affected sibling.7 
1 
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Turner syndrome 
Aetiology, pathology and prognosis 
Turner syndrome (TS) is caused by the complete 
or partial absence of the second sex chromosome 
in girls, with or without cell line mosaicism 
(the presence of two populations of cells with 
different genotypes in one individual), leading 
to the presence of characteristic physical 
features including, but not limited to, short 
stature.10,11  Other features of TS can include 
skeletal abnormalities, higher risk of scoliosis, 
cardiovascular abnormalities, lymphoedema, 
and higher rates of hearing problems and ear 
malformations.11 
 
While short stature is the most common clinical 
feature of TS,11 in the majority of girls with TS 
the missing or abnormal second chromosome 
causes ovarian failure, leading to lack of pubertal 
progression and sexual maturation. TS girls 
therefore receive estrogen replacement therapy as 
part of their treatment. 
 
Untreated, the average AH deficit in women with 
TS is 20 cm, with the average height being 143 cm 
(4 ft 8 in.).12  Cases of reduced stature are thought to 
be predominantly due to haploinsufficiency of the 
short stature homebox-containing (SHOX) gene.13 
Not all girls with TS will require rhGH treatment 
and the condition does not necessarily involve a 
deficiency in natural GH secretion, although there 
may be a relative lack of sensitivity to GH, and, in 
some cases, diminished secretion.6,14 
 
Incidence and prevalence 
The European Surveillance of Congenital 
Abnormalities (EUROCAT) reported in 2003 that 
TS occurred in 2.08 per 10,000 births in the UK 
in 2002,15 which equates to approximately one in 
2500 live-born females.11 A Belgian study analysed 
age at diagnosis of 242 TS girls who were treated 
with rhGH between 1991 and 2002.16  The median 
age at diagnosis was 6.6 (range 0–18.3) years. 
Although the survey found that 22% of girls were 
diagnosed after the age of 12 years, there was a 
general increase in earlier diagnosis in infancy and 
childhood compared with a previous survey. 
 
A study in Denmark17  identified a standardised 
mortality rate (SMR) of 2.89 in their TS 
population, which was increased compared with 
the general population. However, this significantly 
decreased over the 3 years of the study. It is unclear 
if this is due to a real decrease in mortality, better 
care of individuals with TS, or an increase in 
karyotypes with lower mortality.17 
Prader–Willi syndrome 
Prader–Willi syndrome (PWS) is a genetic disorder 
characterised by short stature, abnormal body 
composition, hypogonadism, obesity, dysmorphic 
features, hyperphagia (compulsive overeating), 
hypotonia (diminished muscle tone), and specific 
learning and behavioural issues.18 
 
Aetiology, pathology and prognosis 
The genetic basis of the syndrome is a deletion 
on the long arm of the paternally derived 
chromosome 15 (15q11-q13), which is found in 
approximately 70% of affected individuals.19 Other 
abnormalities have been identified, including 
maternal uniparental disomy (two maternal copies 
of chromosome 15 and no paternal chromosome 
15), imprinting mutations and translocations. 
Abnormalities to chromosome 15 lead to 
disruption of the hypothalamus, which controls 
appetite. The combination of impaired growth, 
abnormal body composition and hypothalamic 
dysfunction (hyperphagia, hypogonadism) is 
suggestive of GHD. 
 
Birth length and weight are normal or just below 
normal in PWS, but growth is slow due to poor 
feeding. The child is noticeably short from around 
the first year of life and remains short throughout 
childhood [mean height standard deviation 
score (HtSDS) –2] despite normal growth rate.20 
Hypotonia at birth improves towards the end of  
the first year of life, and developmental milestones 
are achieved although delayed. By 2 or 3 years of 
age the hyperphagic phase of the condition begins, 
and, unless eating is controlled, the child will 
become obese.18 
 
Behavioural features include food seeking, temper 
tantrums, obsessive–compulsive disorders, high 
pain threshold, sleep disturbances, and skin 
picking. Learning disabilities are always present to 
some degree.20   Hypogonadism causes delayed but 
complete puberty in females, although menses are 
infrequent or absent. Males have cryptorchidism 
(undescended testis) at birth and usually require 
androgen  replacement  therapy  from  mid-puberty, 
even after successful orchidopexy.18 
 
During adolescence, the growth rate declines 
as a result of the absence of pubertal growth 
spurt. Reported mean FHs in the UK are 155 cm 
(–3.2 SD) for males and 147 cm (–2.8 SD) for 
females.21 Body composition shows increased fat 
mass (FM) and reduced fat-free mass, resulting 
in a high fat–lean body mass (LBM) ratio, even 
in children with normal weight–height ratios. 
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In addition, bone mineral density is reduced. 
The reduced bone density is multifactorial; in 
older patients this is due to sex steroid deficiency 
(hypogonadism), whereas in younger patients 
this is due to hypotonia, which responds to rhGH 
therapy.22 
 
The prognosis of the condition in adulthood can 
be reasonable if the person can find occupation 
and can live in an environment where access to 
food can be controlled. However, many adults 
with the disorder develop morbid obesity, often 
accompanied by type 2 diabetes, resulting in 
premature death from cardiorespiratory failure.18 
 
Incidence and prevalence 
One UK study estimated a birth incidence for PWS 
of 1 : 20,000, with a lower bound of 1 : 29,000.23 
The study gave a population prevalence of 
1 : 52,000, considered the lower bound, with county 
rates varying from 1 : 42,000 to 1 : 67,000.23  The 
overall death rate for the PWS population aged 
3.4–56 years was found to be around 3% in one  
UK study compared with the standard death rate  
of about 0.3% each year for people in England and 
Wales up to the age of 55 years.23 
 
Chronic renal insufficiency 
Chronic renal insufficiency (CRI) is defined as a 
persistent elevation of serum creatinine and/or urea 
level. It can be caused by a variety of conditions, 
including  congenital  disorders,  glomerular 
disorders and infections. Growth failure associated 
with CRI can be caused by acidosis, rickets, GH 
resistance,  inadequate  nutrition  and  anorexia.24 
Children with CRI experience impaired growth 
once their glomerular filtration rate (GFR) falls 
to 50% of normal, with increasing problems once 
the GFR falls below 25%.25 Following kidney 
transplantation, chronic graft rejection and 
treatment with steroids can restrict growth and 
development.26 Patients undergoing haemodialysis 
or peritoneal dialysis can be considered for rhGH 
treatment, as well as those who have received 
kidney  transplantations. 
 
Aetiology, pathology and prognosis 
Chronic renal insufficiency is characterised by a 
GFR of < 75 ml/min per 1.73 m2 of body surface 
area (BSA).27 The term chronic kidney disease (CKD) 
is also sometimes used,27 following guidelines 
developed by the National Kidney Foundation 
(NKF) Kidney Disease Outcomes Quality Initiative 
(KDOQI).28 
The aetiology of growth failure in children with 
CRI includes abnormalities in the GH-IGF-1 axis, 
together with nutritional and metabolic problems.27 
Nutritional supplementation in malnourished 
children with CRI can improve growth.29–31 
The NKF KDOQI guidelines recommend that 
patients’ existing nutritional deficiencies and 
metabolic abnormalities should be corrected before 
considering treatment with rhGH.32 However, it is 
estimated that growth remains suboptimal, even 
with energy intake above 80% of the recommended 
daily allowance.33 
 
Not all patients with CRI will be shorter than 
average, but figures from the UK Renal Registry 
indicate that 29% of transplant patients and 41% 
of dialysis patients are below the second percentile 
for height.34 Children with congenital disorders 
(approximately 60% of children with CRI)26 are 
usually of normal length at birth, but are below the 
3rd percentile for height within their first year and 
remain parallel to normal percentiles throughout 
childhood.26 A cohort study of CRI patients who 
grew up before rhGH treatment was available 
reported that more than two-thirds remained 
shorter than the average population.35 One study 
reported a mean height from birth to age 10, which 
was –2.37 SD ± 1.6 below the mean.26 Similarly, 
FH is reported to be reduced to below the 3rd 
percentile in patients who developed end-stage 
renal failure (ESRF) in childhood.26 Adult FH was 
more than 2 SDs below the mean for approximately 
60% of boys and 41% of girls who started renal 
replacement therapy before they were 15 years 
old.36 
 
Incidence and prevalence 
It is difficult to find accurate figures for CRI, and 
these do not appear to be available nationally. 
The UK Renal Registry reports an incidence of 
established renal failure (ERF) of 8.0 per million 
of the population who are under the age of 
15 years.37  However, ERF is more severe than CRI, 
so can really serve only as a guide to the minimum 
number of patients for whom rhGH might be 
appropriate. 
 
The UK Renal Registry reported that in 2005 
there were 748 patients under the age of 18 years 
who were on renal replacement therapy in the 
UK’s 13 paediatric renal centres,34  corresponding 
to a prevalence of 47.7 per million.37  However, 
the number of patients with CRI will be higher 
than this, as not all will require renal replacement 
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therapy. ERF is reported to be more common 
in males than in females (ratio 1.54 : 1), due to 
the prevalence of males with renal dysplasia and 
obstructive uropathy causing ERF.37 
 
Small for gestational age 
There are various thresholds for defining a child  
as being born ‘small for gestational age’ (SGA), the 
most commonly used being where the birth height 
or weight is ≤ 2 SDs below the population average, 
or is below the 10th centile for birthweight.38 
However, this group is heterogeneous in 
composition. Between 50% and 70% of these babies 
are ‘constitutionally small’ but otherwise healthy. 
The other babies in the group are those who have 
not reached their height or weight potential, 
having possibly experienced fetal growth restriction 
(FGR).38  For this reason, the terms intrauterine 
growth restriction/retardation (IUGR) and SGA 
are not synonymous: a child born SGA has not 
necessarily undergone IUGR or FGR, and a child 
who has IUGR or FGR may not necessarily be born 
SGA. 
 
Aetiology, pathology and prognosis 
There are several possible causes for children being 
born SGA. These include maternal factors (such 
as age, ethnicity, weight, height, parity, medical 
conditions, smoking, malnutrition and alcohol 
abuse), placental factors, and fetal factors (such as 
chromosomal abnormalities and genetic defects).39 
Children classified as SGA may have concurrent 
diagnoses, such as familial short stature, TS, GHD 
or skeletal dysplasia.39 
 
More than 80% of babies born SGA will achieve 
catch-up growth (GV greater than the median  
for chronological age and gender39) during their 
first 6 months,40 with catch-up growth completed 
within 2 years for most SGA infants.41,42 However, 
babies born prematurely who are SGA may take 
around 4 years to achieve catch-up growth.43 
Around 50% of the children who do not experience 
catch-up growth at this stage will go on to achieve 
their target height. It has been estimated that 
approximately 10% of SGA children remain at a 
height below –2 SD throughout their childhood.44,45 
Children who are born SGA with low birth weight 
and who do not achieve catch-up growth by the 
age of 2 years face a relative risk of short stature 
(< –2 SDs) of 5.2 at the age of 18 years. 
 
Incidence and prevalence 
A study of US births estimated an annual incidence 
of 91,000 infants born SGA, using a definition of 
SGA as –2 SDs, or equivalent to the 2.3 percentile.39 
A Swedish study of full-term births in 1973–5 found 
that 5.4% of neonates were SGA, defined as being 
< –2 SD for birth length and/or height.46 However, 
other studies have cited an incidence of around 3% 
of babies being born SGA.47,48 
 
SHOX deficiency 
Aetiology, pathology and prognosis 
The SHOX gene is located on the distal ends 
of the X and Y chromosomes. This gene plays 
a significant role in long bone growth, and 
normal growth requires two functional copies.49,50 
Growth impairment can result from having a 
haploinsufficiency of SHOX, or from mutations.49 
Clinical features associated with short stature 
homeobox-containing gene deficiency (SHOX-D) 
include disproportionate shortening of the middle 
sections of the limbs (mesomelia), bowing of the 
forearms and lower legs, cubitus valgus (increased 
carrying angle of elbow) and Madelung deformity 
of the wrist.49 However, not all people with 
SHOX-D will have these physical characteristics. 
Langer syndrome is a rare homozygous (or 
compound heterozygous) form of SHOX-D. It 
is characterised by extreme dwarfism, profound 
mesomelia and severe limb deformity.49,51,52 
 
Incidence and prevalence 
Short stature homeobox-containing gene deficiency 
could be the underlying cause of restricted height 
in some children whose short stature cannot be 
explained by an underlying pathology. Estimates 
of the prevalence of SHOX haploinsufficiency  
in children with short stature of unknown origin 
range from 1% to 12.5%.13,53–59  Rappold and 
colleagues56 studied 900 short children and found 
SHOX mutations in 2.4% of the patients with short 
stature of unknown origin, implying a prevalence 
of at least 1 in 2000 children. Binder and 
colleagues57 reported a lower prevalence of SHOX 
haploinsufficiency, estimating it to be 1 : 4000. 
 
Short stature homeobox-containing gene deficiency 
also causes short stature in people with concurrent 
diagnoses. Huber and colleagues59 reported that 
68% of 56 children with dyschondrosteosis (a rare 
form of dwarfism) had SHOX anomalies. Other 
screening studies have reported it as the cause of 
short stature in approximately 70% of patients 
with Léri–Weill syndrome (LWS).60  Girls with TS 
have only one copy of the SHOX gene, and this 
haploinsufficiency causes short stature in some girls 
and women with the condition.49 
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A small study61 that compared 26 SHOX- 
haploinsufficient people with 45 of their relatives 
and general population standards found that 
the SHOX haploinsufficient cohort was 2.14 SDs 
(3.8 cm) shorter at birth and 2.1 SDs shorter 
throughout childhood. Females were more severely 
affected than males, with women’s FH being 
2.4 SDs (14.4 cm) shorter than unaffected siblings, 
and men’s FH being 0.8 SDs (5.3 cm) shorter. 
SHOX haploinsufficiency led to short stature 
in 54% of the cohort, short arms in 92% and 
Madelung deformity in 73%. It is not clear whether 
the SHOX haploinsufficient cohort in this study 
had concurrent diagnoses.61 
 
Impact of health problem 
Severe short stature may be physically debilitating 
in untreated children,62 with children being 
at greater risk of bullying at school and social 
isolation.63 Some children with short stature may 
also have difficulties with emotionally immature 
behaviour, anxiety and poor school performance.64 
However, not all children who are shorter 
than their peers will experience problems. For 
example, the Royal College of Obstetricians and 
Gynaecologists states that the majority of children 
born SGA do not have any appreciable morbidity 
or mortality.38   However, others indicate that 
children born SGA who remain short may suffer 
from alienation, low self-esteem, impaired social 
dynamics, behavioural problems, lower educational 
achievement  and  professional  success.39,43 
 
Children with short stature can also be at increased 
risk of morbidity and mortality in later life. For 
example, the risk of cardiovascular morbidity is 
increased in patients with GHD,65   TS,66   and PWS,67 
while some patients with growth disorders may  
also be at increased risk of type 2 diabetes and 
metabolic syndrome.67,68  Low birth weight is also 
associated with future increased risk of coronary 
heart rate and stroke.69 
 
Outcome measures 
The main parameter used to measure the efficacy 
of rhGH treatment is growth. This reflects the main 
goals of therapy, which are physiological catch-up 
growth if possible, achievement of normal height 
during childhood, timely and normal growth 
during puberty and normal height in adulthood. 
In children with PWS, treatment with rhGH aims 
to improve body composition as well as boosting 
growth. 
Measures of growth include: 
 
• Final height (FH) or adult height (AH) Measured 
either in centimetres or expressed as a  
standard deviation score (SDS), this is the best 
measure of how rhGH treatment affects growth. 
FH has been achieved when the growth rate  
has slowed to less than some specified amount 
(e.g. 1–2 cm/year), and radiographs of the wrist 
and hand show that the epiphyses have closed 
(often expressed as a bone age of more than 
14–15 years).6 Ideally, FH would be calculated 
in comparison with an untreated control group 
in a randomised controlled trial (RCT). Some 
non-RCT designs use historical controls, 
which may overestimate the effects of rhGH 
treatment. Similarly, database studies may not 
include all relevant factors or be representative 
samples of treated patients.6 
• Near-final height (NFH)   Sometimes reported 
where it is assumed that FH has been reached 
using the above criteria, but it is acknowledged 
that growth may not yet be quite complete.6 
• Height  Usually measured standing, using a 
wall-mounted Harpenden stadiometer or a 
similar device. For very young children, supine 
length is measured. 
• Height standard deviation score (HtSDS) This 
expresses height relative to norms for children 
of the same age, allowing comparisons that are 
independent of age or gender. The normal 
population mean is zero and a normal SD  
score will lie between –2 and +2 SDs. Increase 
over time in SDS or upward centile crossing 
implies catch-up growth and a decrease implies 
growth failure. Calculation of SDS depends on 
the reference data used, i.e. normal height for 
children in the same country. 
• Growth velocity (GV)  Also referred to as height 
velocity, this is the change in height over 
a specified period, e.g. cm/year. Although 
the overall effectiveness of rhGH in treating 
short stature is to be found in measures of 
FH, velocity may be a better interim growth 
measure than height attained at a particular 
age, as it is independent of growth in previous 
years. 
• Growth velocity standard deviation score  
(GVSDS) This is the GV relative to norms for 
children of the same age. 
• Bone age (BA) A measure of skeletal maturity, 
usually determined by examining the relative 
positions of the bones in the left hand and 
wrist from a radiograph. The measurement of 
BA relative to chronological age is important 
in height-prediction models. In addition, BA 
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assessments are used to evaluate when the 
epiphyses have closed and growth is complete. 
The interim assessment of BA is important in 
determining whether treatment is advancing 
bone maturity, such that short-term GV 
might come at the expense of early closure of 
the epiphyses. Clinical trials often measure 
BA to monitor whether this is accelerating 
undesirably fast in rhGH-treated patients 
compared with control patients. Height for BA 
can also be used as an estimate of improved 
height potential in response to rhGH therapy, 
especially in short-term studies. 
 
Measures of body composition assess obesity and 
the amount of fat relative to other body tissues. 
Body mass index (BMI) calculates the ratio of body 
mass to the square of body height, expressed as kg/ 
m2. The National Institute for Health and Clinical 
Excellence (NICE) recommends BMI as providing 
a practical estimate of overweight in children, 
although mentions that it needs to be interpreted 
with caution as it is not a direct measure of 
adiposity.70 Dual-energy X-ray absorptiometry 
(DEXA) can be used to measure lean mass (fat-free 
mass) and percentage body fat, which can be used 
to indicate body composition. 
Older children and adolescents in need of 
continued rhGH therapy may enter transitional 
care arrangements that involve consultations with 
both paediatric and adult growth specialists.74 A 
system of shared care is sometimes used for rhGH 
therapy in the UK,1 with diagnosis and assessment 
of growth being carried out in hospital outpatient 
consultations and some GPs writing prescriptions 
and possibly monitoring adverse events (AEs). In 
other areas, all care including prescriptions and 
monitoring of compliance and side effects takes 
place in secondary care. 
 
Administration of rhGH is usually carried out 
at home by the patient or a family member, 
after training, by subcutaneous injection, using 
either needled or needle-free devices, usually 
pharmaceutical companies’ devices rather than 
syringe and needle. Termination of rhGH therapy 
is indicated if there is a poor response (< 50% 
increment in GV within the first year) or when 
FH is achieved. In children with CRI, therapy 
with rhGH is stopped at the time of a transplant. 
Therapy would not resume until at least 1 year post 
transplant, and is dependent upon the absence of 
catch-up growth.1 
 Relevant guidance 
Physiological outcomes reported in studies of rhGH Current guidance from NICE on the use of 
may include assessments of the concentrations rhGH in England and Wales for children with 
of hormones, glucose, cholesterol, and markers growth failure due to GHD, TS, PWS or CRI was 
of bone and general metabolism. Such measures published in 2002.75 This is discussed further later 
are important for assessing the biochemical, in the chapter (see Place of the intervention in 
metabolic and adverse effects of rhGH, and can the treatment pathway). Since 2002, a range of 
have implications for long-term health. IGF-1 is guidance on the use of rhGH in children with short 
an endocrine hormone that is produced by the stature has been published by various national 
liver, and its production is stimulated by GH. health agencies and clinical expert groups for 
Lower than normal levels are therefore seen in GHD, TS, CRI, PWS and SGA, but guidance for 
people with growth disorders. The insulin-like children with SHOX-D is lacking. 
growth factor building proteins (IGFBPs) act as  
carrier proteins for IGF-1. There are six IGFBPs, Guidelines on the use of rhGH for the treatment 
with IGFBP-3 being the most abundant.71  IGF-1 of girls and women with TS (published in 2007, 
is monitored during rhGH therapy as there is a relevant to US practice) recommended that 
theoretical concern that persistently elevated levels treatment with rhGH should be considered 
may predispose the patient to other diseases later as soon as growth failure has been identified, 
in life. Monitoring levels also helps to tailor the and its potential risks and benefits have been 
dose to the individual. As IGFBP-3 binds IGF-1, discussed with the family. It also provided rhGH 
monitoring this gives an indication of the levels of dosing information and a comprehensive set of 
‘free’ IGF-1 in circulation. High levels of IGF-1 with recommendations for the diagnosis, evaluation, 
low levels of IGFBP-3 may be linked with breast, monitoring and ongoing care of children with TS.11 
colorectal and prostate cancer.72,73  
 Summary guidelines76 and detailed 
Current service provision recommendations27  on the use of rhGH for 
 short stature in children with CRI (published in 
Management of rhGH therapy 2005–6, relevant to US practice) recommended 
Children who receive rhGH therapy require regular 
6 review by consultant paediatric endocrinologists. 
that therapy should not commence unless patients 
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exhibit clearly defined CRI and attain appropriate 
phosphorus and parathyroid hormone status.76 The 
detailed recommendations included rhGH dosing 
information and a treatment algorithm outlining 
appropriate steps to improve growth and overall 
health outcomes.27 
 
Consensus statements on using rhGH therapy in 
children and adults born SGA (published in 200339 
and 2007,77  relevant to European and US practice) 
emphasised the need for accurate diagnosis of SGA 
and recommended that rhGH therapy should be 
considered in children who are SGA and older than 
2 years of age. However, this reflects differences in 
licensing in Europe and America. The Food and 
Drug Administration (FDA) authorisation is for 
children aged 2 years and over with no catch-up 
growth (no criteria specified), and no specified 
HtSDS at start of treatment or reference to mid- 
parental height.78  By contrast, the European 
Medicines Agency (EMEA) authorisation is for 
children aged 4 years and over, with a HtSDS of 
–2.5 at start of treatment, with a GV < 0 SDs and 
HtSDS > 1 SD below mid-parental height.79  In 
addition, the licensed dose is 70 µg/kg/day in the 
USA and 35 µg/kg/day in Europe. 
 
For UK populations, guidelines on rhGH therapy 
for children with GHD, TS, CRI, PWS and SGA 
was published in 2006 by BSPED.1 This guidance 
provided recommendations for shared care 
between GPs and specialists, together with dosing 
information and treatment entry and exit criteria. 
 
Description of technology under 
assessment 
Somatropin (rhGH) has been available since 1985, 
following the withdrawal of cadaveric human 
pituitary GH due to possible transmission of 
Creutzfeldt–Jakob disease.6 rhGH is a synthetic 
form of human GH, produced by recombinant 
deoxyribonucleic acid (DNA) technology, having 
a sequence identical to that of pituitary-derived 
human GH. Licensed dosages vary for the different 
indications (Table 1), depending on whether the 
treatment is aiming to replace GH to normal 
levels (for children with GHD) or being used  
in supraphysiological doses where there is no 
hormone deficiency but some lack of sensitivity 
to the hormone. It is given as a subcutaneous 
injection, usually at night (to mimic the child’s 
natural fluctuations in GH).6 
 
Seven pharmaceutical companies have UK 
marketing authorisations for various indications, as 
shown in Table 1. 
Adverse events (AEs) have been reported in 
patients using rhGH. For example, sleep apnoea 
and sudden death among patients with PWS 
who have one or more of the following risk 
factors: severe obesity, history of upper airway 
obstruction or sleep apnoea, or untreated 
respiratory  infection.80,81   There  are  potential  risks 
of acromegaly, hyperglycaemia and glucosuria if  
the  recommended  dosage  is  exceeded.81   Patients 
receiving rhGH should be monitored for glucose 
intolerance, as the drug may induce a state of 
insulin resistance.81   It is also recommended that 
thyroid function should be monitored.81   Possible 
side effects mentioned for 1–10% of patients 
include hypersensitivity to solvent, hypothyroidism, 
injection site pain (reaction) and  oedema.81 
Treatment should be discontinued in the event 
of intracranial hypertension,81 although it may 
be possible to restart treatment at a lower dose 
for patients who develop benign intracranial 
hypertension. Treatment with rhGH leads to 
increasing sensitivity to GH, expressed as an 
increase in serum IGF-1.81 
 
Omnitrope, marketed by Sandoz, is a biosimilar 
product. This means that it is an active substance 
that is similar, but not identical, to the other drugs 
considered in this review. The issue of rhGH 
therapy and biosimilars in clinical practice was the 
subject of a recent Parliamentary Summit.30   The 
current review assesses the clinical effectiveness and 
cost-effectiveness of rhGH, without reference to 
the brand product or manufacturer. Discussion of 
the comparative safety and efficacy of biosimilars 
compared with reference products is therefore 
beyond the scope of this review. 
 
 
Place of the intervention in 
the treatment pathway 
The place of rhGH in the treatment pathway 
depends on the child’s particular condition or 
syndrome, and age at diagnosis. Appropriate 
timing of treatment with rhGH will depend 
on the underlying pathology. rhGH therapy is 
contraindicated in cases of progressive tumour 
activity and should not be used for growth 
promotion in children with closed epiphyses. 
 
GHD 
Treatment with rhGH is currently recommended by 
NICE to help increase the growth of children with 
GHD.75  For children with congenital GHD, rhGH 
therapy is not generally started before the child is 
4 years old.6 However, if there is profound growth 7 
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved. 
 
Background 
 
 
 
 
 
 
 
TABLE 1 Indications for the use of rhGH in children 
 
Indication Dosea Licensed drugs (manufacturers) 
GHD 23–39 mcg/kg daily, Humatrope (Eli Lilly & Co. Ltd) 
or 0.7–1.0 mg/m2 Zomacton (Ferring Pharmaceuticals UK) 
daily 
NutropinAq (Ipsen Ltd) 
Norditropin Simple Xx (Novo Nordisk Ltd) 
Genotropin (Pfizer Ltd) 
Omnitrope (Sandoz Ltd) 
Saizen (Merck Serono) 
TS 45–50 mcg/kg daily Humatrope (Eli Lilly & Co. Ltd) 
or 1.4 mg/m2 daily Zomacton (Ferring Pharmaceuticals UK) 
NutropinAq (Ipsen Ltd) 
Norditropin Simple Xx (Novo Nordisk Ltd) 
Genotropin (Pfizer Ltd) 
Omnitrope (Sandoz Ltd) 
Saizen (Merck Serono) 
PWS, with GV > 1 cm/year (in combination   35 mcg/kg daily or Genotropin (Pfizer Ltd) 
with energy-restricted diet) 1.0 mg/m2 daily; Omnitrope (Sandoz Ltd) 
max. 2.7 mg daily 
CRI in children 45–50 mcg/kg daily Humatrope (Eli Lilly & Co. Ltd) 
or 1.4 mg/m2 daily NutropinAq (Ipsen Ltd) 
Norditropin Simple Xx (Novo Nordisk Ltd) 
Genotropin (Pfizer Ltd) 
Omnitrope (Sandoz Ltd) 
Saizen (Merck Serono) 
SHOX-D 45–50 mcg/kg daily Humatrope (Eli Lilly & Co. Ltd) 
Growth disturbance (current HtSDS –2.5 35 mcg/kg daily or Humatrope (Eli Lilly & Co. Ltd) 
and parental adjusted HtSDS, –1) in short 1.0 mg/m2 daily Norditropin Simple Xx (Novo Nordisk Ltd) 
children born SGA, with a birth weight 
and/or length below –2 SDs, who failed to Genotropin (Pfizer Ltd) 
show catch-up growth (HV SDS < 0 during Omnitrope (Sandoz Ltd) 
the last year) by 4 years of age or later Saizen (Merck Serono) 
a  Dosing information from the Electronic Medicines Compendium (http://emc.medicines.org.uk/), accessed 30 April 
2008. 
 
 
 
failure or evidence of recurrent hypoglycaemia, 
which may occur in infants under the age of 1, 
treatment may be started earlier. For children who 
acquire GHD at an older age, treatment can start  
at a time that is appropriate to their condition and 
stage of growth. Treatment is discontinued after  
the first year if there is a poor response, i.e. < 50% 
increase in growth rate, or if compliance or growth 
rate remains poor thereafter. Otherwise treatment 
can continue until GV is < 2 cm/year, assessed over 
6–12 months, when FH is achieved. Other clinical 
advice suggests that treatment is necessary for the 
patient to attain peak bone mass, which may not be 
until the age of 25 or 26 in some people. A recent 
survey of paediatric endocrinologists (56 responses 
out of 72 questionnaires) found that 56% of 
clinics provide transfer clinics for patients ending 
paediatric treatment and transferring to the care of 
an adult endocrinologist. Of the 56 respondents, 
80% retest for GHD prior to transfer, 55% transfer 
all rhGH-treated patients and the remainder 
transfer only those who are still GH deficient on 
retesting.74 
 
Transition phase 
The transition phase in GHD is defined as the 
period from near FH, usually around the mid 
to late teens, until about 25 years of age, or 
when final adult height has been reached. At the 
stage of near FH, it is important to re-evaluate 
whether the patient is still GH deficient, and 
if they need to continue with treatment and 
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monitoring. Some cases, such as isolated GHD 
with a genetically identified mutation or multiple 
pituitary hormone deficiency (MPHD), severe GHD 
due to genetic causes, pituitary abnormalities, 
congenital hypopituitarism or acquired GHD 
from tumours or cranial irradiation, are likely to 
require a continuation of therapy. However, cases 
of unknown origin and isolated cases of GHD 
carry a lower likelihood of requiring continuing 
treatment.4  The BSPED consensus document 
suggests testing IGF-1 levels: if these are lower than 
–2 SD then these patients require GH stimulation 
retests. A peak GHD level of < 5µg/l during the 
transition phase is indicative of severe GHD.5 
 
During the transition phase the authors of the 
consensus paper recommend that monitoring 
of patients should include weight and BMI at 
least 6-monthly, IGF-1, quality of life (QoL), 
waist circumference and fasting glucose annually, 
and body composition and total and low-density 
lipoprotein (LDL) cholesterol every 2–5 years.5 
 
Turner syndrome 
Current NICE guidance recommends that rhGH 
treatment for girls with TS should begin at the 
earliest age possible, to boost growth.75 Some 
patients with profound growth retardation and 
failure to thrive may commence treatment earlier 
than those who are diagnosed later. A Belgian 
study16 found that median age at diagnosis of 242 
girls was 6.6 (range 0–18.3) years, although the 
survey found that 22% of girls were diagnosed after 
the age of 12 years. Some clinical expert advice 
suggests that the mean age for starting treatment 
is 8–9 years of age as many girls are not diagnosed 
until later in childhood, although there has been a 
recent trend towards earlier diagnosis. 
 
Prader–Willi syndrome 
NICE guidance currently recommends the use of 
rhGH for children with PWS to improve height, 
body composition and bone mineral density. 
For children with PWS, treatment with rhGH 
is intended to improve body composition and 
metabolism as well as increase FH. Its place in the 
treatment pathway depends on age at diagnosis. 
Children with PWS are assessed for obesity, 
potential for obstructive sleep apnoea and ongoing 
respiratory illness before treatment is considered. 
Low muscle tone and its impact on the child’s 
development are also considered. 
Chronic renal insufficiency 
Treatment with rhGH is currently recommended by 
NICE to help increase the growth of prepubertal 
children with CRI.75  The guidance recommends 
that treatment should be stopped after a renal 
transplantation, and re-established after only 
1 year if it has been ascertained that catch-up 
growth has not occurred.75 The place of rhGH 
in the treatment pathway for children with CRI 
depends on age at diagnosis, and on clinical factors 
related to management of the child’s condition. 
rhGH treatment can take place either before or 
after renal transplant, although allograft rejection 
can be a concern if rhGH treatment is given post 
transplant. 
 
Small for gestational age 
Previous NICE guidelines did not consider 
children born SGA, as rhGH was not licensed for 
this indication at the time.82 Children born SGA 
but with no comorbidities may not be diagnosed 
until they fail to achieve catch-up height by the 
age of 2–4 years,39 or when they start school. 
The International SGA Advisory Board indicated 
that SGA children aged 2–4 years who show no 
evidence of catch-up with a height of –2.5 SD 
should be eligible for rhGH treatment. They also 
recommended that treatment should be considered 
in children older than four years who show no 
catch up at a height –2 SD or less.39  The European 
licence for rhGH is for children aged 4 years and 
over. 
 
SHOX deficiency 
Currently, there is no NICE guidance available  
for the use of rhGH in children with SHOX-D. 
Initiation of rhGH treatment for children with 
SHOX-D depends on age at diagnosis. Clinical 
evaluation is used to assess growth failure, but GH 
provocation tests are not required once SHOX-D 
has been established via a positive SHOX DNA 
blood test. 
 
 
Current usage in the NHS 
 
According to a survey of endocrine clinics 
published in 2006 by BSPED,74  4758 patients 
have been receiving rhGH in the UK, of which 
4168 were in England and Wales. Responses to 
the survey gave a breakdown of rhGH use by 
diagnosis for 3951 of the 4758 patients, indicating 
9 
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that 57.4% of the patients on rhGH were treated  
for GHD, 18.7% for TS, 4.6% for PWS, 5.2% for 
SGA, 2.5% for CRI, and 11.6% for other diagnoses. 
If we assume that these 3951 patients are a 
representative sample of the total population of 
rhGH-treated patients in the UK, the total numbers 
of rhGH-treated patients with each diagnosis would 
be around 2731 with GHD, 890 with TS, 219 with 
PWS, 247 with SGA, 119 with CRI, and 552 with 
other diagnoses. It is possible that the number 
of children with CRI who received rhGH in this 
survey was underestimated, as some patients with 
CRI are managed in nephrology clinics, rather 
than paediatric endocrine clinics.74  The number of 
patients treated with rhGH for SHOX-D was not 
reported in the survey and published figures are 
not available. Expert advice indicates that very few 
SHOX-deficient patients are currently receiving 
rhGH, for example only two of between 350 and 
400 patients in one unit receiving rhGH are being 
treated for this. The level of service provision for 
SHOX-deficient patients would be similar to that 
required for a patient with TS. 
Anticipated costs associated 
with intervention 
The costs associated with rhGH therapy 
interventions comprise: 
 
• the drug (dose adjusted for body weight) 
• self-therapy training of the patients and their 
parents (involving home visits by specialist and 
community nurses) 
• monitoring of treatment effectiveness 
(involving paediatric endocrinology outpatient 
visits for blood tests, a test of pituitary function, 
and an assessment of BA by hand radiograph). 
 
The costs of training patients and their parents are 
limited to the first year of treatment. During each 
year of treatment, until they stop growing, patients 
would typically attend two outpatient consultations. 
Estimates of the current costs of these components 
of the rhGH interventions for patients with GHD, 
TS, PWS, CRI and SGA are provided in Chapter 4 
(see Estimation of costs). 
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Chapter 2 
Definition of the decision problem 
 
 
Decision problem 
Recombinant human growth hormone is currently 
recommended by NICE75 for children with a 
proven clinical diagnosis of GHD, TS or PWS,  
and for prepubertal children with CRI. Since 
the last review, rhGH has received marketing 
authorisation for the treatment of children born 
SGA and for children with growth failure associated 
with SHOX-D. The scope of the current project 
is broader than that for the previous systematic 
review6 in that it covers body composition as an 
outcome measure for all disease areas, and also 
includes biochemical and metabolic markers. 
In addition, evidence for the use of rhGH for 
children born SGA, or with SHOX-D (conditions 
not considered in the original review) are included 
in this report. For these reasons, the current 
systematic review was undertaken as a complete 
review not an update. The aim of this health 
technology assessment (HTA) is to assess the 
clinical effectiveness and cost-effectiveness of rhGH 
for children with GHD, TS, PWS, CRI, SHOX-D 
and those born SGA. 
 
Interventions 
The intervention is rhGH, also known as 
somatropin. It is marketed as the following 
products: Humatrope (Eli Lilly & Co.); Zomacton 
(Ferring Pharmaceuticals); NutropinAq (Ipsen); 
Norditropin SimpleXx (Novo Nordisk); 
Genotropin (Pfizer); Omnitrope (Sandoz) and 
Saizen (Merck Serono). 
 
Population, including subgroups 
The population consists of children with one 
of the following conditions: GHD, TS, PWS, 
CRI, SHOX-D, being born SGA. No age-specific 
definition of a child was given during the scoping 
process for this review. Possible subgroups could 
be children with different causes of GHD, and 
children with CRI who are either pretransplant 
or post transplant. However, analysis of the 
effectiveness of rhGH treatment for any of these 
subgroups of patients is limited by the available 
data and the statistical power of the identified 
trials. 
Transition of care from paediatric to adult 
endocrine services of young people requires 
patients to have repeat testing of their GH axis to 
be sure that they need to continue treatment. This 
transition period is only considered within this 
review where evidence from the identified studies 
allows for patients whose linear growth is not 
complete. 
 
Relevant comparators 
The standard comparator for this review is 
management strategies without rhGH. This 
includes placebo injections and no treatment. 
 
Outcomes 
Clinical outcomes of interest include: FH 
gained, HtSDS, GV, GVSDS, body composition, 
biochemical/metabolic markers, AEs of treatment; 
health-related quality of life (HRQoL). Direct 
costs include estimates of all health-care resources 
consumed in the provision of the intervention, 
including diagnostic tests, administration and 
monitoring costs – as well as consequences of those 
interventions, such as treatment of adverse effects. 
 
 
Overall aims and objectives 
of assessment 
The aim of this report is to assess the clinical 
effectiveness and cost-effectiveness of rhGH 
treatment for children with GHD, TS, PWS, CRI, 
SHOX-D and those born SGA. 
 
The objectives are to: 
 
• summarise the evidence of clinical effectiveness 
and cost-effectiveness of rhGH when compared 
with management strategies without rhGH 
• develop, where appropriate, an economic 
model adapting an existing cost-effectiveness 
model6 or constructing a new model using 
best available evidence to determine cost- 
effectiveness in the UK 
• identify priorities for future research. 
11 
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Chapter 3 
Assessment of clinical effectiveness 
 
 
Methodology 
The methods for the systematic review of clinical 
effectiveness were described a priori in the research 
protocol (Appendix 1), which was sent to experts 
for comment. We received helpful comments 
relating to the general content of the research 
protocol, but there was none that identified specific 
problems with the methods of the review. The 
methods are summarised below. 
 
Search strategy 
An experienced information specialist developed 
and tested search strategies for this review. 
Separate searches were carried out to identify 
studies reporting clinical effectiveness, cost- 
effectiveness, HRQoL, resource use and costs, and 
epidemiology/natural history of the conditions. 
The search strategy for MEDLINE, shown in 
Appendix 2, was adapted as appropriate for 
a number of other electronic databases. We 
searched: The Cochrane Database of Systematic 
Reviews (CDSR); The Cochrane Central Register 
of Controlled Trials; NHS Centre for Reviews and 
Dissemination (NHS CRD, University of York) 
Database of Abstracts of Reviews of Effectiveness 
(DARE) and the NHS Economic Evaluation 
Database (NHS EED); MEDLINE (OVID); 
EMBASE (OVID); National Research Register 
(NRR); Current Controlled Trials; ISI Proceedings; 
Web of Science; and BIOSIS. For all disease areas 
we searched the databases from their inception to 
June 2009. This meant there was some duplication 
of earlier work for the previous review, but this was 
necessary as the present review required searches 
for additional outcomes, such as biochemical and 
metabolic markers. Searches were limited to the 
English language. 
 
Relevant conferences (European Society for 
Paediatric Endocrinology, The Endocrine Society, 
American Association of Endocrinologists, 
Paediatric Academic Societies) were searched for 
recent abstracts (up to June 2009) to assess against 
the inclusion criteria. Bibliographies of related 
papers were screened for relevant studies, and 
we contacted experts to identify any additional 
published or unpublished references. We also 
assessed the MSs to NICE for any additional 
studies that met the inclusion criteria. 
 
Inclusion and data extraction 
process 
Titles and abstracts of studies identified by 
the search strategy were assessed for potential 
eligibility by two reviewers. The full text of relevant 
papers was then obtained, and inclusion criteria 
were applied by two independent reviewers. 
At both stages of the screening process, any 
differences in opinion on inclusion of a particular 
study were resolved through discussion. Data from 
included studies were extracted by one reviewer 
using a standard data extraction form and checked 
by a second reviewer. Any discrepancies were 
identified and resolved through discussion. 
 
Quality assessment 
The quality of included studies was assessed using 
NHS CRD (University of York) criteria.83 Quality 
criteria were applied by one reviewer and checked 
by a second reviewer, with differences in opinion 
resolved by discussion. The criteria used are shown 
in Appendix 3. Publication bias was not assessed. 
 
Inclusion criteria 
Patients 
The inclusion criteria required the patient group to 
be children with growth disturbance due to one of 
the following licensed conditions: 
 
• insufficient secretion of GH (GHD) 
• Turner syndrome, confirmed by chromosome 
analysis 
• Prader–Willi syndrome, confirmed by genetic 
testing 
• chronic renal insufficiency (prepubertal 
children only) 
• short stature homeobox-containing gene 
deficiency, confirmed by DNA analysis 
• small for gestational age (see below). 
 
The licensed indication81 for SGA is for growth 
disturbance (current HtSDS –2.5 and parental 
adjusted HtSDS –1) in short children born SGA, 
13 
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with a birth weight and/or length below –2 SD,  
who failed to show catch-up growth [height velocity 
(HV) SDS < 0 during the last year] by 4 years of 
age or later. However, the review group could not 
find any RCTs whose inclusion criteria matched 
these criteria exactly. Following discussions with 
NICE, the team amended the criteria to be: 
‘growth disturbance (current HtSDS < –2.5, but  
with no reference to parental height) in short children 
born SGA with a birth weight and/or length below 
–2 SD, who failed to show catch-up growth (with no 
particular criteria specified) by 3 years of age or later.’ 
 
Studies that included adolescents and young adults 
who have completed linear growth were excluded 
from the systematic review of effectiveness. 
 
Interventions 
Recombinant human growth hormone 
(somatropin). 
 
Comparators 
Management strategies without somatropin. 
 
Outcomes 
The following outcomes were included in the 
review, where data were available: 
 
• final height gained 
• height standard deviation score (height relative 
to the distribution of height in children of the 
same chronological age) 
• growth velocity 
• growth velocity standard deviation score 
(GV relative to the distribution of growth in 
children of the same chronological age or bone 
age) 
• body  composition 
• biochemical and metabolic markers 
• adverse effects of treatment 
• HRQoL. 
 
Types of studies 
• Fully published RCTs were included in the 
review, and systematic reviews of RCTs were 
included as sources of information. Indicators 
of a systematic review include: explicit search 
strategy, inclusion criteria, data extraction 
and assessment of quality. While important 
information on FH and long-term AEs will only 
be available in longer, observational studies, 
there was a practical limit on the number of 
studies that could be included for this review. A 
pragmatic decision was therefore taken to limit 
study type to RCTs, in an attempt to capture 
the most methodologically robust data for all 
six of the disease areas included in this review. 
• Studies published only as abstracts or 
conference presentations were included in 
the primary analysis of clinical effectiveness 
and cost-effectiveness if sufficient details 
were presented to allow an appraisal of the 
methodology and assessment of results. 
• Non-English language studies were excluded. 
• In an effort to capture all randomised 
evidence, all identified RCTs were included 
with no restriction on length of treatment, 
size of study population, or design (parallel 
group or crossover design). Crossover studies 
could potentially be problematic as children’s 
growth continues without treatment, making 
comparisons between the different arms 
less straightforward than in a parallel-group 
trial. However, we have attempted to include 
discussion of this in the quality assessment of 
studies. 
 
Data synthesis 
• Clinical effectiveness studies were synthesised 
through a narrative review with tabulation 
of results of included studies. Key outcome 
measures are reported in tables in the text, 
and other outcomes are shown in the full 
data extraction forms in Appendix 4. For 
conciseness, where a study reported outcome 
measures after 1 and 2 years, only the final 
year’s outcomes are included in the table, as 
these show the longest duration of treatment 
effect. 
• Where data were of sufficient quality and 
homogeneity, a meta-analysis of the clinical 
effectiveness studies was considered using 
review   manager   5.0  software. 
• Quality-of-life studies were synthesised using 
the same methods as above, i.e. narrative 
review and meta-analysis only if feasible. 
 
 
Results 
 
A brief overview of the results of the searches is 
presented below. Owing to the extensive nature 
of this multiple technology appraisal (MTA), the 
clinical effectiveness results for the six different 
disease areas are presented separately (see sections 
Growth hormone deficiency to SHOX-D). For all 
disease areas throughout the screening and data 
extraction process, differences in opinion were 
generally minor and easily resolved without the 
involvement of a third reviewer. 
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Quantity and quality of research 
available 
The number of references considered at each 
stage of the review is shown in Figure 1. Of the 
674 references identified, 560 were excluded  
on inspection of their titles and abstracts. The 
full papers of 114 references were retrieved and 
assessed against the inclusion criteria. A total of 
77 of the retrieved full papers were rejected at this 
stage, mostly due to the patient group not meeting 
the inclusion criteria (n = 40) or due to a non-RCT 
study design (n = 27). A list of papers excluded at 
this stage is included in Appendix 5, together with 
reasons for exclusion. A total of 28 RCTs in 34 
publications were included in the systematic review 
of clinical effectiveness. Appendix 6 lists conference 
abstracts that were identified as being of interest, 
but which contained insufficient information to be 
included in the review of clinical effectiveness. 
 
An overview of the included studies is given in 
Table 2. Only one SGA paper and one TS paper 
reported FH; none of the other conditions’ studies 
reported FH as an outcome measure. None of the 
papers reported specific QoL measures. All disease 
areas included at least one paper which reported 
outcomes on height gained, body composition, 
biochemical markers and AE. The characteristics 
and quality assessment of the included studies are 
discussed in each of the relevant disease-specific 
results chapters. 
 
Comparison with previous review 
The previous review by Bryant and colleagues6 
included a number of studies that were excluded 
from the present review. As described above (see 
Inclusion and data extraction process) and in the 
research protocol, the present review included only 
RCTs as these form the highest level of evidence 
in the hierarchy of clinical trial designs.83  The 
previous review included two non-RCT studies 
for GHD,115,116  four for TS,117–120  two for CRI121,122 
and one for PWS.123 In addition, the previous 
review included two RCTs for TS, which have 
been excluded from the present review. The 
first of these, by Rosenfeld and colleagues,124,125 
was excluded from the present review as it used 
methionyl growth hormone (met-GH) rather 
than rhGH. The second TS RCT was by Ross and 
colleagues,126 which reported cognitive function. 
This was not one of the outcome measures listed 
in the inclusion criteria for the present review, 
 
 
 
 
Identified on searching 
(after duplicates removed) 
n = 674 
 
 
Titles and abstracts 
inspected 
Excluded 
n = 560 
 
 
Full copies retrieved 
n = 114 
 
 
Papers inspected 
n = 114 
 
 
 
37 includes: 
Systemic reviews n = 3a 
RCTs n = 28 in 34 publications 
GHD n = 1 RCT 
TS n = 6 RCTs, n = 2 SR 
PWS n = 8 RCTs 
CRI n = 6 RCTs 
SHOX n = 1 RCT 
SGA n = 6 RCTs 
Excluded 
n = 77 
 
 
FIGURE 1 Flow chart of identification of published studies for inclusion in the systematic review of clinical effectiveness. aOne of the 
systematic reviews was the previous Health Technology Assessment report written for the National Institute for Health and Clinical 
Excellence, so this was not data extracted. It is discussed briefly (in Summary of previous systematic reviews). 15 
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TABLE 2 Included RCTs 
 
Outcomes included in the systematic review 
 
Height 
gained/ 
 
GV/ 
growth 
 
 
Body 
 
Biochemical/ 
metabolic 
Author and date Total (n) FH HtSDS SDS composition markers QoL AE 
GHD         
Soliman84 19        
TS         
Davenport 200785 89        
Stephure 200586 and 
Rovet 199387 
154        
Quigley 200212 232        
Gravholt 200288 12        
Gravholt 200589 9        
Johnston 200190 58        
PWS         
Festen 200791 20        
Festen 200792 29        
de Lind van Wijngaarden 
200993 and Festen 200894 
42 infants, 
49 children 
       
Carrel 199995 and 
Myers96 
54        
Carrel 200422 and 
Myers97 and Whitman98 
32        
Hauffa 199799 19        
Lindgren100,101 29        
Haqq 2003102 14        
CRI         
Sanchez 2002103 23        
Hokken-Koelega 1991104 20        
Hokken-Koelega 1996105 11        
Powell 1997106 69        
The Pharmacia and 
Upjohn Study Group 
203        
1996107         
Fine 1994108 125        
SHOX-D         
Blum 200749 52        
SGA         
De Schepper 2007109 40        
Lagrou 2008110 40        
Carel 2003111 168        
de Zegher 1996112 54        
de Zegher 2002113 13        
Philip 2009114 151        
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so this RCT was excluded. The previous review  
also included a PWS RCT by Whitman and 
colleagues,127  which was considered for the current 
review. However, the study reported psychological 
outcomes rather than a measure of HRQoL, so this 
study did not meet our inclusion criteria. 
 
 
Growth hormone deficiency 
Quantity and quality of research 
available 
One study met the inclusion criteria for this review, 
and the key characteristics are presented in Table 3. 
The full data extraction form in Appendix 4 has 
further details. 
 
Soliman and Abdul Khadir84  recruited two groups 
of GH-deficient children and one group of children 
who were not GH deficient. These groups were then 
subdivided into treatment groups: group 1a 
received 30 units (U)/m2/week of rhGH and group 
1b received 15 U/m2/week. Group 2a received 15 U/ 
m2/week and group 2b received no treatment. 
Group 3 (non-GHD short children) was subdivided 
in the same way as group 2. Group 2 was the only 
group in this study with GHD and with children 
randomised to either rhGH or no treatment, and, 
as such, is the only group considered in this report. 
The treatment groups’ baseline characteristics  
were similar. The study used a dose of 15 U/m2/ 
week, and it is not clear how this corresponds to 
the licensed dose as neither milligrams (mg) nor 
international units (IUs) are used. 
 
Overall the quality of the reporting of the included 
study was mixed (Table 4). No details were given 
on randomisation or allocation to treatment 
groups. For example, Soliman and Abdul Khadir84 
recruited children into specified groups according 
to peak GH response to provocation, and these 
groups were then divided at random into two 
subgroups. No further details were given. The low 
patient numbers will affect interpretation of results 
from this trial. 
 
The comparator group did not receive placebo: 
this could mean that both care providers and 
patients would have been aware of whether they 
were receiving treatment, which, in turn, can affect 
reporting of some outcomes. Soliman and Abdul 
Khadir84 appear to have carried out an intention- 
 
 
 
TABLE 3 Characteristics of GHD study 
 
 Total randomised Duration of randomised 
Reference Intervention Control group and withdrawals treatment 
Soliman et al. 
199684 
GH 15 U/m2/week 
n = 9 
No treatment 
n = 10 
Total n = 19 
No withdrawals 
1 year 
Overall mean  
age ± SD: 6.8 ± 2.1 
Overall mean  
age ± SD: 6.8 ± 2.1 
reported 
 
 
TABLE 4 Quality assessment of included GHD study 
 
Soliman84 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Inadequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary outcome measure?   Adequate 
9. Did the analyses include an ITT analysis? Adequate 
10. Were withdrawals and dropouts completely described? Adequate 
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to-treat analysis (ITT), which can protect against 
attrition bias. 
 
Growth outcomes 
The Soliman84 study reported GV and HtSDS, and 
these are presented in Table 5. The data extraction 
forms in Appendix 4 list further outcome measures, 
such as BA. 
 
Children in the treated group in the Soliman 
study grew an average of 2.7 cm/year faster than 
those receiving no treatment in the 12 months of 
the study, and the difference between groups was 
statistically significant (p < 0.05). Similarly, children 
in the treated group had a statistically significantly 
higher HtSDS: –2.3 ± 0.45 versus –2.8 ± 0.45 in the 
untreated group (p < 0.05). 
 
Body composition outcomes 
Soliman and Abdul Khadir84 did not report body 
composition outcomes. 
 
Biochemical markers 
The results reported for IGF-1 levels in the Soliman 
study84 are shown in Table 6. Further biochemical 
markers, such as insulin, are included in the data 
extraction tables in Appendix 4. 
 
The IGF-1 levels at 12 months are statistically 
significantly higher in the treated than in the 
untreated group: 91.2 ± 30.4 versus 49.4 ± 19. 
 
Quality of life 
Soliman and Abdul Khadir84 did not report QoL 
results. 
Adverse events 
Adverse events were not reported by Soliman and 
Abdul Khadir.84 
 
Summary 
One trial examining the effectiveness of rhGH for 
GHD met the inclusion criteria for the review. 
 
• The quality of the included study was mixed. 
It was an unblinded study, which can have an 
impact on outcome reporting but did report an 
ITT analysis. 
• Children in the rhGH group grew 2.7 cm/year 
faster than children in the untreated group 
during the 1-year study, and had a statistically 
significantly higher HtSDS: –2.3 ± 0.45 versus 
–2.8 ± 0.45. 
• The IGF-1 levels were statistically significantly 
higher in the treated group than in the 
untreated group. 
• The included study did not report QoL or AE. 
Turner syndrome 
Quantity and quality of research 
available 
Six studies assessing the effectiveness of GH for 
growth restriction in TS met the inclusion criteria 
for the review.12,85,86,88–90 The key characteristics 
of these studies are presented in Tables 7–12. 
Appendix 4 has further details. 
 
Two of the included studies were of a crossover 
design,88,89  and these compared doses of 
0.1 IU/kg/day88 and a mean of 1.3 ± 0.3 mg/day 
(alone or in combination with oestradiol)89 with 
placebo. The group receiving oestradiol is not 
discussed further here. Of the remaining studies, 
 
 
 
TABLE 5 Growth outcomes for GHD 
 
Study Mean (SD) GH No treatment p-value 
Soliman84 HtSDS –2.3 ± 0.45 –2.8 ± 0.45 < 0.05 
GH 15 U/m2/week (n = 9) vs no 
treatment (n = 10); 12 months 
8.4 ± 1.4 5.7 ± 1.8 < 0.05  
 
TABLE 6 Biochemical markers in GHD studies 
 
Study Outcomes GH Control p-value 
Soliman84 IGF-1 (ng/ml) 91.2 ± 30.4 49.4 ± 19 < 0.05 
GH 15 U/m2/week (n = 9) vs no 
treatment (n = 10); 12 months 
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1.  Was the assignment to the treatment groups really random? Un Ad Un Un In Un 
2.  Was the treatment allocation concealed? Un Ad Un Un Un Un 
3.  Were the groups similar at baseline in terms of prognostic factors? Rep Rep Not Not Rep Rep 
  rep rep   
4.  Were the eligibility criteria specified? Ad Ad In In In Ad 
5.  Were outcome assessors blinded to the treatment allocation? Un Un Un Un Un Un 
6.  Was the care provider blinded? In In Un Un Un Un 
7.  Was the patient blinded? In In Un Ad Un Par 
8.  Were the point estimates and measure of variability presented for Ad Ad Ad Ad Ad In 
the primary outcome measure?      
9.  Did the analyses include an ITT analysis? In In In In In In 
10. Were withdrawals and dropouts completely described? Ad Ad In Ad Ad Ad 
Ad, adequate; In, inadequate; Not rep, not reported; Par, partial; Rep, reported; Un, unknown. 
 
 
 
 
 
 
TABLE 7 Characteristics of TS studies 
 
 
 
Reference 
 
 
Intervention 
 
 
Control group 
Duration of 
Total randomised randomised 
and withdrawals       treatment 
Stephure and 
CGHAC 200586 and 
Rovet et al., 1993 87 
 
 
Davenport et al. 
200785 
 
 
 
Gravholt et al. 
200288 
 
 
Gravholt et al. 
200589 
 
 
Johnston et al. 
200190 
 
 
 
Quigley et al. 200212 
rhGH 0.30 mg/kg/week 
(n = 76) 
Mean age (± SD): 10.3 ± 1.8 
 
rhGH 50 µg/kg/day (n = 45) 
Mean age (± SD): 1.98 
± 1.01 
 
rhGH 0.1 IU/kg/day 
Overall age range: 9.5–14.8 
years (median 12.9) 
rhGH (1.3 ± 0.3) mg/day 
Overall mean age (  SD): 
15.9 ± 1.8 
rhGH 28–30 IU/m2/week 
(n = 22) 
Mean age (range): 9.0 
(5.2–15.4) 
rhGH 0.27 mg/kg/week 
No rhGH treatment 
(n = 78) 
Mean age (± SD): 10.9 ± 1.7 
 
No treatment (n = 44) 
Mean age (± SD): 
1.97 ± 1.01 
 
Placebo 
Overall age range: 9.5– 
14.8 years (median 12.9) 
Placebo 
Overall mean age (± SD): 
15.9 ± 1.8 
Ethinyloestradiola 50– 
75 ng/kg/day (n = 13) 
Mean age (range): 9.1 
(6.0–13.7) 
Placebo (n = 41) 
Total n = 154 
Sample attrition: 
rhGH, n = 15; 
control, n = 35 
Total n = 89 
Sample attrition: 
rhGH, n = 4; control 
n = 6 
Total n = 12 
Withdrawals not 
reported 
Total n = 9 
Sample attrition: 
n = 1 
Total n = 58b 
Sample attrition: 
n = 12 
 
 
Total n = 232b 
Until HV < 2 cm/ 
year and BA 
≥ 14 year 
 
 
2 years 
 
, 
 
 
Crossover RCT, 
2 months in each 
arm 
Crossover RCT, 
2 months in each 
arm 
 
1 year 
 
 
 
 
18 months 
 (n = 45) Mean age (± SD): 9.4 ± 2.7 Sample attrition: 
 Mean age (± SD): 9.7 ± 2.7  n = 8 
 rhGH 0.36 mg/kg/week  
 (n = 49)  
 Mean age (± SD): 9.8 ± 2.9  
CGHAC, Canadian Growth Hormone Advisory Committee. 
a  Low-dose estrogen. 
b  Including additional study arm(s) not relevant here. 
 
TABLE 8 Quality assessment of included TS studies 
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two compared rhGH with no treatment,85,86 one 
with low-dose estrogen,90 and one with placebo.12 
Stephure and colleagues86 administered a rhGH 
dose of 0.30 mg/kg/week, with a maximum weekly 
dose of 15 mg. The dose of 50 µg in the Davenport 
study85 is comparable with that of Stephure and 
colleagues. Those in the Quigley study12 were 
slightly different: group 1 received 0.27 mg/kg/week 
and group 2 received 0.36 mg/kg/week. Johnston 
and colleagues90 gave a dose of 28–30 IU/m2/week. 
All studies included at least one treatment arm 
with a dose that was broadly comparable with the 
licensed dose of 45–50 µg/kg/day or 1.4 mg/m2/day. 
 
Four of the six included studies reported growth 
outcomes, including height gain and change in 
HtSDS.12,85,86,90  The remaining two studies reported 
body composition and biochemical marker 
outcomes.88,89 
 
The trials varied considerably in size. The two 
crossover trials were small, with 1288 and nine89 
participants. The Stephure86  and Quigley12 
studies were larger, with 154 and 232 participants, 
respectively. Johnston and colleagues90 recruited 58 
patients, and Davenport and colleagues recruited 
89.85  The included trials also ranged in length. 
The groups in Quigley and colleagues12 remained 
randomised for 18 months, the Davenport study85 
for 2 years and the Johnston study lasted for 
1 year.90  Protocol completion in the Stephure86 
study was defined as annualised GV less than 2 cm/ 
year and BA of 14 years or greater, which we have 
interpreted to mean FH. In contrast, the two 
Gravholt studies88,89 were short crossover trials, with 
rhGH treatment for 2 months. 
 
Five12,86,88–90  of the six trials recruited broadly 
similar age groups, whilst the sixth by Davenport 
and colleagues85 specifically targeted very young 
girls with TS. As a result their girls have much 
younger mean ages of 1.98 ± 1.01 and 1.97 ± 1.01 
for treatment and control groups, respectively. 
 
Four of the included studies reported baseline 
characteristics that were similar between 
groups.12,85,86,90  However, none reported p-values 
for between-group differences, so there may have 
been small differences at baseline. For example, in 
the study by Stephure and the Canadian Growth 
Hormone Advisory Committee (CGHAC) 2005,86 
girls in the rhGH group were on average 3 cm 
shorter than those in the control group. The SD 
values indicate overlapping CI, suggesting there is 
no statistically significant difference between the 
two groups. However, the 3-cm difference could 
have an impact on end of study height. The other 
two studies, reported by Gravholt and colleagues, 
were of crossover design. One reported baseline 
characteristics for the whole study group89 and 
the other did not appear to report any baseline 
conditions.88 
 
The six included trials were generally of poor 
methodological quality, and poorly reported 
(Table 8). Only one reported adequate methods of 
randomisation to treatment groups.85 Davenport 
and colleagues85 stratified their participants by age 
and then randomised them using a blinded phone- 
in process. Four of the six trials did not describe 
randomisation techniques.12,86,88,89  Johnston and 
colleagues90 reported that five participants were 
reallocated from the oestrogen group to receive 
rhGH: it is unclear when this occurred and 
therefore method of randomisation was judged 
inadequate. 
 
Concealment of treatment allocation was also 
judged to be adequate in the Davenport trial, 
and ‘unknown’ in the remaining five. In the 
Gravholt89 study it is unclear how allocation to 
treatment groups had taken place. The study had 
only nine participants, and these were simply 
reported to have been given the treatment regimen 
sequentially and in random order. 
 
Blinding of participants, those who provide care 
and those who assess outcomes can protect against 
the reporting of some outcomes being affected 
by the knowledge of which treatment is being 
received. Blinding of outcome assessors, care 
providers and patients was judged ‘unknown’, 
‘inadequate’ or ‘partial’ in five out of the six trials; 
Gravholt and colleagues89 adequately blinded their 
patients by administering placebo in place of both 
rhGH and the oestradiol. 
 
None of the six studies included here used an 
ITT analysis. This kind of analysis can protect 
the study from attrition bias, where, for example, 
participants withdrawing from the treatment arm 
could represent AE or treatment failure. 
 
Growth outcomes 
Four out of the six included studies reported 
growth outcomes, and key measures are shown 
in Table 9. Please see Appendix 4 for additional 
outcomes. Neither of the studies by Gravholt and 
colleagues88,89 reported growth outcomes. 
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TABLE 9 Growth outcomes for TS studies 
 
Study Outcomes (mean ± SD) GH Control p-value 
Stephure and CGHAC86 Height (cm) 147.5 ± 6.1 141.0 ± 5.4 < 0.001 
Protocol completion, rhGH Change in height (cm) 28.3 ± 8.9 19.0 ± 6.1 < 0.001 
0.30 mg/kg/week (n = 61) vs no     treatment (n = 43) HtSDS (age-specific turner) 1.4 ± 1.0 0.2 ± 0.9 < 0.001 
 HtSDS (adult Turner) 0.7 ± 0.9 –0.3 ± 0.8 < 0.001 
 Change in HtSDS (age-specific Turner) 1.6 ± 0.6 0.3 ± 0.4 < 0.001 
Stephure and CGHAC86 Height (cm) 149.0 ± 6.4 142.2 ± 6.6 < 0.001 
Addendum follow-up, rhGH Change in height (cm) 30.3 ± 8.3 21.6 ± 6.2 < 0.001 
0.30 mg/kg/week (n = 40) vs no     treatment (n = 19) HtSDS (age-specific Turner) 0.9 ± 0.9 –0.1 ± 1.0 < 0.001 
 HtSDS (adult Turner) 0.9 ± 0.9 –0.1 ± 1.0 < 0.001 
 Change in HtSDS (age-specific Turner) 1.1 ± 0.5 0.0 ± 0.5 < 0.001 
Davenport et al.85 Height (cm) 99.5 ± 7.6 91.9 ± 7.2 < 0.0001 
GH (n = 41) vs no treatment HtSDS –0.34 ± 1.10 –2.16 ± 1.22 < 0.0001 
(n = 37); 2 years      GV (cm/year) 8.4 ± 1.6 5.5 ± 1.8 < 0.0001 
 GV SDS 0.70 ± 1.11 –1.63 ± 1.29 < 0.001 
Johnston et al.90 Change in HSDS in first year +0.7 (0.7) +0.4 (0.9) < 0.05 
rhGH 28–30 IU/m2/week (n = ?)a     
vs estrogen (n = ?);a 1 year     
Quigley et al.12 GV 0–18 months (cm/year) 1: 6.6 ± 1.12 4.2 ± 1.1 < 0.001 
GH 1, rhGH 0.27 (n = 45); GH  2: 6.8 ± 1.1   
2, rhGH 0.36 (n = 49) vs placebo     
(n = 41); 1 year     
a  ‘n’ unclear for this outcome. 
 
 
 
Two studies reported height at the end of the 
study: both found a statistically significant 
difference between the treated and untreated 
groups  (p < 0.0001).85,86 
 
Children in the treated group in the Stephure 
study86 were 6.5 cm taller on average than the 
untreated group at protocol completion. However, 
there was a 3-cm difference between the groups’ 
mean heights at baseline. Mean change from 
baseline was therefore 9.3 cm more in the rhGH 
than in the untreated group at the end of protocol 
completion (28.3 ± 8.9 vs 19.0 ± 6.1). 
 
The Stephure study86 also reported an addendum 
follow-up (approximately 10 years since 
randomisation), which included 66% of rhGH 
patients and 44% of the control group. The treated 
group’s mean FH was 149.0 ± 6.4 cm compared with 
142.2 ± 6.6 cm in the untreated group (p < 0.001), 
i.e. a difference of 6.8 cm. Mean change from 
baseline to FH was 8.7 cm more in the rhGH than 
in the untreated group. 
In the Davenport study85 the mean difference was 
7.6 cm (height at study end was 99.5 ± 7.6 cm in 
the treated group vs 91.9 ± 7.2 cm in the untreated 
group, p < 0.0001). 
 
Height standard deviation score is also reported 
by Davenport and colleagues85 and Stephure  
and CGHAC.86 Both authors report statistically 
significant differences between groups for this 
outcome, with the treated groups both achieving 
higher HtSDS. In the Stephure study86 the HtSDS 
is reported for the age-specific Turner population 
and for the adult Turner population. 
 
The difference in change in height was statistically 
significant between groups in the two studies that 
reported it. Stephure and colleagues86  report 
a change in height at protocol completion of 
28.3 ± 8.9 cm versus 19 ± 6.1 in the untreated group, 
p < 0.001. Davenport and colleagues85  reported a 2-
year height gain of 20.4 ± 3.3 cm (treated group) 
versus 13.6 ± 3.5 cm (untreated group), p < 0.001 
(not shown in table). Change in HtSDS in both the 
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Stephure86 and Johnston90 studies was higher in the 
treated than untreated group: 1.6 ± 0.6 (treated) 
versus 0.3 ± 0.4 (untreated), p < 0.001, at protocol 
completion in the Stephure study; 0.7 (0.7) versus 
0.4 (0.9), p < 0.05, in the Johnston study90 after 
1 year. 
 
Growth velocity was statistically significantly 
greater in the treated groups in the Stephure,86 
Davenport85   and Quigley12   studies. Davenport and 
colleagues85  reported GV at the end of the first 
and second year. Although this was greater in the 
treated groups at both times, GV fell in the second 
year in both groups: 8.4 ± 1.6 cm/year (treated 
group) versus 5.5 ± 1.8 (untreated). Additionally, 
Davenport and colleagues85 measured GV SDS 
at the end of the first and second years. Again, 
this was greater in the treated group at the end 
of the first year: 1.75 ± 1.25 versus 0.8 ± 0.95, p 
< 0.001, but was reduced by the end of the second 
year in both groups: 0.70 ± 1.11 (treated) versus 
–1.63 ± 1.29 (untreated), p < 0.001. Quigley and 
colleagues reported GV after 18 months. This was 
broadly similar in both the lower- and higher- 
rhGH-dose groups: both were significantly higher 
than that in the placebo (Pla) group: 6.6 ± 1.1 
(GH 0.27/Pla group) versus 6.8 ± 1.1 (GH 0.36/Pla 
group) versus 4.2 ± 1.1 (Pla/Pla group), p < 0.001 
compared with placebo. 
 
Bone age differences for the younger participants 
in the Davenport study were statistically 
significant:85 the GH-treated group at 2 years 
had a mean BA of 4.24 ± 1.35 versus 3.38 ± 1.11 
in the untreated group, p = 0.0033. Davenport 
and colleagues85 also reported BA/chronological 
age; this is lower in the treated group, and the 
difference was statistically significant: 0.64 ± 0.80 
versus 0.21 ± 0.96, p < 0.001. 
 
Body composition outcomes 
Three of the TS studies reported body composition 
outcomes, and these are presented in Table 10. One 
of the studies reported weight, weight standard 
deviation score (WtSDS) and BMI,85 whereas the 
remaining two reported FM, bone mineral content 
(BMC) and LBM for arms, legs, trunk and head, 
and as a total.88,89  Please see Appendix 4 for BMC 
results. 
 
Weight and WtSDS were significantly greater in 
the group receiving rhGH than in the untreated 
group in the Davenport study,85 reported as 
16.62 kg ± 2.86 versus 13.81 kg ± 2.50, and 
0.20 ± 1.06 versus –1.37 ± 1.36, respectively 
(p < 0.0001 for both comparisons). 
 
Two studies considered FM, BMC and LBM.88,89 
In both studies the total FM was greater in the 
untreated group than in the treated group, 
and LBM was slightly higher in treated than in 
untreated patients (Table 10). The differences 
between groups were of borderline statistical 
significance in one study88 but no p-values were 
presented in the other study.89 
 
Biochemical markers 
Three of the studies85,88,89  reported biochemical 
outcomes. Key results are shown in Table 11 – other 
outcomes are in Appendix 4. 
 
Two studies reported mean levels of IGF-1 at  
end of treatment. In both studies IGF-1 levels 
were statistically significantly higher in the group 
receiving rhGH. One study88   reported values of 
380.5 ± 116.3 versus 179.8 ± 79.4 in the treated and 
untreated groups, respectively (p < 0.0005). The 
other89  reported 661 ± 192 versus 288 ± 69 (p-value 
not reported) for treated and untreated patients, 
respectively. 
 
Davenport and colleagues85  reported that IGF-1 
SDS was significantly greater in the treated group 
(1.26 ± 0.72 vs –0.69 ± 0.84, p < 0.0001). Change in 
IGF-1 SDS from baseline to year 2 was 1.53 ± 0.93 
versus –0.09 ± 0.87 in the treated and untreated 
groups, respectively. 
 
One Gravholt study88 reported that IGFBP-3 levels 
were statistically significantly higher in the treated 
group than in the untreated group (5982 ± 1557 
vs 4344 ± 787, respectively, p = 0.002). The other 
study by Gravholt and colleagues89 reported  
higher IGFBP-3 SDS values in treated patients,  
but no clear p-value was reported.89 Davenport and 
colleagues85 found that IGFBP-3 SDS was higher 
in their treated group (0.97 ± 0.94 vs –1.12 ± 1.13, 
p  < 0.0001). 
 
Fasting glucose and fasting insulin were reported in 
the two studies by Gravholt and colleagues,88,89 both 
of which were raised in the groups receiving GH in 
each study. Mean glucose (nmol/l) was 4.28 ± 0.5988 
and 4.46 ± 0.4089  in the treated groups, versus 
4.02 ± 0.4488  and 4.04 ± 0.4789  in the untreated 
groups. This difference reached statistical 
significance in the first study,88  p = 0.046. Mean 
fasting insulin levels in the first Gravholt study88 
were 17.17 ± 8.30 versus 8.58 ± 4.27, p = 0.007. 
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TABLE 10 Body composition outcomes for TS studies 
 
 
Study 
Outcomes 
(mean ± SD) 
 
GH 
 
Control 
 
p-value 
Davenport et al.85 Weight (kg) 16.62 ± 2.86 13.81 ± 2.50 < 0.0001 
GH (n = 41) vs no treatment (n = 37); WtSDS 0.20 ± 1.06 –1.37 ± 1.36 < 0.0001 
2 years      BMI (kg/m2) 16.72 ± 1.70 16.24 ± 1.29 0.1724 
Gravholt et al.88 FM total (g/kg) 231.0 ± 49.5 247.8 ± 58.1 0.04 
GH 0.1 IU/kg/day vs placebo; 2 LBM total (g/kg) 725.4 ± 44.8 710.5 ± 54.6 0.05 
monthsa     
Gravholt et al.89 FM total (g/kg) 274.5 ± 55.5 312.9 ± 74.7 nr 
GH 1.3 mg/day vs placebo; 2 monthsb LBM total (g/kg) 692.8 ± 55.5 655.2 ± 73.7 nr 
nr, not reported. 
a  Crossover study, total n = 12. 
b  Crossover study, total n = 9. 
 
 
TABLE 11 Biochemical markers in TS studies 
 
 
Study 
Outcomes 
(mean ± SD) 
 
GH 
 
Control 
 
p-value 
aDavenport et al.85 IGF-1 SDS 1.26 ± 0.72 –0.69 ± 0.84 < 0.0001 
GH (n = 41) vs no treatment (n = 37); 2 IGFBP-3 SDS 0.97 ± 0.94 –1.12 ± 1.13 < 0.0001 
years      ∆IGF-1 SDS 1.53 ± 0.93 –0.09 ± 0.87 nr 
Gravholt et al.88 IGF-1 (µg/l) 380.5 ± 116.3 179.8 ± 79.4 < 0.0005 
GH 0.1 IU/kg/day vs placebo; 2 monthsa IGFBP-3 (µg/l) 5982 ± 1557 4344 ± 787 0.002 
Gravholt et al.89 IGF-1 (µg/l) 661 ± 192 288 ± 69 nr 
GH 1.3 mg/day vs placebo; 2 months IGFBP-3 (µg/l) 5157 ± 741 4146 ± 573 Unclear 
a  Baseline data missing for eight control subjects and three GH treated subjects; end point data missing for four control 
subjects and seven rhGH subjects. 
 
 
Quality of life 
None of the TS studies reported QoL as an 
outcome. 
 
Adverse events 
Adverse events were reported by only four of the 
studies.12,85,86,90 Details presented by three of the 
studies are shown in Table 12 (the fourth study did 
not present figures90). 
 
The group receiving GH in the Stephure study86 
experienced a statistically significantly greater 
level of all AEs (where statistical significance was 
reported), with the exception of goitre, and one 
instance of death from ruptured aortic aneurysm, 
which occurred in the untreated group. The one 
case of elevated transamine levels in the treated 
group led to withdrawal from the study. 
 
 
Davenport and colleagues85 report the same level of 
serious adverse events (SAEs) for both the treated 
and untreated groups. For treatment-emergent  
AEs, defined as ‘events or conditions that began or 
worsened after study entry’, the results were similar. 
There were 42 (93%) in the treated group and 43 
(98%) in the untreated group. Most treatment- 
emergent AEs were ear disorders. 
 
Quigley and colleagues12 found a significant 
difference in levels of occurrence or worsening 
of otitis media between the treated group (29%) 
and the control group (13%), p = 0.037. Ear pain 
and ear disorder were reported as not differing 
between groups. Three girls discontinued rhGH 
due to hypertension, ulcerative colitis and brain 
tumour. The authors stated that these were not 
directly related to GH. Overall, AEs were not 
presented separately for the groups; however, 23 
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TABLE 12 Adverse events for TS studies 
 
Study AE (n) GH Control p-value 
Stephure and CGHAC86 Surgical procedures 37 17 0.005 
GH (n = 74) vs no treatment Otitis media 35 17 0.014 
(n = 64) Ear disorder 15 4 0.024 
 Joint disorder 10 2 0.036 
 Respiratory disorder 8 1 0.037 
 Sinusitis 14 4 0.041 
 Goitre 0 4 0.004 
 Death (ruptured aortic aneurysm) 0 1 nr 
 Elevated transamine levels 1 0 nr 
 Intracranial hypertension 1 0 nr 
Davenport et al.85 Serious AEs, n (%) 4 (9) 4 (9) nr 
GH (n = 45) vs no treatment Treatment-emergent AEs, n (%) 42 (93) 43 (98) nr 
(n = 44), 2 years     
Quigley et al.12 Otitis media (occurrence/worsening), n (%) 54/186 (29%) 6/46 (13%) 0.037 
nr, not reported. 
 
 
five were reported to have accidentally overdosed 
on the study drug. Five further events described 
as possibly related to the study drug were 
hypertension (two), surgical procedures (two) and 
scoliosis  (one). 
 
Five participants were reallocated from the group 
receiving estrogen to rhGH after concerns over 
early breast development in the study by Johnston 
and colleagues.90 Seven patients developed 
‘coincidental disorders’ not severe enough to 
warrant treatment discontinuation. The authors 
reported that compliance problems led to the 
withdrawal of four patients, but no details were 
given. It is unclear which treatment groups these 
latter events occurred in. 
 
Summary 
Six trials examining the effectiveness of GH for 
growth disturbance in patients with TS met the 
inclusion criteria for the review. 
 
The reporting and methodological quality 
of the studies was poor. Of the six included 
studies, one reported adequate randomisation to 
treatment groups,85 one study described adequate 
concealment of treatment allocation85  and one 
adequately blinded the patient to treatment by 
administering placebo.89 None of the included 
trials used an ITT analysis. 
Children in the rhGH group in the Stephure86  
study grew an average of 9.3 cm more from baseline 
than those in the untreated group. In a study of 
younger children85 the difference was 7.6 cm. Both 
of these were statistically significant results. In the 
same two studies85,86 the groups receiving rhGH 
achieved a significantly higher HtSDS. 
 
Change in height and change in HtSDS were 
statistically significantly greater in the groups 
treated  with  rhGH.85,86,90 
 
Growth velocity was greater in the treated groups 
in three studies that reported this outcome,12,85,86 
although this was greater in the first year and fell 
in the second year in both treatment groups where 
this was reported separately.85 
 
One study86 found a significant difference in  
BA between groups, being higher in the treated 
patients. 
 
Fat mass and LBM were reported in two studies.88,89 
In both, the total FM was at a lower level in the 
treated groups, compared with those untreated, 
and LBM was higher in the treated groups 
compared with untreated. There was no statistically 
significant difference in BMI between treated and 
untreated girls in one study.85 
 
The IGF-1 levels were substantially higher in 
the treated groups in the studies reporting this 
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outcome.88,89 IGF-1 SDS was also significantly 
higher in the group receiving GH.85 Levels of 
IGFBP-3 and IGFBP-3 SDS were also found to be 
higher in children treated with GH.85,88,89 
 
Levels of fasting glucose and fasting insulin were 
both raised in the treated groups in two studies.88,89 
 
There were variable levels of detail in the reporting 
of AEs across the six studies. Two studies did not 
discuss these.88,89 In those studies that did, no clear 
picture emerges. One found greater levels of AEs in 
the treated group,86 one found similar levels across 
groups,85 one found significantly higher levels of or 
worsening of otitis media, and one reported seven 
patients with ‘coincidental disorders’ and four 
withdrawals due to compliance problems, but gave 
no further details. 
 
 
Prader–Willi syndrome 
Quantity and quality of research 
available 
Eight RCTs in 13 publications of the clinical 
effectiveness of rhGH in patients with PWS met 
the inclusion criteria for this review.22,91–102  Their 
key characteristics are shown in Table 13 – see 
Appendix 4 for further details. 
 
It was not possible to perform any meta-analysis of 
outcomes from the PWS studies due to variation in 
the trials’ participants’ ages, dosing calculations, 
and methods of presenting results. The included 
studies had well-matched patient groups, whose 
baseline characteristics were generally similar 
in the treated and untreated groups. Median 
baseline HtSDS was lower in the rhGH group 
than in the untreated group in the study reported 
by both Festen and colleagues94 and by de Lind 
van Wijngaarden and colleagues,93 although the 
interquartile ranges (IQRs) were similar [–2.0 (–3.1 
to –1.7) versus –2.5 (–3.3 to –1.9), respectively]. 
Other exceptions were the crossover study by 
Haqq and colleagues,102 which presented baseline 
characteristics for the study population as a whole, 
and the study by Lindgren and colleagues,100,101 
which reported slightly lower baseline GV SDS in 
the rhGH group [–1.9 ± 2.0, range –6.4 to –0.9, vs 
–0.1 (SD not reported) range –1.7 to –2.71]. 
 
Five of the studies were RCTs, which compared 
1 mg/m2/day rhGH with no treatment for 122,92–
98  or 291,93,94  years. The study by Haqq and 
colleagues102 was a crossover RCT, which compared 
0.043 mg/kg/day of rhGH with placebo injections, 
with patients spending 6 months in each treatment 
arm. There does not appear to have been a 
washout phase between the two treatment phases, 
which could affect the generalisability of results. 
 
The doses used in the included studies reflect the 
various marketing authorisations for this drug 
(0.035 mg/kg body weight or 1.0 mg/m2 BSA), with 
1 IU of rhGH being equivalent to approximately 
0.33 mg/kg. The study reported by both de Lind 
van Wijngaarden and colleagues93 and Festen and 
colleagues94 reported results separately for infants 
and children. Two RCTs reported results for infants 
and toddlers aged between 1 and 2.5 years.22,92,97,98 
The five remaining trials were in children aged 
between approximately 6 and 10 years old. 
The studies were generally small, randomising 
between 14102  and 5495,96  children. The study 
reported by both de Lind van Wijngaarden and 
colleagues93 and Festen and colleagues94 had a 
total of 91 participants, but as children and infants 
were randomised separately, the randomised 
comparisons were of rhGH versus no treatment 
within two smaller groups (42 infants and 49 
children). This was the only study to report a 
sample size/power calculation,93,94 and it is not clear 
whether the other studies were adequately powered 
to detect a difference between treatment groups. 
 
With the exception of the two RCTs by Festen and 
colleagues,91,92 the studies did not clearly state 
which of their reported outcomes were primary or 
secondary measures of effect. Seven of the eight 
trials reported measures of body composition. The 
two RCTs by Festen and colleagues91,92 focused 
on body composition and biochemical markers, 
and did not report any measure of change in 
height. The other six studies all reported GV 
SDS or an indicator of linear GV.102  IGF-1 and 
other biochemical markers were reported by five 
RCTs.22,92–99 
 
One RCT was reported in three papers, by Carrel 
and colleagues,22 Myers and colleagues97 and 
Whitman and colleagues.98 The most complete data 
were reported by Carrel and colleagues,22 and these 
data are included in the tables in this section. 
 
The included studies were generally poorly 
reported (Table 14) and lacked information on 
method of randomisation or concealment of 
allocation. It is possible that selection bias could 
have affected the trials if they were not properly 
randomised, but there is insufficient information 
provided on which to make such a judgement. The 
trial by Haqq and colleagues102 was a crossover 
25 
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TABLE 13 Characteristics of included PWS studies 
 
Duration of 
Total randomised randomised 
Reference Intervention Control group and withdrawals treatment 
Carrel et al. 2004,22 rhGH 1 mg/m2/day No treatment n = 32 1 year 
Myers et al. 2007,97 and   n = 15 n = 14 Sample attrition: n = 3a 
Whitman et al. 200498 
Mean age ± SD (months): Mean age ± SD 
13 ± 8 (months):15 ± 0 
Carrel et al. 199995 and   GH 1 mg/m2/day No treatment n = 54 1 year 
Myers et al. 199996 n = 35 n = 19 No withdrawals 
Mean age (years): 9.8 Mean age (y): 10.0 
 
de Lind van 1 mg/m2/day No treatment n = 104 enrolled 1 year for 
Wijngaarden et al. Infants (< 3.5 years): n = 19   Infants (< 3.5 years): n = 19   Sample attrition: 4 infants, 2 years 
200993 and Festen et  infants and 5 children for children 
al. 200894 Children (> 3.5 years): Children (> 3.5 years): n = 23 n = 21 
Median (IQR) age: infants Median (IQR) age: infants 
2.0 (1.6–3.1), children 6.8 1.3 (1.0–2.8); children 5.9 
(5.4–8.8) (4.7–7.4) 
Festen et al. 200791 GH 1 mg/m2/day No treatment n = 20 2 years 
n = 10 n = 10 Withdrawals: none 
Median age (IQR) (years): Median age (IQR) (years): 
6.2 (5.1–71) 5.8 (4.9–7.8) 
 
 
Festen et al. 200792 GH 1 mg/m2/day No treatment n = 43 12 months 
n = 15 n = 14 Sample attrition: n = 14 
Median (IQR) age, yr: 2.3 Median (IQR) age, year: 
(1.7–3.0) 1.5 (1.2–2.7) 
Haqq et al. 2003102 GH 0.043 mg/kg/day Placebo 14 randomised Crossover 
n = 6 n = 6 Sample attrition: n = 2 RCT, 6 months 
in each arm 
Overall mean age ± SD Overall mean age ± SD 
(years): 9.7 ± 3.3 (years): 9.7 ± 3.3 
Hauffa 199799 GH: 0.15 IU/kg/day No treatment N = 19 1 year 
n = 8 n = 9 Sample attrition: n = 3 
Mean age ± SD (years): Mean age ± SD (years): 
8.25 ± 2.4 7.56 ± 2.0 
Lindgren et al. 1998101 GH 0.1 IU/kg/day No treatment Total n = 29 1 year 
and 1997100 n = 15 n = 14 Sample attrition: n = 2 
Mean age (range) (years): Mean age (range) (years): 
6.8 (3.6–11.9) 6.4 (3.3–11.7) 
a  Difference between patient numbers in Whitman97 and Carrel22 = 3. 
 
 
study, and did not report baseline characteristics 
separately for the two groups. The other studies 
reported baseline characteristics, which indicated 
that patients in the two treatment groups were 
comparable at the start of the study. With the 
exception of the crossover trial by Haqq and 
colleagues,102 which had a placebo-injection group, 
the studies were open label, with the comparator 
groups receiving no treatment. Although this  
could have allowed a degree of bias in reporting 
and assessing results, measurement of objective 
outcomes, such as height gained, is less likely to 
be open to bias. Only two of the studies reported 
results on an ITT basis,91,96  so attrition bias could 
have affected the remaining studies. 
 
The outcome measures for the included studies 
are shown in Tables 15–17. The p-values in the 
tables refer to between-group differences, as this 
is the comparison of interest for this report. Some 
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TABLE 14 Quality assessment of included PWS studies 
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1. Was the assignment to the Un 
treatment groups really random? 
2. Was the treatment allocation Un 
concealed? 
3. Were the groups similar at baseline   Rep 
in terms of prognostic factors? 
4. Were the eligibility criteria Ad 
specified? 
5. Were outcome assessors blinded Un 
to the treatment allocation? 
6. Was the care provider blinded? In 
7. Was the patient blinded? In 
8. Were the point estimates and Ad 
measure of variability presented for 
the primary outcome measure? 
 
9. Did the analyses include an ITT In 
analysis? 
10. Were withdrawals and dropouts In 
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Ad, adequate; In, inadequate; Not rep, not reported; Rep, reported; Un, unknown. 
 
 
of the studies reported statistical significance in 
change from baseline for each of the treatment 
groups individually, but not for between-group 
comparisons. To avoid confusion with the between- 
group comparison p-values, such results have not 
been included in the tables below and are not 
discussed in the text. The full data extraction tables 
in Appendix 4 include any statistical significance 
for change from baseline for individual treatment 
groups without between-group comparisons. 
 
Growth outcomes 
Changes in height and other growth outcome 
measures are shown in Table 15. The infants in 
the study by Carrel and colleagues22 who received 
rhGH for a year grew an average of 6.2 cm more 
than those in the untreated group (p < 0.001). 
None of the other studies reported change in 
height as an outcome measure. 
Two studies reported a statistically significant 
difference in HtSDS at end of treatment between 
treated and untreated patients.93–96  Treated 
patients in the study reported by both Carrel 
and colleagues95 and Myers and colleagues96 
had a mean HtSDS of –0.6 ± 1.2 compared with 
–1.6 ± 1.2 in the untreated group (p < 0.01). The 
studies reported by de Lind van Wijngaarden and 
colleagues93 and by Festen and colleagues94 also 
reported statistically significant improvements 
in height for rhGH-treated infants and children 
compared with unmatched controls. The rhGH- 
treated infants in their study had a median HtSDS 
of –0.9 compared with –1.8 in the untreated 
patients (p = 0.003). This reflected a change from 
baseline HtSDS of +1.2 for treated infants and –0.2 
for untreated infants (p < 0.0001). After 2 years 
of treatment with rhGH, children had a median 
HtSDS of –0.5 compared with –2.6 in untreated 
children (p < 0.001).93 
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TABLE 15 Growth outcomes for PWS studies 
 
Study Outcomes (mean ± SD) GH Control p-value 
Carrel et al.22 
rhGH 1 mg/m2/day (n = 15) vs. no 
treatment (n = 14); 1 year 
Change in height (cm) 
Height SDS 
15.4 ± 2.3 
–0.2 ± 1.5 
9.2 ± 3.2 
–1.5 ± 0.7 
< 0.001 
nr 
 
 
Carrel et al.95 and Myers et 
GV SDS 5.0 ± 1.8 1.2 ± 1.4 nr 
Height SDS –0.6 ± 1.2 –1.6 ± 1.2 < 0.01 
al.96 
GH 1 mg/m2/day (n = 35), vs. no 
Mean GV (cm/year) 10.1 ± 2.5 5.0 ± 1.8 < 0.01 
treatment (n = 19); 1 year 
de Lind van Wijngaarden et 
al.,93 Festen et al.94 (infants) 
rhGH 1 mg/m2 (n = 19) vs. no 
treatment (n = 19); 1 year 
de Lind van Wijngaarden et 
al.,93 Festen et al.94 (children) 
rhGH 1 mg/m2 (n = 23) vs. no 
treatment (n = 21); 2 years 
Festen et al.91 
rhGH 1 mg/m2/day (n = 10) vs. no 
treatment (n = 10); 2 years 
Festen et al.92 
rhGH 1 mg/m2/day (n = 15) vs. no 
treatment (n = 14); 1 year 
Haqq et al.102 
rhGH 0.043 mg/kg/day (n = 12) vs. 
placebo (n = 12); 6 months 
Hauffa99 
rhGH 0.15 IU/kg/day (n = 7) vs. no 
treatment (n = 9); 1 year 
Lindgren et al.101 and 
Lindgren et al.100 
rhGH 0.1 IU/kg/day (n = 15) vs. no 
treatment (n = 12); 1 year 
Mean GV SDS 4.6 ± 2.9 –0.7 ± 1.9 < 0.01 
HtSDS median (IQR) –0.9 (–1.6 to –0.1) –1.8 (–3.5 to –1.4) 0.003 
∆HtSDS median (IQR) 1.2 (1.0 to 1.6) –0.2 (–0.6 to 0.3) < 0.0001 
 
 
HtSDS median (IQR) –0.5 (–0.8 to 0.0) –2.6 (–3.4 to –2.3) < 0.0001 
∆HtSDS median (IQR) 1.4 (1.3 to 1.8) –0.1 (–0.4 to 0.1) < 0.0001 
 
 
Height SDS median (IQR) –0.6 (–0.9 to –0.3) –3.0 (–3.5 to –1.8) nr 
 
 
 
Height SDS median (IQR) –1.6 (–2.1 to –0.8) –2.3 (–3.9 to –1.5) nr 
 
 
 
HtSDS –1.2 ± 1.1 –1.3 ± 1.3 nr 
GV (cm/year) 7.5 ± 3.5 4.5 ± 2.7 < 0.05 
 
Height SDS 1.07 –0.25 nr 
HV SDS 5.5 –2.3 0.0012 
HtSDS mean (range) –0.4 (–2.7 –1.9) –1.8 (–5.1 –0.2) nr 
GV (SDS) mean ± SD (range) 6.0 ± 3.2 (1.4–11.9) –1.4 (–3.2 –0.3) nr 
 
 
 
 
Festen and colleagues91  reported that the difference 
between the two groups was statistically significant 
at year 1 (year 1 HtSDS –1.3 vs –2.8, p < 0.01). 
At year 2, the difference between the two groups 
was even greater (–0.6 compared with –3.0 in the 
treated and untreated groups, respectively), but no 
p-value was reported.91  The other five studies all 
reported that HtSDS values were higher in treated 
than in untreated children, but did not report 
whether or not differences between groups were 
statistically significant. 
 
The five studies that used GV as an outcome 
measure all reported faster growth in the treated 
group than in the untreated group, although 
statistical significance for differences between 
groups was only reported for three of these. The 
mean GV in the studies reported by Carrel and 
 
 
 
 
colleagues95 and by Myers and colleagues96 was 
twice as fast in the treated children as in the 
untreated children (10.1 vs 5.0, p < 0.01). The 
corresponding mean GV SDS values were 4.6 in the 
treated children and –0.7 in the untreated children 
(p < 0.01), indicating faster than average growth in 
the treated group and slower than average growth 
in the untreated patients. Similarly, Hauffa and 
colleagues99 reported a positive GV SDS for treated 
children and a negative one for untreated children 
(5.5 vs –2.3, p = 0.0012). Haqq and colleagues102 
calculated GV that was 3 cm/year faster in patients 
receiving rhGH than in patients in the placebo arm 
(7.5 vs 4.5, p < 0.05). 
 
Two of the included studies reported BA as an 
outcome measure. There was no statistically 
significant difference in BA at follow-up between 
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Study 
Outcomes 
(mean ± SD) 
 
GH 
 
Control 
 
p-value 
Carrel et al.22 Mean % body fat 23.2 ± 8.9 32.7 ± 8.8 0.03 
rhGH 1 mg/m2/day (n = 15) vs no treatment Change in body –4.8 ± 5.7 +4.1 ± 4.6 0.001 
(n = 14); 1 year fat (%)    
 Change in LBM 3.6 ± 0.5 1.8 ± 0.7 < 0.001 
 (kg)    
Carrel et al.,95 Myers et al.96 Body fat (%) 38.4 ± 10.7 45.8 ± 8.8 < 0.01 
GH 1 mg/m2/day (n = 35), vs no treatment Lean mass (kg) 25.6 ± 4.3 21.7 ± 5.0 < 0.01 
(n = 19); 1 year      BMI (kg/m2) 23.7 ± 6.3 25.2 ± 8.9 n/s 
de Lind van Wijngaarden et al.,93 BMI (kg/m2) 16.3 (15.7 to 18.2) 16.4 (15.4 to 19.8) nr 
Festen et al.94 (infants) BMI (SDS) 0.3 (–0.1 to 1.6) 0.3 (–0.6 to 1.6) 0.72 
rhGH 1 mg/m2 (n = 19) vs no treatment     
(n = 19); 1 year median (IQR)     
 
de Lind van Wijngaarden et al.,93 
 
BMI (kg/m2) 
 
17.5 (16.1 to 21.1) 
 
19.1 (17.8 to 20.8) 
 
Festen et al.94 (children)a BMI (SDS) 1.1 (–0.2 to 1.7) 1.4 (1.1 to 1.6) 0.19 
rhGH 1 mg/m2 vs no treatment; 2 years     
median (IQR) Fat % (SDS) 1.9 (0.7 to 2.3) 2.4 (2.1 to 2.7) < 0.001 
 Fat (SDS) 1.1 (0.6 to 2.0) 4.5 (0.9 to 2.0) < 0.01 
 LBMage  (SDS) –0.1 (–1.3 to 0.6) –2.5 (–3.8 to –1.4) < 0.001 
 LBM –1.9 (–2.4 to –1.4) –2.3 (–2.7 to –1.3) < 0.05 
 
HtSDS 
   Festen et al.91 BMI (kg/m2) 16.3 (15.8 to 19.0) 18.5 (17.5 to 20.6) < 0.05 
rhGH 1 mg/m2/day (n = 10) vs no treatment BMI SDS 0.4 (–0.3 to 1.1) 1.2 (0.9 to 1.5) < 0.05 
(n = 10); 2 years median (IQR) LBM SDS –1.2 (–1.7 to –1.1) –2.8 (–3. to 1.9) nr 
 Fat % SDS 1.7 (0.9 to 1.9) 2.1 (1.9 to 2.4) nr 
Festen et al.92 BMI (kg/m2) 16.4 (15.2 to 18.5) 15.5 (14.9 to 17.6) nr 
rhGH 1 mg/m2/day (n = 15) vs no treatment BMI SDS 0.3 (–0.9 to 1.8) –0.4 (–0.8 to 1.3) nr 
(n = 14); 1 year median (IQR) Body fat (%) 22.5 (11.3 to 33.2) 22.8 (19.5 to 32.9) nr 
 LBM (%) 74.8 (63.7 to 82.3) 73.6 (61.6 to 75.9) nr 
Haqq et al.102 BMI (kg/m2) 31.2 ± 8.9 32.8 ± 9.7 < 0.05 
rhGH 0.043 mg/kg/day (n = 12) vs placebo BMI (SDS) 2.4 ± 0.5 2.5 ± 0.6 nr 
(n = 12); 6 months      Body fat (%) 49.7 ± 5.8 54.1 ± 5.6 < 0.05 
 FM (kg) 26.1 ± 12.8 29.1 ± 14.1 < 0.05 
 Lean mass (kg) 24.1 ± 8.8 22.4 ± 8.5 < 0.05 
Lindgren et al.,101 Lindgren et al.100 BMI (SDS) 2.0 (–2.4 to 6.7) 2.5 (0.1 to 6.1) nr 
rhGH 0.1 IU/kg/day (n = 15) vs. no Body fat (%) 30.9 ± 11.4 38.2 ± 9.1 nr 
treatment (n = 12)     
n/s, not significant. 
a  ‘n’ is unclear for many of these outcomes. 
 
 
 
 
 
 
patients in the treated and untreated groups in  
the study reported by both Carrel and colleagues95 
and by Myers and colleagues.96 Lindgren and 
colleagues100,101  reported similar change from 
baseline in both groups (1.4 in the treated group, 
1.5 in the untreated group), but did not report 
whether or not there was any statistical significance 
to their results. 
Body composition 
Seven of the trials reported changes in body 
composition, as shown in Table 16.22,91–94,100–102  The 
trial by Hauffa and colleagues99 did not report any 
results but stated that there were no significant 
within- or between-group changes for BMI, 
skinfold thickness, waist or hip circumference. 
 
TABLE 16 Body composition outcomes for PWS studies 
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Four of the trials reported a statistically 
significantly lower percentage of body fat in 
patients treated with rhGH than in those with  
no treatment or placebo. In the trial reported by 
Carrel and colleagues22   mean percentage body 
fat was 10% lower for treated patients than for 
untreated patients (p = 0.03). On average, treated 
patients in this trial experienced an approximately 
5% reduction in body fat, compared with an 
average 4% increase in the untreated patients’ body 
fat (p = 0.001). The other two trials that found a 
statistically significant difference reported that 
treated patients had approximately 4% (Haqq 
and colleagues102) or 7% (Carrel95  and Myers96) 
less body fat than those in the comparator group. 
De Lind van Wijngaarden and colleagues93 did 
not report percentage body fat for infants, but 
did report this outcome for the children in their 
study who were over 4 years of age (n = unclear). 
Children who received rhGH for 1 year had a 
median percentage body fat SDS of 1.5, compared 
with 2.3 in the control group (p < 0.001). After 
2 years of treatment, the SDS values were 1.9 
versus 2.4 for the treated and untreated groups. 
respectively (p < 0.001). 
 
Four trials reported that patients treated with rhGH 
had  statistically  significantly  higher  LBM93,95,96,102 
or a larger improvement in LBM than untreated 
patients.22  In the trial reported by Carrel and 
colleagues,22 treated patients’ LBM increased by 
1.8 kg more than the improvement seen in the 
untreated group (3.6 vs 1.8 kg, p < 0.001). Treated 
patients in the other two studies had approximately 
2 kg102  or 4 kg95,96  more LBM than their untreated 
counterparts (p < 0.05 and p < 0.01, respectively). 
De Lind van Wijngaarden and colleagues93  
reported that change in trunk LBM was statistically 
significantly better for treated than for untreated 
infants (1.7 vs 0.7, respectively). For children, 
they reported SDS for LBM adjusted for age and 
height, as well as change in trunk LBM. All of these 
outcomes were statistically significantly better for 
treated children than for untreated children after 
both 1 and 2 years of treatment. 
 
Six of the studies reported BMI, with mixed results. 
Festen and colleagues91  reported a BMI of 16.1 at 
year 1 for treated patients and 18.5 for untreated 
patients (p < 0.05), with similar results at year 2. 
Haqq and colleagues102 also reported a statistically 
significant difference of 1.6 in BMI (31.2 vs 32.8 
for treatment phase vs placebo phase in a small 
crossover RCT, p < 0.05). By contrast, the RCTs 
reported by Carrel95 and Myers96 and by de Lind 
van Wijngaarden93 found no statistically significant 
difference between treated and untreated patients. 
Neither of the other RCTs that reported BMI gave 
a value for between-group statistical significance, 
and both treated and untreated patients had 
similar values.92,100,101 
 
There was no statistically significant difference 
in bone mineral density between treated and 
untreated patients in the study reported by Carrel 
and colleagues.22 No statistically significant 
differences in progression of scoliosis or onset of 
scoliosis in either infants or children were reported 
by de Lind van Wijngaarden.93 
 
Biochemical and metabolic 
markers 
The included studies reported a range of 
biochemical and metabolic markers, and key 
results are included in Table 17 – see Appendix 4 
for further outcomes. For conciseness, only the key 
outcomes of IGF-1, IGFBP-3, insulin and glucose 
are discussed in the narrative summary below. 
 
All of the RCTs reported IGF-1 values or IGF-1 SDS 
as an outcome measure, and found that levels were 
higher in rhGH-treated patients than in untreated 
children. Three studies reported that IGF-1 values 
were statistically significantly higher in rhGH- 
treated patients than in untreated patients.22,95,96,102 
Three studies reported that IGF-1 SDS values were 
statistically significantly higher in treated than in 
untreated patients.91–94 
 
The included studies had well-matched patient 
groups, whose baseline characteristics were 
similar in the treated and untreated groups. The 
only exception was the crossover study by Haqq 
and colleagues,102 which presented baseline 
characteristics for the study population as a whole, 
and the study by Lindgren and colleagues,100,101 
which reported slightly lower baseline GV SDS in 
the rhGH group [–1.9 ± 2.0, range –6.4 to –0.9, vs 
–0.1 (SD not reported) range –1.7 to –2.71]. 
 
Three of the RCTs reported IGFBP-3 values,93,95,96 
and these were higher in treated patients than in 
untreated patients. In the trial reported by Carrel95 
and Myers,96 patients treated with rhGH had a 
mean level of 3.5 mg/ml compared with 2.07 in the 
untreated patients (p < 0.01). Haqq and colleagues 
reported mean values of 6029 ng/ml in the treated 
patients and 4247 ng/ml in the untreated patients 
(p < 0.01).102 Treated children and infants in the 
study reported by de Lind van Wijngaarden and 
colleagues93 had higher IGFBP-33 values than 
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TABLE 17 Biochemical and metabolic markers for PWS studies 
 
 
Study 
Outcomes 
(mean ± SD) 
 
GH 
 
Control 
 
p-value 
Carrel et al.22 IGF-1 (ng/ml) 231 ± 98 51 ± 28 < 0.001 
rhGH 1 mg/m2/day (n = 15) vs no treatment     
(n = 14); 1 year     
Carrel et al.95 and Myers et al.96 IGF-1 (ng/ml) 522 ± 127 121 ± 52 < 0.01 
GH 1 mg/m2/day (n = 35), vs no treatment IGFBP-3 (mg/l) 3.5 ± 0.73 2.07 ± 0.45 < 0.01 
(n = 19); 1 year     
de Lind van Wijngaarden et al.93 and IGF-1 (ng/ml) 179.0 (119.5 to 241.0) 33.0 (22.5 to 47.8) nr 
Festen et al.94 (infants)  (n = 12) (n = 15)  
rhGH 1 mg/m2 (n = 19) vs no treatment IGF-1 SDS 2.5 (1.4 to 2.9) –2.6 (–4.1 to –0.7) < 0.0001 
(n = 19); 1-year median (IQR) IGFBP-3 (ng/ml) 2.2 (1.6 to 2.4) 0.9 (0.7 to 1.3) nr 
  (n = 12) (n = 12)  
 IGFBP-3 SDS 0.5 (0.0 to 1.2) –2.4 (–3.5 to –1.2) nr 
  (n = 12) (n = 12)  
de Lind van Wijngaarden et al.93 and IGF-1 (ng/ml) 424.0 (313.0 to 570.0) 92.0 (61.8 to 130.0) nr 
Festen et al.94 (children)a  (n = 20) (n = 16)  
rhGH 1 mg/m2 vs no treatment; 2-year IGF-1 SDS 2.4 (2.1 to 2.8) –1.6 (–2.5 to –1.0) < 0.0001 
median (IQR) IGFBP-3 (ng/ml) 2.8 (2.6 to 3.2) 1.5 (1.2 to 1.8) nr 
  (n = 20) (n = 16)  
 IGFBP-3 SDS 0.6 (0.3 to 1.1) –1.7 (–2.3 to –1.2) < 0.001 
  (n = 20) (n = 16)  
Festen et al.91 IGF-1 SDS year 2 2.3 (2.1 to 2.9) –2.0 (–2.7 to 1.0) < 0.001 
rhGH 1 mg/m2/day (n = 10) vs no treatment IGFBP-3 SDS 0.6 (0.4 to 1.1) –1.8 (–2.7 to –1.5) < 0.001 
(n = 10); 2-year median (IQR) year 2    
Festen et al.92 IGF-1 SDS 1.7 (0.1 to 2.5) –2.6 (–4.1 to –0.4) < 0.001 
rhGH 1 mg/m2/day (n = 15) vs no treatment IGFBP-3 SDS 0.4 (–0.3 to 1.1) –3.1 (–4.0 to –2.2) < 0.05 
(n = 14); 1-year median (IQR)     
Haqq et al.102 IGF-1 (ng/ml) 720 ± 379 232 ± 182 < 0.001 
rhGH 0.043 mg/kg/day (n = 12) vs placebo IGFBP-3 (ng/ml) 6029 ± 1311 4247 ± 1209 < 0.01 
(n = 12); 6 months     
Lindgren et al.101 and Lindgren et al.100 IGF-1 SDS 1.8 (–0.1 to 4.1) –1.4 (–2.9 to –0.3) nr 
rhGH 0.1 IU/kg/day (n = 15) vs no treatment     
(n = 12); 1 year     
a  n = unclear for IGF-1 SDS. 
 
 
 
untreated children, although no p-values were 
reported for between-group comparisons. 
 
The three studies that reported IGFBP-3 SDS 
found positive values in the treated children, 
with SDS of 0.492,93  and 0.5 (year 1) or 0.6  
(year 2).91,93  In comparison, untreated patients’ 
median scores were between –2.491,93  and –3.192 
in year 1 and between –1.793  to –1.891  in year 2. 
Differences between treated and untreated patients 
were statistically significant in all three studies 
(p < 0.05,92 p < 0.001,93 p < 0.00191). 
The RCT reported by Carrel and colleagues22 
reported that there was no statistically significant 
difference in fasting insulin levels between the 
treated and untreated infants in their study (5.6 vs 
5.7 µIU/ml, respectively). Two other studies91,95,96 
reported slightly higher insulin levels in treated 
patients, but did not report p-values. The study by 
Haqq and colleagues102   reported very similar levels 
in both treated and untreated patients. Glucose 
levels appeared to be similar in both treated and 
untreated patients in the two studies that presented 
this as an outcome, but neither study reported any 
p-values.91,102 
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Quality of life 
None of the included studies reported a measure of 
HRQoL. 
 
Adverse events 
None of the studies reported AEs in any detail. 
Neither of the studies reported by de Lind van 
Wijngaarden and colleagues93 and by Festen 
and colleagues94  nor the one reported by 
Festen and colleagues91 reported on AEs at all. 
In the other study by Festen and colleagues,92 
the paper stated that rhGH treatment did not 
induce disadvantageous effects on carbohydrate 
metabolism, sleep-related breathing disorders or 
thyroid hormone levels. Hauffa and colleagues99 
reported that one patient in the rhGH group 
developed pseudotumour cerebri after increasing 
the starting dose to the final dose, but their 
symptoms resolved on discontinuation. No 
abnormalities of glucose regulation were observed 
in either group. None of the patients in the study 
reported by Carrel and others95,96  experienced 
pseudotumour cerebri. Two of their patients who 
received rhGH experienced headaches within the 
first 3 weeks, but these resolved with temporary 
stoppage and gradual reinstitution of treatment. 
 
Carrel and colleagues22  commented that there 
was no evidence of changes in the prevalence of 
scoliosis with rhGH treatment, although another 
paper reporting the same study reported that 
there was progression of scoliosis in one patient.97 
Lindgren and colleagues100,101  and Haqq and 
colleagues102 reported that there was no severe 
progression of scoliosis (angle ≥ 20°) during their 
RCTs. 
 
Lindgren and colleagues100,101  noted that one child 
in their study developed low levels of thyroxine 
without any change in TSH levels. He received 
substitution with l-thyroxine during the rhGH 
treatment. Carrel and colleagues22  commented that 
no child in their RCT required thyroid hormone 
therapy. Haqq and colleagues102 reported that only 
one patient required thyroid hormone replacement 
while receiving rhGH treatment. 
 
Summary 
The evidence for the clinical effectiveness of HGH 
as a treatment for PWS comes from eight small 
RCTs (one crossover trial and seven parallel group 
trials), reported in 13 publications. The included 
studies were generally poorly reported and only 
two91,96  presented results on an ITT basis. 
 
Only one of the studies reported changes in height. 
Infants who received rhGH for 1 year grew an 
average of 6.2 cm more than those in the untreated 
group (p < 0.001).22  Two studies reported a 
statistically significant difference in HtSDS between 
treated and untreated patients. The difference was 
1 SDS (favouring rhGH treatment) in one study,95,96 
and > 2 (year 2) in the other.93 
 
Treated patients grew 3 cm/year faster than 
untreated patients in one RCT102 and 5 cm/year 
faster in another.95,96  Another study reported 
a positive GV SDS for treated patients and a 
negative one for untreated children (5.5 vs –2.3).99 
The differences between groups were statistically 
significant in all three studies. 
 
Two of the included studies reported BA as an 
outcome measure, and this was similar in both 
treatment   groups.95,96,100,101 
 
Four trials reported a statistically significantly lower 
percentage of body fat (between 1%93   and 10%22 
lower) in patients treated with rhGH than in those 
with no treatment or who were given placebo. 
 
Three trials reported that patients treated  
with rhGH had statistically significantly higher 
LBM,95,96,102  or a larger improvement in LBM, 
than untreated patients.22 One study reported that 
LBM SDS was significantly better in treated than in 
untreated children.93 
 
Two studies found that BMI was statistically 
significantly lower in treated patients than in 
untreated patients.91,102  However, another RCT95,96 
found no statistically significant difference between 
the two groups, and three more studies did not 
report a p-value for between-group statistical 
significance.92,93,100,101 
 
Insulin-like growth factor-1 values were statistically 
significantly higher in patients treated with rhGH 
than in untreated patients in three studies. 
 
Two RCTs reported IGFBP-3 values that were 
statistically significantly higher in treated patients 
than in untreated patients.95,96,102  Three studies91–93 
reported positive IGFBP-3 SDS values in treated 
patients and negative values in untreated children; 
differences between the groups were statistically 
significant. 
32  
Health Technology Assessment 2010; Vol. 14: No. 42 DOI: 10.3310/hta14420 
 
 
 
 
 
 
 
Four of the studies reported insulin levels, with 
varying results. One study22 reported that there 
was no statistically significant difference between 
treated and untreated infants. Insulin levels in 
another study95,96 appeared to be considerably 
higher in treated patients than in untreated 
patients. Another study91 reported higher insulin 
levels in treated patients at year 1 but lower levels 
than in untreated patients at year 2. Similar values 
in both groups were also reported.102 
 
None of the included studies reported a measure of 
HRQoL. 
 
None of the studies reported AEs in any detail. 
 
 
Chronic renal insufficiency 
Quantity and quality of research 
available 
Six RCTs of patients with CRI met the inclusion 
criteria for this review,103–108  and their key 
characteristics are shown in Table 18 – further 
details are shown in Appendix 4. The inclusion 
criteria for this systematic review specified that 
children should be prepubertal. Five of the 
studies stated in their inclusion criteria that 
patients should be prepubertal/Tanner stage 1, 
but one study included both prepubertal and 
pubertal patients.107 However, we have included 
outcome measures from this study where data were 
presented separately for prepubertal children and 
pubertal children. 
 
The included RCTs were of different designs (two 
crossover and four parallel group). Three of the 
parallel-group RCTs were open label, with the 
comparator groups receiving no treatment,103,106,107 
and one was placebo controlled.108 The two 
crossover studies104,105  had placebo and treatment 
phases. There does not appear to have been a 
washout phase in either of the crossover trials, 
so a carry-over effect could have affected results. 
The doses all appeared to correspond to those 
specified in the marketing authorisation, but 
dosages were reported differently, with some using 
IUs and others using mgs, and some using doses 
based on weight, whereas others used surface area. 
Randomised treatment duration was 6 months in 
the two crossover trials,104,105 2 years in one study108 
and 12 months in the other studies. 
 
Three of the studies investigated rhGH treatment 
in children who had received a kidney transplant at 
least 1 year before starting the study103,105,107 and the 
other three studied children who had CRI.104,106,108 
There was considerable variation in the age of 
children in the included studies, ranging from  
5.6106 to 12.6107 years old. Two of the studies were 
relatively large (n = 203107 and n = 125108), one was 
of medium size (n = 69106), and the remaining three 
were rather small (n = 23,103  n = 20104  and n = 11105). 
 
Only one study107   specified a primary outcome. The 
Pharmacia and Upjohn Study Group107   designed 
their study to test GFR, with GV and HtSDS being 
used as secondary outcomes. The other studies 
reported various outcomes relating to growth, body 
composition and biochemical/metabolic markers, 
but did not specify which were primary outcomes. 
Only Sanchez and colleagues103   mentioned a power 
calculation, and this appears to have been based 
on bone formation rates in a previous study, so it 
is not clear what the primary outcome was for the 
included study. The lack of clarity around primary 
outcomes and power calculations, together with the 
small size of three of the studies,103–105 suggests that 
the trials may have been underpowered to detect 
differences in outcomes relating to growth and 
body composition. 
 
The included studies had well-matched patient 
groups, whose baseline characteristics were similar 
in the treated and untreated groups. 
 
None of the included RCTs provided clear 
information on method of randomisation or 
concealment of allocation (Table 19), so it is not 
possible to say whether or not selection bias 
may have affected these studies. The studies all 
reported eligibility criteria, and presented baseline 
characteristics that indicated that groups (within 
trials) were similar at the start of the studies. 
 
The studies gave little information on whether 
or not outcome assessors were blinded to 
patients’ treatment groups, although Sanchez 
and colleagues103 did comment that skeletal 
radiographs were reviewed by a single observer 
who had no information about patients’ clinical 
condition or treatment status. In addition, three of 
the trials gave patients in the comparator group no 
treatment, so it would have been clear to patients 
and their care providers whether or not they were 
receiving rhGH. In three trials, patients in the 
comparator group had placebo injections. It is 
not clear whether or not their care providers were 
also blinded to treatment group. Lack of blinding 
could have led to performance bias in measuring 
treatment effect, but the objective nature of 
outcomes such as height change and GV would 
have protected against bias to a certain degree. 
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1.  Was the assignment to the treatment groups really random? Un Un Un Un Un Un 
2.  Was the treatment allocation concealed? Un Un Un Un Un Un 
3.  Were the groups similar at baseline in terms of prognostic Rep Rep Rep Rep Rep Rep 
factors?   
4.  Were the eligibility criteria specified? Ad Ad Ad Ad Ad Ad 
5.  Were outcome assessors blinded to the treatment Un Un Un Un Un Par 
allocation?   
6.  Was the care provider blinded? In Un Un Un In In 
7.  Was the patient blinded? In Ad Ad Ad In In 
8.  Were the point estimates and measure of variability Ad Ad Ad Ad Ad Ad 
presented for the primary outcome measure?   
9.  Did the analyses include an ITT analysis? In In In Ad In In 
10. Were withdrawals and dropouts completely described? Ad Ad Ad Ad Ad Ad 
Ad, adequate; In, inadequate; Not rep, not reported; Par, partial; Rep, reported; Un, unknown. 
 
 
 
 
 
 
TABLE 18 Characteristics of CRI studies 
 
Duration of 
Total randomised and randomised 
Reference Intervention Control group withdrawals treatment 
The Pharmacia rhGH 1 IU/kg/week No treatment Total n = 203 1 year 
and Upjohn Study   n = 106 n = 97 Sample attrition: n = 49 
Group 1996107 
Mean ± SD age (years): Mean ± SD age (years): 
12.6 ± 3.4 12.1 ± 3.1 
Fine et al. 2004108 rhGH 0.05 mg/kg/day Placebo n = 43 Total n = 125 2 years 
n = 82 Mean ± SD age (years): Sample attrition: rhGH 26, 
Mean ± SD age (years): 
5.7 ± 3.6 placebo 15
 
6.0 ± 3.9 
Hokken-Koelega rhGH 4 IU/m2/day then Placebo, then 4 IU/m2/ Total n = 20 6 months in 
et al. 1991104 placebo day rhGH Sample attrition: n = 4 each arm 
n = 8 n = 8 
Median (range) age Median (range) age 
(years): 8.7 (4.4 to 11.3) (years): 8.6 (4.4 to 16.0) 
Hokken-Koelega rhGH/placebo 4 IU/m2 Placebo/4 IU/m2 rhGH Total n = 11 6 months in 
et al. 1996105 daily s.c.i. daily s.c.i. No withdrawals each arm 
n = 6 n = 5 
Median (range) age Median (range) age 
(years): 12.1 (9.1 to 18.7) (years): 11.1 (8.3 to 14.9) 
Powell et al. rhGH 0.05 mg/kg/day No treatment Total: n = 69 1 year 
1997106 n = 30 n = 14 Sample attrition: 20 
Mean age (years) ± SD: 5.6 Mean age (years) ± SD: withdrew; 4 rhGH patients 
± 2.0 5.7 ± 2.6 and 1 control patient 
excluded from analyses 
Sanchez et al. rhGH 0.05 mg/kg/day No treatment Total: n = 23 12 months 
2002103 n = 12 n = 11 Sample attrition: rhGH, 
Mean age (± SD) 9.7 ± 4.5 Mean age (± SD) 11 ± 1.8 n = 1; control, n = 1 
s.c.i., subcutaneous injection. 
TABLE 19 Quality assessment of CRI studies 
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All the studies presented results as mean values 
with SDs or standard errors to give a measure 
of variability. The studies all provided adequate 
details of any patients who withdrew from the 
study, but only one study105 presented results on an 
ITT basis (no patients withdrew from this study). 
Attrition bias could therefore have affected the 
results of the non-ITT studies, i.e. if there had 
been unbalanced and selective withdrawal from 
different treatment groups within a study, or if 
particular patients were more likely to withdraw or 
be excluded from the analysis. 
 
There was a statistically significant difference 
between treated and untreated children’s birth 
length SDS in one study,111  but baseline height was 
the same in both groups. The very small study by 
de Zegher and colleagues113   reported slightly lower 
baseline GV in treated compared with untreated 
children [5.1 (range 4.0–6.8)  vs 6.4 (range 5.3–  
7.5) cm/year, respectively]. Otherwise, the studies’ 
treatment groups were generally comparable at 
baseline, with no discernible differences between 
treated  and  untreated  patients. 
 
The outcome measures for the included studies are 
shown in Tables 20–22 below. The p-values in the 
tables refer to between-group differences. 
 
Growth outcomes 
Key growth outcome measures are shown in Table 
20 – see Appendix 4 for other outcome measures. 
Only one of the included studies reported height 
gain. Powell and colleagues106 found that treated 
children grew an average of 3.6 cm more than their 
untreated counterparts after 1 year of treatment 
(9.1 cm vs 5.5 cm, p < 0.0001). All children in 
the study by The Pharmacia and Upjohn Study 
Group107  experienced an improvement in HtSDS, 
but this was statistically significantly higher in the 
children treated with rhGH than in the untreated 
children (0.6 vs 0.1, p < 0.0001). RhGH-treated 
children in the study by Powell and colleagues106 
had a statistically significantly higher HtSDS at end 
of 12 months than untreated children (0.8 vs 0.0, 
p < 0.0001). 
 
One of the six studies reported change in GV,  
and this was statistically significantly faster in 
treated than in untreated children.107  Four studies 
reported GV at end of treatment, all reporting 
statistically significantly faster growth in children 
who received rhGH treatment than in untreated 
children.103–105,107,108  The 2-year study by Fine and 
colleagues108  reported that rhGH-treated patients’ 
GV in the first year was 4.2 cm/year faster than the 
untreated patients’ (p < 0.00005). The difference 
between the two groups was less in the second year 
(2.3 cm/year faster in rhGH-treated children) but 
the difference between groups was still statistically 
significant (p < 0.00005) when comparing the 
difference in change from baseline in those 
patients who completed 2 years of the study. A 
statistically significant difference in GV between 
groups of just over 3 cm/year was reported by 
both The Pharmacia and Upjohn Study Group107 
(3.4 cm/year difference, p < 0.0001) and by Sanchez 
and colleagues103 (3.2 cm/year difference, p < 0.01). 
 
The two crossover studies by Hokken-Koelega 
and colleagues104,105 also reported statistically 
significantly faster growth velocities in patients 
during the rhGH phase compared with the 
placebo phase, with an average of 2.9 cm/6 months 
difference in velocity. In the study of children 
with CRI, patients who received rhGH followed 
by placebo grew at an average velocity of 
5.2 cm/6 months during treatment compared  
with 1.5 cm/6 months in the placebo phase. 
Patients who received placebo followed by rhGH 
grew 2.4 cm/6 months during the placebo phase 
compared with 4.4 cm/6 months in the treatment 
phase. The overall mean effect of rhGH was 
statistically significant (p < 0.0001). Statistical  
tests showed that there was no significant carry- 
over effect (–0.04 cm/6 months, p = 0.94). The 
crossover study in children who had received a 
renal transplant had similar results. Patients grew, 
on average, 3.8 cm/6 months faster during the 
active treatment phase in the group who received 
rhGH followed by placebo, and 2 cm/6 months 
faster in the active treatment phase for patients 
who received placebo followed by rhGH (p < 0.0001 
for overall effect of rhGH vs placebo).105 Hokken- 
Koelega and colleagues reported that there was 
no significant carry-over effect (0.5 cm/6 months, 
p = 0.30).104,105 
 
The two crossover trials,104,105  but none of the 
parallel-group RCTs, reported GVSDS. Both trials 
reported positive SDS values during the active 
treatment phases and negative scores during the 
placebo phases. The reported difference in scores 
between active treatment and placebo phases in the 
trial of children with chronic renal failure (CRF) 
was 7.7 (p < 0.0001),104  and in the trial of children 
who had received a renal transplant the difference 
was 8.0 (p < 0.0001).105 
 
Bone age was reported by five of the six studies. 
The studies by Powell and colleagues106 and 
Sanchez and colleagues103  reported that there 
was no statistically significant difference in BA 35 
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Study 
Outcomes 
(mean ± SD) 
 
rhGH (SD) 
 
Control (SD) 
 
p-value 
The Pharmacia and Upjohn Study Group107 Change in HtSDS +0.6 0.3 +0.1 ± 0.3 < 0.0001 
rhGH 1 IU/kg/week (n =30) vs no treatment 
(n = 28); 1 year 
Change in GV (cm/ 
year) 
3.7 ± 1.6 0.3 ± 1.6 < 0.0001 
Fine et al.108 HtSDS –1.6 –2.9 nr 
rhGH 0.05 mg/kg/day (n = 82) vs placebo (n = 43); 
2 years 
GV (cm/year) 7.8 ± 2.1 
(n = 55) 
5.5 ± 1.9 (n = 27) < 0.00005 
Powell et al.106 Height gain (cm) 9.1 ± 2.8 5.5 ± 1.9 < 0.0001 
rhGH 0.05 mg/kg/day (n = 30) vs no treatment 
(n = 14); 1 year 
HtSDS change 
from baseline 
0.8 ± 0.5 0.0 ± 0.3 < 0.0001 
Sanchez et al.103 HtSDS –1.1 ± 1.0 nr nr 
rhGH 0.05 mg/kg (n = 12) vs no treatment (n = 11); 
1 year 
Annual GV (cm/ 
year) 
8.0 ± 2.1 4.8 ± 1.7 < 0.01 
Hokken-Koelega et al.104 GV (cm/6 months) 1: 5.2 (1.2) 1: 1.5 (0.4) < 0.0001 
1: 4 IU/m2 rhGH then placebo (n = 8)  2: 4.4 (1.6) 2: 2.4 (1.0)  
2: Placebo then 4 IU/m2 rhGH (n = 8); 6 months HV SDS 1: 6.9 (2.4) 1: –3.0 (1.6) < 0.0001 
 
 
 
 
 
 
 
TABLE 20 Growth outcomes for CRI studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
each arm 
 
Hokken-Koelega et al.105 
1: 4 IU/m2 rhGH then placebo (n = 6) 
2: Placebo then 4 IU/m2 rhGH (n = 5); 6 months 
each arm 
 
2: 5.0 (4.5) 2: –0.5 (3.2) 
GV (cm/6 months) 1: 5.3 (1.0) 1: 1.5 (0.9) < 0.0001 
2: 3.9 (1.3) 2: 1.9 (0.7) 
HV SDS 1: 9.1 (2.9) 1: –1.3 (2.9) < 0.0001 
2: 5.3 (4.0) 2: –0.4 (1.7) 
 
 
 
between the treated and untreated patients. The 
two crossover studies by Hokken-Koelega and 
colleagues reported small differences with slightly 
lower mean ages for rhGH overall compared 
with placebo (mean differences –0.01 years104 and 
–0.5 years105) but did not present any p-values for 
these comparisons. Fine and colleagues108  reported 
that the change in BA between baseline and 2 years 
was greater in patients treated with rhGH than in 
untreated patients for those who completed both 
years of the study (2.3 vs 1.6 years, p = 0.0001). 
 
Body composition 
Measures of body composition were reported 
by three of the studies, and selected outcomes 
are shown in Table 21.103,106,108  Other outcomes 
are tabulated in the data extraction forms in 
Appendix 4. Children treated with rhGH gained 
statistically significantly more weight than those 
in the control groups in the studies reported by 
Fine and colleagues108  (2.1 kg more in 2 years, 
p = 0.0004) and by Powell and colleagues106  (1.3 kg 
more in 1 year, p = 0.007). However, there was no 
statistically significant difference between groups 
in change in weight for HtSDS. Sanchez and 
colleagues103 did not report actual weight gain, 
but reported a statistically significant difference in 
change in SDS for weight that favoured treatment 
with rhGH (0.2 vs –0.3, p < 0.01). Although 
Powell and colleagues106 reported a statistically 
significantly greater weight gain in treated patients, 
the weight for HtSDS was the same for both groups 
(0.4,  p = 0.8703). 
 
Biochemical markers 
The included studies reported a range of 
biochemical and metabolic markers, and these are 
included in Table 22. For conciseness, only the key 
outcomes of IGF-1, IGFBP-3, insulin and glucose 
are discussed in the narrative summary below. In 
addition, the studies reported a range of markers 
related to liver function. These are not reported 
in Table 22 or discussed in the narrative summary 
below, but are included in the data extraction 
forms in Appendix 4. No data from Sanchez and 
colleagues are included in Table 22 as their results 
focussed on liver function and did not report IGF, 
insulin or glucose. 
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TABLE 21 Body composition outcomes for CRI studies 
 
 
Study 
Outcomes 
(mean ± SD) 
 
GH 
 
Control 
 
p-value 
Fine et al.108 Weight gain after 2 years 6.7 ± 2.2 4.6 ± 2.7 0.0004 
rhGH 0.05 mg/kg/day (n = 82) vs placebo (kg)    
(n = 43)     
Powell et al.106 Weight gain (kg) 3.5 ± 1.5 2.2 ± 1.0 0.007 
rhGH 0.05 mg/kg/day (n = 30) vs no 
treatment (n = 14) 
Change in weight for 
HtSDS 
0.4 ± 0.7 0.4 ± 0.5 0.8703 
Sanchez et al.103 Change in SDS for weight 0.2 ± 0.3 –0.3 ± 0.3 < 0.01 
rhGH 0.05 mg/kg (n = 12) vs no     
treatment (n = 11)     
 
TABLE 22 Biochemical and metabolic markers from CRI studies 
 
Study Outcomes (mean ± SD)   GH Control p-value 
Fine et al.108 
rhGH 0.05 mg/kg/day (n = 82) vs placebo 
(n = 43) 
IGF-1 (µg/l) 244 ± 128 
(n = 47) 
135 ± 80 (n = 20)   0.0001 
Powell et al.106 
rhGH 0.05 mg/kg/day (n = 30) vs no 
treatment (n = 14) 
IGF-1 SDS change from 
baseline 
IGFBP-3 SDS change from 
baseline 
0.2 ± 1.0 nr 0.006 
4.0 ± 3.2 nr 0.011 
Hokken-Koelega et al.104 
1: 4 IU/m2 rhGH then placebo (n = 8) 
2: Placebo then 4 IU/m2 rhGH (n = 8) 
 
 
 
 
 
 
 
 
 
 
Hokken-Koelega et al.105 
1: 4 IU/m2 rhGH then placebo (n = 6) 
2: Placebo then 4 IU/m2 rhGH (n = 5) 
IGF-1 ng/ml 1: 264 ± 168 1: 160 (104) nr 
2: 268 ± 120 2: 160 (95) 
IGF-1 SDS for BA 1: 2.6 ± 2.0 1: –0.2 ± 1.5 < 0.0001 
2: 2.9 ± 2.0 2: 0.3 ± 1.6 
IGFBP-3 ng/ml 1: 7708 ± 2323 1: 6102 ± 1892 nr 
2: 8706 ± 2275 2: 6501 ± 1988 
IGFBP-3 SDS for BA 1: 5.0 ± 1.3 1: 3.7 ± 1.3 < 0.0001 
2: 5.2 ± 1.4 2: 3.9 ± 1.4 
IGF-1 ng/ml 1: 594 ± 180 1: 240 ± 143 nr 
2: 488 ± 237 2: 321 ± 94 
IGF-1 SDS for BA 1: 5.4 ± 2.8 1: 1.0 ± 2.5 < 0.0001 
2: 3.4 ± 0.5 2: 6.4 ± 1.9 
IGFBP-3 ng/ml 1: 7457 ± 2088 1: 5681 ± 1588 nr 
2: 8495 ± 2921 2: 6228 ± 2193 
IGFBP-3 SDS for BA 1: 4.5 ± 1.5 1: 3.7 ± 2.9 nr 
2: 3.9 ± 1.5 2: 5.3 ± 1.5 
 
 
Four studies reported IGF-1 as an outcome 
measure,104–106,108 and levels were higher in treated 
patients than in untreated patients. IGF-1 values 
were statistically significantly higher in treated 
patients at both years 1 and 2 in the study by 
Fine and colleagues108 (p = 0.0004 and p = 0.0001, 
respectively), but only approximately one-half 
of the randomised patients were included in this 
analysis. Powell and colleagues106 also reported  
that IGF-1 and IGF-1 SDS values were statistically 
significantly higher for treated patients than 
untreated patients (p < 0.006).106  The two crossover 
studies by Hokken-Koelega and colleagues104,105 
reported that IGF-1 SDS for BA was statistically 
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significantly higher for treated than for untreated 
patients (2.7 higher in treated children with CRF104 
and 3.7 higher in treated children who were post 
transplant,105   p < 0.0001 for both). 
 
Three studies reported IGFBP values,104–106  and 
in all three the IGFBP-3 values were higher in 
the treated patients. Powell and colleagues106 
reported that IGFBP-3 and corresponding SDS 
values were statistically significantly higher 
in treated patients than in untreated patients 
(p < 0.011). Hokken-Koelega and colleagues104 
reported that the IGFBP-3 SDS for bone age was 
statistically significantly higher for treated patients 
(p < 0.0001). 
 
Fine and colleagues108 reported that fasting insulin 
levels were statistically significantly higher in 
rhGH patients than in untreated patients after 
2 years (p = 0.03). Similarly, Hokken-Koelega and 
colleagues105 reported slightly higher insulin values 
in treated children, but did not present p-values. 
 
Quality of life 
Five of the included studies did not report QoL as 
an outcome measure. One study107  reported QoL 
but did not present data for prepubertal patients 
(the licensed patients) separately from pubertal 
patients, so it is not discussed here. 
 
Adverse events 
Hokken-Koelega and colleagues105  reported that 
no patients in their study had an acute rejection 
episode, and that there were no SAEs. Sanchez 
and colleagues103 reported that two patients with 
normal rates of bone formation experienced acute 
rejection episodes after 3 and 12 months of rhGH 
therapy. One of these episodes was associated 
with non-compliance to immunosuppressive 
medications and both reversed after treatment 
with methylprednisolone. There were no rejection 
episodes in untreated patients. 
 
Fine and colleagues108  reported that there were 
no differences between groups in year 1. In the 
second year, eight of 55 rhGH patients experienced 
asthma or wheezing, but all episodes were  
preceded by upper respiratory tract infections. 
Fine and colleagues108  reported that there were  
no clinically significant side effects associated with 
rhGH treatment. Hokken-Koelega and colleagues104 
reported that serum alkaline phosphate was 
significantly increased during rhGH treatment, 
but returned to pretreatment levels when rhGH 
therapy was replaced by placebo (p < 0.0001). 
There was no significant change in parathyroid 
hormone concentration during either treatment 
schedule, and thyroid function was reported to 
have been normal. The Pharmacia and Upjohn 
Study Group107 did not present AEs separately for 
prepubertal and pubertal children, so no data are 
reported here. Powell and colleagues106 did not 
report AEs from their study.106 
 
Summary 
The evidence for the clinical effectiveness of rhGH 
as a treatment for short stature owing to CRI comes 
from six RCTs, two of which were crossover trials. 
The trials were generally poorly reported, and only 
one105  presented ITT results. Three of the studies 
had fewer than 25 participants, which suggests that 
the trials may have been underpowered to detect 
differences in outcomes relating to growth and 
body composition. 
 
One study reported that rhGH-treated patients 
grew an average of 3.6 cm more than their 
untreated counterparts after 1 year of treatment. 
Two studies reported that HtSDS was statistically 
significantly better in treated children than in 
untreated children. 
 
Five studies reported that change in GV or GV  
SDS was statistically significantly faster for children 
who received rhGH treatment than for untreated 
children, with between-group differences in velocity 
ranging from 3.2 cm/year103 to 4.2 cm/year108 in the 
parallel-group trials. 
 
Two studies reported that there was no statistically 
different difference in BA between the treated and 
untreated patients. Two reported small differences 
with slightly lower mean ages for rhGH overall 
compared with placebo, but did not present any 
p-values for these comparisons. One study reported 
that the change in BA between baseline and 2 years 
was greater in patients treated with rhGH than in 
untreated patients for those who completed both 
years of the study. 
 
IGF-1 levels were statistically significantly higher in 
treated patients than in untreated patients in two of 
the four studies that reported this outcome. 
 
Three studies reported that IGFBP-3 values were 
higher in the treated patients. Only one of these 
reported that differences between groups were 
statistically significant. 
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Total randomised Duration of 
Reference Intervention Control group and withdrawals randomised treatment 
Phillip et al. 1: rhGH 0.033 mg/kg/ No treatment, Total n = 151 1 year 
2009114 day (n = 51), mean age (n = 47) Sample attrition: 2 
(± SD): 5.5 ± 1.5 Mean age (± SD): 
2: rhGH 0.1 mg/kg/ 5.6 ± 1.4 
day (n = 51), mean age 
(± SD): 5.5 ± 1.4 
Carel et al. 2003111      rhGH: 0.2 IU/kg/day, No treatment, Total n = 168 Until AH reached       
n = 112 n = 56 Sample attrition: (mean = 2.7 ± 0.6 years) 
Mean age Mean age (± SD): For treatment: rhGH, 
(± SD):12.7 ± 1.4 12.8 ± 1.6 n = 21; control, n = 23 
For analysis: rhGH, n = 10; 
control, n = 9 
De Schepper et al.   High-dose rhGH: No treatment, Total n = 40 2 years 
2007 109 66 ± 3 µg/kg/day, n = 11 n = 14 Sample attrition: n = 15 
Mean age (± SD): Mean age (± SD): 
5.1 ± 1.6 5.1 ± 1.4 
de Zegher et al. 1: rhGH 0.2 IU/kg/day, No treatment, Total: n = 54 2 years 
1996112 n = 20 n = 13 Sample attrition: 
2: rhGH 0.3 IU/kg/day, Mean age (± SD): rhGH 1: n = 2 
n = 21 4.9 ± 0.5 
rhGH 2: n = 1
 
Mean age (± SD): 
Control: n = 1
 
1: 5.4 ± 0.5 
2: 5.1 ± 0.4 
de Zegher et al. High-dose rhGH No treatment, n = 4   Total n = 13 2 years 
2002113 100 µg/kg/day, n = 9 Mean age (range): Sample attrition: not 
Mean age (range): 6.3 4.7 (2.3–6.3) reported 
(4.0–8.0) 
Lagrou et al. rhGH 0.066 mg/kg/day,   No treatment, Total n = 40 2 years 
2008110 n = 20 n = 20 Sample attrition: 1 
Mean age (± SD): Mean age (± SD): 
5.5 ± 1.6 5.1 ± 1.3 
Licensed dose = 35 µg/kg/day = 0.035 mg/kg/day = 0.105 IU/kg/day. 
 
 
 
 
 
 
 
Insulin levels were statistically significantly higher 
in children receiving rhGH than in those receiving 
placebo injections or no treatment. 
 
Four studies presented data on AEs. Two rhGH- 
treated patients in one study experienced acute 
rejection episodes (one associated with non- 
compliance to immunosuppressive medications) 
but both reversed after treatment with 
methylprednisolone. There were no SAEs reported. 
 
 
Children born SGA 
Quantity and quality of research 
current HtSDS of < 2.5, with a parental adjusted 
HtSDS of –1, had a birth weight and/or length SDS 
of < –2, and have failed to show catch-up growth 
during the previous year (HV SDS < 0). No RCTs 
meeting these criteria were identified. Following 
discussion with NICE, the criteria were amended 
in order to include evidence from RCTs on rhGH. 
As discussed above (see Inclusion criteria), the 
following amended criteria were agreed: growth 
disturbance (current height < –2.5, no reference 
to parental height), birth weight and/or length 
< –2 SD and failure to show catch-up growth (no 
stated criteria) by the age of 3 years. 
 109–114 
available Six studies met the amended inclusion criteria 
 
In the UK, rhGH is licensed for use in children 
born SGA who are over 4 years of age, have a 
for this review, and their key characteristics are 
shown in Table 23 – see Appendix 4 for further 
details. In the UK, the licensed dose of rhGH for 
 
 
TABLE 23 Characteristics of SGA studies 
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SGA children is 0.035 mg/kg/day, which equates 
to 0.105 IU/kg/day. Only the study by Phillip 
and colleagues114 included a treatment arm with 
the licensed dose; the other studies all used 
approximately two or three times the UK licensed 
dose. 
 
Treatment duration was comparable across five 
of the six included studies. Four of the trials 
stated a treatment duration of 2 years.109,110,112,113 
Carel and colleagues111  administered GH for an 
average of 2.7 ± 0.6 years, until the participants 
reached AH. The children in the study by Phillip 
and colleagues114 received treatment for 2 years, 
but only the first year allowed a randomised 
comparison between GH and no treatment. 
 
The mean age of participants was similar both 
across groups within studies and across five of the 
six trials included.109,110,112–114 The mean ages of 
groups in these trials ranged from 4.7 (2.3–6.3)113 
to 6.3 (4.0–8.0) years. The Carel study111 included 
older children with mean ages of 12.7 ± 1.4 in the 
rhGH group and 12.8 ± 1.6 in the control group. 
 
The six included trials were generally of poor 
methodological quality (Table 24). 
 
 
TABLE 24 Quality assessment of included SGA studies 
Phillip and colleagues114 reported that a centralised 
computer-controlled system was used to randomly 
assign children to groups. In the other five trials it 
was unclear whether the assignment to treatment 
groups was really random. This was reflected in 
the assessment of whether treatment allocation was 
concealed, with one exception being the study by 
Carel and colleagues,111 which reported that group 
assignment was not masked and this was therefore 
judged to be inadequate. 
 
The blinding of outcome assessors can defend 
against bias affecting the measurement of some 
outcomes. In two trials112,114 outcome assessors 
for BA were blinded to chronological age and 
treatment allocation. It was not stated whether this 
extended to assessors of other outcomes. In the 
remaining four trials it was not stated whether the 
outcome assessors were blinded. 
 
Performance bias, where knowledge of treatment 
can potentially lead to differences in care provided 
can be protected against by blinding care givers 
and patients. The care provider was not blinded to 
treatment in the studies by Carel and colleagues111 
or Phillip and colleagues,114  and in the four 
remaining trials this was unknown. In each of the 
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1.  Was the assignment to the treatment groups really Un Un Un Un Un Ad 
random?       
2.  Was the treatment allocation concealed? In Un Un Un Un Un 
3.  Were the groups similar at baseline in terms of Rep Rep Rep Rep Rep Rep 
prognostic factors?       
4.  Were the eligibility criteria specified? Ad Ad Ad Ad Ad Ad 
5.  Were outcome assessors blinded to the treatment Un Un Par Un Un Par 
allocation?       
6.  Was the care provider blinded? In Un Un Un Un In 
7.  Was the patient blinded? In In In In In In 
8.  Were the point estimates and measure of variability Ad Ad Ad Ad Ad Ad 
presented for the primary outcome measure?       
9.  Did the analyses include an ITT analysis? In In In Ad In In 
10. Were withdrawals and dropouts completely Ad Ad Ad Ad In In 
described?       
Ad, adequate; In, inadequate; Not rep, not reported; Par, partial; Rep, reported; Un, unknown. 
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six trials blinding of the patient was inadequate 
as no placebo was used. Only one of the trials 
conducted an ITT analysis.113  This guards against 
bias arising where for example only the results of 
patients who did not experience AE or compliance 
issues are included in the analysis. 
 
Growth outcomes 
All six studies109–114 reported growth outcomes, and 
these are presented in Table 25. 
 
Carel and colleagues111  reported AH for the 70% 
of control patients and 89% of treated patients for 
whom these data were available. They reported a 
mean gain in AH of 26 ± 7 cm in the treated group 
compared with 22 ± 6 cm in their untreated group 
(p = 0.005). They also reported AH SDS, which was 
statistically significantly higher in the rhGH treated 
group (–2.1 ± 1.0) compared with the untreated 
group (–2.7 ± 1.0), p = 0.005. Similarly, the SDS 
for AH total gain was statistically significantly 
higher in treated patients than with untreated 
patients (1.1 ± 0.9 vs 0.5 ± 0.8, p = 0.002). Carel  
and colleagues111  also reported the difference from 
target HtSDS. This was statistically significantly 
lower in the group receiving GH, compared 
with the control group (–0.9 ± 1.2 vs –1.7 ± 1.2, 
p = 0.005). 
 
Children who received the licensed dose of 
0.033 mg/kg/day for 1 year in the study by 
Phillips and colleagues114 gained an average of 
3.3 ± 0.2 cm in height compared with children in 
the untreated control group. Those receiving the 
higher dose of 0.1 mg/kg/day rhGH gained an 
average of 6.5 ± 0.2 cm compared with untreated 
children. No p-values were presented for between- 
group comparisons, although the CIs suggest a 
statistically significant difference. 
 
de Zegher and colleagues112 found that gain 
in HtSDS at the end of the study was higher 
in the group receiving a higher dose [2.1 ± 0.1 
(0.2 IU/kg/day) vs 2.5 ± 0.1 1 (0.3 IU/kg/day) vs 
0.2 ± 0.1  (untreated),  p < 0.001  treated  vs  untreated 
groups]. The other study by de Zegher and 
colleagues113   reported  higher  HtSDS  in  treated 
patients, but did not present p-values. However, 
there were only four patients in the no-treatment 
group, so between-group comparisons are difficult. 
 
Phillips and colleagues114 found that HtSDS was 
higher in the two rhGH-treated groups than in 
the untreated groups (–2.3 ± 0.6, –1.8 ± 0.8 and 
–3.0 ± 0.6 for the 0.033 mg/kg/day (licensed dose), 
1.1 mg/kg/day and untreated groups, respectively). 
These scores reflected changes of 0.8 and 1.4 
in SDS for the licensed- and high-dose groups, 
respectively, compared with a change of only 0.1 in 
the untreated patients’ mean SDS value. 
 
Three109,110,113  of the included studies that used 
higher doses of rhGH reported that HtSDS was 
higher in the treated groups than in the untreated 
groups. De Schepper and colleagues109  and de 
Zegher and colleagues113  reported HtSDS at the 
end of the first and second years of treatment. 
In each of these studies, at both time points, the 
SDS was higher in the treated group, and this 
difference between groups increased in the second 
year. In De Schepper and colleagues’109 study at 
the end of year 1, HtSDS in the treated group was 
–2.1 ± 0.7 versus –3.1 ± 1 in the untreated group 
(p < 0.0001). In year 2, HtSDS in the treated 
group was –1.7 ± 0.7 compared with 3.1 ± 1 in the 
untreated group (p < 0.0001). At the end of 2 years’ 
treatment, the treated group in the Lagrou110  study 
had a statistically significantly higher mean HtSDS 
(–1.9 ± 0.7) than the untreated group (–3.1 ± 0.9), 
p < 0.001. 
 
Two studies109,110  were suitable for meta-analysis of 
the HtSDS outcome because they were sufficiently 
homogeneous in terms of dose, duration of 
treatment, and the children’s mean age at start of 
treatment. However, both trials were small (≤ 20 
girls in each treatment group), which affects the 
validity of tests for heterogeneity, and both used 
twice the licensed dose, so a meta-analysis of these 
was considered unlikely to add to the evidence 
base. 
 
Growth velocity (cm/year) was greater at the end 
of year 2 in the groups receiving rhGH in the two 
studies that presented results for this outcome.112,113 
de Zegher and colleagues 1996112 found an 
increased GV in their group receiving a higher 
dose of GH, and a greater GV for their treated 
participants overall: 10.2 ± 0.2 (0.2 IU/kg/day) 
versus 11.0 ± 0.4 (0.3 IU/kg/day) versus 5.7 ± 0.3 
(untreated), p < 0.001 untreated versus treated. 
The de Zegher 1996 study112  also found that GV 
SDS was statistically significantly higher at the 
end of treatment in the treated groups [4.3 ± 0.3 
(0.2 IU/kg/day) and. 5.2 ± 0.4 (0.3 IU/kg/day)] 
compared with –0.9 ± 0.3 in the untreated group 
(p < 0.001 for untreated vs treated groups). 
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TABLE 25 Growth outcomes for SGA studies 
 
Study Outcomes (mean ± SD)   rhGH Control p-value 
Phillip et al.114 HtSDS 1: –2.3 ± 0.6 –3.0 ± 0.6 nr 
1: rhGH 0.033 mg/kg/day (n = 51)  2. –1.8 ± 0.8   
2: rhGH 0.1 mg/kg/day (n = 51) vs     untreated (n = 47); 1 year Change in HtSDS 1: 0.8 ± 0.3 0.1 ± 0.3 nr 
  2: 1.4 ± 0.4   
 Additional height gained 1: 3.3 ± 0.2, 95% CI n/a nr 
 (cm)a 2.9 to 3.7   
  2: 6.5 ± 0.2, 95% CI   
  6.0 to 6.9   
Carel et al.111 AH total height gain (cm) 26 ± 7 22 ± 6 0.005 
0.2 IU/kg/day (n = 91) vs untreated End of treatment: HtSDS –2.1 ± 1.0 nr nr 
(n = 33)      AH HtSDS –2.1 ± 1.0 –2.7 ± 1.0 0.005 
 AH total height gain SDS 1.1 ± 0.9 0.5 ± 0.8 nr 
 AH difference from target –0.9 ± 1.2 –1.7 ± 1.2 0.005 
 HtSDS    
De Schepper et al.109 HtSDS year 2 –1.7 ± 0.7 –3 ± 1 < 0.0001 
High-dose rhGH (n = 11) vs untreated     
(n = 14); 2 years     
de Zegher et al.112 Gain in HtSDS 1: 2.1 ± 0.1 0.2 ± 0.1 < 0.001b 
1: rhGH 0.2 IU/kg/day (n = 20)  2: 2.5 ± 0.1   
2: rhGH 0.3 IU/kg/day (n = 19) vs     untreated (n = 13); 2 years Gain in HtSDS for BA 1: 1.0 ± 0.2 0.0 ± 0.3 < 0.05b 
  2: 1.2 ± 0.4   
 GV (cm/year) 1: 10.2 ± 0.2 5.7 ± 0.3 < 0.001 
  2: 11.0 ± 0.4   
 GV SDS 1: 4.3 ± 0.3 –0.9 ± 0.3 < 0.001b 
  2: 5.2 ± 0.4   
de Zegher et al.113 HtSDS –1.8 (–3.9 to –0.5) –3.0 (–3.3 to nr 
High-dose rhGH (100 µg/kg/day) (n = 9)   –2.5)  
vs no treatment (n = 4); 2 years GV (cm/year) 8.5 (6.3 to 10.2) 5.6 (4.4 to nr 
   6.8)  
Lagrou et al.110 HtSDS –1.9 ± 0.7 –3.1 ± 0.9 < 0.001 
rhGH 0.066 mg/kg/day (n = 20) vs     
untreated (n = 19)     
a  Compared with untreated controls. 
b  Untreated vs treated. 
 
de Zegher and colleagues 1996112  reported BA. 
The gain in BA (years) was statistically significantly 
greater in the groups receiving GH than in those 
who were untreated. The 0.2 IU/kg/day rhGH 
group had a mean gain of 1.35 ± 0.16, compared 
with 1.33 ± 0.24 in the 0.3 IU/kg/day rhGH group 
and 0.84 ± 0.07 in the untreated group (p < 0.001 
treated vs untreated groups). This is reflected in 
the gain in HtSDS for BA: 1.0 ± 0.2 (0.2 IU/kg/day) 
versus 1.2 ± 0.4 (0.3 IU/kg/day) versus 0.0 ± 0.3, 
p < 0.05, treated versus untreated groups. 
Body composition outcomes 
Four of the included studies reported body 
composition outcomes.109,110,112,113 These results are 
shown in Table 26. It should be noted that all of 
these studies used higher doses of rhGH than the 
UK licensed dose. 
 
De Schepper and colleagues reported a WtSDS 
for treated patients that was almost half that for 
untreated patients (–1.8 vs –3.4; p < 0.0001). 
Lagrou and colleagues110 found that WtSDS at 
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TABLE 26 Body composition outcomes for SGA studies 
 
Study Outcomes (mean ± SD) rhGH Control p-value 
De Schepper et al.109 WtSDS –1.8 ± 1 –3.4 ± 1.6 < 0.0001 
High-dose rhGH (n = 11)a vs Lean mass (kg) 15.5 ± 3.4 12.2 ± 2.5 < 0.0001 
untreated (n = 14); 2 years      FM (kg) 2.9 ± 1 3.1 ± 1.1 n/s 
 Lean mass (%) 82 ± 3 77 ± 5 < 0.05 
 FM (%) 15 ± 2 20 ± 5 < 0.05 
de Zegher et al.112 Weight gain (kg) 1: 6.9 ± 0.6 3.6 ± 0.4 < 0.001a 
1: rhGH 0.2 IU/kg/day (n = 20)  2: 7.8 ± 0.5   
2: rhGH 0.3 IU/kg/day (n = 19) vs Gain in WtSDS 1: 1.3 ± 0.1 0.4 ± 0.1 < 0.001a 
untreated (n = 13); 2 years       2: 1.8 ± 0.1   
de Zegher et al.113 WtSDS (mean and range) –2.1 (–3.6 to –0.9) –3.8 (–4.8 to –3.2) nr 
High-dose rhGH (100 µg/kg/day) BMI SDS(mean and range) –1.2 (–3.4 to –0.4) –2.1 (–2.9 to –1.4) nr 
(n = 9) vs no treatment (n = 4); 2     
years     
Lagrou et al.110 WtSDS –2.3 ± 1.2 –3.7 ± 1.5 < 0.01 
rhGH 0.066 mg/kg/day (n = 20) vs BMI (SDS) –1.5 ± 1.1 –2.0 ± 1.5 ns 
untreated (n = 19)     
ns, not significant. 
a  Untreated vs treated. 
 
 
the end of year 2 was statistically significantly 
higher in their treated group (–2.3 ± 1.2) than 
in their untreated group (–3.7 ± 1.5; p < 0.01). 
Similar values were reported by de Zegher and 
colleagues,113 although no p-values were given. 
 
de Zegher and colleagues 1996112   also reported 
gain in WtSDS and weight gain (kg). For both  
of these outcomes the difference was statistically 
significant and higher in the groups treated with 
GH. Mean weight gain (kg) was 6.9 ± 0.6 (0.2 IU/kg/ 
day) versus 7.8 ± 0.5 (0.3 IU/kg/day) versus 3.6 ± 0.4 
in the untreated group (p < 0.001 treated vs 
untreated groups). This pattern was reflected in the 
gain in WtSDS, which was 1.3 ± 0.1 in the 0.2 IU/ 
kg/day group, 1.8 ± 0.1 in the 0.3 IU/kg/day group 
and 0.4 ± 0.1 in the untreated group (p < 0.001 
untreated vs treated groups). 
 
Lean mass and FM were reported in kilograms 
and as a percentage by De Schepper and 
colleagues.109 Lean mass (kg) increased from year 
1 to year 2 in both groups, and was greater in the 
group receiving GH at both times (13.2 ± 3.4 vs 
10.9 ± 2.4 and 15.5 ± 3.4 vs 12.2 ± 2.5 for years 1 
and 2, respectively). The p-value was reported as  
p < 0.0001, but it is unclear at which time point 
this p-value refers to. Lean mass (%) remained 
virtually unchanged from year 1 to year 2, but was 
higher in the rhGH group (82 ± 3 vs 77 ± 5 at year 
2). The difference between treated and untreated 
groups was statistically significant (p < 0.05), but it 
is unclear whether this refers to the year 1 or year 
2 data. 
 
The difference in FM (%) between the two groups 
was statistically significant: 15 ± 2 versus 20 ± 5, 
p < 0.05. 
 
Two studies reported BMI SDS.110,113  One of these 
reported that there was no statistically significant 
difference between treated and untreated 
children,110  and the other reported similar values 
but gave no p-value.113 
 
Biochemical markers 
Two of the included studies, both of which used 
higher doses than the UK licensed dose, reported 
biochemical markers.112,114  These results are shown 
in Table 27. 
 
Serum IGF-1 levels were statistically significantly 
higher in rhGH treated groups at the end of 
treatment. In one study,112  children receiving 
1.2 IU/kg/day rhGH had values of 332 ± 29, 
compared with 655 ± 69 in the 0.3 IU/kg/day group 
and 168 ± 46 in the untreated group (p < 0.01, 
0.2 IU/kg/day vs untreated group) after 2 years’ 
treatment. Phillip and colleagues114  reported 
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 Outcomes  
Study (mean ± SD) rhGH Control p-value 
de Zegher et al.112 Serum IGF-1 (µg/l) 1: 332 ± 29 168 ± 46 < 0.01 untreated vs 
 
 
 
 
 
 
TABLE 27 Biochemical markers in SGA studies 
 
 
 
 
1: rhGH 0.2 IU/kg/day (n = 20) 
2: rhGH 0.3 IU/kg/day (n = 19) vs 
untreated (n = 13) 
2 years 
 
 
 
Serum IGFBP-3 
(mg/l) 
2: 655 ± 69 
1: 6.10 ± 0.35 
2: 6.50 ± 0.52 
group 1 
 
4.00 ± 0.58 < 0.001 untreated vs 
group 1 
Phillip et al. 114 
1: rhGH 0.033 mg/kg/day (n = 51) 
2: rhGH 0.1 mg/kg/day (n = 51) vs 
untreated (n = 47) 
1 year 
IGF-1 (ng/ml) 1: 345.6 ± 177 
2. 594.3 ± 221 
IGF-1 SDS 1: 0.9 ± 1.9 
2. 3.3 ± 2.1 
IGFBP-3 (µg/l) 1: 4.8 ± 1.1 
2: 6.1 ± 1.4 
176 ± 107 nr 
 
 
–0.9 ± 1.2 nr 
 
 
3.9 ± 1.1 nr 
 
 
 
similar IGF-1 values as de Zegher and colleagues112 
after 1 year’s treatment, and, in addition, reported 
that IGF-1 SDS was higher in rhGH treated 
patients than in untreated patients. Values were 
0.9 ± 1.9 and 3.3 ± 2.1 in the low- and high-dose 
groups, respectively, and 0.9 ± 1.2 in the untreated 
group. 
 
Serum IGFBP-3 levels were also greater in the 
groups receiving rhGH. In the 1-year study,114 
values were lowest in untreated patients 
(3.9 ± 1.1 µg/l) and higher in the two rhGH groups 
(4.8 ± 1.1 and 6.1 ± 1.4 for the low- and high-dose 
groups, respectively). No p-values were reported.  
At the end of year 2 in the second study, mean 
values were 6.10 ± 0.35 in the 0.2 IU/kg/day rhGH 
group, 6.50 ± 0.52 in the 0.3 IU/kg/day rhGH group 
and 4.00 ± 0.58 in the untreated group (p < 0.001, 
untreated vs 0.2 IU/kg/day rhGH group).112 
 
Quality of life 
None of the included studies reported QoL 
outcomes. 
 
Adverse events 
Four of the included studies discussed AEs in 
varying  detail.109,111,112,114 
 
Carel and colleagues111 found that 44% of patients 
reported AE, with 10% of these reporting four 
or more. It was not stated whether these patients 
were from the treated or untreated group. The 
authors described two AEs that they believed 
to be causally related to treatment; one slipped 
capital epiphysis after 1.5 years of treatment and 
one simple seizure episode 10 minutes after first 
injection. The authors do not state if these led to 
withdrawal. Sixteen severe AEs in 14 patients were 
reported. These were not thought by the authors 
to be related to treatment, and included trauma, 
psychiatric symptoms, abdominal symptoms, 
otitis, asthma, variocele, striae and migraine. 
De Schepper and colleagues109 stated only that 
no participants ‘had a noteworthy adverse event 
during the two years of study’. No further details 
were given. 
 
de Zegher and colleagues 1996112  reported four 
SAEs. The authors suggested that these might not 
be linked to GH, but gave no further details. The 
authors described two treated children versus one 
untreated child hospitalised as a result of viral 
disease (group/dose not reported). There was one 
case of aggravated cutaneous eczema reported in 
group 1 (0.2 IU/kg/day). Three treated children 
(group/dose not given) reported possible increase 
in size or number of pigmented naevi. Treatment 
was not interrupted in any of these cases. 
 
Phillip and colleagues114 reported AEs only for 
the 2-year study overall, so it was not possible  
to compare the treated and untreated children. 
The majority (349/358) of AEs in the study were 
of mild to moderate severity, the most common 
events (57%) being childhood infections. Of 16 
SAEs reported, three were described as likely to 
be related to rhGH. Two of these (convulsions 
and papilloedema) resolved on discontinuation of 
treatment, and the third (epilepsy) stabilised when 
treatment was withdrawn. 
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Summary 
Six109–113  trials examining the effectiveness of GH 
in children born SGA met the inclusion criteria for 
the review. The quality of the included studies was 
generally poor, and only one undertook an ITT 
analysis.113 All but one114 of the trials used higher 
than licensed doses of rhGH. 
 
One trial reported total gain in AH, and found this 
was approximately 4 cm higher in people who had 
received rhGH. The difference between groups was 
statistically significant (p < 0.005).111  AH gain SDS 
was also statistically significantly higher in people 
who had received rhGH.111 However, the study used 
a dose which was approximately twice the licensed 
dose, and it was carried out in children with a mean 
age of 12.7 years at start of treatment. This may 
limit the generalisability of the trial. 
 
One study114 reported that patients who received 
0.033 mg/kg/day of rhGH (the licensed dose) 
gained an additional 3.3 cm height compared 
with untreated children, and those who received 
1.1 mg/kg/day gained 6.5 cm of additional height 
after 1 year’s treatment. 
 
Height SDS was found to be statistically 
significantly higher in children treated with GH in 
two studies,109,110 and higher, but with no reported 
p-value, in two others.113,114 
 
Growth velocity (cm/year) was greater in the treated 
groups at the end of year 2 in the two studies that 
reported this outcome,112,113  but the difference was 
reported to be statistically significant in only one.112 
 
Weight standard deviation score was statistically 
significantly higher in children treated with 
rhGH in one110   of the three studies reporting this 
outcome. 
 
Lean mass was reported in one study,109  and was 
statistically significantly greater in the treated 
group.  Two  studies  reported  BMI  SDS.110,113   One 
of these reported that there was no statistically 
significant difference between treated and 
untreated children,110  and the other reported 
similar values but gave no p-value.113 
 
One study112  reported that serum IGF-1 and 
IGFBP-3 levels were statistically significantly higher 
in patients treated with rhGH, and another114 
reported similar results but did not present 
p-values. 
 
Reporting of AEs was limited in detail, and only 
reported by four of the trials.109,111,112 One trial111 
reported two events in treated children that may 
have been linked to GH. They did not discuss 
if these led to discontinuation of the drug. A  
second trial109   reported only that there were ‘no 
noteworthy’ AEs recorded. A third trial112   reported 
four SAEs, which were not linked to the study drug. 
Three of 16 SAE in another trial114  were linked with 
rhGH, and these resolved/stabilised once treatment 
was discontinued. 
 
 
SHOX deficiency 
Quantity and quality of research 
available 
Only one study of patients with SHOX met the 
inclusion criteria for this review,49 and its key 
characteristics are shown in Table 28. The 2-year 
multicentre RCT by Blum and colleagues49 
compared a daily injection of 50 µg of rhGH 
with no treatment in 52 prepubertal children 
with confirmed SHOX-D. The manufacturer’s 
recommended dose is 45–50 µg/kg body weight,81 
but as the study did not report mean baseline 
weight of participants it is not possible to comment 
on whether or not the study reflects the licensed 
dose. The study also included a non-randomised 
rhGH-treated group of patients with TS, but this 
group will not be discussed further in this report. 
 
The included study was generally poorly reported 
(Table 29), with little information on method of 
randomisation or concealment of allocation. 
 
 
 
TABLE 28 Characteristics of SHOX-D study 
 
 Total randomised Duration of randomised 
Reference Intervention Control group and withdrawals treatment 
Blum et al. 200749 rhGH 50 µg/day, n = 27 No treatment, n = 25 Total n = 52 2 years 
 Mean age ± SD (years): 
7.5 ± 2.7 
Mean age ± SD 
(years): 7.3 ± 2.1 
Sample attrition: 1  
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TABLE 29 Quality assessment of SHOX-D study 
 
1. Was the assignment to the treatment groups really random? Un 
2. Was the treatment allocation concealed? Un 
3. Were the groups similar at baseline in terms of prognostic factors? Rep 
4. Were the eligibility criteria specified? Ad 
5. Were outcome assessors blinded to the treatment allocation? Para 
6. Was the care provider blinded? In 
7. Was the patient blinded? In 
8. Were the point estimates and measure of variability presented for the primary outcome measure? Ad 
9. Did the analyses include an ITT analysis? In 
10. Were withdrawals and dropouts completely described? In 
 
Ad, adequate; In, inadequate; Par, partial; Rep, reported; Un, unknown. 
a  Blood analyses were carried out at a central facility. 
 
 
 
 
Patients in the comparator arm received no 
treatment, so the patients themselves and their care 
providers would have been aware of whether or not 
they were receiving the study drug. The patients in 
the two groups had similar baseline characteristics, 
although target HtSDS was statistically significantly 
lower for the rhGH group (–1.3 ± 1.0 vs –1.5 ± 0.9, 
p = 0.013). Baseline IGFBP-3 SDS was slightly 
higher for the rhGH group (0.6 ± 1.3 vs 0.1 ± 1.1), 
although the difference was not statistically 
significant. The analysis was not reported on 
an ITT basis as one discontinuing patient was 
excluded from the analysis. The study did not 
include discussion of sample size or a power 
calculation, so it is not possible to determine 
whether or not it was adequately powered to detect 
a difference in the primary outcome (first-year GV). 
 
Growth outcomes 
Table 30 shows growth outcomes at the end of  
2 years’ treatment. Children treated with rhGH 
gained approximately 6 cm more height than 
those in the control group (p < 0.001). Although  
all children remained below average height, the 
HtSDS was statistically significantly lower in the 
untreated group (–3.0 ± 0.2 vs –2.1 ± 0.2, p < 0.001). 
Blum and colleagues49 also commented that 41% 
of rhGH-treated patients reached a height within 
the normal range for age and gender (> –2.0 SDS), 
compared with only one patient in the untreated 
group. There was no statistically significant 
difference between the groups in catch-up of BA. 
 
The difference in GV (1.9 cm/year) between the 
two groups during the second year of the study 
was statistically significant (p < 0.001). Children 
in the rhGH group had a positive HV SDS, i.e. 
their GV was above average for their age group. 
By comparison, those in the untreated group had 
a negative score, indicating slower growth than 
normal for their age group. Again, the difference 
between the groups was statistically significant 
(p < 0.001). 
 
Body composition 
The included study did not report body 
composition as an outcome measure. 
 
Biochemical markers 
Blum and colleagues49 did not report biochemical 
outcomes in any detail. However, they did state that 
IGF-1 SDS values were in the low-normal range 
for both groups at baseline, but increased to the 
upper-normal range in the rhGH-treated group. 
In 10 (37%) of the rhGH-treated children, IGF-  
1 concentrations exceeded +2 SDS at least once 
during treatment, whereas none of the untreated 
patients experienced this. Similarly, IGFBP-3 SDS 
values were close to the normal mean in both 
groups at baseline, but increased to the upper- 
normal range in the treated group. 
 
Quality of life 
The included study did not report QoL as an 
outcome measure. 
 
Adverse events 
The rate of treatment-emergent AE was higher 
in the rhGH group than in the no-treatment arm 
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Outcomes (mean ± SD) rhGH Control p-value 
At least 1 treatment-emergent AE (%) 85 68 nr 
Arthralgia 3 2 nr 
Increased number of cutaneous naevi 2 0 nr 
Recurrent otitis media 
Scoliosis 
1 
1 
1 
0 
nr 
nr 
 
 
 
 
 
 
TABLE 30 Growth outcomes for SHOX-D study 
 
Study Outcomes (mean ± SD)   rhGH Control p-value 
Blum et al.49 
rhGH 50 µg (n = 27) vs no 
treatment (n = 24); 2 years 
Height gain (cm)                 16.4 ± 0.4                  10.5 ± 0.4                  < 0.001 
Ht SDS                           –2.1 ± 0.2                   –3.0 ± 0.2                   < 0.001 
HV (cm/year)                   7.3 ± 0.2                    5.4 ± 0.2                    < 0.001 
HV SDS                              2.3 ± 0.3                    –0.4 ± 0.1 (n = 22)       < 0.001 
 
 
 
(Table 31), but these were reported to have mostly 
been common childhood illnesses. 
 
There were no significant changes in thyroid 
function reported during the study, and no SAEs 
occurred in the patients with SHOX-D. 
 
Summary 
The evidence for the clinical effectiveness of rhGH 
as a treatment for short stature owing to SHOX-D 
comes from the single RCT that met the inclusion 
criteria for this review. The study was unblinded 
and did not report an ITT analysis. 
 
By the end of the second year, children treated  
with rhGH had gained statistically significantly 
more height than those in the control group 
(approximately 6 cm more), with no statistically 
significant difference in catch-up of BA. HtSDS was 
statistically significantly higher in treated than in 
untreated patients. 
 
Treatment with rhGH led to a statistically 
significantly greater GV in both years 1 and 2 
(3.5 cm/year greater than untreated patients in 
year 1, and 1.9 cm/year greater in year 2). The 
HV SDS was positive, i.e. above the average for 
chronological age, during both years of rhGH 
treatment whereas untreated children had negative 
HV SDS. 
Treatment with rhGH raised IGF-1 and IGFBP-3 
levels to the upper normal range. 
 
Treatment of the children with SHOX-D in this 
RCT was not associated with any SAE. 
 
 
Transition phase in GHD 
 
The scope for this review requested that, if 
evidence allows, the assessment report should 
consider the transition of care from paediatric to 
adult endocrine services of young people whose 
linear growth is not complete. Although a number 
of ‘transition phase’ studies were assessed for 
inclusion in the review of clinical effectiveness, 
these included patients who had completed linear 
growth. Therefore, they did not meet the inclusion 
criteria for this review. 
 
Once a patient’s linear growth has ceased, he or 
she may still not have reached peak bone mass, 
which would increase the risk of osteoporosis 
later in life. Continued rhGH treatment in these 
patients beyond completion of linear growth can be 
beneficial for improving bone mass. For example, 
Conway and colleagues128 randomised 160 18- to 
25-year-olds with severe GHD who had received 
rhGH during childhood to continued treatment 
(n = 109) or no treatment (n = 51). They reported 
that 2 years of continued treatment was associated 
 
 
 
TABLE 31 Adverse events for SHOX-D study 
 
Study 
Blum et al.49 
rhGH 50 µg (n = 27) vs no 
treatment (n = 24); 2 years 
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with approximately 3.5% greater increase in bone 
mineral density of the lumbar spine than in those 
who had discontinued treatment.128 
 
Continued rhGH treatment can also improve body 
composition in young adults whose linear growth 
is complete. Five papers129–133 were identified that 
reported changes in body composition, biochemical 
markers, QoL or AE for this patient group. 
However, as the patients had completed linear 
growth they did not meet the inclusion criteria for 
this review and are therefore beyond the scope of 
this review. 
 
 
Summary of previous 
systematic reviews 
The searches for this systematic review identified 
three systematic reviews. One of these was the 
previous HTA report,6 discussed above (see 
Comparison with previous review), and another 
was a Cochrane review related to that work.134 The 
third reference was a new systematic review of GH 
in TS,135 and this is discussed below. 
 
The new systematic review was conducted in 
Canada in 2007 by the Canadian Agency for 
Drugs and Technologies in Health (CADTH).135 
The quality of the systematic review was good. 
Inclusion and exclusion criteria relating to the 
primary studies were reported. The review included 
RCTs or comparative observational studies that 
compared rhGH with placebo or no treatment, 
included females with TS, measured growth 
(FH, interim height, GV), AE and QoL. Those 
studies that included fewer than 20 patients, or 
administered rhGH for less than 1 year, were 
excluded. The Jadad scale and the Hailey scale 
were used in quality assessment, but no further 
details were reported. 
 
The CADTH included 19 studies, 10 of which 
reported data from six RCTs.135  Three of the 
six RCTs included in the CADTH review were 
excluded from the present systematic review. One 
was excluded as it was a conference abstract from 
1991, another was excluded because its outcome 
measures did not match our inclusion criteria, and 
the third was excluded because it did not compare 
rhGH with a treatment arm that did not contain 
somatropin. 
 
The CADTH authors judged the RCTs to be of 
good quality, and the observational studies of fair 
quality, using the Jadad scale. However, they do not 
describe this in detail in their report. The present 
systematic review used the CRD quality assessment 
criteria83  rather than the Jadad scale. This, along 
with the difference in included studies, may explain 
this discrepancy in judgement of quality between 
the two reports. 
 
The CADTH systematic review found that growth 
was accelerated and height increased in girls taking 
rhGH for TS. There were no SAEs reported in 
the included studies. The cost-effectiveness and 
cost–utility analyses (CUA) in the CADTH study  
are discussed in Chapter 4 (see Description of the 
identified studies). The CADTH study135 concluded 
that the evidence suggested that rhGH is effective 
in improving growth and FH in girls with TS, but 
found no evidence available to suggest that rhGH 
improves QoL. 
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Chapter 4 
Assessment of cost-effectiveness 
 
 
Introduction 
 
The aim of this section is to assess the cost- 
effectiveness of GH treatment in children with 
GHD, TS, PWS, CRI, SGA and SHOX-D compared 
with no treatment. The economic analysis 
comprises the following: 
 
• a systematic review of the literature on the cost- 
effectiveness of GH treatment (see first section: 
Systematic review of existing cost-effectiveness 
evidence) 
• a review of the HRQoL of people with GHD, 
TS, PWS, CRI, SGA, SHOX-D (see second 
section: Review of research on QoL) 
• a review of the MSs to NICE (see third section: 
Review of manufacturers’ submissions) 
• a de novo Southampton Health Technology 
Assessments Centres (SHTAC) economic 
model and cost-effectiveness evaluation (see 
fourth section: SHTAC independent economic 
evaluation). 
 
A previous HTA report has estimated the cost- 
effectiveness of GH treatment.6   In that report, a 
cost-effectiveness model, which estimated lifetime 
treatment costs and benefits in terms of cost per 
centimetre gained, was constructed. Those analyses 
are extended in the present report by including 
QoL factors in the economic modelling. 
 
 
Systematic review of 
existing cost-effectiveness 
evidence 
Methods for the systematic 
review of cost-effectiveness 
A systematic literature search was undertaken 
to identify economic evaluations for rhGH in 
children. The details of the search strategy for the 
cost-effectiveness studies are in Appendix 2. The 
MSs were reviewed for any additional studies. Titles 
and abstracts of studies identified by the search 
strategy were assessed for potential eligibility 
by two health economists. Full text versions of 
relevant papers were retrieved and checked by two 
health economists. Any differences in judgement 
 
were resolved through discussion. The quality of 
the cost-effectiveness studies was assessed using 
a critical appraisal checklist based on that by 
Drummond and Jefferson,136  the International 
Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) checklist137  and the NICE 
reference case.138 
 
Results of the systematic review 
of cost-effectiveness 
A total of 220 potentially relevant studies were 
identified in the cost-effectiveness searches and one 
in the QoL searches. Five full papers were retrieved 
with only two economic evaluations meeting the 
inclusion criteria. For all disease areas throughout 
the screening and data extraction process, 
differences in opinion were generally minor and 
easily resolved without the involvement of a third 
reviewer. The characteristics and results of the 
evaluations are discussed below. 
 
Description of the identified 
studies 
The literature search did not identify any economic 
evaluations conducted across the entire range of 
conditions of interest or any for the population of 
England and Wales. Table 32 provides a summary  
of the characteristics and base-case findings for 
the two published North American economic 
evaluations for human GH for children with TS135 
and  GHD.139 
 
The cost-effectiveness studies were assessed against 
the critical appraisal checklist (Table 33). Generally, 
the CADTH study135  was of a higher quality; the 
effectiveness of the treatment had been established 
through a systematic review, and the estimates for 
parameter values are more appropriate than the 
study by Joshi and colleagues.139 
 
Modelling approach 
Both economic evaluations presented cost- 
effectiveness analyses using simple deterministic 
decision-analytical models. Both assumed that 
the clinical benefit achieved as a result of the 
rhGH treatment in the patients’ early years will 
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TABLE 32 Characteristics of economic evaluations of rhGH treatment in children 
 
Study/Details CADTH135 Joshi et al.139 
Publication year 2007 2006 
Organisation Canadian agency for drugs and technologies in Novo Nordisk 
health 
Country Canada USA 
Study type CEA and CUA CEA and CUA 
Study perspective Canadian health-care system The US health-care payers’ perspective 
Study population Female population aged 10 years at baseline with   1. Cohort 5 years old at baseline with GHD, 
TS, receiving treatment for 5 years until 15 years   receiving treatment for 11 years until 16 years old 
old 
2. Cohort 3 years old at baseline with GHD, 
receiving treatment for 15 years until 18 years old 
Intervention rhGH rhGH (Norditropin) 
Model type Deterministic decision-analytical model Deterministic decision-analytical model 
Time horizon Lifetime (assumed to be until age of 81 years) Lifetime (assumed to be the age of 78 years for 
males and age 80 for females)a 
Discounting 5% applied to both costs and benefits (QALYs) 3% applied to both costs and benefits (QALYs) 
The primary 147.5 cm was the FH in the intervention group, The ‘success’ of treatment is defined as achieving 
clinical treatment 141 cm was the FH in the control group ‘normal height’, i.e. FH within two SDs of the 
effects modelled/  gender-specific population mean 
assessed 
Source of clinical Stephure and colleagues86 Not indicated. Appears to be an assumption. The 
evidence for the probability of ‘success’ was assumed to be 90% 
primary effect if treatment started at age 3 and continued until 
age 18. The probability of ‘success’ was assumed 
to be 75% if treatment started at the age of 5 and 
continued until the age of 16 
Health-benefit QALY QALY 
outcome 
QoL gain, per year   0.042 0.189 
Results Individuals with rhGH treatment had an For the cohort of 5–16 years, individuals 
additional discounted cost of C$153,593 and an with rhGH had an additional discounted cost 
additional discounted benefit of 0.63 QALY. The of US$155,005 and an additional discounted 
cost-effectiveness was estimated as C$243,078 benefit of 4.2 QALY. The cost-effectiveness was 
per QALY gained US$36,995 per QALY gained. For the cohort of 
3–18 years, cost per QALY was US$42,556 
CEA, cost-effectiveness analysis; CUA, cost–utility analysis; QALY, quality-adjusted life-year. 
a  The authors did not report a gender distribution at baseline and whether all-cause mortality rates were used in the 
calculations. 
 
 
last through their lifetime. Joshi and colleagues139 
assumed that age-adjusted normal height 
was achieved after the first year of treatment. 
Subsequently, the benefits in terms of ‘normal 
height years’ and associated utility gain were 
assigned from the second year of treatment. 
Conversely, the CADTH study135 did not assume 
that patients experienced any improvement in 
HRQoL during the treatment. The utility gain is 
associated with the completion of treatment rather 
than with achieving normal height, as normal 
height was not achieved in the review of clinical 
effectiveness. 
The cohorts differed with respect to age at 
baseline, duration of treatment and probability of 
achieving normal height at the end of treatment 
(see Table 32 above). The CADTH study135 used 
the characteristics and clinical effectiveness data 
from the TS RCT,86  whereas Joshi and colleagues139 
did not provide any clinical evidence for either 
the baseline characteristics of the two cohorts 
of patients with GHD or the assumed clinical 
effectiveness  estimates. 
 
Joshi and colleagues139 assumed a 20% dropout 
rate after 12 months of treatment and related it to 
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TABLE 33 Critical appraisal checklist of economic evaluation 
 
Item CADTH135 Joshi et al.139 
1 Is there a well-defined question? Yes Yes 
2 Is the patient group in the study similar to those of interest in UK NHS? Yes Yes 
3 Is the correct comparator used that is routinely used in the UK NHS? Yes Yes 
4 Is the study type and modelling methodology reasonable? Yes Yes 
5 Is an appropriate perspective used for the analysis? ? ? 
6 Is the health-care system or setting comparable to UK? ? ? 
7 Is the effectiveness of the intervention established based on a systematic Yes No 
 review?   
8 Is the model structure appropriate and does it fit with the clinical theory of Yes Yes 
 the disease process?   
9 Are assumptions reasonable and appropriate? Yes No 
10 Are health benefits measured in QALYs using a standardised and validated ? No 
 generic instrument from a representative sample of the public?   
11 Are the resource costs used reasonable and appropriate for the UK NHS? Yes Yes 
12 Are the health states and parameters used in the model described clearly and Yes No 
 are they reasonable and appropriate for the UK NHS?   
13 Is an appropriate discount rate used? Yes Yes 
14 Has the model been validated appropriately? ? ? 
15 Is sensitivity analysis undertaken and presented clearly? ? ? 
?, unclear or partially true. 
 
 
the slight pain experienced by patients, although 
no clinical evidence was presented to support this 
assumption. The CADTH study135 did not adjust 
the final outcomes for the dropout rate, effectively 
assuming it to be zero. As none of the TS patients 
achieved normal height, the CADTH study135 did 
not differentiate between partial and complete 
success of rhGH treatment. In contrast, Joshi and 
colleagues139 assumed that those patients who 
completed treatment but did not achieve normal 
height still acquire a partial utility gain. However, 
no justification for this assumption is provided. 
 
Discounting was appropriately applied to costs and 
benefits in both studies, although the discounting 
rates were different from the 3.5% recommended 
by NICE138 (3% in the study by Joshi and 
colleagues139 and 5% in the CADTH study135). 
 
Estimation of final outcomes 
(QALYs) 
Both studies highlighted the difficulty of 
translating intermediate (clinical) outcomes to final 
outcomes (QALYs). There is an apparent paucity of 
utility-based estimates of HRQoL in rhGH patients 
and an absence of such estimates obtained from 
children eligible for rhGH treatment (see below, 
Review of research on quality of life). Therefore, 
the authors chose alternative utility estimates 
that, despite acknowledged shortcomings, were 
judged to meet the requirements of their economic 
models. The utility increment associated with rhGH 
treatment reported in the two studies ranged from 
0.04135    to  0.189.139 
 
Joshi and colleagues139  adapted the QoL indexes 
presented in the Wessex Development and 
Evaluation Committee (DEC) report.140  The 
indexes estimated in the report were not derived 
using one of the methodologically rigorous 
techniques for obtaining utility estimates, such as 
time trade-off (TTO) or standard gamble (SG)141 
and cannot therefore be interpreted as ‘utilities’. 
Furthermore, the utility element of that report 
was a set of scenarios not based on primary or 
secondary data sources and thus could not be 
considered reliable or valid.6  Joshi and colleagues139 
used utility estimates of 0.781 for the pretreatment 
and no treatment groups, although this is different 
to the value 0.884, reported in the DEC report. 
Those patients who achieved success, i.e. normal 
height, had a utility of 0.97 applied from the start 
of the second year of treatment. Patients with 
partial success were assumed to acquire a partial 
utility gain defined as 35% less than the full utility 
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gain associated with achieving normal height. The 
value was stated to be between 0.884 and 0.940. 
 
The CADTH study135 did not use absolute utility 
values associated with each health state but  
applied an incremental utility value of 0.04 for 
patients receiving treatment with rhGH. The utility 
increment was estimated from a TTO survey in 
a small sample of adults with TS142 (see below, 
Review of research on qulity of life). The patients 
in the QoL study were asked how many years they 
would be willing to lose from their life to attain  
an average stature. The answers were translated 
into the incremental utility estimate of 0.04. The 
CADTH study135 stated that TS patients do not 
attain an average stature, and so this estimate is 
likely to be an overestimate and bias the result of 
economic evaluation in favour of rhGH treatment. 
 
Estimation of costs 
Joshi and colleagues139 included costs for 
paediatric consultations and rhGH treatment. 
The CADTH study135 also included costs for X-
ray examination. The unit costs reported in 
the economic evaluations reflect the difference 
in clinical practices in Canada and the USA, the 
price difference of the unit of resources expressed 
in Canadian and US dollars, and the difference  
in methodological approach adopted in the two 
studies. For example, the CADTH study135 excluded 
the specialist visits as these do not differ between 
the intervention and the control groups. The total 
incremental cost reported varies according to the 
length of treatment but is consistent between the 
two studies. 
 
Model results 
The cost-effectiveness analysis in the CADTH 
study135 used an incremental difference of 6.5 cm in 
FH between the intervention and control groups, 
based on their clinical review. They calculated the 
undiscounted cost-effectiveness as C$26,529 per 
centimetre of improved FH and the discounted 
incremental cost-effectiveness ratio (ICER) was 
C$23,630 per centimetre of improved FH. They 
estimated an ICER of C$243,078 per QALY  
gained. The authors concluded that for an average 
patient with TS, rhGH treatment is unlikely to be 
cost-effective unless the payer is willing to pay more 
than C$200,000 to obtain a QALY. 
 
Joshi and colleagues139  calculated the difference in 
‘normal height years’ between the intervention and 
the control groups to estimate the incremental cost 
per normal height year. It was assumed that normal 
height was achieved by patients in the intervention 
group, but not in the control group. The 
incremental gain in ‘normal height years’ in the 
cohort of 5- to 16-year-olds was 17.4 (discounted). 
The corresponding value in the cohort of 3- 
to 18-year-olds was 21.1 (discounted), which 
translated into an incremental cost per additional 
year of normal height of $8900 (discounted) in the 
cohort of 5- to 16-year-olds and an incremental 
cost per additional year of normal height of $9300 
(discounted) in the cohort of 3- to 18-year-olds. 
They estimated an ICER of about $37,000 per 
QALY gained for treating children with GHD from 
ages 5 to 16 years and an ICER of about $42,600 
per QALY gained for treating children with GHD 
from ages 3 to 18 years. The authors concluded 
that the cost-effectiveness of rhGH compares 
favourably to accepted threshold values and 
represents reasonable value for money. 
 
In both studies the deterministic one-way analyses 
indicated that the results were sensitive to 
variations in the utility estimate, the starting age 
of treatment, the duration of treatment and the 
daily dosage. The results were also sensitive to 
assumptions about clinical effectiveness139 and to 
variations in the price of rhGH.135 
 
The two economic evaluations arrived at opposite 
conclusions about the value for money of the rhGH 
treatment in children. The economic evaluation 
conducted for the CADTH study135 may provide a 
more reliable estimate of the cost-effectiveness as 
it has used clinical data from a reasonable quality 
RCT and TTO utility estimates. In contrast, the 
assumptions about clinical effectiveness of rhGH 
treatment by Joshi and colleagues139 did not seem 
to be supported by clinical evidence. Furthermore 
they also used indexes, interpreted as utility 
weights, which do not appear to be reliable or 
valid. 
 
Summary and conclusion of 
the systematic review of cost- 
effectiveness studies 
We undertook a systematic review of the literature 
in order to identify existing models in this area. 
The systematic review of published economic 
evaluations identified two North American studies 
relevant to the target population and no studies 
conducted in the UK. The results of the two 
identified studies produced two very different 
estimates of cost-effectiveness. This difference is 
largely due to the choice of utility estimates and 
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assumptions on the effectiveness. As discussed 
below (see next section, below, Review of research 
on QoL), there is a paucity of reliable estimates 
of utility gains associated with GH treatment. 
Therefore, the results of both studies should be 
treated with caution. In particular, Joshi and 
colleagues139 adapted QoL indexes that were not 
derived according to the NICE reference case 
and could not be considered reliable or valid.6 
The literature study did not identify studies that 
we could use for this review and so a de novo 
independent economic model was required. 
 
 
Review of research on QoL 
Systematic review of HRQoL 
studies 
A systematic review was undertaken to identify 
HRQoL studies for rhGH for children. The 
HRQoL searches were undertaken to populate a 
lifetime economic model with utilities to calculate 
QALYs, so studies with adults and children were 
eligible for inclusion. Titles and abstracts of studies 
identified by the search strategy were assessed for 
potential eligibility by two health economists. Full 
text versions of relevant papers were retrieved and 
checked by two health economists. Any differences 
in judgement were resolved through discussion. 
The details of the search strategy for QoL are in 
Appendix 2. 
 
The titles and abstract of the studies identified by 
the search strategy were assessed on the basis of the 
following criteria: 
 
• disease condition as defined in Table 1 (Chapter 
1) of this report 
• primary research using a preference/utility 
based measure for the conditions interest 
• primary research using a generic measure 
[i.e. Short Form questionnaire-36 items (SF- 
36)] that can be translated into a utility-based 
estimate 
• primary research using a condition-/disease- 
specific QoL measure and an algorithm that 
allowed disease-specific QoL to be converted 
into utility values. 
 
Exclusion criteria for the systematic literature 
search were: 
 
• primary research reporting QoL that could 
not be converted into utility values using a 
validated mapping algorithm 
• background or discussion papers that did not 
report a QoL measure for the conditions of 
interest 
• papers reported in language other than 
English. 
 
The search strategy identified 391 articles that were 
potentially relevant. After the abstracts had been 
screened, 24 articles were identified and full papers 
were retrieved for these articles. After checking 
the retrieved studies, six papers met the inclusion 
criteria. These are summarised in Table 34. A 
further targeted search linking height to HRQoL 
is reported below (see Height and health-related 
QoL). 
 
Growth hormone deficiency 
Three relevant studies were identified that met 
the inclusion criteria.145,147,148  Sandberg and 
colleagues148 used the SF-36 in participants with 
GHD. The study reported no baseline data, and 
reported SF-36 only after rhGH treatment had 
finished compared with non-GHD siblings and the 
general population. Therefore, the study was of  
no value in investigating the gain in HRQoL from 
rhGH   treatment. 
 
The second study, by Busschbach and colleagues,145 
used the TTO method, a preference-based 
approach that asks people to quantify the numbers 
of years of life they would be willing to give up 
to overcome a particular state of health. The 
participants were asked the number of years they 
were willing to trade off at the end of their life  
in order to obtain average stature. The TTO was 
completed by people with GHD, TS and CRI (see 
below for TS and CRI). There were 25 adults with 
isolated GHD included in the study. The sample  
of GHD men made only a negligible trade off (less 
than 2%), whereas the sample of GHD women were 
willing to make a slightly larger trade off of around 
2% of their expected length of life to reach average 
height. The major drawbacks with this study were 
the small sample of between 17 and 25 people 
with each condition of interest, the retrospective 
design and the lack of a control group. Also it is 
unlikely that gaining average stature is a realistic 
possibility for most people with the conditions of 
interest. Furthermore, for one of the conditions 
of interest (GHD) the patients had received rhGH 
treatment, and for another condition (CRI) it was 
unclear whether they had or had not received 
rhGH treatment as children. It is likely that any 
rhGH treatment will underestimate the TTO made 
to gain average stature, as these participants have 
already benefited from an increase in extra height. 
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TABLE 34 Characteristics of included QoL studies 
 
Study/ 
Details 
 
Bannink et al.143 
 
Bertella et al.144 
 
Busschbach et al.145 
 
Carel et al.146 
Koltowska-Haggstrom 
et al.147 
 
Sandberg et al.148 
Publication 
year 
2006 2007 1998 2005 2008 1998 
Country The Netherlands Italy The Netherlands France England and Wales USA 
Study type QoL observational cohort QoL observational QoL observational QoL observational Estimated utilities from QoL observational 
 study matched to normal 
population 
cohort study case–control study cohort study matched 
to normal population 
a survey of general 
population in England and 
Wales, and mapped to an 
observational cohort study 
case–control study 
Study 
population 
49 participants with TS 13 participants with PWS 17 participants with 
CO renal failure 
568 participants with 
TS 
894 participants with CO 
and AO GHD 
140 participants with 
GHD 
   25 with TS  CO-onset GHD occurred 53 participants with 
25 with GHD in 21.6% GHD who had siblings 
Study 
population age 
19.6 ± 3.0 years (14.8–25.8 
years) 
27.08 ± 4.55 years (20–33 
years) 
Between 24 years ± 4.1 
(ISS) and 28 years ± 4.9 
(TS) 
22.6 ± 2.6 years 40 ± 16.5 years 26.1 ± 6.5 years (18.8– 
46.9 years) 
Comparator 
population 
Dutch general population No comparator 44 normal short 
participants (not 
diagnosed with ISS) 
French general 
population 
England and Wales general 
population 
53 controls (unaffected 
siblings) 
Intervention 
(s) 
GH treatment was for 
7.1 ± 2.7 years 
GH treatment in 5 
participants, but had 
ceased treatment 1–4 
years before being 
enrolled in the study 
GHD treated with 
rhGH during childhood 
GH treatment for 
4.8 ± 2.2 years 
72% received estrogen 
treatment 
GH treatment Pituitary-derived rhGH 
and recombinant GH. 
GHD treatment was for 
4.5 ± 3.1 years 
(0.9 to 14.3) 
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Study/ Koltowska-Haggstrom 
Details Bannink et al.143 Bertella et al.144 Busschbach et al.145 Carel et al.146 et al.147 Sandberg et al.148 
Included QoL SF-36 SF-36 TTO SF-36 QoL-AGHDA with utility SF-36 
instrument     weights from EQ-5D 
used 
Time period HRQoL evaluation HRQoL evaluation HRQoL evaluation in HRQoL evaluation HRQoL evaluation at After rhGH 
when HRQoL occurred 2.8 (1.6) years at the beginning, adulthood after rhGH occurred 6 years after baseline and last reported discontinuation 
instruments after rhGH discontinuation   during and after rhGH discontinuation if rhGH discontinuation visit follow up for 1–6 
administered discontinuation applicable years 
Methodology The SF-36 was The SF-36 was TTO asked the A postal survey Both the EQ-5D and QoL-   Eligible GHD subjects 
of collecting administered after rhGH administered at the participants the including the SF-36 AGHDA were completed completed SF-36 
QoL data treatment had been beginning of the maximum number of and GHQ-12 sent to by general population questionnaire over the 
discontinued for at least 6 treatment and then again years they were willing participants A regression model was telephone, in addition 
months and FH had been at intervals of 6, 12 and to give up in order to used to estimate utility to same-sex siblings 
reached 24 months to patients obtain average stature weights for QoL-AGHDA 
and parents  items in an observational 
study 
Results Women with TS treated PWS showed significant The patients with GHD   HRQoL was not QoL-AGHDA scores The GHD sample had 
UTILITY 
with rhGH reported improvement during were hardly prepared statistically different were higher in patients only a significantly 
significantly better HRQoL    rhGH therapy on SF- to make a trade-off from the reference with CO than with AO, lower score from the 
in social functioning, role 36 in vitality, physical Participants with TS values obtained for both at baseline 0.75 (SD sibling control group 
limitations, and emotional functioning, general or renal failure had an young French women 0.173) vs 0.64 and at the on general health scale 
and bodily pain domains health, social functioning,   estimated reduction in from the general last reported visit) 0.82 (p < 0.05) The rest 
compared with normal role limitation because QoL of 2–4% population (SD 0.167) vs 0.76. of the QoL domains 
population of emotional problems, 
Women with TS made  Patients with CO-GHD 
showed not significant 
Other domains were general mental health an average TTO for gained less than AO 
difference 
roughly equal to normal and total scale their infertility of 9% patients with regard to the 
population total gain 0.18 (SD 0.488) 
vs 0.35 
AGHDA, adult growth hormone deficiency assessment; AO, adult onset; CO, childhood onset; EQ-5D, European Quality of Life-5 Dimensions; GHQ-12, General Health 
Questionnaire-12; ISS, idiopathic short stature. 
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It was decided that this study did not provide a 
robust enough estimate of preference of health 
states to be used in the model. 
 
The third study, by Koltowska-Haggstrom and 
colleagues,147   mapped  European  Quality  of  Life-5 
Dimensions quality of life measure (EQ-5D) values 
to a disease-specific QoL assessment of GHD 
(QoL-AGHDA) instrument from a survey. This was 
then used to transform QoL-AGHDA scores from 
a cohort of patients from the Kabi International 
Metabolic Database (now Pfizer) (KIMS) database 
into utility-weighted QoL-AGHDA scores (QoL- 
AGHDAUTILITY). A good response rate of 84% was 
achieved, and 921 individuals from the general 
population of England and Wales responded to the 
survey. A regression model was used to estimate 
utility weights for QoL-AGHDA (R2 = 0.42). The 
EQ-5D responses were used as the dependent 
variable and the QoL-AGHDA responses were used 
as independent dummy variables with age as a 
covariate. 
 
The patient cohort from the KIMS database 
consisted of 894 patients from England and 
Wales. However, only 21.6% had childhood-onset 
(CO)-GHD (applicable to the scope). The study was 
carried out in adults and it is unclear whether the 
CO-GHD group had had prior rhGH treatment. 
This may undervalue gain in HRQoL if this is the 
case. An inclusion criterion for the study was no 
treatment for rhGH for a minimum of 6 months 
prior to entry. The mean age for the whole cohort 
was 40 years old (SD16.5) at diagnosis and 45 years 
old (SD 14.3) at entry into KIMS. The study 
reported that patients with CO-GHD had a QoL- 
AGHDAUTILITY  value of 0.75 (SD 0.173) at baseline 
compared to the last reported visit score of 0.82 
(SD 0.166). The study reports mean gain in QoL- 
AGHDAUTILITY  per year of 0.05 (SD 0.117). They 
also reported a total gain of 0.18 (SD 0.488), and 
it is assumed that this is the QALY gain over the 
study duration worked out using trapezoid formula 
compared to the baseline QoL-AGHDAUTILITY 
values. A last observation carried forward (LOCF) 
method was used. The average length of follow-up 
in the study for the CO-GHD was not reported and 
so is not possible to verify the QALY gain or gain 
per year. 
 
In the combined cohort of adult-onset GHD (AO- 
GHD) (78%) and CO-GHD (22%) the greatest 
improvement in utility occurred within the first 
year of rhGH treatment. Subsequently, the QoL 
improvement is maintained when compared with 
the general population over a 6-year follow-up. It is 
unclear whether this benefit from rhGH treatment 
is maintained after treatment has stopped. 
 
The limitations of this study were that it was 
observational with no control, and that the EQ-5D 
had not been conducted amongst the participants 
of the KIMS database. Furthermore, the regression 
model used to translate EQ-5D scores to disease 
specific measure explained less than one-half 
of the sample variation of the EQ-5D values. 
Nevertheless, the study provided an estimate of 
utility at baseline and at the last reported visit 
in one of the conditions of interest. The study’s 
generalisability to the other conditions of interest 
is unclear and it was felt that any attempt to link 
utilities in this study to the other conditions of 
interest was difficult due to the difference in height 
outcomes. 
 
Turner’s syndrome 
There were three studies that met the inclusion 
criteria for people with TS.143,145,146  Two143,146  of 
these were not useful as they reported SF-36 only 
scores after rhGH treatment had been completed 
compared to a cohort of women from the general 
population. Therefore, they could not be used 
to investigate the gain in HRQoL from rhGH 
treatment. Busschbach and colleagues142 used a 
TTO method (described above) with 25 women 
with TS who had not received rhGH treatment 
as children. Their average TTO was small in the 
region of 4% of their life-years to reach an average 
height for the general population. 
 
Prader–Willi syndrome 
One study met the inclusion criteria.144 This was 
potentially useful as it shows the gain in HRQoL 
from rhGH treatment over a 24-month period. 
However, the study had several limitations that 
make its results highly uncertain. It was a small 
study with only 13 Italian adult participants with 
PWS, of whom five had previously undergone 
rhGH treatment. There was no control group. At 
the last recorded observation (24 months) there 
were only nine participants left in the study. A new 
study mapping from SF-36 to a UK based EQ-5D 
preference-based utility index has recently been 
published, which provides an algorithm for this to 
be done.149 
 
However, the PWS QoL study is for adults who have 
received rhGH and it is unclear how this relates to 
the QoL gain for a group of children, and whether 
this QoL benefit would be maintained throughout 
their lifetime. 
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CRI 
One study was identified that met the inclusion 
criteria.142  Busschbach and colleagues used a TTO 
approach for 17 adults who had childhood-onset 
renal failure. It is unclear whether the participants 
received any rhGH treatment prior to the TTO 
assessment. The participants were asked what 
percentage of the years of their expected life 
they were willing to trade to reach normal height 
and to not experience health states involving 
a kidney transplant and dialysis. The resulting 
TTO associated with renal failure was 4% to reach 
normal height. 
 
SGA 
No relevant HRQoL studies that were identified 
met the inclusion criteria. 
 
SHOX-D 
No relevant HRQoL studies that were identified 
met the inclusion criteria. 
 
Height and health-related QoL 
The NICE reference case clearly states that the 
measure of health outcome used in the cost- 
effectiveness analysis should be QALYs calculated 
with utilities derived from a validated, generic, 
preference-based measure of HRQoL.138  The 
clinical effectiveness review in Chapter 3 found 
no RCTs that reported HRQoL measures as an 
outcome and the additional search for HRQoL 
studies (above) located only one relevant study by 
Koltowska-Haggstrom147 in one of the conditions 
of interest (GHD) that was strictly applicable to the 
NICE reference case.138 
 
Therefore, a targeted search was conducted to 
identify publications that reported gains and losses 
in utility in relation to variation in height, as height 
is one of the primary outcome measures of GH 
treatment. Details of the search are in Appendix 
2. One full paper by Christensen and colleagues150 
was identified. 
 
The study used the 2003 Health Survey for 
England, with 14,416 observations for adults (aged 
> 18 years).151  HRQoL was measured using the EQ-
5D with the UK tariff. Height was converted from 
centimetres to HtSDS using a UK population 
algorithm. Inter-relationships between variables 
were assessed using ordinary least squares (OLS) 
linear regressions, controlling for age, weight 
and gender. All OLS analyses were controlled 
for multicollinearity (close interaction between 
explanatory variables). Where there were any 
highly correlated variables (weight and BMI) then 
one variable was omitted from the regression. The 
regression analyses included two-level categorical 
variables (‘sex’, ‘limiting longstanding illness’ and 
‘social class’) to explore the relationship between 
height and HRQoL while controlling for these 
confounding factors.150 
 
There was a positive correlation between an 
increase in height and a participant’s EQ-5D score. 
The mean EQ-5D scores were lower in the shorter 
compared with taller subjects, as well as lower than 
the overall population mean. The authors’ report 
an analysis of variance (ANOVA) combined with 
post hoc Tukey’s Honestly Significant Difference 
(HSD) test for homogeneous subgroups, which 
showed that the sample could be split into three 
meaningful subgroups, each significantly different 
(p < 0.05) from each other in terms of their EQ-  
5D scores. The first subgroup ‘HtSDS ≤ –2.0’ had 
significantly lower EQ-5D scores than the second 
group ‘–2.0 > HtSDS ≤ 0’ and the third group 
‘HtSDS > 0’. The second subgroup had significant 
lower scores than the third group. A multivariate 
linear analysis using the previously identified 
subgroups was undertaken to predict the variation 
in HRQoL. The full model predicted only one- 
third of the sample variation in EQ-5D (R2 = 0.318, 
0.343 and 0.290) based on 11,946 observations.150 
 
The model predicted that for those people shorter 
than –2.0 HtSDS, an improvement of 1 HtSDS  
will result in a change in EQ-5D score of 0.061. 
However, for the subgroup between –2.0 and 0 
HtSDS the gain in EQ-5D is much reduced (a 
1- HtSDS improvement increases EQ-5D score by 
only 0.010). One drawback to the Christensen 
study150 is that the population used to elicit QoL 
values are not from the conditions of interest but 
from the general population. 
 
Summary and conclusions of the 
QoL review 
The systematic review of QoL identified six  
studies that met the inclusion criteria. None of the 
studies was in a childhood population. This is to 
be expected, given the difficulties in conducting 
preference-based QoL studies in children.152  Three 
studies reported the SF-36 in adults but were not 
useful on further examination, as they reported 
SF-36 scores only after rhGH treatment. One poor- 
quality study reported SF-36 at baseline, 6 months, 
12 months and 24 months for a small cohort of 
adult participants with PWS, and the scores from 
this study were mapped to a UK-based EQ-5D 
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preference-based utility index by a subsequent 
study. 
 
There were only two studies that reported change 
in QoL using preference-based measures in the 
conditions of interest.145,147  The first study145  used 
TTO methodology for people with GHD, TS and 
CRI. The number of years that the participants 
were willing to trade to reach average height was 
in the range of 0–4%. However, there were several 
limitations to this study and it was felt that it did 
not generally provide a robust estimate of utility 
gain from rhGH treatment. The second study147 
used a regression model to give utility weights 
(based on the EQ-5D from a UK population) to the 
disease-specific QoL-AGHDA. The KIMS database 
was then used to transform patients QoL-AGHDA 
values into QoL-AGHDAUTILITY values. However, 
it was in an adult population and it is unclear 
whether they had previously had rhGH treatment 
as children. This study was specific to patients with 
GHD and is unlikely to be generalisable to the 
other conditions of interest. 
 
An additional targeted search was undertaken for 
QoL in relation to height. One study was identified 
by Christensen and colleagues,150 which provided 
utility estimates based on the EQ-5D for different 
HtSDS from the Health Survey for England for 
an adult general population. The study provides a 
common utility gain that could be compared across 
all of the conditions of interest that could be used 
with the clinical effectiveness outcomes from the 
RCTs. 
 
Based on the review of the QoL literature, there  
is likely to be a small gain in utility for individuals 
receiving GH treatment. However, this is based on 
a proxy measure of gain in height from shorter 
people in the general population. This excludes 
many relevant potential benefits and disadvantages 
of rhGH treatment that it is not possible to 
capture without good-quality evidence from the 
conditions of interest. This is especially true for 
PWS as additional HRQoL gain from improved 
body composition is unlikely to be captured with 
this method. Furthermore, there is also uncertainty 
over the impact of extrapolating back into 
childhood with adult utility data. 
 
 
Review of the 
manufacturers’ submissions 
Six of the seven manufacturers submitted evidence 
to be considered for this review. Five out of the six 
MSs consisted of a written report and an electronic 
model supporting the cost-effectiveness analyses. 
The sixth MS by Sandoz did not comply with the 
NICE template for the MTA and presented a 
description of the product (Omnitrope) and what 
appears to be a cost-minimisation analysis using 
Genotropin as a comparator (defined as a reference 
product). The collaborative submission is appraised 
below and a critique of the Sandoz submission is 
presented below (see Sandoz submission to NICE). 
 
A de novo economic model has been used by the 
five collaborating manufacturers involved in the 
submission to the MTA of rhGH. Under Pfizer’s 
leadership, a common modelling framework 
was developed and used in the cost-effectiveness 
analysis of treatment in children with GHD, TS, 
PWS, CRI and SGA. Each of the collaborating 
manufacturers presented essentially the same 
model with some minor modifications, for 
example changes in the unit price of rhGH. The 
model developed was based upon the previous 
HTA report6  but has been extended to consider 
longer-term outcomes in order to estimate cost- 
effectiveness in terms of QALYs. One manufacturer, 
Merck Serono, produced its own version of the 
model and so the health benefits differ slightly to 
the other models. 
 
The MSs also included a rapid review on QoL 
that was undertaken by Eli Lilly on behalf of the 
collaboration of manufacturers. The aim of the 
main review was to provide a rapid search to 
identify the key papers that explored the impact of 
short stature in childhood, and the impact of short 
stature in transition to adulthood and as adults. 
The overall conclusion from this review highlighted 
the inconsistent findings relating to the role of 
short stature in QoL and psychosocial functioning 
in both childhood and adulthood. 
 
Modelling approach 
In the MSs, the base-case analyses estimated 
the incremental cost of rhGH per centimetre of 
height gained relative to no treatment (in order 
to compare with previous HTA report6) and the 
incremental cost of rhGH per QALY gained 
relative to no treatment. The utility scores used 
in the model in children with GHD, TS, CRI and 
children who were SGA were based upon the study 
by Christensen and colleagues,150 discussed above 
(see Description of the identified studies). A gain 
in height was assumed to be associated with QoL 
improvements, which was assessed using the EQ- 
5D utility scale. In patients with PWS the QoL gain 
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Parameter GHD TS PWS CRI SGA 
No. of patients 
Start of treatment 
 
 
7036 
 
 
2749 
 
 
485 
 
 
806 
 
 
990 
Near adult height 2547 1349 75 157 127 
Age      
Start 9.14 9.3 7.42 9 8.18 
End 16.37 16.45 15.21 13.95 14.18 
Dropout rate 
Percentage at 1 year 
 
 
0.04 0.0273 0.02 0.117 0.03 
 
 
 
 
 
 
 
was based upon a small study of adult patients 
with PWS, together with an estimation of the 
benefits associated with a reduced risk of diabetes. 
The assumptions used to derive QoL utility 
improvements are discussed above (see Review of 
research on QoL). 
 
The economic evaluation of rhGH treatment in 
conditions such as GHD, TS, SGA and CRI is  
based on a single clinical effect of additional height 
gained as a result of treatment. This clinical effect 
and many of the other parameters used in the 
model are estimated from the Kabi International 
Growth Study (KIGS) database,153 which is a large- 
scale collaborative database developed by Pfizer 
for the safety and efficacy of treatment with rhGH. 
It includes data from more than 60,000 treated 
patients in over 50 countries for all licensed 
indications, i.e. GHD, TS, PWS, SGA and CRI. 
Table 35 shows the input parameters used in the 
manufacturers’ model that have been derived  
from the KIGS database. The costs used in the 
manufacturers’ model were based upon those used 
in the previous HTA report, and inflated to current 
prices where appropriate.6 
 
The cost-effectiveness analysis of rhGH treatment 
in PWS is based on an alternative structure of the 
model that estimates the utility gain based on a 
small study of 13 adult patients with PWS144 (see 
Review of research on QoL, above) who received 
rhGH for 2 years and a further utility gain for 
reduced diabetes risk. However, the PWS QoL  
study is for adults who have received rhGH and it  
is unclear how this relates to the QoL gain for a 
group of children, and whether this QoL benefit 
would be maintained throughout their lifetime. 
Furthermore, the two methods154,155  used by the 
Pfizer submission to translate SF-36 scores into 
utilities were not based on choice-based methods 
like TTO or SG, which produce utilities more 
rigorously.141 The model assumes that individuals 
with PWS and diabetes would have a 10% lower 
QoL than those without. Based on Pfizer’s 
submission to the Pharmaceutical Benefits Advisory 
Committee in Australia, it was assumed that the 
prevalence of diabetes in patients with PWS would 
reduce from 8% to 2%, although it was not possible 
to verify these assumptions in the reference 
provided. 
 
An alternative model structure that allowed for 
the second clinical effect (a reduction in the risk 
of osteoporosis) was also presented in a scenario 
analysis for GHD. In this model it was assumed that 
a proportion of GHD children continue treatment 
until they reach the age of 25 years. 
 
 
TABLE 35 Input parameters from MSs from KIGS database (from Pfizer MS) 
 
 
 
 
 
 
 
 
 
    
   
   
Dose 
0–17 years of age (mg/kg/day) 
 
 
0.03 
 
 
0.04 
 
 
0.03 
 
 
0.04 
 
 
0.04 
Utility 
Treated 
 
 
0.83 
 
 
0.8 
 
 
0.76 
 
 
0.8 
 
 
0.81 
Untreated 0.69 0.69 0.67 0.69 0.69 
HtSDS 
Treated 
 
 
–1.17 
 
 
–2.24 
 
 
–1.36 
 
 
–2.17 
 
 
–2.01 
Untreated –2.99 –3.18 –2.22 –2.99 –3.23 
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The manufacturers’ model makes the following 
assumptions: 
 
1. Patients with conditions of interest have the 
same life expectancy as the general population 
of England and Wales in the treated and 
untreated groups. 
2. Patients can continue rhGH treatment or 
discontinue treatment at the end of 1 year. 
3. Untreated children do not gain any utility 
benefit throughout the course of the lifetime of 
the model. 
4. Treatment costs and monitoring costs are 
applied over the treatment years. Health 
benefits, as measured by QoL associated with 
particular attained heights, are maintained 
over patients’ lifetimes. The full utility value is 
applied after 2 years of treatment. 
5. Compliance is assumed to be 90% in the base- 
case analysis and this was assumed to not 
impact efficacy. 
6. Adverse events are not considered in the model 
for both the treated and non-treated patients. 
7. In the base case, for all conditions except 
PWS, rhGH treatment affects only FH and 
does not affect the risk of morbidities, such as 
osteoporosis fracture or diabetes. 
8. The MS estimated the average height at the 
end of treatment for the control group from 
the previous HTA report. 
Appraisal of the manufacturer cost-
effectiveness analysis 
A summary of the MS compared with the NICE 
reference case requirements138  is given in Table 36 
and indicates that the submission meets most of the 
requirements. See Appendix 9 for a tabulation of 
the critical appraisal of the submission against the 
Drummond and colleagues’ checklist.136 
 
Cost-effectiveness results 
The mean daily per-patient cost for each of the 
manufacturer’s GH treatments was based upon the 
unit cost shown in Table 37. Merck Serono stated 
that there will be a reduced cost of £20.87 through 
the use of the Merck Serono Easypod™, which  
they report will reduce vial wastage and increase 
compliance. 
 
The base-case analyses for Pfizer, Eli Lilly, Ipsen 
and Merck Serono are shown in Table 38. Merck 
Serono produced their own version of the model 
and so the health benefits differ slightly from the 
other models. 
 
The base-case results for the Novo Nordisk model 
using KIGS data are shown in Table 39. They also 
reported alternative ICERs using patient level data. 
 
 
 
 
TABLE 36 Assessment of MS against NICE reference case requirements 
 
NICE reference case requirements Included in submission 
Decision problem: as per the scope developed by NICE  
Comparator: no treatment alternative  
Perspective on costs: NHS and PSS  
Perspective on outcomes: all health effects on individuals  
Type of economic evaluation: cost-effectiveness analysis  
Synthesis of evidence on outcomes: based on a systematic review No evidence synthesis 
Measure of health benefits: QALYs  
Description of health states for QALY calculations: use of a standardised and validated  
generic instrument  
Method of preference elicitation for health-state values: choice-based method (e.g.  
TTO, SG, not rating scale)  
Source of preference data: representative sample of the public  
Discount rate: 3.5% p.a. for costs and health effects  
, yes. PSS, Personal Social Services. 
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TABLE 37 Unit cost of rhGH for different manufacturers 
 
Manufacturer/product Unit cost (£/mg) 
Genotropin (Pfizer) 23.19 
Humatrope (Eli Lilly) 18.00 
NutropinAq (Ipsen) 20.70 
Saizen (Merck Serono) 23.19 
Manufacturers’ conclusions 
The authors suggested that many of the health 
benefits associated with rhGH treatment are not 
quantifiable and cannot be modelled easily. Many 
of these benefits would improve overall patient 
QoL and, possibly, duration of life. These benefits 
include self-esteem, improvements in sleep and 
Norditropin SimpleXx (Novo 
Nordisk) 
21.39 concentration, and increased appetite as well as 
increases in LBM, total bone mass and muscle 
strength. These benefits may lead to reduced risk 
of diabetes, obesity and cardiovascular diseases. 
TABLE 38 Base-case results for Pfizer, Eli Lilly, Ipsen and Merck Serono 
 
 
Manufacturer 
 GHD 
continueda GHD 
 
TS 
 
PWS 
 
CRI 
 
SGA 
 Incremental QALY 3.48 3.48 2.83 2.30 2.53 2.98 
 Height gain (cm) 32.24 32.24 7.95 25.59 4.48 21.92 
Pfizer Incremental cost (£) 72,003 61,124 84,078 74,849 40,325 54,088 
 ICER (£/QALY) 20,673 17,552 29,757 32,540 15,962 18,167 
 Cost per cm gain (£) 2233 1896 10,576 2925 9001 2467 
Eli Lilly Incremental cost (£)  57,043 65,654  31,574 42,340 
 ICER (£/QALY)  16,176 36,237  12,498 14,221 
 Cost per cm gain (£)  1747 8258  7048 1932 
Ipsen Incremental cost (£) 65,198 54,779 75,243  36,129  
 ICER (£/QALY) 18,721 15,730 26,630  14,301  
 Cost per cm gain (£) 2022 1699 9464  8065  
Merck Seronob Incremental cost (£) 72,719  84,077  40,325 54,087 
  65,711  75,847  36,416 48,839 
 ICER (£/QALY) 20,881  29,757  15,962 18,167 
  18,869  26,844  14,414 16,404 
 Cost per cm gain (£) 2256  10,576  9001 2467 
  2038  9540  8129 2228 
a  GHD continued is the scenario with rhGH treatment during childhood and a transition period. 
b  Figures in italics are for the EasyPod device. 
 
 
TABLE 39 Base-case results for Novo Nordisk using KIGS database 
 
GHD continueda GHD TS CRI SGA 
Incremental QALY 3.70 3.70 2.89 2.90 2.77 
Height gain (cm) 27.45 27.45 7.95 3.65 5.67 
Incremental cost (£) 71,264 58,637 79,976 41,388 51,745 
Cost per QALY (£) 19,276 15,861 27,720 14,254 18,655 
Cost per cm gain (£) 2596 2136 10,060 11,345 9123 
a  GHD continued is the scenario with rhGH treatment during childhood and a transition period. 
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The manufacturers concluded that their economic 
analyses demonstrated that rhGH is cost-effective 
for the treatment of short children with GHD, 
CRI and those born SGA, and borders on cost- 
effectiveness for the treatment of TS and PWS. 
They stated that the values for cost/centimetre 
compared favourably to those reported in the 
previous NICE assessment6 and supported the 
recommendation of rhGH for children with GHD, 
TS and CRI, plus its extension to include SGA 
children. 
 
Summary of general concerns 
• Clinical effectiveness estimates for height gain 
were taken from an observational cohort rather 
than an RCT. It is not clear whether the subset 
of the KIGS database chosen was representative 
of the UK patient population or, for example, 
whether the subset chosen may be more severe. 
• For three of the conditions (GHD, PWS 
and SGA) the estimates of height gain, in 
centimetres, were considerably higher than 
those shown in the trials due to the estimates 
used for end height in the control group. 
• All conditions, except PWS, used mortality 
rates from the general population. It is likely 
that individuals with these conditions, in 
particular CRI, will have increased mortality 
compared with the general population. 
• The manufacturers have used the Christensen 
study150 for their HRQoL utility values but 
have not taken these from the regression 
analysis from this study. Instead, they have 
used the relationship between EQ-5D and 
height without controlling for other factors. 
Utility gain attributed to height is likely 
to be capturing the combined effects of 
other (unobserved) variables, such as age, 
longstanding illness and gender. For example, 
older generations generally have lower 
QoL because of their age. Not controlling 
for other factors, in particular age, results 
in the overestimation of the utility values. 
Furthermore, the group with the lowest height 
and QoL (< –3 SDS) had few observations and 
individuals in this group were generally elderly 
(mean age > 70 years). 
• Treatment cost is calculated by rounding up to 
the nearest whole year of treatment. 
• There is high uncertainty associated with the 
assumptions and sources used to estimate QoL 
gain in the PWS model. These were based on  
a small study of adult patients with PWS and 
it is unclear how this relates to the QoL gain 
benefit would be maintained throughout their 
lifetime. The methods used to derive values 
from the SF-36 for utilities were based on  
rating scales and therefore did not use choice- 
based methods, such as the SG and TTO. QoL 
gain also estimated utility gain from reduced 
diabetes prevalence but this evidence could not 
be verified. There are considerable difficulties 
extrapolating the benefit from treating children 
with rhGH to their health benefits as adults. 
 
Sandoz submission to NICE 
Sandoz presented an analysis comparing 
Omnitrope with  Genotropin. The MS contained  
a comparison of the annual cost of treatment with 
Omnitrope and with Genotropin in patients with 
GHD and TS. However, the MS did not comply 
with NICE guidance for a MTA,138  as QALYs were 
not estimated and a cost-effectiveness analysis  
was not presented. The MS attempted a cost- 
minimisation analysis, implicitly suggesting that 
treatment with Omnitrope is equally effective 
as treatment with Genotropin (in terms of 
additional height in children with GHD and TS) 
but is associated with less cost to the UK NHS.  
A critical appraisal of the Sandoz MS is given in 
Appendix 10. 
 
 
SHTAC independent 
economic evaluation 
Overview 
A comparison of the costs and benefits of rhGH 
compared with no treatment in cohorts of children 
with GHD, TS, PWS, CRI and SHOX-D and 
children who are SGA was made using decision- 
analytical models. Models were constructed in 
Microsoft excel according to standard modelling 
methods.138 To identify data to populate the model, 
systematic searches were conducted to locate 
studies on the natural history and epidemiology of 
the indicated conditions, HRQoL and costs. 
 
Costs were derived from published studies (where 
available), and from national and local NHS unit 
costs. The model was from the perspective of 
the NHS and PSS, as only these direct costs were 
included. The model estimates the lifelong costs 
and benefits from rhGH treatment. The costs and 
benefits were discounted at 3.5%, as recommended 
by NICE.138  The base year for the costs was 2008. 
The intervention effect in terms of improvement 
in HtSDS was derived from the systematic review of 
for a group of children, and whether this QoL effectiveness reported in Chapter 3. The outcome 
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of the economic evaluation is reported as cost per 
QALY gained and cost per centimetre gained. 
 
Description of the model 
A decision-analytical model was designed for the 
economic evaluation of rhGH for treatment of 
GHD, TS, PWS, CRI, SGA and SHOX-D, and was 
based upon one developed in the previous HTA 
report.6  The current model compares a cohort of 
patients receiving rhGH during their childhood 
with a cohort of patients who were not treated  
with rhGH. The state transition Markov model  
has a cycle length of 1 year and a lifetime horizon. 
A Markov model was used as these are suitable 
for lifetime analyses with few health states.156  The 
base-case decision-analytical model includes health 
states for alive and dead. The England and Wales 
population mortality rates are applied in each cycle 
for patients, with an adjustment using the SMRs for 
each of the conditions. 
 
The model assumes that a daily subcutaneous 
injection of rhGH is administered for the duration 
of treatment, unless a patient from the treatment 
cohort drops out of treatment or dies. The 
parameters of the model that determine the age  
at the start of treatment, the duration of treatment 
and the annual dropout rates are estimated from 
the KIGS database described in the MS or based 
upon advice from our clinical advisory group, and 
vary between conditions. A daily dose is calculated 
according to the child’s weight. The dose regimen 
corresponds to the licensed indication of rhGH in 
children (and adults, in a scenario analysis of the 
GHD cohort). 
 
Health-care resources included for the cost of 
patient monitoring apply to both the treatment 
and no treatment cohorts. The cost categories and 
unit costs are consistent with the costs used in the 
previous HTA report for rhGH.6  The discount rate 
of 3.5% is applied to both costs and final outcomes. 
 
Patients from the treatment cohort who stay in 
treatment receive a benefit of an additional height 
gain relative to patients in the no treatment 
cohort. Patients who drop out of treatment 
stop accumulating height gain, so their growth 
progression is no different from the height gain  
in the no treatment cohort. In each yearly cycle, 
individual HRQoL is estimated based upon their 
height gain. Individuals are assumed to maintain 
the same HRQoL after treatment has stopped for 
the rest of their lifetime. In each cycle, the total 
costs and QALYs are calculated by multiplying the 
individual costs and HRQoL by the number of 
people in the cohort still alive for the treatment 
and no treatment cohorts. The total lifetime costs 
and QALYs are calculated for the treated and 
non-treated groups by aggregating the costs and 
QALYs in each cycle. The total discounted QALY 
gain, and cost of treatment for the treatment and 
no treatment cohorts are calculated. Thus, the cost- 
effectiveness of rhGH is calculated: 
 
Cost-effectiveness = 
     Cost for treatment cohort – Cost for no treatment cohort   
QALYs for treatment cohort – QALYs for no treatment cohort 
 
 
 
Parameters used in the model and the data sources 
used to derive them are described in more detail 
below (see Model validation). 
 
A list of the model assumptions is given below. 
Assumptions are applied to all conditions unless 
explicitly stated otherwise. All assumptions were 
tested in sensitivity analyses. 
 
• The diagnostic costs were not included in 
the analysis as they were assumed to be the 
same for both rhGH-treated and no-treatment 
patients. 
• The base case assumes no dropout or 
discontinuation of treatment. This was based 
upon advice from our clinical advisory group 
that this was likely to be a relatively rare 
occurrence. The base-case model therefore 
evaluates just rhGH treatment versus no 
treatment. 
• There are two health states for alive or dead in 
the model, and the transition between them is 
based on age-related mortality data. 
• The mortality rates were assumed to be higher 
than for the England and Wales general 
population estimates for untreated and treated 
cohorts for all conditions. 
• It was assumed that there would be no 
reduction in mortality as a result of rhGH 
treatment. There is a lack of data to assume 
otherwise. 
• The model time horizon is 100 years and all 
individuals are assumed to die by this age. 
• Effectiveness estimates for the conditions 
were based on selection of the best-quality 
evidence from the clinical effectiveness review 
in Chapter 3. RCTs were only selected if the 
follow up length was at least 2 years after 
the start of treatment. Where there were no 
appropriate RCTs, long-term observational 
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studies were considered. In the case of SGA, 
the most appropriate RCT was for only 1 year. 
• Compliance was assumed to be 85% in the 
base case, with no loss of efficacy for rhGH 
treatment.157 
• An additional scenario was undertaken for the 
GHD condition where treatment continued 
for a transition phase into adulthood to age 
25. This was only applicable for 34% of the 
GHD population.158  No additional benefit, in 
terms of height gained, was assumed from this 
additional treatment. 
• In the treatment and no-treatment cohorts, 
all children are monitored until they reach 
adulthood, assumed to be the age of 17 years. 
 
Evaluation of uncertainty 
The evaluation of the cost-effectiveness of GH 
treatment is based on uncertain information 
about variables, such as clinical effect, HRQoL 
and resource use. This uncertainty was evaluated 
using deterministic and probabilistic sensitivity 
analyses. One-way deterministic sensitivity analyses 
were conducted to evaluate the influence of 
individual parameters on the model results and to 
test the robustness of the cost-effectiveness results 
to variations in the structural assumptions and 
parameter inputs (see Sensitivity analyses, below). 
 
Multiparameter uncertainty in the model 
was addressed using probabilistic sensitivity 
analysis (PSA) (see below).159 In PSA, probability 
distributions are assigned to the point estimates 
used in the base-case analysis. The model is 
run for 1000 iterations, with a different set of 
parameter values for each iteration, by sampling 
parameter values at random from their probability 
distributions. The uncertainty surrounding 
the cost-effectiveness of the GH treatment is 
represented on a cost-effectiveness acceptability 
curve (CEAC) according to the probability that the 
intervention will be cost-effective at a particular 
willingness-to-pay threshold. Appendix 12 reports 
the parameters included in the PSA, the form of 
distribution used for sampling each parameter, 
and the upper and lower limits assumed for each 
variable. 
 
Model validation 
The Southampton Health Technology Assessments 
Centre (SHTAC) model was validated by checking 
the model structure, calculations and data inputs 
for technical correctness. The completed cost- 
effectiveness model was verified by another health 
economist. The SHTAC model was checked for 
internal consistency against the MS economic 
64 models by running the SHTAC model with the 
inputs used in MS models to ensure similar 
results. The robustness of the model to changes in 
input values was tested using sensitivity analyses  
to ensure that any changes to the input values 
produced changes to the results of the expected 
direction and magnitude. Finally, the model results 
were compared with those from previous studies 
including the previous HTA report and this is 
discussed in more detail in Chapter 6. 
 
Data sources 
Life expectancy 
Several studies have attempted to assess the 
mortality rate of adults with the conditions of 
interest. Nielsen and colleagues160 conducted a 
meta-analysis to assess overall SMR for men and 
women with benign pituitary disease. Six studies 
were included in the meta-analysis of sex-specific 
mortality. Studies (total 5412 patients) reported 
SMR for men of 2.06 (CI 1.94 to 2.2) and women 
2.8 (CI 2.59 to 3.02). However, these analyses were 
for hypopituitarism rather than GHD. 
 
Shoemaker and colleagues161 followed up 3439 
women in the UK, who were diagnosed with TS 
between 1959 and 2002, to the end of 2006. 
Mortality in women with TS is three times higher 
than in the general population, is raised for almost 
all major causes of death, and is raised at all ages. 
SMR was 3.9 in women aged 15–44 years old and 
2.6 in women aged 45–84 years. 
 
Population-based morbidity and mortality data 
for PWS are not available, except from regional 
cross-sectional surveys.162 A recent regional survey 
in England indicates high morbidity and mortality 
rates. Lifetime mortality rates were roughly three 
times higher than the general population. Within 
these studies the data are insufficient to construct 
survival curves. 
 
Mortality and causes of death in treatment for 
children with end-stage renal disease was estimated 
in a Dutch cohort study between 1972 and 1992.163 
Of all 381 patients, 85 had died. The SMR was 31.0 
over this period and 21.0 in the last cohort between 
1992 and 2002. 
 
Kajantie and colleagues164   studied the relationship 
between small size at birth and all-cause and non- 
cardiovascular mortality in 13,830 individuals born 
between 1924 and 1944 in Helsinki, Finland. They 
found that small size at birth is associated with 
increased all-cause mortality at all ages among 
adult women but only with premature death in 
adult men. 
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We were unable to find any information on 
mortality rates for SHOX-D. 
 
Using UK life tables, we estimated the life 
expectancy of adults with these conditions using 
the SMRs described above. Normal adult life 
expectancy was estimated to be 75 years for men 
and 79 years for women. Life expectancy for 
patients with hypopituitarism was reduced to 
68 years for men and 70 years for females. Life 
expectancy with TS was reduced to 70 years for 
females. We estimated the life expectancy with CRI 
to be reduced to 35 years for men and 42 years for 
females, using the end-stage renal disease mortality 
rates as a proxy in the absence of any available data 
for CRI. This may underestimate life expectancy, as 
not all patients with CRI will go on to develop end- 
stage renal disease. 
 
In the base-case model, we assume that for all 
conditions the life expectancy is lower than that of 
the general UK population, and investigate general 
population life expectancy in sensitivity analyses. 
 
Effectiveness data 
The start and end age of treatment, and the 
duration of treatment, are shown in Table 40. For 
GHD, CRI, PWS and SGA there are no RCTs  
with a duration of more than 3 years, so we used 
data from the KIGS database.153  SHOX-D was not 
included in the KIGS database and so we assumed 
that these children start treatment at the same age 
as those in the Blum RCT49  and continue treatment 
for the same duration as for children with TS in the 
KIGS database. For the purposes of the model we 
rounded the start age and treatment duration. 
 
For GHD, some children continue to receive 
rhGH treatment into adulthood. This is shown 
as an additional scenario for GHD, for which it 
is assumed that 34% of GHD patients continue 
treatment158 until age 25 years with a dose of 
0.4 mg/day.6 These individuals do not receive any 
additional benefit associated with height gain from 
this treatment in the model. 
The clinical effect of rhGH was taken from the 
systematic review in Chapter 3. Where possible the 
clinical effect was taken from the best-quality RCT, 
for which children had treatment for a sufficiently 
long time to capture HtSDS height gain, which 
we assumed would be at least 2 years. For GHD, 
these data were not available, as the only available 
RCT was for only 1 year, and so we have used 
observational data (KIGS database)153 to estimate 
the clinical effect (Table 41). For SGA, there were 
no RCTs available for the licensed dose and so 
we used a study with 1-year treatment.114 For TS, 
height gain was reported in terms of age-specific 
TS HtSDS, but the mean age-specific value was 
not reported. We assumed that the age-specific TS 
HtSDS was that reported in the KIGS database.153 
Several studies have not reported the height gain 
in centimetres, and for these studies we converted 
HtSDS values to centimetres, using the height table 
from the Health Survey for England (HSE) 2003.151 
 
A review of compliance with rhGH was conducted 
by Merck Serono as part of the MSs. It found that 
estimates for compliance ranged from 69% to 95% 
for the studies identified. One study estimated 
concordance in 75 children by using data on GP 
prescriptions over 12 months.157  Between one 
and two injections/week were missed by 16% of  
the children, and 23% missed more than two 
injections/week. Based on this study, we assumed a 
compliance of 85%. 
 
Health-related quality of life 
There was a lack of good-quality HRQoL data 
expressed in terms of utility in the RCTs and 
other QoL studies for most of the conditions of 
interest (see Review of research on QoL, above). 
Only one study was found that was appropriate to 
the conditions of interest and this was for GHD.147 
However, it was in an adult population and it was 
uncertain whether the participants had already 
benefited from GH as children; the QoL utility 
gain from this study was similar to that from the 
Christensen and colleagues study150   for GHD. 
For the other studies the most appropriate utility 
 
TABLE 40 Input parameters used in the SHTAC model 
 
 
 
Source 
GHD TS PWS CRI SGA SHOX-D 
KIGS153 CGHAC86 KIGS153 KIGS153 KIGS153 Blum49 
Starting age (years) 9 10 7 9 8 7 
Age at end of treatment (years) 16 16 15 14 14 14 
Treatment duration (years) 7 6 8 5 6 7 
Sex (males, %) 70 0 50 71 60 48 
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TABLE 41 Clinical effect for rhGH used in the SHTAC model 
 
Parameter GHD TS PWS CRI SGA SHOX-D 
Source KIGS153 CGHAC86 ade Lind van Fine et Philip et Blum et al.49 
   Wijngaarden et al.93 al.108 al.114  
Treatment cohort       
Starting HtSDS –2.99 –3.4b –2.0 –2.9 –3.1 –3.3 
Final HtSDS –1.17 –1.8b –0.5 –1.6 –2.3 –2.1 
Control cohort       
Starting HtSDS –2.99 –3.3b –2.5 –2.9 –3.1 –3.3 
Final HtSDS –2.99 –3.0b –2.6 –2.9 –3.0 –3 
Treatment effect       
Treatment height gain (SDS) 1.82 1.3 1.6 1.3 0.7 0.9 
Treatment height gain (cm) 12.8c 9.3 11.1c 9.2c 3.3 5.9 
QoL gain 0.069 0.069 0.021 0.059 0.043 0.055 
a  Results reported as median values. 
b  Estimated, based on age-specific turner SDS score, converted to SDS score using KIGS database.153 
c  HtSDS gain converted to centimetres using HSE 2003.153 
 
 
measurement was from the study by Christensen 
and colleagues,150 which measured QoL using  
the EQ-5D in a large sample of the general UK 
population (HSE). The utility values are not  
from the conditions of interest; nevertheless it 
does provide a common utility gain that could be 
compared across all the conditions of interest and 
that could be used with the clinical effectiveness 
outcomes from the RCTs. It was assumed for 
children that the adult gain in utility from 
increased height derived from the Christensen and 
colleagues study would be the same as a utility gain 
in  children. 
 
This study assessed HRQoL estimates through 
the use of ordinary least squares (OLS) linear 
regression, which controlled for age, weight and 
gender. More details on the study are reported 
above (see Height and health-related QoL, above). 
We assumed that individuals in the treated and 
untreated cohorts would have no difference in 
terms of age, gender, social class, weight and 
longstanding illness. The differences in HRQoL 
utility estimates between the treated and untreated 
cohorts are therefore derived from their differences 
in height. According to the regression, for those 
people shorter than –2.0 HtSDS an improvement 
of 1 HtSDS will result in a change in HRQoL utility 
of 0.061; for the subgroup between –2.0 and 0 
HtSDS, a 1 HtSDS improvement increases utility  
by 0.01. These values were used in the SHTAC 
estimation of cost-effectiveness. 
For patients with PWS there may be an additional 
health benefit associated with improved body 
composition. Any improvements in body 
composition may lead to reduced risk of diabetes 
and cardiovascular disease. However, there is 
considerable difficulty estimating the magnitude of 
this effect and  extrapolating short-term treatment 
in childhood to lifelong benefit. There was one 
study of poor quality in adults with PWS but this 
was not considered to be a robust estimate of QoL 
benefit (see Review of research on QoL). The MS 
estimated a QoL benefit from reduced diabetes  
risk but it was not possible to verify this evidence. 
Due to the high uncertainty around the estimates 
of QoL benefit, we assumed no benefit due to body 
composition in the base case and then conducted 
sensitivity analyses using the studies mentioned 
above. 
 
Estimation of costs 
The costs used in the SHTAC model were based 
upon those used in the previous HTA report.6 The 
annual cost of monitoring associated with each 
condition was calculated for each arm of the model 
using treatment pathways described in that report. 
Treatment costs are calculated on the basis of mean 
dose of rhGH. Unit costs for drugs were taken  
from the British National Formulary (BNF)165 and, 
for consultations, outpatient visits and procedures, 
from NHS Reference Costs.166 The base year used for 
the analysis was 2008; where necessary, costs were 
inflated to that year. 
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Based on advice from our clinical advisory 
group, the resource use was the same as for the 
previous HTA report except for nurse visit time 
was assumed to be the same for all conditions and 
patients would have two outpatient visits per year. 
Furthermore, patients would no longer have a hand 
X-ray at the end of treatment. The resource use is 
similar for all conditions, except GHD where 20% 
of treated children have a pituitary test each year. 
The unit costs applied to the resource use estimates 
for monitoring tests were provided by the finance 
department at Southampton University Hospital 
Trust [personal communication, Southampton 
University Hospitals Trust: unit costs (unpublished 
database), 2008]. The hourly cost of community 
nursing is taken from the Unit Costs of Health and 
Social Care.167 All children are monitored until 
they reach adulthood, assumed to be at the age of 
17 years old. The unit costs and resource use are 
shown in Tables 42 and 43, respectively. 
 
 
TABLE 42 Unit costs used in the SHTAC model 
 
Costs component Cost (£) Source 
Cost per outpatient attendance first contact face-to-face paediatric 206.28 NHS ref costs 2007/8166 
endocrinology (HRG code 302F) 
Cost per outpatient attendance subsequent contact face-to-face 127.97 NHS ref costs 2007/8166 
paediatric endocrinology (HRG code 302F) 
Specialist community nurse per patient contact (1 hour) 73 PSSRU 2008167 
Community nurse per patient visit (1 hour) 64 PSSRU 2008167 
Blood tests (for full blood count, chemical profile, thyroid and IGF) 51 SUHT 2008 
X-ray, hand (BA test) 28.64a NHS ref costs 2006/7166 
Pituitary function test (glucagon, insulin stress test), includes 2 hours’ 207.50 SUHT 2008 
nurse time 
a  Original cost of £27.71 inflated to 2008 costs. 
HRG, Healthcare Resource Group; PSSRU, Personal Social Services Research Unit; SUHT, Southampton University 
Hospitals Trust. 
 
 
TABLE 43 Administration and monitoring resource use 
 
 
 
No treatment monitoring 
GHD TS, PWS, CRI, SGA, SHOX-D 
Outpatient visit 2  2 
Blood test 1  1 
Treatment 1st year 
Specialist nurse home visit (hours) 1  1 
Community nurse home visits (hours) 4  4 
Outpatient visit 2  2 
Blood test 1  1 
Pituitary function test 0.2 0 
GH treatment subsequent year 
Outpatient visit 2  2 
Blood test 1  1 
Hand X-ray 1  1 
Pituitary function test 0.2 0 
End of treatment 
Outpatient visit 1  1 
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The unit cost of the drug used in the 
manufacturers’ models varies between £18.00 and 
£23.19 per milligram. As this review is for the 
cost-effectiveness of somatropin, rather than being 
dependent on manufacturers’ different device 
costs, we have assumed an rhGH cost in the base 
case that is the average of the six manufacturers’ 
unit cost of rhGH given in the BNF 58 (Table 
44). This gives an average price of £21.06. This 
was done for consistency between the different 
conditions, despite the average cost of rhGH for 
each condition actually varying depending on 
which and how many manufacturers have a licence 
for the condition of interest. The maximum and 
minimum price of rhGH will be used in a sensitivity 
analysis. Drug costs are calculated according to 
the dosage used (Table 45) and the weight of the 
child.165 The weight of children at different ages 
was taken from a long-term observational database 
(Appendix 13).153 
 
 
Estimation of cost- 
effectiveness 
This section reports the cost-effectiveness results 
for a cohort of children for each of the conditions 
of interest who received rhGH treatment. Results 
for costs and QALYs are presented for children in 
the cohort for a treated and untreated cohort, with 
costs and benefits discounted at 3.5%. The cost- 
 
 
 
TABLE 44 Individual prices of rhGH and the average cost used 
in the cost-effectiveness analyses 
 
BNF 58 price (£) 
 
 
 
 
 
 
effectiveness of rhGH compared to no treatment 
is presented as incremental cost per QALY and 
incremental cost per centimetre gained. The results 
are shown in Table 46 for each condition. In the 
base-case analysis, all conditions, except GHD,  
used the clinical benefit seen in the best-quality 
RCT for each condition (see Chapter 3). The cost- 
effectiveness of rhGH versus no treatment varied 
from £23,196 for GHD to £135,311 for PWS per 
QALY gained. 
 
The incremental cost per QALY gained for PWS is 
very high despite a similar or greater height gain 
compared with the other conditions as a result of 
rhGH treatment. This is due to the PWS cohort 
having a starting HtSDS that is much closer to 
population norms with most of the gain in height 
occurring between –2.0 and 0 HtSDS. Therefore, 
using the Christensen regression estimates, this 
is associated with a lower utility gain (see Health- 
related quality of life, above) and a smaller QALY 
gain when compared with the other conditions. 
With the exception of PWS, all conditions have an 
ICER lower than £41,000 per QALY gained. 
 
A further analysis was undertaken to see the effect 
of continuation of rhGH treatment into adulthood 
for 34% of the original cohort until the age of 
25 years. The incremental cost per QALY was 
£28,244 (Table 47). 
 
 
Sensitivity analyses 
Cost-effectiveness of rhGH 
treatment – deterministic 
sensitivity analysis 
rhGH (per mg) One-way deterministic sensitivity analyses were 
performed, in which model parameters were 
Genotropin 23.19 
Humatrope 18.00 
Norditropin 21.39 
Saizen 23.18 
Nutropin 20.70 
Zomacton 19.92 
Average cost 21.06 
TABLE 45 Drug dosage 
systematically and independently varied, using  
a realistic minimum and maximum value. The 
sensitivity analysis investigated the effect of 
uncertainty around the model structure and for 
variation in parameters on the cost-effectiveness 
results, in order to highlight the most influential 
parameters. The effects of uncertainty in multiple 
parameters were addressed using PSA, which is 
Condition 
Drug dosage 
(mg/kg/day) 
GHD TS PWS CRI SGA SHOX-D 
0.025 0.045 0.035 0.045 0.035 0.045 
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TABLE 46 Cost-effectiveness results for the base-case analysis 
 
 
Condition 
 
Treatment 
 
Costs (£) 
 
QALYs 
Inc. costs 
(£) 
Inc. 
QALYs 
ICER 
(£/QALY) 
Gain 
(cm) 
ICER 
(£/cm) 
GHD No rhGH 2211 16.8      
 rhGH 38,031 18.4 35,820 1.54 23,196 12.80 2798 
TS No rhGH 1965 15.9      
 rhGH 62,752 17.4 60,787 1.54 39,460 9.30 6536 
PWS No rhGH 2646 17.6      
 rhGH 67,794 18.1 65,148 0.48 135,311 11.10 5869 
CRI No rhGH 1876 11.6      
 rhGH 35,877 12.4 34,001 0.87 39,273 9.20 3696 
SGA No rhGH 2432 17.1      
 rhGH 34,431 18.1 31,999 0.97 33,079 3.30 9697 
SHOX-D No rhGH 2646 16.8      
 rhGH 53,434 18.1 50,788 1.25 40,531 5.90 8608 
Inc., incremental. 
 
 
TABLE 47 Cost-effectiveness results for continuation of rhGH treatment into adulthood for patients with GHD 
 
    Inc. costs Inc. ICER Gain ICER 
Condition Treatment Costs (£) QALYs (£) QALYs (£/QALY) (cm) (£/cm) 
GHD No rhGH 2211 16.8      
continuers rhGH 45,826 18.4 43,615 1.54 28,244 12.80 3407 
Inc., incremental. 
 
 
 
reported later in this section. Where possible, the 
parameters were varied according to the ranges  
of the CIs of these parameters, based on the 
published estimate. Where these data were not 
available an alternative suitable range was chosen. 
The same ranges were used in the deterministic 
and probabilistic sensitivity analyses and these are 
described in Appendix 12. 
 
Table 48 shows the results for each of the conditions 
using the KIGS database153 for estimate of the 
clinical benefit. The KIGS database, a large 
observational study of children treated with rhGH, 
was used for the effectiveness of GHD in the base 
case reported above. According to these results, 
an ICER of rhGH versus no treatment varied from 
an ICER of £18,980 per QALY gained for SGA 
to £144,050 per QALY gained for PWS. Results 
are of a similar magnitude to the base case with 
the exception of the SGA analyses. The ICER for 
SGA is much lower in this analysis because the 
incremental clinical height gain is lower in the RCT 
effectiveness data than in the KIGS effectiveness 
data. 
 
The discount rates used for the analyses have 
a large effect on the results, due to the upfront 
costs and the health outcomes stretching over the 
life time of the model. Table 49 shows the results 
using the discount rates used in the previous HTA 
report, i.e. costs 6% and benefits 1.5%. Using 
these discount rates, rhGH treatment is more cost- 
effective. For all conditions, except PWS, the ICER 
reduces to less than £30,000 per QALY. 
 
Tables 50–55 report the results of the deterministic 
sensitivity analyses for the conditions for the 
most influential parameters. Other variables 
were varied in sensitivity analyses but were found 
to only have a negligible effect on the results. 
The cost-effectiveness results are fairly sensitive 
to the variation in parameters included in the 
deterministic sensitivity analysis. For all of the 
conditions the model results are most sensitive to 
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TABLE 48 Cost-effectiveness results with clinical benefit from KIGS database 
 
 
Condition 
 
Treatment 
Height 
(HtSDS) 
 
Costs (£) 
 
QALYs 
Incremental 
costs (£) 
Incremental 
QALYs 
ICER 
(£/QALY) 
TS No rhGH –3.18 1965 15.8    
 rhGH –2.24 62,752 17.1 60,787 1.28 47,553 
PWS No rhGH –2.22 2646 17.4    
 rhGH –1.36 67,794 17.9 65,148 0.45 144,050 
CRI No rhGH –2.99 1876 11.5    
 rhGH –2.17 35,877 12.2 34,001 0.74 46,245 
SGA No rhGH –3.23 2432 16.8    
 rhGH –2.01 34,431 18.4 31,999 1.69 18,980 
SHOX-D No rhGH –3.18 2646 16.6    
 rhGH –2.24 53,434 17.9 50,788 1.31 40,531 
 
TABLE 49 Cost-effectiveness results with alternative discount rates 
 
Condition Incremental costs (£) Incremental QALYs ICER (£/QALY) Gain (cm) ICER (£/cm) 
GHD 32,407 2.49 12,999 12.80 2532 
TS 55,753 2.49 22,358 9.30 5995 
PWS 58,075 0.79 73,836 11.10 5232 
CRI 31,609 1.22 25,804 9.20 3436 
SGA 29,362 1.57 18,690 3.30 8898 
SHOX-D 45,937 2.05 22,436 5.90 7786 
 
 
treatment start age and length, compliance and 
utility gain. 
 
The deterministic sensitivity results for GHD are 
shown in Table 50. The results varied between 
£19,187 and £35,917 per QALY gained and were 
most sensitive to dosage. 
 
The deterministic sensitivity results for TS are 
shown in Table 51. The results varied between 
30,505 and £48,778 per QALY gained and were 
most sensitive to utility gain. 
 
The deterministic sensitivity results for PWS are 
shown in Table 52. The results varied between 
£111,560 and £159,062 per QALY gained and were 
most sensitive to compliance. 
 
The deterministic sensitivity results for CRI are 
shown in Table 53. The results varied between 
£28,080 and £54,105 per QALY gained and were 
most sensitive to the treatment start age and length 
of treatment. 
 
The deterministic sensitivity results for SGA are 
70 shown in Table 54. The deterministic sensitivity 
results varied between £25,675 and £41,180 per 
QALY gained and were most sensitive to utility 
gain. 
 
The deterministic sensitivity results for SHOX-D 
are shown in Table 55. The deterministic sensitivity 
results varied between £33,406 and £50,457 per 
QALY gained and were most sensitive to utility 
gain. 
 
For patients with PWS there may be an additional 
health benefit associated with improved body 
composition, which may reduce the risk of diabetes 
and other morbidities. In addition, there is 
considerable difficulty estimating the magnitude of 
this effect and extrapolating short-term treatment 
in childhood to lifelong benefit. In the base case 
we have assumed that there is no HRQoL benefit 
associated with changes in body composition. 
In this section we present a scenario analysis for 
additional changes in body composition. However, 
there is a difficulty linking changes in lean FM to 
changes in utility, as there are no utility studies 
for lean FM. For this reason we have focused on 
changes in BMI. 
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Parameter 
 
Baseline 
Upper 
value 
Lower 
value 
 
Upper value 
 
Lower value 
 
Range 
Utility gain per HtSDS 0.061 0.073 0.049 33,131 48,778 15,647 
Treatment age (years) 10–16 12–16 8–16 30,505 45,105 14,600 
Compliance 85% 100% 70% 46,376 32,544 13,832 
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 43,424 33,766 9658 
Dosage (mg/kg) 0.045 0.05 0.4 43,815 35,106 8709 
Utility benefit spread over 2 years 1 year 6 years 38,672 42,753 4081 
SMR 2.4 2.4 1 39,460 37,308 2152 
 
 
 
 
 
 
TABLE 50 Deterministic sensitivity analyses for GHD 
 
  
Upper 
 
Lower 
ICER (£/QALY) 
Parameter Baseline value value Upper value Lower value Range 
Dosage (mg/kg) 0.025 0.039 0.023 35,917 21,379 14,538 
Utility gain per HtSDS 0.061 0.073 0.049 19,776 28,047 8271 
Compliance (%) 85 100 70 27,205 19,187 8018 
Treatment age (years) 9–16 11–16 7–16 19,279 25,659 6380 
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 25,493 19,895 5598 
Utility benefit spread over 2 years 1 year 7 years 22,732 25,638 2906 
SMR 2.4 2.4 1 23,196 22,184 1012 
 
TABLE 51 Deterministic sensitivity analyses for TS 
 
ICER (£/QALY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 52 Deterministic sensitivity analyses for PWS 
 
 
 
Parameter Baseline 
 
Upper 
value 
 
Lower 
value 
ICER (£/QALY) 
Upper value Lower value Range 
 
Compliance (%) 85 100 70 159,062 111,560 47,502 
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 148,924 115,755 33,169 
Treatment age (years) 7–15 9–15 5–15 119,036 144,159 25,123 
Utility benefit spread over 
(years) 
2 1 8 132,645 152,275 19,630 
Dosage (mg/kg) 0.035 0.035 0.03 135,311 116,084 19,227 
Utility gain per HtSDS 0.061 0.073 0.049 128,030 143,471 15,441 
SMR 2.4 2.4 1 135,311 129,640 5671 
 
 
Picot and colleagues168 conducted a targeted search 
to identify published utility estimates for the BMI 
values relevant to an adult obese population. The 
search aimed to identify estimates of the change 
in utility scores based on the unit change in BMI 
values. Utility estimates were considered only 
where they used a validated, multiattribute utility 
scale (e.g. EQ-5D) or appropriate methodology 
(e.g. SG or TTO techniques) and provided a clear 
definition of utility scores. They suggest the values 
reported by Hakim and colleagues169 represent the 
most methodologically sound estimates derived 
from subjects across a wide range of obesity 
levels. Hakim and colleagues169 found that a one- 
unit decrease in BMI, over a period of 1 year,  
was associated with a gain of 0.017, which was 
independent of age or gender. 
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Parameter 
 
Baseline 
Upper 
value 
Lower 
value 
 
Upper value 
 
Lower value 
 
Range 
Treatment age (years) 9–14 11–14 7–14 28,080 46,477 18,397 
Utility benefit spread over 2 years 1 year 5 years 38,253 54,105 15,852 
Utility gain per HtSDS 0.061 0.073 0.049 33,188 48,091 14,903 
Compliance (%) 85 100 70 46,181 32,365 13,816 
SMR 21 21 1 39,273 28,820 10,453 
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 43,232 33,585 9647 
Dosage (mg/kg) 0.045 0.05 0.04 43,623 34,923 8700 
 
 
Parameter 
 
Baseline 
Upper 
value 
Lower 
value 
 
Upper value 
 
Lower value 
 
Range 
Utility gain per HtSDS 0.061 0.073 0.049 27,641 41,180 13,539 
Treatment age (years) 8–14 10–14 6–14 25,675 37,921 12,246 
Compliance (%) 85 100 70 38,888 27,270 11,618 
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 36,408 28,296 8112 
Dosage (mg/kg) 0.035 0.04 0.035 37,781 33,079 4702 
Utility benefit spread over 2 years 1 year 6 years 32,422 35,818 3396 
SMR 2.4 2.4 1 33,079 31,657 1422 
 
 
Parameter 
 
Baseline 
Upper 
value 
Lower 
value 
 
Upper value 
 
Lower value 
 
Range 
Utility gain per HtSDS 0.061 0.073 0.049 33,868 50,457 16,589 
Compliance (%) 85 100 70 47,657 33,406 14,251 
Treatment age (years) 7–14 9–14 5–14 33,787 44,666 10,879 
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 44,615 34,664 9951 
Dosage (mg/kg) 0.045 0.05 0.04 45,018 36,045 8973 
Utility benefit spread over 2 years 1 year 7 years 39,733 44,729 4996 
SMR 2.4 2.4 1 40,531 38,822 1709 
 
 
 
 
 
 
TABLE 53 Deterministic sensitivity analyses for CRI 
 
ICER (£/QALY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 54 Deterministic sensitivity analyses for SGA 
 
ICER (£/QALY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 55 Deterministic sensitivity analyses for SHOX-D 
 
ICER (£/QALY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Chapter 3 (see Body composition), RCTs for 
PWS reported mixed results for changes in BMI 
with a maximum BMI difference of 1.8 kg/m2 
between treated and untreated groups after 
2 years’ treatment. Assuming this change in BMI 
is maintained lifelong, and therefore there is an 
additional utility of 0.031, the cost-effectiveness of 
PWS would be £54,800 per QALY gained. 
Probabilistic sensitivity analyses 
In the probabilistic sensitivity analyses (PSAs) the 
main parameters were sampled probabilistically 
from an appropriate distribution using similar 
ranges as used in the deterministic sensitivity 
analyses. The parameters sampled were: starting 
age, length of treatment, dose, HtSDS at the start 
and end of treatment for both the rhGH and no 
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Condition 
Incremental QALYs 
Min. Max. 
Incremental costs (£) 
Min. Max. 
ICERs 
Min. 
 
 
Max. 
GHD 1.27 1.83 25,306 46,043 15,752 31,309 
TS 0.77 2.35 43,478 77,707 21,758 81,026 
PWS –0.33 1.43 49,419 78,677 –838,603 1,055,815 
CRI 0.43 1.30 21,580 44,294 21,553 77,929 
SGA 0.52 1.48 23,179 40,773 19,945 64,614 
SHOX-D 0.53 2.12 37,854 62,023 21,524 95,600 
Max., maximum; Min., minimum. 
 
 
 
 
 
 
 
treatment cohorts, utility increment for gains in 
height and all costs used in the base case excluding 
the cost of rhGH. 
 
The distribution assigned to each variable included 
in the PSA and the parameters of the distribution 
are reported in Appendix 12. One thousand 
simulations were run for each condition of interest 
in this analysis. Table 56 reports the mean costs and 
outcomes from the PSA and the ICER for rhGH 
compared with no treatment, based on the mean 
values generated in the PSA. Table 57 shows the 
2.5% and 97.5% percentiles for the PSA. 
 
The cost-effectiveness results from the PSA are 
slightly lower than those from the deterministic 
analyses for GHD, TS, CRI, SGA and SHOX-D 
(which were £23,196, £39,460, £39,273, £33,079 
and £40,531, respectively). The cost-effectiveness 
results from the PSA for PWS, however, are much 
lower than the deterministic estimates. This is due 
to non-linearity in the PWS model as a result of 
 
TABLE 56 Costs and outcomes from the PSA 
the baseline starting HtSDS for the treated group 
being at –2.0 HtSDS. This is also the height at 
which the utility gain per unit HtSDS changes and 
thus an individual with a starting height slightly 
lower than –2.0 HtSDS will have much higher 
utility gain than one with a starting height slightly 
higher than –2.0 HtSDS. This non-linearity results 
in a higher incremental QALY in the PSA results, 
therefore decreasing the ICER in the PSA. 
 
Scatter plots are shown for the incremental 
cost and incremental QALYs for each of the 
conditions in Figures 2–7. The difference in the 
dispersion of costs and QALY data points between 
the six conditions reflects the different levels of 
uncertainty in each condition. The spread of costs 
and to a greater extent QALYs is more compact in 
GHD than for the other conditions. This is because 
the standard errors are much smaller due to the 
effectiveness data coming from the KIGS database, 
which has a large number of observations. This 
 
Condition Treatment QALYs Costs (£) Inc. QALYs Inc. costs (£) ICER (£/QALY) 
GHD No rhGH 16.81 2277    
 rhGH 18.36 37,719 1.543 35,517 23,019 
TS No rhGH 15.89 1952    
 rhGH 17.43 62,128 1.546 60,176 38,931 
PWS No rhGH 17.61 2639    
 rhGH 18.19 67,716 0.576 65,076 113,075 
CRI No rhGH 11.57 1874    
 rhGH 12.44 35,702 0.868 33,828 38,951 
SGA No rhGH 17.09 2429    
 rhGH 18.06 34,283 0.966 31,854 32,963 
SHOX-D No rhGH 16.80 2633    
 rhGH 18.07 53,027 1.267 50,394 39,781 
Inc., incremental. 
TABLE 57 Range of results from the PSA (2.5% and 97.5% percentiles) 
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FIGURE 2 Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in growth 
hormone deficiency. 
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FIGURE 3 Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in Turner 
syndrome. 
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FIGURE 4 Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in Prader–Willi 
74 syndrome. 
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FIGURE 5 Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in chronic renal 
insufficiency. 
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FIGURE 6 Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment for the condition 
‘small for gestational age’. 
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FIGURE 7 Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in short stature 
homeobox-containing gene deficiency. 75 
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creates a tighter probability distribution around the 
mean value. 
 
In addition, a CEAC was also derived, representing 
the proportion of simulations when GH treatment 
is cost-effective for a range of willingness-to-pay 
thresholds, up to £100,000, see Figure 8. 
 
In this analysis, rhGH treatment had the 
probability of being cost-effective at willingness-to- 
pay thresholds of £20,000, £30,000 and £50,000 
per QALY as: 22%, 95% and 100% for GHD, 2%, 
19% and 78% for TS, 0%, 1% and 8% for PWS, 2%, 
16% and 80% for CRI, 4%, 38% and 90% for SGA, 
and 1%, 15% and 74% for SHOX-D, respectively. 
 
 
Summary of cost- 
effectiveness 
• A systematic search of the literature found two 
fully published economic evaluations of rhGH 
treatment for TS and GHD. The results from 
the studies varied due to the choice of utility 
estimates and assumptions on the effectiveness. 
• A systematic search for published studies of 
QoL for patients with individuals with the 
conditions of interest who had rhGH identified 
six studies, although none of these was in 
children. These were generally small studies 
of poor quality. One study was considered of 
reasonable quality.147 This study estimated 
HRQoL for adults with GHD. 
• An additional targeted search was undertaken 
for QoL in relation to height, which identified 
one study150 that provided utility estimates 
based on the EQ-5D for different HtSDS from 
HSE. 
• Six of the seven manufacturers submitted 
evidence to be considered for this review. 
One MS by Sandoz did not comply with the 
NICE template for MTA and presented a 
description of the product (Omnitrope) and 
what appears to be a cost-minimisation analysis 
using Genotropin as a comparator (defined 
as a reference product). The other five out 
of the six MSs consisted of a written report 
and an electronic model supporting the cost- 
effectiveness analyses. This model was used by 
the five collaborating manufacturers involved 
in the submission to the MTA of rhGH in 
the cost-effectiveness analysis of treatment in 
children with GHD, TS, PWS, CRI and SGA. 
• Each of the collaborating manufacturers 
presented essentially the same model with  
some minor modifications. The model 
developed was based upon the previous HTA 
report6  but has been extended to consider 
longer term outcomes in order to estimate cost- 
effectiveness in terms of QALYs. 
• The utility scores used in the MS model in 
children with GHD, TS, CRI and SGA were 
based upon the study by Christensen and 
colleagues,150 which estimates QoL associated 
with height for a general population survey. 
However, they used the utility point estimates, 
based only on height, instead of the regression 
analysis from the study, which controlled for 
other key variables. 
• In the manufacturers’ base case, the cost- 
effectiveness results for all conditions were 
less than £30,000 per QALY gained. They 
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FIGURE 8 Cost-effectiveness acceptability curve for rhGH treatment and no treatment for all the conditions. 
76 
 
Health Technology Assessment 2010; Vol. 14: No. 42 DOI: 10.3310/hta14420 
 
 
 
 
 
 
 
estimated ICERs of: £17,552 for GHD, £29,757 
for TS, £32,540 for PWS, £15,962 for CRI, and 
£18,167 for SGA per QALY gained. 
• The authors of this report developed an 
independent model, based upon the previous 
HTA report, and extended to consider longer 
term outcomes in order to estimate cost- 
effectiveness in terms of QALYs. 
• From this independent model, the incremental 
cost per QALY estimates of rhGH compared 
to no treatment were: £23,196 for GHD, 
£39,460 for TS, £135,311 for PWS, £39,273 
for CRI, £33,079 for SGA and £40,531 for 
SHOX-D. A further analysis was run for PWS, 
which included a lifelong improvement of 
body composition of 1.8 kg/m2 BMI and an 
associated additional utility of 0.031. Under 
these assumptions there was a more favourable 
ICER of £54,800 per QALY gained. 
• The effect of a range of parameter values 
in the economic model were evaluated in 
sensitivity analyses. The model results were 
found to be most sensitive to the discount rate 
used. When the previous NICE discount rate of 
6% for costs and 1.5% for benefits was used, all 
conditions were cost-effective for a willingness- 
to-pay threshold of £30,000 per QALY. The 
model results are also sensitive to treatment 
start age and length, compliance and utility 
gain. 
• The PSA estimated the probability of each of 
the conditions to be cost-effective at £30,000 
to be: 95% for GHD, 19% for TS, 1% for 
PWS, 16% for CRI, 38% for SGA and 15% for 
SHOX-D. 
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Chapter 5 
Assessment of factors relevant to 
the NHS and other parties 
 
 
uidance from NICE already recommends 
treatment with rhGH for children who have 
short stature that is associated with GHD, TS, 
PWS and CRI. Prescriptions associated with these 
conditions are therefore already part of primary 
care trusts’ (PCTs’) budgets, and are unlikely to 
increase significantly. However, advice from our 
clinical advisory group indicates that many families 
of children with PWS are now seeking treatment 
in infancy rather than in mid-childhood, and 
there may also be some increase in the number of 
prescriptions for GHD associated with oncology, 
as greater numbers of children are surviving 
childhood cancers. The newly licensed conditions 
SHOX-D and SGA are not covered by NICE 
guidance at the time of writing. Of the estimated 
4758 UK patients currently receiving rhGH,74  a 
breakdown by diagnosis for 3951 of them found 
that only 5.2% (205 patients) were receiving 
treatment for short stature that was associated with 
being born SGA. Advice from our clinical advisory 
group indicates that there is unlikely to be a large 
increase in prescriptions for children who were 
SGA. 
 
The BSPED survey74 did not include patients 
with SHOX-D, and it is not clear how many 
children with this condition are currently receiving 
treatment. Children with short stature due to 
unknown causes, or with other conditions, such 
as LWS, not currently covered by NICE guidance, 
might have an underlying SHOX-D. The 
availability of prescriptions to these new groups of 
patients could therefore have a budgetary impact. 
However, these conditions are very rare, so there is 
unlikely to be a large increase in people requiring 
treatment. 
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Chapter 6 
Discussion 
 
 
Statement of principal 
findings 
Growth hormone deficiency 
 
The use of rhGH as replacement therapy is well 
established in children who have a deficiency of 
the natural hormone. Therefore, most clinicians 
would consider it unethical to withhold treatment 
and there is a corresponding lack of RCT evidence 
in the literature. Only one trial84  met the inclusion 
criteria for the review of rhGH in children with 
GHD, and this did not report FH. No details 
were reported on randomisation or allocation 
to treatment groups or blinding. The included 
patients (n = 19) were part of a larger study, which 
was generally poorly reported. After a year’s 
treatment, HtSDS was statistically significantly 
higher in treated than in untreated children, 
although actual height was not reported. Children 
who received rhGH for 1 year had grown at a 
mean velocity of 2.7 cm/year faster than untreated 
children, which was statistically significantly faster. 
The low patient numbers mean that the evidence 
base for GHD is weak. Thus, there is very limited 
evidence of a slight increase in growth for children 
with GHD treated with GH, based on one study 
of mixed quality. Estimates of height gain in the 
previous HTA report6 suggested FH gains of 
approximately 1.3–1.6 SDS (i.e. within 2 SDs of 
the normal mean) with rhGH treatment. However, 
these figures were from retrospective single-cohort 
studies that were not included in the present 
review. 
 
The cost-effectiveness estimate of rhGH treatment 
in GHD is about £23,200 per QALY gained or 
£2,800 per centimetre gained. As there were no 
appropriate RCTs, the KIGS database was used 
for the estimate of height gain from rhGH.153 
This estimate for height gain was higher than for 
the other conditions. The previous HTA report6 
estimated a cost per centimetre gained of £6000 
using 8 years’ treatment compared to the 7 years 
used in our analysis and a slightly lower height gain 
from the KIGS database.153  The cost-effectiveness 
estimate for the cohort of GHD who continue  
rhGH treatment into adulthood was £28,200 per 
QALY gained and £3400 per centimetre gained. 
Turner syndrome 
Six trials met the inclusion criteria for the 
review of GH for growth disturbance in patients 
with TS.12,85,86,88–90  There is some evidence of 
effectiveness across all reported growth outcomes 
for girls with TS. However, these results are 
reported in studies of poor reporting and 
methodological quality, and in some cases of short 
duration. Of the six included studies, none of the 
included trials used an ITT analysis, one reported 
adequate randomisation to treatment groups,85 one 
study described adequate concealment of treatment 
allocation,85 and one adequately blinded the 
patient to treatment by administering placebo.89 
 
In a large RCT that followed girls until FH, 
children in the rhGH group grew an average 
of 9.3 cm more from baseline than those in the 
untreated group.86 In a study of younger children 
over 2 years, the difference was 7.6 cm.85 Both of 
these were statistically significant results. Weight 
and WtSDS were found to be significantly greater 
in the treated group in one study of younger girls 
with TS.85 
 
The searches for this study identified a new 
systematic review, conducted in Canada in 2007.135 
The review concluded that rhGH is effective in 
improving growth and FH in girls with TS, but 
found no evidence available in the clinical trials to 
suggest that rhGH improves QoL. The evidence 
discussed in the present review reflects this, as we 
found some evidence for increased height but no 
RCT evidence for improvements in QoL. 
 
In summary, there is some evidence of effectiveness 
across all reported growth outcomes for girls with 
growth disturbance as a result of TS. There is also 
evidence of improved body composition. These 
results are reported in studies of poor reporting 
and methodological quality, and, in some cases, 
short duration, issues that may affect the validity 
of these findings. The previous HTA report6 found 
that treated girls’ FH was approximately 5 cm taller 
than untreated controls. The full publication of 
the large Canadian RCT86  since the earlier HTA 
report6 has shown a slightly larger difference in FH 
of 9.3 cm, as reported in the present review. 
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The cost-effectiveness estimate of rhGH treatment 
in TS is about £39,500 per QALY gained, or £6500 
per centimetre gained. The estimate of cost- 
effectiveness compares with the estimate of about 
£130,000 per QALY (at current exchange rates) 
from CADTH,135 which used a lower QoL benefit 
for rhGH of 0.042 than used in our analysis. The 
previous HTA report estimated a less favourable 
cost per centimetre gained of £16,000 as a lower 
estimate for height gain of 3.9 cm (compared with 
9.3 cm) was used. 
 
PWS 
Eight small, rather poorly reported RCTs were 
included for PWS.22,91–102  Participants’ average 
ages ranged from 13 months to 10 years. Only 
the crossover study102 used a placebo injection; 
the parallel-group RCTs had no treatment as the 
comparison arm. 
 
Treated patients grew an average of 3–5 cm/year 
faster than untreated patients. Only one22  of the 
studies reported actual change in height, with 
infants treated with rhGH growing an average of 
6.1 cm more than untreated patients during 1 year. 
HtSDS was statistically significantly greater in 
treated patients than in untreated patients after 
1 year (1–1.5 SDS higher) or 2 years of rhGH 
treatment (> 2 SDSs). 
 
Four22,95,96,102    trials  reported  a  statistically 
significantly lower percentage of body fat (between 
1% and 10% lower) in patients treated with rhGH 
than in those receiving placebo or no treatment. 
Three93,95,96,102  trials reported that patients treated 
with rhGH had statistically significantly higher 
LBM or a larger improvement in LBM than 
untreated patients. Clinical advice indicates that 
rhGH characteristically increases LBM and reduces 
FM, although weight and BMI do not always 
change. This is reflected in the RCTs’ findings, 
where changes in BMI were statistically significant 
in two studies,91,102 there were no statistical 
differences in two other studies,93,95,96 and results 
were similar between groups in the other two 
studies.92,100,101 
 
In summary, patients treated with rhGH grew 
faster than untreated patients, and tended to  
have lower body fat percentages. Measurements 
in treated patients were reported to be statistically 
significantly better than in untreated patients 
in several studies, but the included studies were 
rather small and did not report power calculations 
or specify a primary outcome, so it is not clear 
whether they were adequately powered. These 
findings were comparable with growth and body 
composition outcomes reported in the previous 
HTA review.6 However, the previous review also 
reported an uncontrolled, single-cohort study of 
16 children, which suggested that rhGH treatment 
normalised FH. 
 
The cost-effectiveness estimate of rhGH treatment 
in PWS is about £135,300 per QALY gained or 
£5,900 per centimetre gained. The ICER values 
for PWS were higher due to the majority of the 
height gain occurring within –2 HtSDS of average 
height where a lower utility gain is experienced. 
The previous HTA report6  presented a cost per 
HtSDS gained of £40,815 and this compares with 
the current report’s estimate of £44,718. 
 
For PWS patients, there may be an additional 
health benefit associated with improved body 
composition, which may reduce the risk of diabetes 
and other morbidities. There is considerable 
difficulty with extrapolating between childhood 
treatment and adult morbidity and QoL. 
 
In the clinical effectiveness review, RCTs for PWS 
reported mixed results for changes in BMI, with a 
maximum BMI difference of 1.8 between treated 
and untreated groups after 2 years’ treatment. 
Assuming this change in BMI is maintained 
lifelong, and therefore there is an additional utility 
of 0.031, the cost-effectiveness of PWS would be 
£54,800 per QALY gained. 
 
Chronic renal insufficiency 
The evidence for rhGH in children with CRI came 
from six RCTs,103–108  three of which had fewer 
than 25 participants,103–105  and these might not 
have been sufficiently powered to test for a real 
difference between groups. Three103,105,107  of the 
studies included children who had received renal 
transplants, and three104,106,108  were for children 
with CRI who had not had a transplant. 
 
One study106 reported that treated children grew an 
average of 3.6 cm more than untreated children in 
1 year, with HtSDS being statistically significantly 
better in treated children than in untreated 
children in two studies. Growth was statistically 
significantly faster in treated children than in 
untreated children, with between-group differences 
in velocity ranging from 3.2 cm/year to 4.2 cm/ 
year in the parallel-group trials.103,106–108 Children 
treated with rhGH showed statistically significant 
improvements in weight gain or WtSDS compared 
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with untreated children in three studies.103,106,108 
No QoL data were reported for prepubertal 
children with CRI. Two rhGH-treated patients 
in one study91,102  experienced acute rejection 
episodes but both reversed after treatment with 
methylprednisolone. There were no SAEs reported. 
 
In summary, treatment with rhGH led to small but 
statistically significant improvements in growth in 
children with CRI in two trials,106,107 one of which 
included post-transport patients and the other 
included children with CRI who had not received 
a transplant. The previous HTA review6 reported 
differences in HtSDS of approximately 0.8 SD and 
1.3 SD for 1 and 2 years of treatment, respectively. 
The present review found slightly greater 
differences, favouring rhGH, of approximately 1 
SDS for 1 year and just over 2 SDSs for 2 years’ 
treatment. 
 
The cost-effectiveness estimate of rhGH treatment 
in CRI is about £39,300 per QALY gained or 
£3,700 per centimetre gained. The previous HTA 
report estimated a cost per centimetre gained of 
£7,403 and this was based upon treatment for only 
3 years compared with 5 years in this analysis. CRI 
has a lower QALY gain than the other conditions 
as we assumed that children with CRI would have 
a much shorter life expectancy than the general 
population due to their renal failure. 
 
SGA 
The licensing criteria for rhGH in children born 
SGA with growth disturbance state that eligible 
children need to have a current HtSDS ≤ –2.5, 
a parental-adjusted HtSDS ≤ –1, a birth weight/ 
length SDS ≤ –2 SDS, and have failed to show 
catch-up growth, defined as GV SDS < 0 during the 
previous year, by 4 years of age or later. None of 
the RCTs screened for this review met the inclusion 
criteria; these were therefore modified, retaining 
the current height and birth weight/length SDS 
criteria. Studies’ inclusion criteria were required 
to state that no catch-up growth had taken place 
by 3 years of age but no specific criteria were used 
for this. The amended inclusion criteria did not 
require any definition of parental height. 
 
This could affect the generalisability of the results 
as it is possible that the trials included children 
with a genetic factor for short stature. However, 
such children would presumably have a shorter 
target height than children whose parents are 
closer to the population mean. So children who 
meet the marketing authorisation may actually 
have a greater possibility for increased growth than 
those in the clinical trials. The other difference 
between the marketing authorisation criteria and 
the adapted inclusion criteria used in this review 
was that the included trials had children as young 
as 3 years of age, whereas the licensed population 
in the UK is children over the age of 4 years. It is 
possible that an early start for treatment could lead 
to better results than would be generalisable to 
the licensed population. However, in practice, the 
mean age of the children in the included studies 
was over 4 years of age for all the trials, so results 
should be generalisable to the licensed population. 
 
Six trials met the modified inclusion criteria for 
this review of growth disturbance in children born 
SGA.109–114 However, only one of the studies used 
the licensed dose for rhGH;26  the others all used 
two or three times the licensed dose. Several trials 
did not meet the inclusion criteria for this review 
as they included patients with heights of < –2 SDS 
rather than < –2.5 SDS as stated in the marketing 
authorisation. These are listed in Appendix 5, with 
reason for exclusion given as ‘wrong patient group’. 
 
One trial reported AH,111 and patients who had 
received rhGH gained an extra 4 cm of height 
compared with the control group. The difference 
between treated and untreated patients was 
statistically significant, as was the difference in  
adult HtSDS. Another study114 reported that 
patients who received 0.033 mg/kg/day rhGH (the 
licensed dose) gained an additional 3.3 cm height 
compared with untreated children, and those who 
received 0.1 mg/kg/day gained 6.5 cm of additional 
height after 1 year’s treatment. HtSDS was found to 
be greater in children treated with GH in the four 
studies that reported this outcome.110,111,113,114 
 
Weight standard deviation score was higher in 
treated than in untreated groups after both 1 and 
2 years of treatment in three studies reporting this 
outcome.109,110,113 Lean mass was reported in one 
study, being greater in the treated group. 
 
There is very limited evidence of a slight increase 
in AH gained in centimetres and SDS, and some 
evidence of an increase in HtSDS in children 
receiving rhGH in these studies. There is also 
limited evidence of improved body composition 
outcomes, including a statistically significant mean 
difference in WtSDS between treated and untreated 
children. This evidence is from trials that did 
not meet the licensed inclusion criteria exactly, 
used higher than the licensed dose in all but one 
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study, and were generally of poor quality, with few 
participants in many cases. 
 
The cost-effectiveness estimate of rhGH treatment 
in SGA is about £33,000 per QALY gained or 
£9700 per centimetre gained. The height gain 
from the clinical review indicated that the gain for 
SGA was smaller than for the other conditions. 
 
SHOX deficiency 
Only one study49 reported the use of rhGH in 
children with SHOX-D, and this was open label 
and generally poorly reported. Treated children 
grew approximately 2 cm/year faster than their 
untreated counterparts after 2 years of treatment, 
with a rate of 3.5 cm/year quicker than untreated 
children during the first year. After 2 years of 
treatment, children were approximately 6 cm taller 
than the control group and HtSDS was statistically 
significantly higher in treated than in untreated 
patients. Treatment with rhGH raised IGF-1 and 
IGFBP-3 levels to the upper-normal range, but 
there were no SAEs reported during the study. 
 
The ICER estimate of rhGH treatment in SHOX-D 
is about £40,500 per QALY gained or £8000 per 
centimetre gained. 
 
 
General discussion 
 
This review updates a previous assessment  
report.6 The criteria for this extended review were 
broadened to include children with SHOX-D or 
who were born SGA, as well as those with GHD, 
TS, PWS or CRI. In addition, we actively searched 
for all outcome measures including growth, body 
composition, biochemical markers and QoL. 
 
The review focuses on increase in height as 
‘centimetres gained’ and also as HtSDS, i.e. a 
comparison with average heights for the child’s 
peer group. One goal of treatment is to prevent 
future loss of height, i.e. a child may remain  
short compared with their peers, but still be taller 
than they would have been without treatment. 
This is an important outcome, especially where 
attainment of average AH is sometimes an 
unrealistic possibility. Unrealistic expectations of 
height gain have been shown to affect QoL. For 
example, a French survey of young women with 
TS found that higher expectations from treatment 
were associated with lower QoL scores.146 This 
review identified a paucity of evidence for QoL 
data in children receiving rhGH, and as such it is 
difficult to quantify the way in which a child’s life 
can be changed by treatment other than in terms of 
centimetres of height gained. 
 
In the previous HTA report,6 a cost-effectiveness 
model was constructed that estimated lifetime 
treatment costs and benefits in terms of cost per 
centimetre gained. Those analyses are extended  
in the present report by including QoL factors in 
the economic modelling. The cost-effectiveness of 
rhGH has been evaluated by decision-analytical 
models using clinical trial data for the gain in 
height, apart from GHD, which used KIGS data.153 
The analysis presented both cost-per-QALY 
outcomes and cost per centimetre height gained 
for comparison with the previous HTA report, as 
shown in Tables 58–60. 
 
The cost-effectiveness results from the SHTAC 
model for rhGH treatment vary widely between 
conditions, from about £23,000 for GHD to 
£135,000 for PWS per QALY gained. The ICERs 
for TS, CRI and SGA and SHOX-D were between 
about £33,000 and £40,500 per QALY gained. 
This indicates that rhGH is unlikely to be cost- 
effective for TS, PWS, CRI, SGA and SHOX-D 
at a willingness-to-pay threshold of £20,000 to 
£30,000. However, the results were sensitive to the 
discount rate used. All conditions, except PWS, 
would be cost-effective at a £30,000 willingness-to- 
pay threshold using the previous NICE discount 
rate of 6% for costs and 1.5% for benefits. For all 
the conditions, the model results are most sensitive 
to treatment start age and length, compliance and 
utility gain. 
 
The cost-effectiveness results in the current report 
varied from those in the MS and the previous 
HTA report.6  The incremental costs reported are 
generally consistent between the three models, with 
slight variations due to different dose, cost, and 
treatment start age and duration. In general, the 
results, presented in terms of centimetres gained, 
are more favourable in the current analyses than 
in the previous HTA report.6 This is due to higher 
estimates in height gain and lower incremental 
costs in the current report. The height gains in 
the MS for GHD, PWS and SGA appear extremely 
high and inconsistent with those found in the 
review of clinical effectiveness. The ICERs in the 
MS are considerably more favourable than the 
current analysis, due to higher estimates of utility 
gain. The current analyses and the MS have chosen 
utility estimates from the same study.150 However, 
the manufacturers have not taken these values from 
the regression analysis from this study. Instead they 
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TABLE 58 Base-case results for the SHTAC cost-effectiveness model 
 
 GHD TS PWS CRI SGA SHOX-D 
Incremental QALYs 1.54 1.54 0.48 0.87 0.97 1.25 
Incremental costs (£) 35,820 60,787 65,148 34,001 31,999 50,788 
ICER (£/QALY) 23,196 39,460 135,311 39,273 33,079 40,531 
Height gain (cm) 12.8 9.3 11.1 9.2 3.3 6.3 
Cost per cm gain (£) 2798 6536 5869 3696 9697 8062 
 
TABLE 59 Base-case results for Pfizer 
 
 GHD TS PWS CRI SGA 
Incremental QALYs 3.48 2.83 2.3 2.53 2.98 
Incremental costs (£) 61,124 84,078 74,849 40,325 54,088 
ICER (£/QALY) 17,552 29,757 32,540 15,962 18,167 
Height gain (cm) 32.24 7.95 25.59 4.48 21.92 
Cost per cm gain (£) 1896 10,576 2925 9001 2467 
 
TABLE 60 Base-case results for the previous GH HTA6 
 
GHD TS PWSa CRI 
Incremental costs (£) 53,373 61,770 56,663 54,009 
Height gain (cm)b 8.85 3.9 1.36 7.29 
Cost per cm gain (£) 6029 15,997 40,815 7403 
a  Height gain expressed in terms of HtSDS gained. 
b  Discounted and adjusted for dropouts. 
 
 
have used the relationship between EQ-5D and 
height without controlling for other factors. 
 
In general, the incremental costs consist primarily 
of the rhGH drug costs, while other costs have little 
effect on model results. For the cost-effectiveness 
results, the key issue is the choice of utility values. 
The utility gain from rhGH is assumed to last over 
the patients’ lifetimes and hence most of the QALY 
gain is in adulthood. 
 
The results were sensitive to the length of 
treatment, for example by treating children from 
an earlier age. Current best practice is usually 
regarded as treating children as early as possible 
and this is likely to mean a longer treatment 
duration, which increases the cost of treatment 
and thus the ICER. It is unclear whether there will 
be an associated extra increase in height as most 
of the RCTs followed up children for a short time 
period, for less than 3 years. The previous HTA 
report suggested that height gains were greatest 
in the first year or two of treatment but stopping 
treatment before achieving FH generally leads to 
loss of growth gains, and so should not be advised. 
 
The results were sensitive to the clinical effect. The 
treatment effect has been obtained, where possible, 
from the best-quality RCT available. However, as 
indicated in Chapter 3 (see Results), these trials 
were generally of poor quality and were not long- 
term trials. We also used the clinical treatment 
effect from the KIGS observational study but the 
results were largely similar to those reported from 
the RCTs. 
 
There are limitations to the QoL estimates used in 
the model. There was a lack of good QoL studies 
conducted in the conditions of interest. Therefore, 
evidence based on these studies was not used 
in the main analysis. The utility estimates were 
based upon a study that estimated utility in the 
general adult population according to height. The 
study provides a common utility gain that could 
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be compared across all the conditions of interest. 
Furthermore, it also provided the possibility the 
outcomes from the RCTs identified in the clinical 
effectiveness could be used. However, this still 
remains a major source of uncertainty in the 
model. 
 
The QoL gains were highest for individuals with 
lower starting height; for those with starting 
height < –2 HtSDS the QoL gain was minimal. For 
example, those with PWS had a starting height of 
–2 HtSDS, and so for this group of patients the 
health gain is small and therefore rhGH has high 
ICER values compared with no treatment. Patients 
with PWS may experience an improvement in body 
composition due to rhGH but this was difficult to 
quantify, especially in the long term, due to lack of 
long-term data. 
 
The current analysis assumes in the base case 
that all children with the conditions of interest 
will have reduced life expectancy. This was based 
upon some evidence to suggest that these children 
would have a lower life expectancy due to increased 
risk of cardiovascular disease, due to abdominal 
obesity and raised blood pressure. Furthermore, 
those children with CRI have a much reduced 
life expectancy. We have used the end-stage renal 
disease mortality rates as a proxy in the absence of 
any available data for CRI. This may underestimate 
life expectancy and overestimate ICER values, as 
not all patients with CRI will go on to develop 
end-stage renal disease. Bengtsson170 suggests 
that rhGH can rectify most of the cardiovascular 
abnormalities associated with GHD, although there 
appear to be few long-term observational studies 
that confirm this claim. Therefore, we assumed that 
rhGH will not increase life expectancy. 
 
Apart from as a scenario analysis for PWS, the 
current analysis has not considered other benefits 
in addition to height gain within the model. The 
base case does not include possible benefits from 
changes in body composition, such as reduced 
risk of diabetes or cardiovascular disease, which 
may even result in increases in life expectancy. 
At this stage, these health gains would be purely 
speculative and it is not possible to verify if they 
exist or quantify them. It is also possible that there 
may be additional psychological benefits such as 
improved  self-esteem. 
Strengths and limitations of the 
assessment 
Strengths 
• The systematic review and economic evaluation 
were carried out independently, with no 
vested interest, and results are presented in a 
consistent and transparent manner. 
• Evidence for clinical effectiveness came from 
RCT data, considered to be the highest level of 
evidence. 
• The project followed established methodology 
and principles for conducting a systematic 
review. The methods used were defined a 
priori in a research protocol (see Appendix 1), 
and this was circulated to clinical experts and 
agreed with NICE before the project started. 
• A clinical advisory group reviewed and 
commented on drafts of the protocol and the 
final report. 
• A de novo economic model was developed 
following recognised guidelines. 
 
Limitations and uncertainties 
As specified in the protocol, the systematic review 
was restricted to RCTs, because these provide the 
highest level of evidence for clinical effectiveness. 
The majority of the studies included in this review 
lasted for between 6 months and 2 years, with 
very few continuing long term or to AH. Many of 
the trials excluded patients from analyses due to 
incomplete follow-up data or patient withdrawal. 
The short duration of the RCTs means it is difficult 
to assess effectiveness of rhGH in the context in 
which it would be prescribed in real life, i.e. for 
many years in some cases. 
 
None of the RCTs included in this review reported 
any assessment of QoL issues, and the literature 
has conflicting conclusions regarding the effect 
of short stature on QoL. It is therefore difficult to 
make any judgement about the impact of rhGH 
on the quality of a person’s daily life. Many of  
the children with the health conditions covered 
in this review will have a variety of other physical 
problems. While rhGH treatment can help to 
improve growth, height and body composition to 
some extent, QoL issues associated with underlying 
health problems will continue to affect some 
children. 
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Given the lack of QoL data for this patient group, 
it is possible that QALYs do not capture all the 
benefits of treatment for these children. 
 
We did not identify any RCTs that met the original 
inclusion criteria for children born SGA. Following 
discussion with NICE, we therefore amended the 
criteria as detailed in Chapter 3 (Inclusion and 
data extraction process). The main difference was 
that we included studies of children who failed to 
show catch-up growth by 3 years of age (rather 
than 4 years) but did not specify exact criteria 
for this. Although this will have allowed slightly 
younger children to be included, the evidence 
presented in this report is still relevant to the UK 
SGA population. We also removed the reference to 
parental height, so it is possible that children in the 
included trials were naturally shorter than those in 
the general population. Only one of the included 
trials used the licensed dose, so results from the 
other five could overstate the effectiveness of rhGH 
treatment for this patient group. 
 
We found only one RCT of rhGH in children with 
GHD,84 so the evidence base for this condition is 
rather weak. However, the previous HTA report6 
also included observational studies for GHD, TS, 
PWS and CRI. Non-randomised evidence for 
this condition has therefore been summarised 
previously in the literature and is publicly available. 
 
The included trials were generally poorly reported, 
and often had low numbers of participants. 
Primary outcomes were not clearly specified, 
and few studies reported power calculations. 
It is therefore possible that some trials were 
underpowered to detect ‘real’ differences between 
the treatment groups, even where such differences 
were reported to be statistically significant. 
 
The included studies were heterogeneous in terms 
of participants, dosages and study duration. The 
results are therefore presented as a narrative 
summary, and it was not appropriate to meta- 
analyse the data. 
 
The review did not assess publication bias or 
selective reporting of outcomes, so it is not possible 
to comment on the degree to which these affect the 
evidence base. 
 
The economic model used the suggested doses 
given in the BNF.165 However, the RCTs used doses 
that were sometimes outside the licensed doses. 
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Chapter 7 
Conclusions 
 
 
Implications for service 
provision 
Guidance from NICE already recommends 
treatment with rhGH for children who have short 
stature that is associated with GHD, TS, PWS 
and CRI, so prescriptions associated with these 
conditions are already in place. Advice from our 
clinical advisory group indicates that there may be 
a trend towards earlier prescribing for PWS, and 
many families are now seeking treatment in infancy 
rather than in mid-childhood. There may also be 
an increase in treatment associated with acquired 
GHD as the proportion of children surviving 
cancers and associated treatment increases. 
 
The newly licensed conditions SHOX-D and SGA 
are not covered by NICE guidance at the time 
of writing. Of the estimated 4758 UK patients 
currently receiving rhGH, only approximately 
5% were receiving treatment for short stature 
associated with being born SGA. A recent survey by 
BSPED found that there had been little change in 
the number of prescriptions in recent years.74 
 
It is not clear how many children with SHOX-D are 
currently receiving treatment. The availability of 
prescriptions to these new groups of patients could 
theoretically have a budgetary impact. However, 
the number of children with this condition is 
small so there is unlikely to be a large increase in 
prescriptions. 
 
 
Suggested research 
priorities 
• There is a lack of RCT evidence for the effects 
of rhGH treatment on FH, as it is impractical 
to run such long studies. However, longer 
studies beyond 2 years would be helpful in 
improving the evidence base for long-term 
treatment, even if near-FH rather than final 
AH were reported. 
• None of the included RCTs reported measures 
of HRQoL. There is a need to develop and 
validate a standardised QoL assessment that is 
specifically designed for children and adults. 
Future RCTs should include this as an outcome 
measure in order to assess the impact of small 
increases in height on daily QoL. This would 
also be helpful for developing utilities for cost- 
effectiveness analysis of rhGH treatment for 
these conditions. 
• Good-quality trials of continuation/ 
discontinuation of rhGH in children who have 
finished growing are required, which report 
consistent and clinically relevant outcomes, and 
which are standardised in terms of dose. 
• Good-quality trials are needed of GH in 
children born SGA, where the children 
included and the dose administered match the 
licensing criteria. 
• It was difficult to establish when treatment is 
initiated for the different disease areas, as this 
depends on age at diagnosis. Further work to 
survey national practices or policies would be 
helpful in terms of providing information for 
future updates of this review and economic 
evaluation. 
• Although figures for the use of renal 
replacement therapy are available, there is little 
epidemiological data available on the incidence 
and prevalence of CRI. Epidemiological studies 
would therefore be useful. 
• Good-quality observational studies are needed, 
which show the long-term effects of rhGH, 
particularly the effect of treatment on body 
composition, psychological benefits (such as 
improved  self-esteem),  long-term  morbidities 
(such as diabetes or cardiovascular disease) and 
life expectancy, particularly for PWS. 
• Further research is also necessary to establish 
the QoL benefits associated with rhGH in 
adults and children with these conditions. Well- 
conducted qualitative studies could provide 
data to inform future developments in this 
area. 
• Monitoring of AEs associated with long-term 
rhGH treatment is required, with a central 
register to record the effects of long-term 
elevations in IGF-1 levels. 
• More research is needed to assess the long- 
term effect on QoL for individuals who had 
rhGH as  children. 
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Appendix 1 
Protocol methods 
 
 
review of the evidence for the clinical 
effectiveness and cost-effectiveness of 
somatropin will be undertaken systematically 
following standard guidelines from the NHS 
Centre for Reviews and Dissemination (CRD).83 
An expert advisory group of clinical experts and 
service users where appropriate will support the 
review team at key stages of the project. 
 
Search strategy 
A search strategy will be developed and tested by 
an experienced information scientist. The strategy 
will be designed to identify studies reporting 
clinical effectiveness, cost-effectiveness, HRQoL, 
resource use and costs, epidemiology and natural 
history. 
 
The draft clinical effectiveness search strategy for 
MEDLINE is shown in Appendix 2. This will be 
adapted for other databases. 
 
A number of electronic databases will be searched 
including: The Cochrane Database of Systematic 
Reviews (CDSR); The Cochrane Central Register of 
Controlled Trials; NHS CRD (University of York) 
Database of Abstracts of Reviews of Effectiveness 
(DARE) and the NHS Economic Evaluation 
Database (NHS  EED); MEDLINE (Ovid); EMBASE 
(Ovid); National Research Register; Current 
Controlled Trials; ISI Proceedings; Web of Science; 
and BIOSIS. Bibliographies of related papers will 
be assessed for relevant studies where possible. 
 
The MSs to NICE will be assessed for any 
additional studies that meet the inclusion criteria. 
 
Experts will be contacted to identify additional 
published and unpublished references. 
 
Searches will be carried out from the inception 
date of the database. Although this will involve 
duplication of searches carried out for the  
previous review, it will be necessary to identify 
trials reporting body composition as an outcome 
measure, as these may not have been identified for 
all conditions in the previous review. For databases 
of abstracts and conference presentations searches 
will only be carried out for the past 2 years to 
capture any research that has not yet been fully 
published. All searches will be limited to the 
English language, and will be updated around 
February 2009. 
 
Inclusion and exclusion criteria 
Patients 
 
Children with growth disturbance, as per licensed 
indication for each preparation available. 
 
Interventions 
Recombinant human growth hormone 
(somatropin). 
 
Comparators 
Management strategies without somatropin. 
 
Outcomes 
The following outcomes will be included, where 
data are available: 
 
• final height gained 
• height standard deviation score 
• growth velocity 
• growth velocity standard deviation score 
• body composition, and biochemical/metabolic 
markers  as  appropriate 
• adverse effects of treatment 
• HRQoL. 
 
Types of studies 
• Fully published RCTs or systematic reviews 
of RCTs will be included. Indicators of a 
systematic review include: explicit search 
strategy, inclusion criteria, data extraction 
and assessment of quality. Where we judge it 
necessary and appropriate, we will consider 
the inclusion of evidence from other non- 
randomised studies. Full economic evaluations 
(cost-effectiveness studies, cost–utility studies, 
cost–benefit studies) and reviews of economic 
evaluations will be included in the review of 
cost-effectiveness. 
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• Studies published only as abstracts or 
conference presentations will be included only 
in the primary analysis of clinical effectiveness 
and cost-effectiveness if sufficient details 
are presented to allow an appraisal of the 
methodology and assessment of results. 
• Non-English language studies will be excluded. 
 
Inclusion and data extraction 
process 
• Two reviewers will assess the titles and abstracts 
of studies identified by the search strategy for 
potential  eligibility. 
• The full text of relevant papers will be 
requested for further assessment, and these will 
be screened independently by two reviewers. 
• Data will be extracted by one reviewer using a 
standard data extraction form and checked by 
a second reviewer. 
• At each stage, any discrepancy will be resolved 
by discussion, with involvement of a third 
reviewer where necessary. 
 
Quality assessment 
The quality of included clinical effectiveness studies 
will be assessed using NHS CRD (University of 
York) criteria.83   The methodological quality of 
the economic evaluations will be assessed using 
accepted frameworks such as the international 
consensus-developed list of criteria developed 
by Evers and colleagues171  and Drummond and 
colleagues.141   For any studies based on decision 
models we will also make use of the checklist for 
assessing good practice in decision-analytical 
modelling  (Philips  and  colleagues).172 
 
Quality criteria will be applied by one reviewer and 
checked by a second reviewer, with differences in 
opinion resolved by discussion and involvement of 
a third reviewer where necessary. 
 
Methods of analysis/synthesis 
• Clinical effectiveness and cost-effectiveness 
studies will be synthesised through a narrative 
review with tabulation of results of included 
studies. 
• Where data are of sufficient quality and 
homogeneity, a meta-analysis of the clinical 
effectiveness studies will be performed using 
appropriate  software. 
• Quality-of-life studies will be synthesised using 
the same methods as above, i.e. narrative 
review and meta-analysis as appropriate. 
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Appendix 2 
Literature search strategies 
 
 
earch strategies for MEDLINE are shown below. 
Strategies for other databases are available from 
the authors. 
 
rhGH clinical effectiveness 
MEDLINE: all years 1950–2008, search date: 23 
June 2009. 
 
1. growth disorders/ 
2. growth  failure.ti,ab. 
3. growth deficien*.ti,ab. 
4. Prader-Willi Syndrome/ 
5. prader-willi.ti,ab. 
6. turner syndrome/ 
7. (Turner*2 adj syndrome).ti,ab. 
8. growth hormone deficien*.ti,ab. 
9. GH deficien*.ti,ab. 
10. GHD.ti,ab. 
11. exp renal insufficiency chronic/ 
12. (chronic adj2 (renal or kidney*) adj2 (failure or 
insufficien*)).ti,ab. 
13. (CRI or CRF).ti,ab. 
14. “small for gestational age”.ti,ab. 
15. “short for gestational age”.ti,ab. 
16. infant small for gestational age/ 
17. “short stature homeobox-containing gene”. 
ti,ab. 
18. “short stature homeobox”.ti,ab. 
19. SGA.ti,ab. 
20. SHOX.ti,ab. 
21. PHOG.ti,ab. 
22. “Pseudoautosomal   homeobox-containing 
osteogenic gene”.ti,ab. 
23. or/1-22 
24. human growth hormone/or growth hormone/ 
25. (somatropin* or somatotropin* or 
somatotrophin* or genotropin* or saizen* or 
zomacton* or nutropin* or norditropin* or 
omnitrope* or humatrope*).ti,ab. 
26. 24 or 25 
27. exp child/or exp adolescent/or exp infant/ 
28. child preschool/ 
29. (child* or infant* or adolescen* or girl* or 
boy* or prepubert* or pre-pubert*).ti,ab. 
30. or/27-29 
31. 23 and 26 and 30 
32. randomized controlled trial.pt. 
33. controlled clinical trial.pt. 
34. exp Randomized Controlled Trial/ 
35. exp Randomized Controlled Trials as Topic/ 
36. exp random allocation/ 
37. Double-Blind Method/ 
38. Single-Blind Method/ 
39. ((singl* or doubl* or trebl*) adj9 (blind* or 
mask*)).ti,ab. 
40. placebo*.ti,ab,sh. 
41. random*.ti,ab. 
42. (medline or medlars or embase or scisearch or 
cinahl).ti,ab,sh. 
43. (systematic* adj5 review*).mp. 
44. (systematic adj5 overview*).mp. 
45. (methodolog* adj5 review).mp. 
46. (methodolog* adj5 overview).mp. 
47. (methodolog* adj5 research*).mp. 
48. meta analysis.pt. 
49. meta-analysis.sh. 
50. (meta-analys* or meta analys* or metaanalys*). 
mp. 
51. ((hand adj5 search*) or (manual* adj5 search)). 
mp. 
52. (electronic* database* or bibliographic* 
database* or computer* database* or online 
database*).mp. 
53. (Health Technology Assessment* or Medical 
Technology Assessment*).ti,ab,in. 
54. or/32-53 
55. 31 and 54 
56. limit 55 to (english language and humans) 
57. kidney transplantation/ 
58. (renal or kidney*).ti,ab. 
59. 57 or 58 
60. 26 and 30 and 54 and 59 
61. 60 not 56 
62. growth hormone/or human growth hormone/ 
63. 30 and 54 and 59 and 62 
64. 63 not 56 
65. 61 or 63 
66. limit 65 to (english language and humans) 
67.  55 or 66 
68. (editorial or letter or comment).pt. 
69. 67 not 68 
70. from 69 keep 1-13,21-22 
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Cost-effectiveness 
MEDLINE: all years 1950 to current, search date 
24 June 2009. 
 
1. exp economics/ 
2. exp economics hospital/ 
3. exp economics pharmaceutical/ 
4. exp economics nursing/ 
5. exp economics medical/ 
6. exp “Costs and Cost Analysis”/ 
7. Cost Benefit Analysis/ 
8. value of life/ 
9. exp models economic/ 
10. exp fees/and charges/ 
11. exp budgets/ 
12. (value adj2 (money or monetary)).tw. 
13. (economic adj2 burden).tw. 
14. (expenditure* not energy).tw. 
15. budget*.tw. 
16. (economic* or price* or pricing or financ* 
or “fee” or “fees” or pharmacoeconomic* or 
pharma economic* or pharmaco-economic*). 
tw. 
17. (decision adj1 (tree* or analys* or model*)).tw. 
18. Resource Allocation/ 
19. (unit cost or unit-cost or unit-costs or unit costs 
or drug cost or drug costs or hospital costs or 
health-care costs or health care cost or medical 
cost or medical costs).tw. 
20. ((value or values or valuation) adj2 (money or 
monetary or life or lives or costs or cost)).tw. 
21. (cost adj2 (util* or effective* or efficac*  
or benefit* or consequence* or analys* or 
minimi* or saving* or breakdown* or lowering 
or estimate* or variable* or allocation* 
or control* or illness* or affordable* or 
instrument* or technolog* or fee* or charge* 
or charges)).tw. 
22. Markov Chains/ 
23. Monte Carlo Method/ 
24. exp Decision Support Techniques/ 
25. (resource adj2 (use* or utili* or allocat*)).tw. 
26. or/1-25 
27. growth disorders/ 
28. growth  failure.ti,ab. 
29. growth deficien*.ti,ab. 
30. Prader-Willi Syndrome/ 
31. prader-willi.ti,ab. 
32. turner syndrome/ 
33. (Turner*2 adj syndrome).ti,ab. 
34. growth hormone deficien*.ti,ab. 
35. GH deficien*.ti,ab. 
36. GHD.ti,ab. 
37. exp renal insufficiency chronic/ 
38. (chronic adj2 (renal or kidney*) adj2 (failure or 
insufficien*)).ti,ab. 
39. (CRI or CRF).ti,ab. 
40. “small for gestational age”.ti,ab. 
41. “short for gestational age”.ti,ab. 
42. infant small for gestational age/ 
43. “short stature homeobox-containing gene”. 
ti,ab. 
44. “short stature homeobox”.ti,ab. 
45. SGA.ti,ab. 
46. (SHOX or PHOG).ti,ab. 
47. “idiopathic short stature”.ti,ab. 
48. “Pseudoautosomal   homeobox-containing 
osteogenic gene”.ti,ab. 
49. or/27-48 
50. human growth hormone/ 
51. (somatropin* or somatotropin* or 
somatotrophin* or genotropin* or saizen* or 
zomacton* or nutropin* or norditropin* or 
omnitrope* or humatrope*).ti,ab. 
52. or/50–51 
53. 26 and 49 and 52 
54. growth disorders/ec or growth hormone/ec 
55.  53 or 54 
56. limit 55 to (human and english language) 
57. (editorial or letter).pt. 
58. 56 not 57 
59. “growth  hormone”.ti,ab. 
60. 26 and 49 and 59 
61. 58 or 60 
62. limit 61 to (english language and humans) 
 
Quality-of-life searches 
Searched 30 September 2008. 
 
1. “Quality of Life”/ 
2. (hql or hqol or “h qol” or hrqol or “hr qol”). 
ti,ab. 
3. (“hye” or “hyes”).ti,ab. 
4. (euroqol or “euro qol” or “eq5d” or “eq 5d”). 
ti,ab. 
5. Quality-Adjusted Life Year/ 
6. “quality adjusted life”.ti,ab. 
7. (qaly$or qald$or qale$or qtime$).ti,ab. 
8. “disability adjusted life”.ti,ab. 
9. “quality of wellbeing”.ti,ab. 
10. “quality of well being”.ti,ab. 
11. daly$.ti,ab. 
12. (SF-36 or SF-36 or short form 36 or shortform 
36 or sf thirtysix or sf thirty six or shortform 
thirtysix or shortform thirty six or short form 
thirty six or short form thirtysix or short form 
thirty six).ti,ab. 
13. health$year$equivalent$.tw. 
14. disutil*.ti,ab. 
15. “Value of Life”/ 
16. rosser.ti,ab. 
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17. willingness to pay.tw. 
18. standard gamble$.tw. 
19. time trade off.tw. 
20. time tradeoff.tw. 
21. health utilit*.ab. 
22. exp Health Status/ 
23. exp Health Status Indicators/ 
24. “Activities of Daily Living”/ 
25. “Patient Acceptance of Health Care”/ 
26. “health-related quality of living”.ti,ab. 
27. “health-related quality of life”.ti,ab. 
28. (patient* adj2 (preference* or satisfaction or 
acceptance)).ti,ab. 
29. (health adj (“state” or “status” or “states”)). 
ti,ab. 
30. or/1-29 
31. growth disorders/ 
32. growth  failure.ti,ab. 
33. growth deficien*.ti,ab. 
34. Prader-Willi Syndrome/ 
35. prader-willi.ti,ab. 
36. turner syndrome/ 
37. (Turner*2 adj syndrome).ti,ab. 
38. growth hormone deficien*.ti,ab. 
39. GH deficien*.ti,ab. 
40. GHD.ti,ab. 
41. exp renal insufficiency chronic/ 
42. (chronic adj2 (renal or kidney*) adj2 (failure or 
insufficien*)).ti,ab. 
43. (CRI or CRF).ti,ab. 
44. “small for gestational age”.ti,ab. 
45. “short for gestational age”.ti,ab. 
46. infant small for gestational age/ 
47. “short stature homeobox-containing gene”. 
ti,ab. 
48. “short stature homeobox”.ti,ab. 
49. SGA.ti,ab. 
50. SHOX.ti,ab. 
51. PHOG.ti,ab. 
52. “Pseudoautosomal   homeobox-containing 
osteogenic gene”.ti,ab. 
53. or/31-52 
54. human growth hormone/ 
55. (somatropin* or somatotropin* or 
somatotrophin* or genotropin* or saizen* or 
zomacton* or nutropin* or norditropin* or 
omnitrope* or humatrope*).ti,ab. 
56. 54 or 55 
57. 30 and 53 and 56 
58. limit 57 to (english language and humans) 
59. (edtorial or letter or comment).pt. 
60. 58 not 59 
61. HIV.ti,ab. 
62. 60 not 61 
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Appendix 3 
Quality assessment 
 
 
 
Criteria Judgement 
1. Was the assignment to the treatment groups really random? Adequate/partial/inadequate/unknown 
2. Was the treatment allocation concealed? Adequate/inadequate/unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported/unknown 
4. Were the eligibility criteria specified? Adequate/partial/inadequate/unknown 
5. Were outcome assessors blinded to the treatment allocation? Adequate/inadequate/unknown 
6. Was the care provider blinded? Adequate/partial/inadequate/unknown 
7. Was the patient blinded? Adequate/partial/inadequate/unknown 
8. Were the point estimates and measure of variability presented for the 
primary outcome measure? 
Adequate/partial/inadequate/unknown 
9. Did the analyses include an ITT analysis? Adequate/inadequate 
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Appendix 4 
Data extraction tables 
 
GHD data extraction forms 
 
Reference and 
design Intervention 
 
Participants 
  
Outcome measures 
Soliman et al. (Group 1 not data Target population: prepubertal children Primary outcomes: not stated 
199684 extracted as dose– with GHD Secondary outcomes: GV, 
Study design: 1a. GH 30 U/m
2/week as group 2) glucose, FT4, TSH, GH 
Number of 1b. GH 15 U/m
2/week as response to provocation < 7 µg (not data height measured on a 
stated 2a. GH 15 U/m2/week as 2. Group 2: 19 children with peak GH data were according to Tanner, 
reported 2b. No treatment 10 µg/l (2a: 9, 2b: 10) 
according to Greulich and 
(Group 3 not data 3. Group 3: 24 children with normal peak 3-month intervals, and height 
GHD) 
a daily s.c. dose Sample attrition/dropout: none reported for   HtSDS calculated using age- 
Inclusion criteria for study entry: Inclusion height and SD 
year 
< 10 years at initiation of therapy, and 
< 3rd percentile height for chronological 
age 
None of the children had 
haemoglobinopathy, hepatic or renal 
impairment. No child had a reduced 
weight relative to height, other systemic 
disease, history of head trauma or cranial 
irradiation, malnutrition, psychosocial 
dwarfism or hypothyroidism 
BA, bone age; FT4, free thyroxine; TSH, thyroid-stimulating hormone; s.c., subcutaneous; U, unit. 
 
Characteristics of participants: growth parameters and hormonal data 
 
Characteristic GH 15 U/m2/week (n = 9) No treatment (n = 10) Overall 
Age (years) 7.1 ± 1.9 6.6 ± 1.6 6.8 ± 2.1 
GV (cm/years) 3.65 ± 1.1 4.3 ± 1 3.9 ± 1.1 
HtSDS (–) 3.4 ± 0.8 3.1 ± 0.6 2.8 ± 1 
BA delay 2.1 ± 0.8 1.8 ± 0.65 1.9 ± 1 
GH peak after clonidine   8.4 ± 1.3 
(µg/l)    
GH peak after insulin   8.1 ± 1.6 
(µg/l)    
IGF-1 (ng/ml) 58.5 ± 42.5 52.4 ± 21.3 59 ± 33 
Glucose (mmol/l) 0 min 3.6 ± 0.6 4.1 ± 0.5  
Glucose (mmol/l) 120 min 5.4 ± 0.5 4.9 ± 0.45  
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FT4 (pmol/l) 16.5 ± 2.1 14.6 ± 1.4 
TSH (µIU/ml) 1.4 ± 0.4 1.6 ± 0.3 
 
Results 
Outcomes GH 15 U/m2/week (n = 9) No treatment (n = 10) p-value 
GV (cm/years) 8.4 ± 1.4a,b 5.7 ± 1.8 
HtSDS (–) 2.3 ± 0.45a,b 2.8 ± 0.45 
BA delay 2.25 ± 0.8 1.93 ± 0.75 
GH peak after clonidine 
(µg/l) 
GH peak after insulin 
(µg/l) 
8.6 ± 1.1 8.2 ± 1 
 
8.5 ± 1.4 8.3 ± 1.2 
IGF-1 (ng/ml) 91.2 ± 30.4a,b 49.4 ± 19 
Glucose (mmol/l) 0 min 4.3 ± 0.6 4.5 ± 0.8 
Glucose (mmol/l) 120 min   5.1 ± 0.4 4.4 ± 0.6 
FT4 (pmol/l) 17.4 ± 2.2 15.6 ± 1.4 
TSH (µIU/ml) 2.4 ± 0.5 2.2 ± 0.5 
a  p < 0.05 before vs after 1 year. 
b  p < 0.05 ‘a’ vs ‘b’ subgroups. 
Methodological comments 
Allocation to treatment groups: Three groups of children were identified and recruited according to their peak GH response 
to provocation then subsequently allocated ‘at random’ to two subgroups within that group. No further details on 
randomisation were provided. 
Blinding: Blinding is not reported. 
Comparability of treatment groups: Treatment groups appear comparable, but no p-value is reported. 
Method of data analysis: Data are presented as mean ± SD. 
Sample size/power calculation: None reported. 
Attrition/dropout: None reported for group 2, although n = 4 excluded from group 1b due to lack of compliance. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Inadequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Adequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants 
 
Outcome measures 
Quigley et al. 1. Growth hormone Target population: prepubertal girls with Primary outcomes: NFH (cm) 
200212 (GH) (Humatrope) TS (first 18 months of the study data (no placebo group), changes in 
Country: USA 0.27 mg/kg/week, with extracted, as placebo group joined group HtSDS from baseline to end 
Study design: Pla) Number of participants: total = 232, Secondary outcomes: changes in: 
response 2. GH 0.27 mg/kg/week stratified by age and randomised. 224 BA, height (cm), impact of GH 
Number of (not data extracted) have baseline data reported Method of assessing outcomes: 
3. GH 0.36 mg/kg/week 1. 45 subjects were assessed every 3 
group appear to 0.36/Pla) months until study completion: 
Eli Lilly & Co. 4. GH 0.36 mg/kg/week 4. 42 and pubertal status. Blood 
(not data extracted) 5. 41 chemistry and thyroid function 
oral placebo (Pla/Pla) details on withdrawals are given (n = 8) 
and insulin every 6 months. 
GH/placebo injections: Inclusion criteria for study entry: 18 months, at 24 months then 
s.c., in equally divided Karyotypically proven TS ≥ 5 years old annually. X-ray of the left wrist 
per week; oral placebo every 6 months for 24 months 
Duration of treatment: on NCHS standard HV < 6 cm/year with reference to general 
Placebo group for first Exclusion criteria for study entry: population and to Lyon TS 
18 months of the study; Presence of any Y chromosomal growth data 
subjects completed the component in karyotype Length of follow-up: 18 months 
full study when HV was Concurrent treatment with agent that for placebo-controlled study 
BA ≥ 15 year 
Other interventions used: 
Ethinyl E2 daily, 25–  
200 ng/kg/day depending 
on age 
BA, bone age; LDE, low-dose estrogen; NCHS, National Center for Health Statistics; Pla, placebo. 
 
Characteristics of participants 
Baseline (mean ± SD) GH 0.27/Pla (n = 45) GH 0.36/Pla (n = 49) Pla/Pla (n = 41) 
Age (years) 9.7 ± 2.7 9.8 ± 2.9  9.4 ± 2.7 
BA (years) 7.9 ± 2.3 7.9 ± 2.3  7.9 ± 2.4 
Height (cm) 119.2 ± 13.6 118.6 ± 12.5  117.6 ± 13.6 
HtSDS (NCHS) –2.7 ± 0.9 –2.9 ± 0.9  –2.9 ± 0.9 
HtSDS (NCHS) 0.3 ± 1.0 0.2 ± 0.8  0.2 ± 0.9 
Mid-parental height (cm) 164.6 ± 6.1 162.9 ± 5.9  162.4 ± 5.0 
Mid-parental height SD 0.27 ± 0.93 0.00 ± 0.91  –0.08 ± 0.77 
score     
Prestudy GV 4.1 ± 1.2 4.0 ± 1.2  4.1 ± 1.2 
Results     
Outcomes GH 0.27/Pla (n = 45) GH 0.36/Pla (n = 49) Pla/Pla (n = 41) p-value 
GV 0–18 months (cm/ 6.6 ± 1.1 6.8 ± 1.1 4.2 ± 1.1 < 0.001a 
year) 
a  Compared with placebo. 
The 6-monthly GV results are presented on a difficult-to-read graph – could not data extract. Authors state that HV 
declined slightly in all GH groups after the initial peak but was significantly greater than that of the placebo group. 
 
 
 
 
 
 
TS data extraction forms 
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Adverse effects GH Placebo p-value 
Otitis media 
(occurrence/ 
worsening) 
Comments 
54/186 (29%) 6/46 (13%) 0.037 
Ear pain and ear disorder were not different in frequency between groups. Otitis media was reported in 41% of 
subjects overall, ear pain in 27% and hypothyroidism in 16% and oedema in 3%. There were no disorders that occurred 
significantly more frequently in subjects receiving the higher dose. Serious AEs (defined as death, life-threatening cancer, 
hospitalisation, permanently disabling, drug overdose or resulting in congenital anomaly in an offspring) were reported 
for 47 out of 232 subjects; 31/47 of these were hospitalised for surgical procedures, either for elective management of 
conditions associated with TS or related to accidental injury; 11 were hospitalised for other reasons: infectious illness/ 
dehydration n = 5, psychosis n = 1, abnormal liver function tests n = 1, vaginal bleeding n = 1, haematuria n = 1, cardiac failure 
n = 1, hypertension n = 1; and the remaining five were reported to have accidentally overdosed on the study drug. AEs that 
were considered unexpected and possibly related to the study drug were reported for 5/232 subjects (2%): hypertension 
n = 2 (in 1 subject this had been present for 11 years), surgical procedures n = 2, scoliosis n = 1. There were no reports of 
deaths, cancer or neoplasia. 
Methodological comments 
Allocation to treatment groups: Authors state that subjects were randomised in a double blind fashion, but no further details 
are given. 
Blinding: States double blind. Placebo is given by injection. BA radiographs were read by a single observer who was blinded 
to treatment status. 
Comparability of treatment groups: Treatment groups appear similar at baseline. 
Method of data analysis: Data obtained during the initial 18-month placebo-controlled phase are reported for each of the 
five original randomisation groups. ITT performed for all subjects who received 180 days of active treatment. 
Sample size/power calculation: Not reported. 
Attrition/dropout: Withdrawals not discussed; eight patients were randomised but did not complete treatment. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Partial 
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? 
Inadequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
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Reference and 
design Intervention Participants Outcome measures 
Stephure and Intervention: (GH group) Target population: prepubertal girls, Primary outcomes: BA (years), 
The Canadian rhGH (Humatrope, Eli aged 7–13 years, with a diagnosis of height (cm), HtSDS (age specific/ 
Growth Lilly Canada) by daily s.c.i.   TS documented by peripheral blood adult Turner), change in height 
Hormone 6 times weekly (0.30 mg/ karyotype (cm), change in HtSDS (age- 
Advisory kg/week, maximum Number of participants: 154 (95 in Rovet) specific Turner) 
Committee86 weekly dose 15 mg) prepubertal girls Secondary outcomes: and Rovet et Control: no GH treatment   Intervention: 76 (51 in Rovet) Method of assessing outcomes: 
al. 199387 (no 
extractable data,   Other interventions Control: 78 (44 in Rovet) routine haematology, 
so no further used: girls with primary Sample attrition/dropout: Overall, 15 
biochemistry and thyroid 
information ovarian failure received withdrew from GH; 35 from control: 
function studies were monitored 
extracted here) standardised sex  every 3 months (every 6 in 
steroid replacement: addendum follow-up 8 from GH; 9 from   control after first year), BA 
Year: 2005 ethinyloestradiol 2.5 µg/ control interpreted by central reader 
Country: Canada day at age 13, 5.0 µg/  1997 follow-up only, 5 from GH; 13 using Greulich and Pyle annually. 
Study design: day at age 14, and 2.0 µg from control Age-specific and AH SD scores 
RCT on days 1–24 with  core protocol data only, 2 from GH; 13 (SDS, height SD score) and the medroxyprogesterone change in height SD scores at 
Number acetate 10 mg on days from control protocol completion and follow- 
of centres: 15–24 of each month at Sample crossovers: N/A up relative to baseline were 
multicentre age 15 and thereafter Inclusion criteria for study entry: calculated according to published 
Funding: Eli Lilly  Height less than the 10th percentile for standards for girls with TS Canada Inc. chronological age on the growth charts Length of follow-up: subjects 
of the NCHS of the USA returned for follow-up every 3 
An annualised GV less than 6.0 cm/year months until study completion, 
during a 6-month prerandomisation protocol completion criteria 
period required annualised GV less than 
2 cm/year and BA 14 years or 
Diagnosis of TS documented by greater 
peripheral blood karyotype. Phenotypic 
females with identifiable Y chromosome Addendum follow-up = height 
eligible to participate if had undergone and safety follow-up at least 
prior gonadectomy 1 year following latest core 
protocol visit 
Exclusion criteria for study entry: 
Clinically significant chronic systemic 
illness, prior treatment with GH, 
anabolic steroids, estrogens, craniospinal 
radiation or inadequate thyroxine 
replacement for hypothyroidism were 
excluded 
A spontaneous or stimulated serum 
GH level was 8.0 µg/l or greater in all 
subjects 
Characteristics of participants (mean ± SD) 
Baseline 
           Age 10.3 ± 1.8 10.9 ± 1.7 
Baseline BA (years) 8.8 ± 1.4 8.9 ± 1.3 
Baseline height (cm) 119.1 ± 8.5 122.0 ± 7.8 
Baseline HtSDS (age- –0.2 ± 0.9 –0.1 ± 0.8 
specific Turner) 
Adjusted mid-parental 160.7 ± 6.2 159.3 ± 5.8 
height (cm)a 
45,X karyotype (%) 62.3  58.1 
Comments 
a  Adjusted mid-parental height = [(father height – 13 cm) + mother height]/2. 
Baseline results for patients who completed the protocol. Baseline data for patients who also had follow-up are very 
similar. No baseline characteristics differed at p < 0.05. 
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Results: protocol completion characteristics (mean ± SD) 
No treatment GH effect:b mean 
Primary outcomes GH (n = 61) (n = 43) (95% CI) 
 
 
 
p-value 
Age (years) 16.0 ± 0.8 16.5 ± 0.9 c 0.002 
Time since randomisation 5.7 ± 1.6 5.7 ± 1.6 
(years) 
BA (years) 14.4 ± 0.8 14.5 ± 0.9 –0.1 (0.5 to 0.3) ns 
Height (cm) 147.5 ± 6.1 141.0 ± 5.4 7.2 (6.0 to 8.4) < 0.001 
HtSDS (age-specific 1.4 ± 1.0 0.2 ± 0.9 1.2 (1.0 to 1.5) < 0.001 
Turner) 
HtSDS (adult Turner) 0.7 ± 0.9 –0.3 ± 0.8 1.1 (0.8 to 1.3) < 0.001 
Change in height (cm) 28.3 ± 8.9 19.0 ± 6.1 7.2 (6.0 to 8.3) < 0.001 
Change in HtSDS (age- 1.6 ± 0.6 0.3 ± 0.4 1.3 (1.1 to 1.5) < 0.001 
specific Turner) 
ns, not significant. 
b ANCOVA model with treatment, baseline HtSDS, baseline HtSDS by treatment interaction, baseline age, and baseline 
age by treatment interaction. Explanatory variables were removed from the model when not significant. GH effect is 
estimated by differences of least-squares means for treatment. 
c Age at protocol completion was significantly different between control and GH, p=0.002, this reflects the similar 
numerical difference at baseline and completion, and the lower SD at completion due to the narrower age range. 
Protocol completion criteria required an annualised GV of less than 2 cm/year and a BA of 14 years or greater. 
Results: addendum follow-up characteristics (mean ± SD) 
No treatment GH effect:b mean 
Primary outcomes GH (n = 40) (n = 19) (95% CI) p-value 
Age (years) 20.7 ± 2.5 21.2 ± 2.0   
Time since randomisation 10.6 ± 1.7 10.7 ± 1.4   
(years)    
BA (years) 15.1 ± 1.0 15.2 ± 1.0 0.0 (–0.6 to 0.6) ns 
Height (cm) 149.0 ± 6.4 142.2 ± 6.6 73. (5.4 to 9.2) < 0.001 
HtSDS (age-specific 0.9 ± 0.9 –0.1 ± 1.0 1.1 (0.8 to1.4) < 0.001 
Turner)    
HtSDS (adult Turner) 0.9 ± 0.9 –0.1 ± 1.0 1.1 (0.8 to 1.4) < 0.001 
Change in height (cm) 30.3 ± 8.3 21.6 ± 6.2 7.3 (5.4 to 9.1) < 0.001 
Change in HtSDS (age- 1.1 ± 0.5 0.0 ± 0.5 1.1 (0.8 to 1.4) < 0.001 
specific Turner)    
Comments    
As for completion characteristics.    
Adverse event GH (n = 74)  No treatment (n = 64) p-value 
Surgical procedures 37  17 0.005 
Otitis media 35  17 0.014 
Ear disorder 15  4 0.024 
Joint disorder 10  2 0.036 
Respiratory disorder 8  1 0.037 
Sinusitis 14  4 0.041 
Goitre 0  4 0.004 
Death (ruptured aortic 0  1 nr 
aneurysm)    
Elevated transamine 1  0 nr 
levelsd    
Intracranial hypertension   1  0 nr 
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Comments 
d  Leading to withdrawal from study. 
After protocol completion there was no significant difference in auditory acuity (conductive or neurosensory) between 
groups (data not shown). 
There were no significant between group differences in change from baseline to end point in fasting blood glucose, glycated 
haemoglobin (HbA ), serum T4 or TSH (data not shown). 
Methodological comments 
Allocation to treatment groups: Eligible subjects were stratified for height relative to chronological age at entry and randomly 
assigned. 
Blinding: Unblinded – control received no treatment. No mention of blinding of assessors. 
Comparability of treatment groups: No statistically significant differences between groups at baseline (stated, p-values not 
given). 
Method of data analysis: Data are reported as mean ± 1 SD unless stated otherwise. Differences between groups at baseline 
and end point for characteristics such as age and duration of therapy were assessed by one-way ANOVA or Fisher’s exact 
test, as appropriate. No ITT analysis. 
Sample size/power calculation: Not calculated. 
Attrition/dropout: Dropout is discussed: 15 withdrew from the GH group; 35 from the control. Addendum follow-up: eight 
from GH, nine from control; 1997 follow up only: five from GH, 13 from control; core protocol data only: two from GH, 13 
from control. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate (no treatment) 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
 
Davenport et al. 
200785 
Country: USA 
Study design: RCT, 
open label 
Number of centres: 
11 
Setting: US 
paediatric 
endocrine centres 
Funding: 
Supported by 
Eli Lilly (EL) & 
Co., along with 
grants from 
universities; four 
of the authors 
are employed 
by EL, most of 
the authors have 
received grant 
support from 
EL, as well as 
consulting and 
lectureship fees 
from EL and other 
pharmaceutical 
companies in the 
past 
 
1. Recombinant growth 
hormone (Humatrope) 
daily s.c.i. of 50 µg/kg/ 
day 
2. No treatment 
Duration of treatment: 2 
years 
Other interventions used: 
none 
Target population: girls with TS, aged 
9 months to 4 years 
Number of participants: total: 89 (The 
efficacy data exclude 1 subject who 
was found after study entry to have 
a 46,XX karyotype) 
1. 45 
2. 44 
Sample attrition/dropout: Overall 
dropouts 10, GH group 4, no 
treatment 6 
Reasons for discontinuation: 
Control: 
Parents’ decision n = 2 
Scheduling problems n = 1 
Request for GH n = 2 
Lost to follow-up n = 1 
GH: 
Relocation n = 1 
Lost to follow-up n = 3 
Compliance rated as excellent by 
authors: 95% of subjects received 
80% of scheduled injections 
Inclusion criteria for study entry: 
Aged 9 months to 4 years 
Karyotype proven TS 
Normal urinalysis, haemoglobin and 
thyroid stimulating hormone 
Adequate thyroid hormone 
replacement for at least 6 months in 
those with hypothyroidism 
Written informed consent from 
legal guardians 
Exclusion criteria for study entry: 
Presence of Y-chromosomal 
component in the karyotype in 
subjects with gonads in situ 
Autosomal abnormality 
Concurrent treatment that might 
influence growth 
Clinically relevant systemic illness 
No specific eligibility criteria based on 
height or GV 
Primary outcomes: change in SDS for 
length or height (depending on age) 
from baseline to 2 years. A height 
gain of at least 0.5 was considered 
clinically significant 
Secondary outcomes: serum IGF-I, 
IGFBP-3, bone tumour markers, 
identify factors associated with 
treatment response, determine 
whether outcome could be 
predicted by regression model using 
these factors, assess safety of GH 
treatment in young cohort 
Method of assessing outcomes: 
Age-appropriate measures were 
obtained at each visit for length 
using infant measuring box (children 
< 2 years or older, children 
for whom accurate standing 
measurements could not be 
obtained) 
Standard wall-mounted stadiometer 
(children older than 2 years) 
Both length and height measured 
for girls between 2 and 3 years old; 
length measurements in these cases 
were used for the analyses 
Length/HtSDS were calculated on 
the basis of data for aged matched 
girls from the US Centers for 
Disease Control 
Mid-parental height 
calculated as follows: (father’s 
height – 13 cm + mother’s height)/2 
and converted to SDS using 
normative height data for women at 
20 years of age 
Serum IGF-1, IGFBP-3 and bone 
turnover markers were measured 
at baseline, 4 months, 1 year and 2 
years 
SDSs were calculated using 
Esoterix’s data for healthy controls 
BA radiographs obtained at 
baseline, 1 year, and 2 year and read 
by blinded independent assessors 
Safety was assessed on each visit 
based on reported AE, detailed 
history and physical examinations 
Length of follow-up: 4-monthly 
intervals for the 2 years of 
treatment 
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Baseline characteristics of participants (mean ± SD) 
Variable GH (n = 45) No treatment (n = 43) p-value 
Chronological age (years) 1.98 ± 1.01 1.97 ± 1.01 nr 
BA (years)a 1.95 ± 0.89 1.88 ± 0.96 nr 
BA–CA –0.06 ± 0.56 –0.14 ± 0.42 nr 
Length/height (cm) 78.9 ± 8.6 77.6 ± 8.7 nr 
Length/HtSDS –1.42 ± 1.00 –1.76 ± 1.07 nr 
MPH (cm)b 164.4 ± 5.0 164.4 ± 4.7 nr 
MPH SDSb 0.17 ± 0.77 0.16 ± 0.73 nr 
Weight (kg) 10.35 ± 2.28 9.92 ± 2.47 nr 
WtSDS –1.31 ± 1.18 –1.77 ± 1.46 nr 
BMI (kg/m2) 16.48 ± 1.37 16.24 ± 1.29 nr 
Head circumference (cm)c 47.2 ± 2.4 46.7 ± 2.1 nr 
Head circumference SDSc 0.09 ± 1.05 –0.14 ± 1.19 nr 
Karyotype distribution: 27/45 (60%) 29/43 (67%) 
45,X 
Karyotype distribution: 7/45 (16%) 7/43 (16%) 
45,X/46,XX 
Karyotype distribution: 11/45 (24%) 7/43 (16%) 
other 
IGF-1 SDSd –0.25 ± 0.85 –0.39 ± 0.95 nr 
IGFBP-3d –0.66 ± 1.08 –0.83 ± 1.05 nr 
CA, chronological age. 
a Baseline BA missing for two subjects in each group. 
b Father’s height missing for one GH subject at both baseline and end point. 
c Baseline data missing for one subject in each group; one control subject had an erroneous value at baseline, so the value 
was not used; end point data missing for two control subjects. 
d Baseline data missing for eight control subjects and three GH-treated subjects; end point data missing for four control 
subjects and seven GH subjects. 
Results (mean ± SD) 
Outcomes GH (n = 41) No treatment (n = 37) p-value 
Chronological age (years) 4.03 ± 1.05 4.03 ± 1.03 0.9944 
BA (years)a 4.24 ± 1.35 3.38 ± 1.11 0.0033 
BA–CA –0.64 ± 0.80 0.21 ± 0.96 < 0.0001 
Length/height (cm) 99.5 ± 7.6 91.9 ± 7.2 < 0.0001 
Length/HtSDS –0.34 ± 1.10 –2.16 ± 1.22 < 0.0001 
MPH (cm)b 164.7 ± 4.9 164.1 ± 4.9 0.5608 
MPH SDSb 0.22 ± 0.76 0.12 ± 0.76 0.5607 
Weight (kg) 16.62 ± 2.86 13.81 ± 2.50 < 0.0001 
WtSDS 0.20 ± 1.06 –1.37 ± 1.36 < 0.0001 
BMI (kg/m2) 16.72 ± 1.70 16.24 ± 1.29 0.1724 
Head circumference (cm)c 51.1 ± 1.5 49.9 ± 1.4 0.0004 
Head circumference SDSc 1.17 ± 1.03 0.30 ± 0.99 0.0004 
IGF-1 SDSd 1.26 ± 0.72 –0.69 ± 0.84 < 0.0001 
IGFBP-3d 0.97 ± 0.94 –1.12 ± 1.13 < 0.0001 
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Comments 
For table footnotes, see corresponding notes above, under Baseline characteristics of participants. 
The between group difference for change in HtSDS after 2 years was 1.6 ± 0.6, p < 0.001 – this analysis was performed on 
data from the 78 subjects with karyotype proven TS who completed the 2-year study. The between-group difference was 
significant by 4 months and increased progressively. Total 2-year height gain was 13.6 ± 3.5 cm for the control group, vs 
20.4 ± 3.3 cm for the GH group (p < 0.001). Data are reported as mean ± SD unless noted otherwise. 
No treatment (n = 37) GH (n = 41) p-value 
First-year GVe (cm/year) 8.0 ± 2.4 11.7 ± 2.4 < 0.0001 
Second-year GV (cm/year) 5.5 ± 1.8 8.4 ± 1.6 < 0.0001 
First-year GV SDS –0.83 ± 0.95 1.75 ± 1.25 < 0.0001 
Second-year GV SDS –1.63 ± 1.29 0.70 ± 1.11 < 0.001 
e Numbers in groups not known for first-year results; data are reported as mean ± SD unless noted otherwise. At the 
2-year time point (when heights of both groups were compared with US standards), only 7% of GH-treated subjects 
remained below –2.0 SDS (~2.3 percentile); in contrast, 57% of the control subjects were below –2.0 SDS at 2 years 
(p < 0.0001). 
Outcome GH (n = 41) No treatment (n = 37) p-value 
Baseline to 2-year change: 1.53 ± 0.93 –0.09 ± 0.87 nr 
IGF-I SDS 
Adverse effects 
Adverse effects GH (n = 45) No treatment (n = 44) 
Serious AE, n (%)f 4 (9) 4 (9) 
Treatment-emergent AEg 42 (93) 43 (98) 
 
f Control group: one subject each was hospitalised for surgical repair of an atrial septal defect, croup/bronchiolitis, 
gastroenteritis and dehydration. GH: one subject each was hospitalised for gastroenteritis/dehydration, bacterial 
pneumonia, persistent bleeding after tonsillectomy and hypoxaemia after adenoidectomy. 
g Events or conditions that began or worsened after study entry: many of these events were related to ear disorders. 
There was no detrimental effect of GH treatment on frequency of episodes of otitis media, rates of ear tube insertion, 
middle ear function or hearing. Most other events reported with a high frequency were typical childhood illnesses that 
were considered unlikely to have been related to GH treatment. There were no significant changes or between-group 
differences in serum TSH. AEs have been reported for the full group numbers. 
Methodological comments 
Allocation to treatment groups: Children were stratified by age (9 months to 2.5 years and > 2.5–4 years) and then 
randomised using a blinded phone in process, in a 1 : 1 ratio. 
Blinding: Assessors of BA radiographs were blinded; it is not reported if assessors of other outcomes were blinded. 
Control group did not receive placebo injections. 
Comparability of treatment groups: The two groups appear broadly similar at baseline. BA–chronological age, length/HtSDS, 
IGF-1 SDS and IGFBP-3 SDS were slightly lower in the GH group at baseline. Weight measures were slightly higher in this 
group. No p-value, so unknown if these differences are minimal. 
Method of data analysis: The primary efficacy analysis was conducted on the baseline–2-year change in HtSDS for all 
subjects who had measurements at both time points (not ITT) using an ANOVA model with treatment group and baseline 
age group as explanatory variables. For analyses of changes in HtSDS, 1-sided tests were used, with the significance level 
set at 0.05. All other analyses of efficacy variables were conducted using 2-sided tests, with the significance level set at 
0.05. Serious AEs, treatment-emergent AEs and laboratory data were summarised for all subjects who entered the study. 
Data are reported as mean ± SD unless noted otherwise. 
Sample size/power calculation: No calculation. 
Attrition/dropout: Overall dropouts 10, GH group 4, no treatment 6. 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Adequate 
2. Was the treatment allocation concealed? Adequate 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design 
 
Intervention 
 
Participants 
  
Outcome measures 
Gravholt et al. 1. GH 0.1 IU/kg/day s.c. Target population: girls with TS Primary outcomes: not stated 
200588 2. Placebo Number of participants: total 12; Secondary outcomes: body 
Country: Denmark Age-matched control numbers allocated to each group no t   composition, insulin sensitivity, 
Study design: group studied once (not given other biochemical/metabolic 
Randomised, data extracted) Sample attrition/dropout: not reporte d   markers, markers of ovarian 
placebo-controlled Duration of treatment: 2 Inclusion/exclusion criteria for study function (not data extracted) 
crossover study months in each arm. No entry: not stated Method of assessing outcomes: 
Number of centres: washout period betwee n Participants studied at the end 
not reported the two study periods  of every 2-month period, IGF-1, IGFBP-3 and IGFBP-1 and other 
Funding: Governmen t   Other interventions used: biochemical markers tested at 
grant to Novo At least 6 months befor e the end of every study period. 
Nordisk Centre for inclusion in the study all Body composition measured by 
Research in Growth girls had received GH whole body DEXA 
and Regeneration. (0.1 IU/kg/day) 
One author recipient Length of follow-up: 4 months 
of honoraria from 
Pharmacia and 
Novo Nordisk, and 
a second author 
is recipient of a 
research grant 
from Eli Lilly, Novo 
Nordisk and Roche 
DEXA, dual-energy X-ray absorptiometry. 
Characteristics of participants: 12 girls with TS, aged 9.5–14.8 years (median 12.9) – not reported 
Outcomes GH 0.1 IU/kg/day s.c. Placebo p-value 
FM arms (g/kg total body 32.9 ± 8.2 36.0 ± 8.6 0.12 
weight)    
FM legs (g/kg total body 98.7 ± 18.7 104.9 ± 17.8 0.340 
weight)    
FM trunk (g/kg total body 80.7 ± 27.4 88.1 ± 35.4 0.1 
weight)    
FM head (g/kg total body 18.7 ± 3.3 18.7 ± 3.1 0.5 
weight)    
FM total (g/kg total body 231.0 ± 49.5 247.8 ± 58.1 0.04 
weight)    
BMC arms (g/kg total body 3.6 ± 0.8 3.5 ± 0.7 0.6 
weight)    
BMC legs (g/kg total body 10.5 ± 1.7 10.6 ± 1.8 0.3 
weight)    
BMC trunk (g/kg total body 7.9 ± 1.5 8.0 ± 1.4 0.4 
weight)    
BMC head (g/kg total body 7.9 ± 1.1 8.0 ± 1.2 0.9 
weight)    
BMC total (g/kg total body 29.6 ± 3.6 30.1 ± 3.6 0.1 
weight)    
LBM arms (g/kg total body 62.9 ± 6.4 60.5 ± 6.6 0.1 
weight)    
LBM legs (g/kg total body 205.7 ± 23.7 202.0 ± 25.9 0.2 
weight)    
LBM trunk (g/kg total body 378.8 ± 17.4 369.3 ± 29.6 0.046 
weight)    
LBM head (g/kg total body 78.0 ± 15.2 78.8 ± 13.6 0.5 
weight)    
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LBM total (g/kg total body 
weight) 
725.4 ± 44.8 710.5 ± 54.6 0.05 
IGF-1 (µg/l) 380.5 ± 116.3 179.8 ± 79.4 < 0.0005 
IGFBP-1 (µg/l) 3.1 ± 2.4 7.3 ± 4.7 0.002 
IGFBP-3 (µg/l) 5982 ± 1557 4344 ± 787 0.002 
IGF-1/IGFBP-3 ratio 0.065 ± 0.014 0.041 ± 0.013 < 0.0005 
Fasting glucose (mmol/l) 4.28 ± 0.59 4.02 ± 0.44 0.046 
Fasting insulin (pmol/l) 17.17 ± 8.30 8.58 ± 4.27 0.007a 
Fasting glucagon (ng/l) 97.8 ± 43.4 79.2 ± 23.3 0.08 
ISIcomp 10.3 ± 9.8 20.9 ± 16.0 0.003 
HOMA 3.34 ± 1.70 1.56 ± 0.87 0.001 
AUC insulin (pmol/l/24 h) 61 344 ± 28 547 40 868 ± 16 112 0.006 
AUC glucose 6922 ± 570 6707 ± 464 0.3 
AUC lactate (mmol/l/540 min)   5255 ± 1224 4589 ± 1165 0.2 
AUC alanine (µmol/l/540 min)   2230 ± 548 2081 ± 368 0.4 
AUC glycerol 
(µmol/l/540 min) 
648 ± 208 527 ± 104 0.1 
AUC BOH (µmol/l/540 min) 1215 ± 1486 589 ± 385  0.2 
AUC lactate OGTT 
(mmol/l/120 min) 
AUC alanine OGTT 
(µmol/l/120 min) 
AUC glycerol OGTT 
(µmol/l/120 min) 
AUC BOH OGTT 
(µmol/l/120 min) 
AUC FFA OGTT 
(µmol/l/120 min) 
Comments 
11569 ± 2438 10239 ± 1674 0.09 
 
2848 ± 730 2665 ± 459 0.3 
 
444 ± 83 408 ± 96 0.2 
 
564 ± 812 319 ± 268 0.3 
 
2.43 ± 0.77 2.06 ± 0.91 0.1 
AUC, area under the curve; BOH, 3-hydroxybutyrate; FFA, free fatty acids; HOMA, homeostasis model assessment 
index; ISIcomp, composite whole-body insulin sensitivity index; OGTT, oral glucose tolerance test; R, fasting insulin 
(22.5 x e–ln fasting glucose). 
a  Wilcoxon two-tailed test. Numbers entered into each group unclear. 
Adverse effects 
Not reported. 
Methodological comments 
Allocation to treatment groups: States randomised, but no other details. No details of numbers allocated to groups. 
Blinding: States placebo used, no other details given. 
Comparability of treatment groups: Appear comparable, but unclear if the details are from baseline. 
Method of data analysis: Groups were compared using Student’s two-tailed paired t-test, independent t-test, Mann–Whitney 
U-test or Wilcoxon test as appropriate. States that all data were tested for period as well as carry-over effects: authors 
state this did not affect significance. Results expressed as mean ± SD. Statistical significance was assumed for p < 5%. 
Sample size/power calculation: Not reported. 
Attrition/dropout: Not reported/discussed, no numbers allocated to groups specified. 
 
 
 
 
 
 
 
 
 
121 
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.  
Appendix 4 
 
 
 
 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Unknown 
4. Were the eligibility criteria specified? Inadequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Unknown 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
122 
 
Health Technology Assessment 2010; Vol. 14: No. 42 DOI: 10.3310/hta14420 
 
Reference and 
design 
 
Intervention 
 
Participants 
 
Outcome measures 
Gravholt et al. All girls were treated with Target population: girls with TS Primary outcomes: not 
200589 placebo + placebo, GH + placebo Number of participants: total stated 
latter group’s results are not data treatment groups insulin sensitivity, 
each completed by a 24-h blood  composition 
trial regimen was given sequentially and non-compliance with study Method of assessing 
reported Doses: Inclusion/exclusion criteria 
were studied at the 
Funding: Government 1. GH [1.3 ± 0.3 (0.7–1.8)] mg/day TS previously verified by period. IGF-1, IGFBP-3 
Nordisk Centre for 
and Regeneration 0.6)] mg/day 
composition measured by 
A pubertal stage-matched healthy 
once (not data extracted) months (including initial 
Duration of treatment: 6 months months) 
Other interventions used: At least 
5 months before inclusion in 
the study all TS girls received 
GH [1.3 ± 0.3 (0.7–1.8)] mg/ 
day [mean ± SD (range)] and 17β 
oestradiol [0.39 ± 0.16 (0.25– 
0.6)] mg/day 
 
Characteristics of participants: baseline data given for Turner participants as 1 group; did not extract data for 
healthy controls 
TS p-value 
Age (years) 15.9 ± 1.8   
Weight (kg) 49.1 ± 11.0   
Height (cm) 148.3 ± 4.0   
BMI (kg/m2) 22.2 ± 4.0   
Results    
Outcomes GH Placebo p-value 
FM arms 41.2 ± 10.2 46.3 ± 12.9 Unclear which groups 
FM legs 122.4 ± 22.2 135.1 ± 30.2 the p-values in the paper are referring to: not data 
FM trunk 96.2 ± 27.9 116.6 ± 38.7 extracted here 
FM head 14.7 ± 2.1 14.8 ± 2.5 
FM total 274.5 ± 55.5 312.9 ± 74.7 
BMC arms 4.5 ± 0.4 4.2 ± 0.3 
BMC legs 11.7 ± 0.8 11.9 ± 0.9 
BMC trunk 9.0 ± 1.1 8.9 ± 0.7 
BMC head 7.3 ± 1.2 7.2 ± 1.2 
BMC total 32.5 ± 2.6 32.1 ± 2.0 
LBM arms 61.2 ± 6.5 56.5 ± 10.4 
LBM legs 213.2 ± 24.1 197.2 ± 29.0 
LBM trunk 356.8 ± 20.9 339.9 ± 30.4 
LBM head 61.6 ± 10.7 61.3 ± 10.4 
LBM total 692.8 ± 55.5 655.2 ± 73.7 
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IGF-1 (µg/l) 
IGFBP-1 (µg/l) 
IGFBP-3 (µg/l) 
Fasting glucose 
661 ± 192 
1.8 ± 1.2 
5157 ± 741 
4.46 ± 0.40 
288 ± 69 
4.2 ± 2.8 
4146 ± 573 
4.04 ± 0.47 
(mmol/l)   
Fasting insulin (pmol/l) 147.1 ± 54.0 86.1 ± 41.0 
Fasting glucagon (ng/l) 37.4 ± 12.6 43.0 ± 26.1 
ISIcomp 7.0 ± 3.7 14.7 ± 8.7 
RHOMA 4.12 ± 1.60 2.24 ± 1.31 
AUC insulin 
(pmol/l/24 h) 
8710 ± 4728 5848 ± 4312 
AUC glucose 119 ± 10 111 ± 13 
AUC lactate 
(nmol/l/480 min) 
4853 ± 1520 5532 ± 2120 
AUC alanine 
(µmol/l/480 min) 
1864 ± 627 2230 ± 543 
AUC glycerol 
(µmol/l/480 min) 
516 ± 245 491 ± 220 
AUC BOH 
(µmol/l/480 min) 
947 ± 1372 338 ± 437 
AUC lactate OGTT 
(mmol/l/120 min) 
3614 ± 976 3718 ± 948 
AUC alanine OGTT 
(µmol/l/120 min) 
855 ± 190 840 ± 159 
AUC glycerol OGTT 
(µmol/l/120 min) 
117 ± 56 99 ± 42 
AUC BOH OGTT 
(µmol/l/120 min) 
96 ± 96 57 ± 68 
AUC FFA OGTT 
(µmol/l/120 min) 
0.83 ± 0.18 0.75 ± 0.27 
AUC, area under the curve; BOH, 3-hydroxybutyrate; FFA, free fatty acids; HOMA, homeostasis model assessment index; 
ISIcomp, composite whole-body insulin sensitivity index; OGTT, oral glucose tolerance test; R, fasting insulin (22.5 x e–ln 
fasting glucose). 
Adverse effects 
Not reported/discussed. 
Methodological comments 
Allocation to treatment groups: Unclear whether allocation to treatment groups has taken place, or whether participants all 
took the same combination of drugs in the same time period. 
Blinding: No details given, although is stated that placebo + placebo given and GH + placebo in those groups. 
Comparability of treatment groups: Not reported – baseline information given for TS participants as a whole. 
Method of data analysis: Groups were compared using Student’s two-tailed paired t-test and an independent t-test when 
normally distributed, Mann–Whitney and Wilcoxon used for non-parametric data. Results expressed as mean ± SD. 
Statistical significance was assumed for p < 5%. 
Sample size/power calculation: Not reported. 
Attrition/dropout: One patient excluded for non-compliance with study protocol. No further details given. 
No washout period. Unclear on whether is randomised or treatment simply given ‘in a random order’ (p. 617). 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? nr 
4. Were the eligibility criteria specified? Inadequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Adequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
Johnston et al. 1. GH 28–30 IU/m2 surface Target population: girls with TS Primary outcomes: height gain at 
200190 area/week daily s.c.i. AH 
Number of participants: total 58 
Country: UK 2. Low-dose estrogen:  Secondary outcomes: growth- 
ethinyloestradiol 1.0 µg/day 1. 22 enhancing effect of LDE (not 
Study design: for < 10 years and 2.0 µg/day 2. 13 data extracted), change in HSDS 
RCT for > 10 years (approx 50– 
Number of 75 ng/kg body weight daily) 3. 23 
Method of assessing outcomes: 
standing height, sitting height, 
centres: six 3. Combined Sample attrition/dropout: 7 and weight were measured at 
Funding: ethinyloestradiol and GH withdrawals, 5 girls reallocated from 3-month intervals; HtSDSs 
Pharmacia & (not data extracted) estrogen to GH: it is unclear at what were derived from published 
Upjohn Duration of treatment: 1 year 
point this occurred Turner height standards, BA
 
in these groups (group 2 Inclusion criteria for study entry: not 
was initially determined at 
changed to group 3 after the stated 
yearly intervals and calculated 
using the Tanner–Whitehouse 
first year, not data extracted,   Exclusion criteria for study entry: other RUS method applicable to 
and treatment continued growth-limiting disorders, prior normal female population. until height increases had hormone therapy Various biochemical measures 
fallen below 1 cm/year) performed at study entry and 
Other interventions used: not annually, including triglycerides, 
stated for year 1 cholesterol and TSH 
Length of follow-up: 1 year 
RUS, radius, ulna and finger (or short) bones. 
 
Characteristics of participants 
GH 28–30 IU/m2 surface area/week Low-dose estrogen: 
         Age (years) 9.0 (5.2 to 15.4) 9.1 (6.0 to 13.7) 
BA (years) 8.0 (3.3 to 13.5) 7.9 (3.0 to 13.7) 
Height (cm) 113.2 (93.2 to 135.1) 114.0 (94.6 to 140) 
HSDS for CA –0.3 (–2.1 to 1.2) –0.1 (–1.5 to 1.8) 
HSDS for BA 0.6 (–0.8 to 3.3) 1.0 (–0.6 to 2.4) 
Mid parental HSDS –0.2 (0.8) –0.3 (1.1) 
a  Not extracted, as unclear which groups of the three to which this refers. 
Results are expressed as mean (range) or (SD). 
 
Results 
GH 28–30 IU/m2 surface area/week Low-dose estrogen: 
Outcomes (n = unclear) ethinyloestradiol (n = unclear) p-value 
Change in HSDS in first +0.7 (0.7) +0.4 (0.9) < 0.05 
year 
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Adverse effects 
Three of 58 girls ceased GH early because of serious health events not directly related to GH or LDE: one each with 
hypertension, ulcerative colitis and brain tumour. One patient in group 3 died from aortic dissection shortly after 
treatment cessation. Compliance problems led to the withdrawal of four patients. Seven others developed coincidental 
disorders but these were not considered sufficient to invalidate continued participation in the study. Five girls from group 
2 were allocated to LDE were re-allocated to GH due to concerns over early breast development at age range 6.2–8.9 
years. 
Methodological comments 
Allocation to treatment groups: States randomised, no other details given. Five girls reallocated from estrogen to GH; it is 
unclear at what point this occurred. 
Blinding: Unknown, no details given. 
Comparability of treatment groups: Authors state that the groups were similar for the main monitoring parameters. 
Method of data analysis: Within-group results were compared using the paired Student’s t-test. Between-group results were 
compared using analysis of variance. Parental HtSDS values were calculated using normal population data. 
Sample size/power calculation: Not reported. 
Attrition/dropout: Seven withdrawals: three out of 58 girls ceased GH early because of serious health events not directly 
related to GH or LDE. Compliance problems led to the withdrawal of four patients. Treatment centres had the option 
of stopping ethinyloestradiol therapy if girls showed unacceptable premature breast development or excessive bone 
maturation: this occurred in five cases. Group numbers for FH data are lower; for the 1-year data they are unclear. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Inadequate 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Inadequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Unknown 
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
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PWS data extraction forms 
 
Reference and 
design Intervention Participants Outcome measures 
Lindgren et al. 1. 0.1 IU/kg/day GH by Target population: prepubertal children Primary outcomes: not stated 
1997,100 1998,101      s.c.i. aged 3–12 years with PWS Secondary outcomes: HtSDS; GV 
Countries: 2. No treatment Number of participants: total n = 29 SDS, BMI SDS, lean mass, % 
Sweden and Duration of treatment: 2 1. n = 15 body fat 
Denmark years (only year 1 data 2. n = 14 Method of assessing outcomes: 
Study design: extracted, as no control  height and WtSDS calculated 
RCT arm in year 2) An additional group of non-PWS obese with reference to the standard children was also studied, but data from 
Number Other interventions this group were not data extracted 
for healthy Swedish children; 
of centres: used: special dietary  BA was assessed according 
multicentre instructions more Sample attrition/dropout: Two control to Tanner–Whitehouse 2/ 
Funding: than 1 year before 
group patients excluded from analysis RUS; % body fat estimated by 
Pharmacia & start of treatment Inclusion criteria for study entry: fulfilled 
DEXA QoL questionnaires 
Upjohn and throughout the diagnostic criteria for PWS and had either   
completed (but no extractable 
study period to ensure a paternal deletion or maternal disomy of data reported) 
constant energy intake chromosome region 15q11-13; projected Length of follow-up: 1 year 
per kilogram of body FH < 165 cm (boys) and 154 cm (girls) 
weight 
 
Characteristics of participants 
M  ( ) 0 1 IU/k /d  GH (   15) N   (   12) l  Age (years) 6.8 (3.6 to 11.9) 6.4 (3.3 to 11.7) 
BA (years) 6.6 (3.3 to 13.0) 5.4 (3.3 to 10.2) 
Sex (f/m) 7/8 5/7 
Target HtSDS 0.4 (–1.3 to 1.8) –0.1 (–1.5 to 1.0) 
HtSDS –1.6 (–4.0 to 0.5) –1.7 (–5.3 to 0.4) 
BMI (SDS) 3.0 (–0.7 to 7.6) 2.1 (–1.3 to 5.1) 
GV (SDS) mean ± SD –1.9 ± 2.0 (–6.4 to 0.9) –0.1 (–1.7 to 2.71) 
(range) 
IGF-1 (SDS) –1.6 (–3.0 to –0.6) –1.4 (–2.4 to –0.1) 
Fat-free mass (kg) by 14.9 ± 4.1 14.1 ± 3.0 
DEXA: mean ± SD 
Fat-free mass (kg) by 14.6 ± 3.9 13.6 ± 3.3 
BIA: mean ± SD 
Body fat (%) by DEXA: 40.0 ± 10.5 34.8 ± 7.9 
mean ± SD 
Body fat (%) by BIA: 44.6 ± 9.2 41.3 ± 10.7 
mean ± SD 
Comments 
BIA, bioelectrical impedance analyser; DEXA, dual-energy X-ray absorptiometry. 
GV SDS was during 12 months before treatment commenced. 
Results 
Mean (range) 0.1 IU/kg/day GH (n = 15) No treatment (n = 12) p-value 
BA (years) 8.0 (5.5 to 13.9)a 6.9 (3.9 to 11.4) 
BA (years) change from 1.4 (0.0 to 2.8) 1.5 (0.4 to 2.6) 
baseline 
HtSDS –0.4 (–2.7 to 1.9)a –1.8 (–5.1 to –0.2) 
 
BMI (SDS) 2.0 (–2.4 to 6.7)a 2.5 (0.1 to 6.1) 
GV (SDS) mean ± SD 6.0 ± 3.2 (1.4 to 11.9)a –1.4 (–3.2 to –0.3) 
(range) 
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IGF-1 (SDS) 1.8 (–0.1 to 4.1)a –1.4 (–2.9 to –0.3) 
Fat-free mass (kg) by 
DEXA: mean ± SD 
Fat-free mass (kg) by 
BIA: mean ± SD 
Body fat (%) by DEXA: 
mean ± SD 
Body fat (%) by BIA: 
mean ± SD 
19.8 ± 5.2b 15.2 ± 2.9 
 
21.7 ± 8.9b 14.8 ± 3.5 
 
30.9 ± 11.4b 38.2 ± 9.1 
 
30.3 ± 10.5b 43.3 ± 12.9 
a Change from baseline p < 0.05. 
b  Change from baseline p < 0.001. 
Adverse effects 
Intravenous glucose tolerance test was normal and unchanged in all children. Basal fasting insulin levels were significantly 
increased throughout the group in the GH group (from 10.4 mU/I ± 2.7 SD to 19.2 mU/I ± 10.5 SD, p < 0.001). No severe 
progression of scoliosis (angle ≥ 20º) in either group. Bone mineral density did not differ between groups. One child 
developed low levels of thyroxine without any change in TSH levels. He received substitution with l-thyroxine during the 
GH treatment. The increased levels of fasting insulin during the treatment may be regarded as laboratory AE. However, 
both levels of fasting glucose and HbA were unchanged and, although increased compared with pretreatment, insulin 
levels were still within the normal range. 
Methodological comments 
Allocation to treatment groups: States children were randomised, but no further details given. 
Blinding: Open label. 
Comparability of treatment groups: Baseline age, height, BMI and HVs stated to be similar in both PWS groups. 
Method of data analysis: Student’s two-tailed paired and unpaired t-tests were used for normally distributed values, and 
non-parametric tests were used otherwise. Single regression analysis used for statistical comparisons. Not ITT. Data were 
analysed as change from baseline rather than between-group differences. 
Sample size/power calculation: Not reported. 
Attrition/dropout: One patient excluded at baseline evaluation because she had a severe scoliosis that required surgical 
intervention; one patient was excluded after 6 months in the control arm because she developed central precocious 
puberty. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
Carrel et al. 1. 1 mg/m2/day GH Target population: infants and toddlers Primary outcomes: not stated 
2004,22 Myers 2. No treatment with PWS Secondary outcomes: % body fat, 
et al. 2007,97  Number of participants: Total: n = 32 LBM, bone mineral density, GV 
Whitman et al. Duration of treatment: 1 (Whitman et al.); n = 29 (Carrel et al.); SDS, change in height, IGF-1; 
200498 year n = 25 (Myers et al.) mobility (not data extracted as 
Country: USA Other interventions used: 1. n = 15 not per protocol) 0.1 g/kg of deuterium- 
Study design: RCT     labelled water was given    2. n = 14                                         Method of assessing outcomes: 
Number of centres:    on day 1 and 0.15 g/kg of    In Whitman paper – 30 patients           
Harpenden stadiometer used 
two                         oxygen-18 water               completed first 6 months: n = 18, n = 12    
for length/height for children
 > 2, otherwise an infantometer Funding: supported Sample attrition/dropout: none in was used; body composition 
by Pharmacia Inc. difference in n between Whitman paper   measured by DEXA 
(Pfizer) and others suggests seven patients Length of follow-up: 1 year 
dropped out 
Inclusion criteria for study entry: 
confirmed diagnosis of PWS; age 4–37 
months 
 
Characteristics of participants 
M  ± SD 1 / 2/d  GH (  = 15) N  t t t (  = 14) p l  
Age (months) 13 ± 8 15 ± 0 ns 
Per cent female 50 42 ns 
Length/HtSDSa –1.6 ± 1.2 –1.3 ± 1.1 
GV SDS 1.4 ± 1.8 1.2 ± 1.4 
Body fat (%)a 28 ± 7 29 ± 12 
Lean mass (kg)a 5.8 ± 1.9 6.9 ± 2.0 
BMD (g/cm2)a 0.60 ± 0.08 0.64 ± 0.09 
Total cholesterol (mg/dl) 163 ± 34 170 ± 30 
IGF-1 (ng/dl)a 34 ± 21 nr 
Fasting insulin (µIU/ml) 4.8 ± 3.7 
Comments 
a  From Myers paper, which had unclear patient numbers. 
Baseline data are also given by Whitman et al. These have not been data extracted as they differ slightly from the group 
presented here. Whitman’s results were for 6 months, so it is assumed that the Carrel data supersede these. 
 
Results 
Mean ± SD 1 mg/m2/day GH (n = 15) No treatment (n = 14) p-value 
Mean % body fat 23.2 ± 8.9 32.7 ± 8.8 0.03 
Change in body fat –4.8% ± 5.7% 4.1% ± 4.6% 0.001 
Change in LBM (kg) 3.6 ± 0.5 1.8 ± 0.7 < 0.001 
Change in height (cm) +15.4 ± 2.3 9.2 ± 3.2 < 0.001 
GV SDS 5.0 ± 1.8 1.2 ± 1.4 
IGF-1 (ng/ml) 231 ± 98 51 ± 28 < 0.001 
Fasting insulin (µIU/ml) 5.6 ± 7.1 5.7 ± 7.1 ns 
Bone mineral density (%) 14.1 ± 10.4 9.0 ± 6.9 ns 
Total cholesterol (mg/dl) 159 ± 40 183 ± 43 
Length/HtSDSb –0.2 ± 1.5 –1.5 ± 0.7 
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Comments 
b From Myers paper, which had unclear patient numbers. 
GVSDS in GH patients, p < 0.001 compared with baseline. 
Length/HtSDS change from baseline in GH group, p < 0.005. 
Adverse effects 
No changes in the prevalence of scoliosis were seen between the treatment and control groups (Carrel et al.) although 
Myers et al. comment on progression of scoliosis in one patient. No other adverse effects were noted during this study, 
and no subject required thyroid hormone therapy. After the first 6 months, two children showed a 3.5 SD increase in head 
circumference. This was monitored, but the later papers do not mention it. 
Methodological comments 
Allocation to treatment groups: Randomisation following stratification by age (4–18 months and 19–37 months) and sex. No 
further details given. Myers and Whitman papers state that a 60 : 40 ratio was used, but this does not reflect numbers in 
the Carrel study, suggesting that attrition bias may have affected the results. 
Blinding: None. 
Comparability of treatment groups: Similar at baseline. 
Method of data analysis: The t-test for between-group comparisons. Does not appear to be ITT. Data reported by Whitman 
et al. was for 25 patients who completed the first 6 months. All three papers appear to report data for a slightly different 
version of the patient group. 
Sample size/power calculation: Not reported. 
Attrition/dropout: Difference in n between Whitman paper and others suggests that seven patients dropped out. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
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Reference and 
design Intervention Participants 
 
Outcome measures 
Carrel et al. 1999,95     1. GH 1 mg/m2/day Target population: children with PWS Primary outcomes: not clearly 
Myers et al. 199996 2. No treatment without prior GH therapy stated 
Country: USA Duration of treatment: 1 Number of participants: Total: n = 54 Secondary outcomes: HtSDS; GV; 
RCT Other interventions used: 2. n = 19 
BM; IGF-1; IGFBP-3; insulin;
 
Number of centres: standardised caloric Sample attrition/dropout: none and agility (not data extracted 
Funding: Genentech genetically confirmed patients with Method of assessing outcomes: 
Growth and maturation < 13 for girls and < 15 for stadiometer; Greulich and Pyle 
Exclusion criteria for study entry: prior body composition assessed 
GH therapy using DEXA 
Length of follow-up: 1 year 
HDL-C, high-density lipoprotein cholesterol. 
 
Characteristics of participants 
Mean ± SD GH 1 mg/m2/day (n = 35) No treatment (n = 19) p-value 
Sex (% female) 42 58  
Mean age (years) 9.8 10.0  
Prepubertal (n) 34 (97%) 17 (90%)  
HtSDS –1.1 ± 1.3 –1.5 ± 0.8  
Mean GV (cm/year) 4.72 ± 2.2 5.18 ± 1.5  
Mean GV SDS –1.0 ± 2.5 –0.9 ± 1.7  
BA 9.1 ± 3.6 8.4 ± 3.1  
Body fat (%) 46.3± 8.4 42.6 ± 8.1  
Lean mass (kg) 20.5 ± 6.3 20.5 ± 5.0  
BMI (kg/m2) 25.0 ± 6.7 24.2 ± 6.5  
IGF-1 (ng/ml) 127 ± 67 139 ± 64  
IGFBP-3 (ng/ml) 1.73 ± 0.49 1.84 ± 0.64  
Insulin-0 hour (mIU/l) 11.2 ± 9.9 9.3 ± 6.2  
Insulin-2 hour (mIU/l) 49.5 ± 40.7 41.6 ± 42.5  
Total cholesterol (mg/dl) 184 ± 36 190 ± 36  
HDL-C (mg/dl) 42 ± 8 44 ± 9  
Femoral neck BMD (g/cm3) 0.656 ± 0.19 0.636 ± 0.9  
Spine BMD (g/cm3) 0.744 ± 0.14 0.753 ± 0.12  
Scoliosis (°) 9.1 ± 6.0 14.7 ± 11.0  
Free fatty acids (mmol/I) 0.6 ± 0.4 0.6 ± 0.3  
Triglycerides (mg/dl) 91.6 ± 57.9 84.3 ± 39.6  
Results    
Mean ± SD GH 1 mg/m2/day (n = 35) No treatment (n = 19) p-value 
HtSDS –0.6 ± 1.2 –1.6 ± 1.2 < 0.01 
Mean GV (cm/year) 10.1 ± 2.5 5.0 ± 1.8 < 0.01 
Mean GV SDS 4.6 ± 2.9 –0.7 ± 1.9 < 0.01 
BA 10.6 ± 3.5 9.8 ± 3.0 ns 
Body fat (%) 38.4 ± 10.7 45.8 ± 8.8 < 0.01 
Lean mass (kg) 25.6 ± 4.3 21.7 ± 5.0 < 0.01 
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BMI (kg/m2) 23.7 ± 6.3 25.2 ± 8.9 ns 
IGF-1 (ng/ml) 522 ± 127 121 ± 52 < 0.01 
IGFBP-3 (ng/ml) 3.5 ± 0.73 2.07 ± 0.45 < 0.01 
Insulin-0 hour (mIU/l) 18.6 ± 14.6 8.8 ± 5.4  
Insulin-2 hour (mIU/l) 70.2 ± 44.2 47.1 ± 34.1  
Total cholesterol (mg/dl) 166 ± 34 193 ± 34 < 0.01 
HDL-C (mg/dl) 50 ± 10 44 ± 8 < 0.01 
Femoral neck BMD (g/cm3) 0.797 ± 0.09 0.707 ± 0.09 < 0.05 
Spine BMD (g/cm3) 0.834 ± 0.15 0.793± 0.13  
Scoliosis (°) 12.1 ± 7.0 16.6 ± 10.0  
Free fatty acids (mmol/I) 0.72 ± 0.40 0.64 ± 0.30 < 0.01 
Triglycerides (mg/dl) 86.0 ± 62.0 94.2 ± 49.0  
Comments    
The p-values are for paired t-test before and after GH therapy, compared with either baseline values of treated patients or 
12-month values of non-treated patients. 
Adverse effects 
Headaches in two patients treated with GH within first 3 weeks. Symptoms resolved with temporary cessation and 
gradual re-institution of GH. No pseudotumour cerebri. 
Methodological comments 
Allocation to treatment groups: reported as randomised 60 : 40. Method not stated. 
Blinding: None. 
Comparability of treatment groups: Similar at baseline. 
Method of data analysis: ITT. Data were analysed using a Student’s t-test for paired samples or two related samples. 
Sample size/power calculation: Not reported. 
Attrition/dropout: None. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? 
Adequate 
9. Did the analyses include an ITT analysis? Adequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
de Lind van 1. 1 mg/m2 s.c. daily Target population: infants and prepubertal   Primary outcomes: not stated in 
Wijngaarden 2. No treatment children with PWS, who were not Festen paper, scoliosis in Lind et al. 2009,93 severely overweight, naive to GH van Wijngaarden paper 
Festen et al. Duration of treatment: 1 treatment Secondary outcomes: HtSDS, BMI, 
200894 year for infants and 2 Number of participants: total n = 104 BMI SDS, head circumference 
years for children 
Country: The  enrolled, n = 91 were available for SDS, IGF-1, IGF-1 SDS, IGFBP-3, 
Netherlands After 1st year, infants follow-up: 42 infants (< 3.5 years) and IGFBP-3 SDS, IGF-1/BP3 (SDS), were all offered a second 
Study design: RCT   year of GH treatment. 
49 children over 3.5 years. Randomised LBM and scoliosis 
Number of Not discussed here as no   
groups not clear Method of assessing outcomes: 
centres: 18 control group The following are the groups analysed Harpenden stadiometer used to 
at year 1: measure height, using a mean of Funding: not Other interventions used: 
stated caloric intake and activity   Infants:1. n = 19, 2. n = 19 
three values. Anthropometric
 
measurements taken at baseline 
level standardised and        Children:1. n = 23, 2. n = 21          and every 3 months; DEXA used monitored                         Sample attrition/dropout: four infants and     for fat measurements. FM, fat 
five children excluded from analysis % and LBM were transformed 
Inclusion criteria: genetically confirmed into SDS, adjusting for age and 
diagnosis of PWS; age 6 months –14 sex. LBM is related to height, 
years; BA < 14 (girls) or 16 (boys); so LBM HtSDS were computed 
prepubertal – Tanner breast stage ≤ 2 by comparing LBM of PWS with 
for girls and testicular volume < 4ml for LBM of healthy children with the 
boys same height and sex. IGF-1 and 
Exclusion criteria: non-cooperative IGFBP-3 were transformed to 
behaviour; on medication to reduce fat SDS using sex- and age-matched 
Dutch references 
Length of follow-up: 1 year 
(infants), 2 years (children) 
 
Characteristics of participants from Festen et al. 200894 (other than scoliosis and trunk LBM/BSA), as this is the 
most complete 
Baseline characteristics of infants (6 months to 3 years) 
                Sex (m/f) 12/8 16/6 
Age (years) 2.0 (1.6 to 3.1) 1.3 (1.0 to 2.8) 
HtSDS –2.3 (–2.8 to –0.7) –2.1 (–3.2 to –1.0) 
BMI (kg/m2) 16.4 (15.1 to 18.6) 16.1 (14.7 to 18.2) 
BMI (SDS) 0.5 (–0.9 to 1.9) –0.8 (–1.7 to 1.6) 
Head circumference (SDS) –0.8 (–1.6 to –0.3) –1.1 (–1.8 to –0.5) 
IGF-1 (ng/ml) 27.0 (22.0 to 35.0) (n = 11) 47.0 (17.0 to 52.0) 
IGF-1 (SDS) –1.9 (–2.8 to –1.3) (n = 11) –1.6 (–2.6 to –0.4) (n = 11) 
IGFBP-3 (ng/ml) 0.8 (0.7 to 1.1) (n = 11) 1.1 (0.8 to 1.3) (n = 11) 
IGFBP-3 (SDS) –2.6 (–3.3 to –2.0) (n = 11) –1.5 (–2.6 to –0.7) (n = 11) 
IGF-1/BP3 (SDS) –0.9 (–2.0 to –0.4) (n = 11) –0.3 (–1.7 to 0.6) (n = 11) 
Scoliosis (%) 7 (37) (n = 19) 4 (21) (n = 19) 
Trunk LBM/BSA 7.4 (6.9 to 8.0) (n = 19) 7.3 (7.0 to 7.7)(n = 19) 
Baseline characteristics of children (3–14 years) 
Median (IQR) 1 mg/m2 s.c. daily rhGH (n = 25) No treatment (n = 22) p-value 
Sex (m/f) 13/12 8/14 
Age (years) 6.8 (5.4 to 8.8) 5.9 (4.7 to 7.4) 
HtSDS –2.0 (–3.1 to –1.7) –2.5 (–3.3 to –1.9) 
 
BMI (kg/m2) 17.7 (16.0 to 22.3) 18.1 (17.2 to 19.9) 
BMI (SDS) 1.2 (0.1 to 2.2) 1.3 (1.1 to 1.6) 
134 
 
Health Technology Assessment 2010; Vol. 14: No. 42 DOI: 10.3310/hta14420 
 
Head circumference (SDS) –0.8 (–1.5 to –0.2) –0.6 (–1.2 to –0.1) 
IGF-1 (ng/ml) 60.0 (46.5 to 96.5) (n = 21) 56.0 (42.0 to 88.0) (n = 18) 
IGF-1 (SDS) –1.7 (–2.3 to –1.2) (n = 21) –1.9 (–2.6 to –1.2) (n = 18) 
IGFBP-3 (ng/ml) 1.3 (0.9 to 1.5) (n = 21) 1.2 (0.9 to 1.5) (n = 18) 
IGFBP-3 (SDS) –1.9 (–2.8 to –1.2) (n = 21) –2.2 (–3.1 to –1.4) (n = 18) 
IGF-1/BP3 (SDS) –0.5 (–1.0 to 0.5) (n = 21) –0.6 (–1.6 to 0.3) (n = 18) 
Fat% (SDS) 2.1 (1.7 to 2.7) (n = ?) 2.3 (1.9 to 2.6) (n = ?) 
 
 
Fat (SDS) 1.2 (0.8 to 2.0) (n = ?) 1.2 (0.7 to 1.6) (n = ?) 
LBM age (SDS) –1.7 (–3.0 to –1.0) (n = ?) –1.9 (–3.4 to –1.2) (n = ?) 
LBM HtSDS –1.7 (–3.8 to –0.6) (n = ?) –1.4 (–2.9 to 0.9) (n = ?) 
Trunk fat (%) 36.0 (24.8 to 46.2) (n = ?) 36.0 (29.2 to 41.2) (n = ?) 
Scoliosis (%) 7 (30) (n = 23) 9 (43) (n = 21) 
Trunk LBM/BSA 8.0 (7.5 to 8.4)(n = 23) 7.6 (7.1 to 8.1) (n = 21) 
Comments 
n is unclear for body composition measures, as these were only available for children over the age of 4 at the start of the 
study. The p-values are for change in GH group vs control group. 
 
Results: infants (6 months to 3 years), mostly from de Lind van Wijngaarden 2009 et al.93 as this is the most 
complete data 
1 mg/m2 s.c. daily rhGH 1 year 
Median (IQR) (n = 19) No treatment (n = 19) p-value 
HtSDS –0.9 (–1.6 to –0.1) –1.8 (–3.5 to –1.4) 0.003 
∆HtSDS 1.2 (1.0 to 1.6) –0.2 (–0.6 to 0.3) < 0.0001 
BMI (kg/m2) 16.3 (15.7 to 18.2) 16.4 (15.4 to 19.8) (n = 15) 
BMI (SDS) 0.3 (–0.1 to 1.6) 0.3 (–0.6 to 1.6) 0.72 
∆Trunk LBM 1.7 (1.3 to 2.1) 0.7 (0.4 to 0.9) < 0.0001 
∆Trunk LBM/BSA 1.2 (0.7 to 1.8) 0.3 (–0.3 to 0.6) 0.002 
Head circumference (SDS) 0.0 (–0.9 to 0.7) (n = 16) –0.8 (–1.6 to –0.3) (n = 15) < 0.001 
IGF-1 (ng/ml) 179.0 (119.5 to 241.0) (n = 12) 33.0 (22.5 to 47.8) (n = 15) 
IGF-1 (SDS) 2.5 (1.4 to 2.9) –2.6 (–4.1 to –0.7) < 0.0001 
IGFBP-3 (ng/ml) 2.2 (1.6 to 2.4) (n = 12) 0.9 (0.7 to 1.3) (n = 12) 
IGFBP-3 (SDS) 0.5 (0.0 to 1.2) (n = 12) –2.4 (–3.5 to –1.2) (n = 12) 
IGF-1/BP3 (SDS) 2.3 (1.7 to 3.4) (n = 12) –1.1 (–2.1 to 0.0) (n = 12) < 0.001 
Onset scoliosis (%) 4 (21) (n = 19) 2 (11) (n = 19) 0.71 
Progression of scoliosis –6.0 (–12.5 to 12.8) (n = 19) –7.5 (–7.5 to –5.0) (n = 19) 0.48 
 
Results for children (3–14 years), mostly from de Lind van Wijngaarden 2009 et al.,93 as this is the most complete 
data 
Median (IQR) 1 mg/m2 s.c. daily rhGH No treatment p-value 
Year 1 results 
N = 23 N = 21 
HtSDS –1.0 (–1.5 to –0.3) –2.5 (–3.4 to –2.3) < 0.0001 
∆HtSDS 0.9 (0.7 to 1.3) –0.1 (–0.2 to 0.1) < 0.0001 
BMI (kg/m2) 17.5 (15.3 to 19.8) (n = 21) 18.6 (17.6 to 19.7) (n = 21) 
BMI (SDS) 0.8 (–0.1 to 2.1) 1.4 (1.0 to 1.6) 0.05 
 
∆Trunk LBM 1.8 (1.4 to 2.3) 0.7 (0.1 to 0.8) < 0.0001 
∆Trunk LBM/BSA 1.3 (0.7 to 1.7) 0.0 (–0.4 to 0.3) < 0.0001 
Head circumference (SDS) –0.2 (–1.2 to 0.2) (n = 21) –0.6 (–0.9 to 0.3) (n = 21) 
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IGF-1 (ng/ml) 
IGF-1 (SDS) 
IGFBP-3 (ng/ml) 
IGFBP-3 (SDS) 
IGF-1/BP3 (SDS) 
Fat % (SDS) 
Fat (SDS) 
LBM age (SDS) 
LBM HtSDS 
Trunk fat (%) 
Onset scoliosis (%) 
337.0 (274.3 to 474.3) (n = 21) 
2.3 (1.5 to 2.8) 
2.5 (2.2 to 2.9) (n = 21) 
0.4 (–0.1 to 0.8) (n = 21) 
2.5 (2.0 to 3.0) (n = 21) 
1.5 (0.7 to 2.1) (n = ?) 
0.9 (0.2 to 1.4) (n = ?) 
–0.5 (–1.3 to 0.7) (n = ?) 
–1.5 (–2.3 to –0.7) (n = ?) 
28.0 (16.9 to 36.7) (n = ?) 
5 (22) (n = 23) 
55.0 (42.5 to 94.8) (n = 12) 
–2.5 (–3.1 to –1.5) 
1.3 (0.8 to 1.5) (n = 12) 
–2.4 (–3.5 to –1.8) (n = 12) 
–0.8 (–1.4 to –0.2) (n = 12) 
2.3 (2.0 to 2.6) (n = ?) 
1.3 (0.7 to 1.9) (n = ?) 
–2.1 (–4.1 to –1.3) (n = ?) 
–1.9 (–2.9 to 0.0) (n = ?) 
37.2 (32.0 to 42.5) (n = ?) 
6 (29) (n = 21) 
 
 
< 0.0001 
 
 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.05 
< 0.001 
0.52 
Progression of scoliosis –3.5 (–7.3 to 1.8) (n = 23) 0.0 (–1.0 to 1.0) (n = 21) 0.60 
Year 2 results    
 N = 23 N = 21  
HtSDS –0.5 (–0.8 to 0.0) –2.6 (–3.4 to –2.3) < 0.0001 
∆HtSDS 
BMI (kg/m2) 
1.4 (1.3 to 1.8) 
17.5 (16.1 to 21.1) (n = 20) 
–0.1 (–0.4 to 0.1) 
19.1 (17.8 to 20.8) (n = 20) 
< 0.0001 
BMI (SDS) 1.1 (–0.2 to 1.7) 1.4 (1.1 to 1.6) 0.19 
∆Trunk LBM 
∆Trunk LBM/BSA 
Head circumference (SDS) 
2.8 (2.6 to 3.5) 
1.4 (0.5 to 1.7) 
–0.1 (–1.1 to 0.5) (n = 20) 
0.8 (0.4 to 1.0) 
–0.2 (–0.5 to –0.1) 
–0.6 (–1.1 to 0.3) (n = 20) 
< 0.0001 
< 0.0001 
< 0.05 
IGF-1 (ng/ml) 424.0 (313.0 to 570.0) (n = 20) 92.0 (61.8 to 130.0) (n = 16)  
IGF-1 (SDS) 2.4 (2.1 to 2.8) –1.6 (–2.5 to –1.0) < 0.0001 
IGFBP-3 (ng/ml) 2.8 (2.6 to 3.2) (n = 20) 1.5 (1.2 to 1.8) (n = 16)  
IGFBP-3 (SDS) 0.6 (0.3 to 1.1) (n = 20) –1.7 (–2.3 to –1.2) (n = 16) < 0.001 
IGF-1/BP3 (SDS) 2.5 (1.8 to 2.9) (n = 20) –0.6 (–1.2 to –0.1) (n = 16) < 0.001 
Fat % (SDS) 1.9 (0.7 to 2.3) (n = ?) 2.4 (2.1 to 2.7) (n = ?) < 0.001 
Fat (SDS) 1.1 (0.6 to 2.0) (n = ?) 4.5 (0.9 to 2.0) (n = ?) < 0.01 
LBM age (SDS) –0.1 (–1.3 to 0.6) (n = ?) –2.5 (–3.8 to –1.4) (n = ?) < 0.001 
LBM HtSDS –1.9 (–2.4 to –1.4) (n = ?) –2.3 (–2.7 to –1.3) (n = ?) < 0.05 
Trunk fat (%) 33.3 (17.3 to 40.9) (n = ?) 37.9 (35.0 to 45.7) (n = ?) < 0.001 
Onset scoliosis (%) 5 (22) (n = 23) 7 (33) (n = 21) 0.14 
Progression of scoliosis 3.3 (–4.3 to 11.9) (n = 23) –5.0 (–9.0 to –2.0) (n = 21) 0.27 
Comments    
n is unclear for body composition measures, as these were only available for children over the age of 4 at the start of the 
study. The p-values are for change in GH group vs control group. 
Progression of scoliosis is change in Cobb angle during study 
Adverse effects 
Not reported – the reader is referred to three other papers by the same author, but two of these appear to be other 
smaller studies. 
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Methodological comments 
Allocation to treatment groups: Prior to randomisation, infants were stratified for age and children (> 3.5 years) for BMI. All 
participants were randomised to GH treatment or no GH treatment. 
Blinding: A double-blind placebo-controlled study was considered unethical. 
Comparability of treatment groups: Anthropometric parameters were similar in the two groups, although no p-values are 
presented. 
Method of data analysis: Reference data for the DEXA were not available for children under the age of 4, so only those 
> 4 years were included in the analysis. Data were expressed as median (IQR) as most were not Gaussian distributed. 
Differences from baseline between groups were calculated using Mann–Whitney U-tests. The p-values are for change in 
GH group vs control group. 
Sample size/power calculation: De Lind van Wijngaarden reports that the power calculation estimated a total number of 40 
patients (infants and prepubertal children) to yield a power of 0.80. 
Attrition/dropout: Two excluded before treatment (one had a dose reduction due to high IGF-1 levels, another had spinal 
surgery for scoliosis and two other medical problems). In total, four infants and five children excluded from analysis – 
presumably due to incomplete study period for the other patients. Infants with repeated measures were older (p = 0.025), 
possibly reflecting early diagnosis of PWS during recent years. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
Festen et al. 1. 1 mg/m2/day Target population: prepubertal, Primary outcomes: adiponectin levels, 
200791 somatropin by s.c.i. generally not overweight children body composition, carbohydrate 
Country: The (restricted to 0.5mg/m
2/ with PWS metabolism and triglyceride levels 
Netherlands day in the first 4 weeks Number of participants: Total n = 20 Secondary outcomes: associations 
Study design: 
to avoid fluid retention). 
1. n = 10 between adiponectin and body 
RCT 2. No treatment 2. n = 10 
composition, carbohydrate 
metabolism and triglyceride levels; Number of Duration of treatment: 2 Sample attrition/dropout: none effect of GH on these parameters 
centres: not years 
stated Other interventions used: Inclusion criteria for study entry: Method of assessing outcomes: 
Funding: caloric intake and activity   
genetically confirmed diagnosis of anthropometric measurements 
supported by levels standardised 3 
PWS, age 4–9 years, prepubertal at baseline, year 1 and year 2 
Pfizer months before study  
(standing height, weight, BMI); 
body composition assessed using 
DEXA; biochemical marker assays 
performed in the same laboratory. 
HtSDS and BMI SDS calculated 
from age- and sex-specific Dutch 
reference data 
Length of follow-up: 2 years 
 
Characteristics of participants: median (IQR) 
Characteristic 1 mg/m2/day GH (n = 10) No treatment (n = 10) p-value 
N (male/female) 10 (5/5) 10 (3/7) 
Age (years) 6.2 (5.1 to 7.1) 5.8 (4.9 to 7.8) 
HtSDS –2.2 (–3.1 to –1.8) –2.8 (–3.4 to –2.0) 
BMI (kg/m2) 16.9 (15.8 to 17.7) 17.3 (16.4 to 19.3) 
BMI SDS 0.8 (0.1 to 1.2) 1.1 (0.6 to 1.5) 
Adiponectin (mg/l) 15.9 (13.3 to 23.9) 17.1 (13.1 to 23.1) 
Glucose (mmol/l) 4.8 (4.6 to 5.0) 4.4 (4.3 to 4.7) 
Insulin (mU/l) 6.0 (3.8 to 10.0) 5.5 (4.8 to 7.3) 
Insulin–glucose ratio 1.3 (0.8 to 2.1) 1.3 (1.0 to 1.6) 
HOMA index 0.8 (0.5 to1.3) 0.7 (0.6 to 0.9) 
Triglycerides (mmol/l) 0.9 (0.7 to 1.7) 0.7 (0.6 to 1.0) 
IGF-1 SDS –1.7 (–2.2 to –1.2) –1.7 (–2.9 to –1.0) 
IGFBP-3 SDS –2.0 (–3.0 to –1.3) –2.5 (–3.2 to –1.5) 
LBM SDS –2.2 (–2.7 to –2.0) –2.3 (–2.8 to –1.8) 
FM SDS 0.8 (0.6 to 1.0) 0.8 (0.6 to 1.2) 
Per cent fat SDS 1.7 (1.6 to 2.0) 1.8 (1.5 to 2.4) 
Trunk fat/total fat 0.44 (0.34 to 0.47) 0.4 (0.35 to 0.46) 
Comments 
HOMA, Homeostasis Model Assessment index. 
Adiponectin levels were compared with healthy matched controls 
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Results (median, IQR)   
1 mg/m2/day GH (n = 10) No treatment (n = 10) p-value change 
from baseline 
group 1 vs 
Outcomes Year 1 Year 2 Year 1 Year 2 group 2 
HtSDS –1.3a (–1.7 to 
–0.8) 
–0.6a (–0.9 to 
–0.3) 
–2.8 (–3.5 to 
–2.0) 
–3.0 (–3.5 to 
–1.8) 
< 0.01b 
BMI (kg/m2) 16.1c (15.2 to 
17.6) 
16.3 (15.8 to 
19.0) 
18.5 (17.6 to 
19.3) 
18.5 (17.5 to 
20.6) 
< 0.05c 
BMI SDS 0.2c (–0.2 to 0.8) 0.4 (–0.3 to 1.1) 1.3 (1.0 to 1.6) 1.2 (0.9 to 1.5) < 0.05c 
Adiponectin (mg/l) 24.7 (15.0 to 
25.9)a,b 
24.6 (15.4 to 
28.2)a,b 
13.4 (11.6 to 
21.4) 
15.8 (12.5 to 
19.2) 
< 0.05b 
Glucose (mmol/l) 4.4 (4.2 to 5.0) 4.6 (4.2 to 5.0) 4.6 (4.3 to 4.8) 4.7 (4.3 to 4.9)  
Insulin (mU/l) 9.0 (6.5 to 13.5)a 7.5 (6.0 to 11.5) 6.0 (3.3 to 8.3) 11.0 (6.0 to 
24.0)a 
 
Insulin–glucose ratio 2.1 (1.5 to 2.6)a 1.6 (1.5 to 2.2) 1.3 (0.8 to 1.9) 2.3 (1.4 to 2.2)a  
HOMA index 1.2 (0.8 to 1.8) 1.0 (0.7 to 1.5) 0.8 (0.4 to 1.0) 1.4 (0.8 to 3.0)a  
Triglycerides (mmol/l) 0.8 (0.6 to 1.3) 0.7 (0.6 to 0.8) 0.6 (0.5 to 1.0) 1.0 (0.6 to 1.0)  
IGF-1 SDS 2.3 (1.6 to 3.0)a,c 2.3 (2.1 to 2.9)a,c –2.5 (–3.2 to 
–0.8) 
–2.0 (–2.7 to 
1.0) 
< 0.001c 
IGFBP-3 SDS 0.5 (–0.1 to 1.0)a,c 0.6 (0.4 to 1.1)a,c –2.4 (–3.8 to 
–1.9) 
–1.8 (–2.7 to 
–1.5) 
< 0.001c 
LBM SDS –1.6 (–1.9 to 
–1.4)a 
–1.2 (–1.7 to 
–1.1)a 
–2.5 (–3.0 to 
–1.8) 
–2.8 (–3. to 1.9)a  
FM SDS 0.5 (0.2 to 1.0) 0.9 (0.4 to 1.4) 1.1 (0.9 to 1.2)a 1.2 (0.9 to 1.4)a  
Per cent fat SDS 1.4 (0.9 to 1.7)a 1.7 (0.9 to 1.9)a 2.1 (1.8 to 2.2) 2.1 (1.9 to 2.4)a  
Trunk fat/total fat 0.4 (0.33 to 0.42) 0.41 (0.34 to 
0.46) 
0.41 (0.40 to 
0.44) 
0.41 (0.38 to 
0.45) 
 
Comments 
Adiponectin levels were compared with healthy matched controls. 
a  p < 0.05 compared with baseline corrected for multiple testing. 
b p < 0.05 change compared with baseline in GH group vs control group corrected for multiple testing. 
c p < 0.001 change compared with baseline in GH group vs control group corrected for multiple testing. 
Adverse effects 
Not reported. 
Methodological comments 
Allocation to treatment groups: Stratified by age and BMI prior to randomisation. No further details given. 
Blinding: Open-label trial. 
Comparability of treatment groups: Similar at baseline. Note: adeponectin levels were compared against healthy controls, not 
the untreated PWS group. 
Method of data analysis: Most data not Gaussian distributed, so data expressed as median (IQR) and non-parametric 
tests were used. Mann–Whitney U-tests used for differences between groups. Adiponectin levels of PWS children were 
compared with reference data of healthy sex- and age-matched controls (n = 40) with Wilcoxon signed-rank test. 
Sample size/power calculation: Not reported. 
Attrition/dropout: None. 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Adequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
Festen et al. 1. GH 1 mg/m2/day Target population: PWS infants and Primary outcomes: psychomotor 
200792 2. No treatment toddlers development (BSID-II) (not data 
Countries: The Duration of treatment: 12 Number of participants: Total: 43 
extracted as not per protocol) 
Netherlands and   months evaluated at baseline, then 29 Secondary outcomes: body 
Sweden 
Other interventions used: 
entered treatment composition; IGF-1 and IGFBP-3 
Study design: dietary advice given and 1. n = 15 Method of assessing outcomes: 
RCT                     compliance evaluated        2. n = 14                                       height measured with a Harpenden 
Number                every 3 months                 Sample attrition/dropout: 14 were           
stadiometer; Dutch references used 
of centres:                                                       excluded from the study, and this         
to calculate age- and sex- specific 
multicentre appears to have taken place post- 
SDS for median height, BMI and head 
circumference; body composition 
Funding: Pfizer randomisation in Dutch participants measured 
Inclusion criteria for study entry: using DEXA; IGF in Dutch children 
Genetically confirmed diagnosis of measured using an immunometric 
PWS; aged 6 months to 3 years at technique, and in Swedish infants 
start of protocol using a semi-illuminescent technique 
Exclusion criteria for study entry: Length of follow-up: 12 months 
severe scoliosis (> 20°); extremely 
low dietary intake BSID-
II, Bayley Scales of Infant Development II. 
Characteristics of participants 
Median (IQR) GH 1 mg/m2/day (n = 15) No treatment (n = 14) p value 
Sex (m/f) 7/8 8/6 
Age (years) 2.3 (1.7 to 3.0) 1.5 (1.2 to 2.7) 
HtSDS –2.6 (–3.3 to –1.8) –2.3 (–3.3 to –1.1) 
BMI (kg/m2) 16.3 (14.5 to 17.8) 15.9 (14.7 to 16.8) 
BMI SDS –0.3 (–1.1 to 1.3) –0.9 (–1.8 to –0.8) 
Head circumference SDS –1.0 (–1.7 to –0.3) –1.1 (–1.8 to –0.9) 
Body fat (%) 26.2 (22.2 to 28.9) 25.8 (23.1 to 27.7) 
LBM (%) 72.1 (69.8 to 75.7) 73.3 (70.9 to 75.2) 
IGF-SDS –2.1 (–2.7 to –1.7) –2.0 (–2.6 to –0.3) 
IGFBP-3 SDS –2.8 (–3.5 to –2.4) –1.8 (–3.4 to –0.9) 
Results 
Median (IQR) GH 1 mg/m2/day (n = 15) No treatment (n = 14) p-value 
Age (years) 3.3 (2.7 to 4.0) 2.6 (2.3 to 3.8) 
HtSDS –1.6b (–2.1 to –0.8) –2.3 (–3.9 to –1.5) 
BMI (kg/m2) 16.4 (15.2 to 18.5) 15.5 (14.9 to 17.6) 
BMI SDS 0.3 (–0.9 to 1.8) –0.4a (–0.8 to 1.3) 
Head circumference SDS –0.2b,c (–1.2 to 0.6) –1.1c (–1.6 to –0.6) 
Body fat (%) 22.5 (11.3–33.2) 22.8 (19.5 to 32.9) 
LBM (%) 74.8 (63.7 to 82.3) 73.6 (61.6 to 75.9) 
IGF-SDS 1.7b,d (0.1 to 2.5) –2.6d (–4.1 to –0.4) 
IGFBP-3SDS 0.4a,c (–0.3 to 1.1) –3.1c (–4.0 to –2.2) 
a  p < 0.05. 
b  p < 0.005: 12 vs 0 months. 
c  p < 0.05. 
d  p < 0.001: GH vs control. 
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Adverse effects 
No results presented. Paper states that compared to randomised controls, GH did not induce disadvantageous effects on 
carbohydrate metabolism, sleep-related breathing disorders, and thyroid hormone levels. 
Comments 
Methodological comments 
Allocation to treatment groups: Children were stratified for age before randomisation. No further details given. 
Blinding: Open label. 
Comparability of treatment groups: Similar at baseline, although GH group had slightly older median age. 
Method of data analysis: For repeated measurement analysis, only children with 2 BSID-II scores were included. BSID-II can 
only be used if developmental age is maximally 3–5 years. Non-parametric statistics used as data not Gaussian distributed. 
Mann–Whitney U-tests used for two-tail differences at baseline, one-tailed ANCOVA used for data analysis. 
Sample size/power calculation: Not reported. 
Attrition/dropout: 14 of the original 43 were excluded from repeated BSID-II analysis, and therefore do not appear to have 
been randomised. However, the paper later states that results of 14 patients were excluded from analysis – not clear if this 
is the same 14, but assumed to be so, i.e. they were excluded post randomisation. 
Reasons for exclusion: Five children had not reached 1 year of study, one infant was excluded due to thyroid hormone 
deficiency, eight had already passed the upper limit of BSID-II after 1 year of follow-up (divided equally between the GH 
group and the control group). 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
142 
 
Health Technology Assessment 2010; Vol. 14: No. 42 DOI: 10.3310/hta14420 
 
 
 
 
 
 
 
Reference and 
design Intervention Participants Outcome measures 
Haqq et al. 1. GH 0.043 mg/kg/day Target population: children with PWS Primary outcomes: not stated 
2003102 plus inactive ingredients, Number of participants: total n = 14 Secondary outcomes: linear GV, body 
Country: USA by daily s.c.i. randomised, but data only given for composition, pulmonary function, 
Study design: 2. Placebo injection of n = 12 sleep, behaviour, cognition, resting 
Double blind inactive ingredients, by 1. n = 6 energy expenditure (last five not 
placebo- daily s.c.i. 2. n = 6 
data extracted as not per protocol) 
controlled Duration of treatment:  Method of assessing outcomes: 
crossover 6 months in each Sample attrition/dropout: n = 2 assessed at 0.6 and 12 months; 
Number of treatment arm, 12 Inclusion criteria for study entry: PWS; anthropometric measurements, side 
centres: one months overall naive to GH treatment effects and compliance measured at 
Funding: grants Other interventions used: Exclusion criteria for study entry: other 
3 and 9 months; BA determined at 
from the none chronic illnesses, taking medications 
0 and 12 months using Greulich and 
General Clinical  that impact on long-term bone 
Pyle analysis of wrist radiographs; 
Research Center mineralisation or body composition 
height measured at 0.6 and 12 
months using wall-mounted and Pharmacia stadiometer; body composition 
Corp. measured using DEXA 
Length of follow-up: 6 months for 
outcomes, 12 months overall 
 
Characteristics of participants 
M   SD All i  (   12) l  Age (years) 9.7 ± 3.3 
Sex (m/f) 6/6 
BA (years) 10.0 ± 4.2 
BMI SDS 2.5 ± 0.7 
IGF-1 (ng/ml) 169.3 ± 155.7 
IGF-1 SDS –1.10 ± 1.15 
IGFBP-3 (ng/ml) 2169 ± 1010 
IGFBP-3 SDS –1.67 ± 1.10 
Mean height (cm) 128.9 ± 19.7 
BMI (kg/m2) 30.8 ± 8.3 
BMI (SDS) 2.5 ± 0.7 
HtSDS –1.3 ± 1.2 
GV (cm/year) 4.2 ± 2.3 
Body fat (%) 54 ± 5.3 
FM (kg) 29.6 ± 16.7 
Lean mass (kg) 22.5 ± 10.9 
Lumbar spine BMD (SDS) –0.51 ± 0.30 
Total BMC (g) 1263 ± 451 
Comments 
Mean BA also reported as 10.2 ± 4.1 years later in the paper. 
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Results 
Outcomes 
 
 
 
GH 0.043 mg/kg/day (n = 12) 
 
 
 
Placebo (n = 12) 
 
 
 
p-value 
BMI (kg/m2) 31.2 ± 8.9 32.8 ± 9.7 < 0.05 
BMI (SDS) 2.4 ± 0.5 2.5 ± 0.6  
HtSDS –1.2 ± 1.1 –1.3 ± 1.3  
GV (cm/year) 7.5 ± 3.5 4.5 ± 2.7 < 0.05 
Body fat (%) 49.7 ± 5.8 54.1 ± 5.6 < 0.05 
FM (kg) 26.1 ± 12.8 29.1 ± 14.1 < 0.05 
Lean mass (kg) 24.1 ± 8.8 22.4 ± 8.5 < 0.05 
Lumbar spine BMD (SDS) –0.33 ± 1.4 –0.4 ± 1.4  
Total BMC (g) 1337 ± 453 1342 ± 453  
IGF-1 (ng/ml) 720 ± 379 232 ± 182 < 0.001 
IGFBP-3 (ng/ml) 6029 ± 1311 4247 ± 1209 < 0.01 
Leptin (ng/ml) 49.7 ± 39.3 54.3 ± 46.2 0.06 
Ghrelin (pmol/l) 272 ± 204 361 ± 309 0.11 
FT4 (pmol/l) 12.9 ± 1.5 14.8 ± 1.4 < 0.05 
TSH (mU/l) 1.81 ± 0.79 2.04 ± 1.13  
Insulin (pmol/l) 64.2 ± 42.6 64.2 ± 39  
Glucose (mmol/l) 5.0 ± 0.7 4.8 ± 0.5  
Osteocalcin (nmol/l) 10.5 ± 5.7 7.8 ± 5.9 0.06 
Triglycerides (mmol/l) 0.80 ± 0.52 0.92 ± 0.42  
Total cholesterol (mmol/l) 4.7 ± 0.9 4.5 ± 1.7  
Comments    
Mean BA (in all patients) increased to 11.3 ± 3.7 by the end of 12 months, compared with a chronological age of 9.7 ± 3.3 
years. Mean height increased to 134.6 ± 19.3 cm. Only one patient required thyroid hormone replacement while receiving 
GH treatment. 
Adverse effects 
No patient developed a significant degree of scoliosis (> 20°). No evidence of impaired fasting glucose concentrations. GH 
treatment resulted in supranormal IGH-I and normal IGFBP-3 concentrations, but the consequences of this are unknown. 
Methodological comments 
Allocation to treatment groups: Reported to be randomised, but no further details given. 
Blinding: Both GH and placebo injections were given using a Genotropin pen. 
Comparability of treatment groups: Data only presented for whole group – crossover study design. 
Method of data analysis: Not ITT. Differences between groups calculated using paired t-tests. For data not distributed 
normally, Wilcoxon signed-rank tests were used. p < 0.05 considered statistically significant. Weight, height and BMI SDS 
obtained using Epi Info 2000 (www.cdc.gov/epiinfo/). 
Sample size/power calculation: Not reported. 
Attrition/dropout: Two patients withdrew – one due to relocation, one due to non-compliance with daily injections. Not 
clear which group they belonged to. 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? nr 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Adequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
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Reference and 
design Intervention Participants Outcome measures 
Hauffa 199799 1. GH 0.075 IU/kg/ Target population: children aged 3–12 Primary outcomes: not stated 
Country: day for first month, with PWS Secondary outcomes: changes in 
Germany then continued at dose Number of participants: total n = 19 HtSDS, GV SDS, IGF-1, IGFBP-3 
Study design: 
of 0.15 IU/kg/day to a randomised, n = 17 included in study, Method of assessing outcomes: nr 
Open RCT 
maximum of 8 IU/day n = 16 analysed 
Length of follow-up: 1 year 
Number of 
2. No treatment 1. n = 8 
centres: one Duration of treatment: 2. n = 9 
2-year study with 
Funding: control arm during 1st Sample attrition/dropout: two not 
Pharmacia year entered following randomisation, & Upjohn,  one excluded from analysis due to 
Germany Other interventions used: AE-related dose reduction 
not stated 
Inclusion/exclusion criteria for study 
entry: prepubertal, 3–12 years old, 
PWS (confirmed by molecular 
genetics), projected FH < 3rd centile 
for German population 
 
Characteristics of participants 
Mean ± SD GH 0 15 IU/kg/day (n = 7) No treatment (n = 9) p value 
Age (years) 8.25 ± 2.4 7.56 ± 2.0 
Sex f/m 3/4 4/5 
BA (years) 7.91 ± 4.3 6.76 ± 2.4 
Height (cm) 120.9 ± 16.3 120.5 ± 11.2 
Weight (kg) 35.9 ± 18.2 32.5 ± 8.7 
Hip circumference (cm) 78.8 ± 19.6 77.6 ± 11.5 
Target height (cm) 172.9 ± 8.5 174.8 ± 8.2 
 
Results 
HV SDS 5.5 –2.3 0.0012 
HtSDS 1.07 –0.25 
IGF-1 Increased significantly (p < 0.008), ‘At or slightly below lower limit of 
sometimes to above the upper limit reference range’ 
of the reference range 
IGFBP-3 Increased significantly (p < 0.008), ‘Within normal range’ 
mostly to above the upper limit of 
the reference range 
Comments 
Height gain (1.02 SD) remained unchanged when analysed in relation to BA. No significant within- or between-group 
changes were detected for sitting height, BMI, skinfold thickness, waist or hip circumference or serum lipids. 
Adverse effects 
One patient in GH group developed pseudotumour cerebri after increasing the starting dose to the final dose. Symptoms 
resolved on discontinuation. No abnormalities of glucose regulation observed in either group. 
Methodological comments 
Allocation to treatment groups: Randomised (method not stated). 
Blinding: open label. 
Comparability of treatment groups: similar at baseline. 
Method of data analysis: No details given. 
Sample size/power calculation: Not reported. 
Attrition/dropout: 19 randomised, two not entered (reasons not stated), one not included in analysis (discontinued after an 
AE then resumed at half of the dose). 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Inadequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
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CRI data extraction forms 
 
Reference and 
design Intervention Participants Outcome measures 
Sanchez et al. 1. 0.05 mg/kg rhGH, daily   Target population: prepubertal Primary outcomes: appears to be 
2002103 s.c.i paediatric kidney allograft recipients skeletal changes, but not stated 
clearly 
Country: USA 2. No treatment Number of participants: total 23 
Secondary outcomes: HtSDS, WtSDS, 
Study design: Duration of treatment: 12 1. 12 GV 
RCT months 2.    11 Method of assessing outcomes: height Number of Other interventions used: 
centres: one All patients received Sample attrition/dropout: group 1, one; 
and weight measured at 3-month 
either monoclonal group 2, one 
intervals; height measured using 
Funding: partly or polyclonal anti-T Inclusion criteria for study entry: 
fixed wall-mounted stadiometer; 
funded by cell therapy and were pre-pubertal children, stable renal 
bone biopsy and histomorphometry 
Genentech maintained on a 3-drug function for at least 1 year post 
bone mass measured by DEXA; 
Foundation for immunosuppressive operation, normal bone formation 
blood samples every 3 months; BA 
Growth and regimen. None was given   rates, patients with adynamic lesions 
determined by Greulich and Pyle 
Development, vitamin D sterols, oral who had not previously been treated 
method from radiographs of left
 
and the Casey calcium supplements with rhGH were also included 
hand and wrist. WSDS and HSDS 
Lee Ball or anticonvulsant 
calculated using values for 50th 
Foundation medications Exclusion criteria for study entry: 
percentile for children of same CA 
secondary hyperparathyroidism and sex 
Length of follow-up: 12 months 
 
Characteristics of participants 
             
Mean age ± SD (years) 9.7 ± 4.5 11 ± 1.8 ns 
Sex 18 boys, 5 girls (Groups combined) 
Mean interval since transplantation 3.4 ± 2.5 (Groups combined) 
(years) 
HtSDS –2.0 ± 1.1 Not given, but ‘did not differ’ 
stated 
Mean HtSDS 12 months before study   –2.2 ± 0.8 –2.6 ± 1.0 ns 
Annual GV 12 months before study 5 ± 2.0 4 ± 2.0 ns 
(cm/year) 
BA (years) 7.1 ± 3.6 8.8 ± 2.4 ns 
Tanner score 1.9 ± 0.8 2.1 ± 1.1 ns 
GFR (ml/min) 58 ± 15 58 ± 14 
 
Results (mean ± SE) 
Outcomes 0.05 mg/kg rhGH (n = 12) No treatment (n = 11) p-value 
HtSDS for height at end –1.1 ± 1.0 (p < 0.02 compared with No change from baseline 
of study baseline) 
Annual GV (cm/year) 8.0 ± 2.1 4.8 ± 1.7 < 0.01 
Change in WtSDS 0.2 ± 0.3 –0.3 ± 0.3 < 0.01 
BA (years) 8.5 ± 3.4 9.5 ± 2.8 ns 
Tanner score 1.9 ± 0.7 2.2 ± 1.0 ns 
GFR (ml/min) 61 ± 13 (change from baseline p = ns) 67 ± 19 (change from baseline p = ns) 
148 
 
Health Technology Assessment 2010; Vol. 14: No. 42 DOI: 10.3310/hta14420 
 
 
 
 
 
 
 
Biochemical markers Baseline Final Baseline Final 
Serum calcium (mg/dl) 9.8 ± 0.7 10 ± 0.6 9.4 ± 0.5 9.6 ± 0.7 
Serum phosphorous (mg/   4.8 ± 0.8 4.8 ± 0.7 4.5 ± 0.8 4.2 ± 0.7 
dl) 
Serum osteocalcin (ng/ 24 ± 2.7 24 ± 0.3 20 ± 2.3 17 ± 1.7 
ml) 
Serum parathyroid 55 ± 5.0 55 ± 5.3 38 ± 4.0 34 ± 2.5 
hormone (pg/ml) 
Serum alkaline phosphate   239 ± 9.0 255 ± 9.0 225 ± 9.0 198 ± 6.4 
(IU/I) 
Serum 43 ± 4.3 52 ± 4.7 39 ± 3.3 50 ± 3.1 
1,25-dihydroxyvitamin D 
(pg/ml) 
Bone 
histomorphology Baseline Final Baseline Final 
Bone area (%) 20 ± 2.6 21 ± 4.0 20 ± 4.8 22 ± 6.4 
Osteoid area (%) 8.8 ± 4.0 7.9 ± 1.8 6.1 ± 2.5 8.2 ± 2.3 
Eroded perimeter (%) 5.4 ± 4.8 4.0 ± 2.2 2.2 ± 1.7 3.0 ± 1.5 
Bone formation rate 266 ± 212 348 ± 304 262 ± 180 390 ± 232 
(µm2/mm2/day) 
SDS for bone mass at –0.1 ± 1.6 –0.1 ± 1.3 (p = ns) –1.7 ± 0.9 –2.1 ± 1.0 
lumbar spine, based on    (p < 0.5) 
CA 
SDS for bone mass 1.1 ± 1.3 0.7 ± 0.8 (change 0.01 ± 1.0 –0.3 ± 1.2 
corrected for height age  from baseline  (p < 0.05 change 
p = ns) from baseline) 
Comments 
Baseline serum levels of calcium, phosphorous, parathyroid hormone, alkaline phosphate, osteocalcin, and 
1,25-dihydroxyvitamin D did not differ between patients given rhGH and untreated controls. Values remained unchanged 
after 12 months’ follow-up in both groups. IGF-1 baseline values were similar between groups (actual values not given), and 
did not change from baseline in the untreated group. Change from baseline was significant for the treated group (p < 0.001), 
although subgroup analysis indicated that this was only in the subgroup of patients with normal rates of bone formation, 
who experienced an increase in serum IGF-1 levels of 54 ± 25% after 3 months and 98 ± 35% after 12 months of rhGH        
(p < 0.05). Serum IGF-1 levels remained unchanged in patients with adynamic bone, and values did not differ from those 
obtained in the untreated group. Cumulative dose of prednisone did not differ between groups. Two patients with normal 
rates of bone formation experienced acute rejection episodes after 3 and 12 months of rhGH therapy. One was associated 
with non-compliance to immunosuppressive medications. Both episodes reversed after treatment with methylprednisolone. 
No rejection episodes in untreated patients. 
Methodological comments 
Allocation to treatment groups: Statistician who had no information about patients’ clinical or biochemical characteristics 
randomised to treatment groups depending on their initial bone histological finding. Details of randomization procedure 
not given. Not stratified by height, etc. 
Blinding: Control group did not receive placebo injections. 
Comparability of treatment groups: p = ns for difference in age at baseline. 
Method of data analysis: Not ITT as two patients who withdrew were excluded from analysis. Unpaired t-tests were used to 
compare changes from baseline. 
Sample size/power calculation: Sample size estimated with 80% power to detect differences in group means and a two group 
comparison that required 20 patients per group. Appears to have been based on bone formation rates in a previous study, 
and it is not clear what the primary outcome for the present study is. 
Attrition/dropout: Two withdrawals: one in group 1 due to glucose intolerance after 3 months (which resolved in stopping 
treatment); one in group 2 due to being assigned to control group. Two group 1 patients also failed to undergo second 
bone biopsy. 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Adequate 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Partial 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention 
 
Participants 
 
Outcome measures 
The 1. Daily s.c.i. of GH Target population: children who had Primary outcomes: GFR 
Pharmacia (1 IU/kg/week) received a kidney transplant Secondary outcomes: transplant 
Study Group 
year of randomised 2. n = 97 where reported separately for Country: 
international 1 year of GH treatment Sample attrition/dropout: 23 excluded from 
open-label RCT year 1 randomised data from analysis of growth 
auxological and biochemical
 
Number included here) Inclusion criteria for study entry: ≥ 12 GFR measured by insulin 
multicentre not reported measurements over last 6 months; height clearance (Morris method) 
Funding: GFR ≥ 20ml/min/1.73m2; normal serum Length of follow-up: 1 year (later 
Upjohn < 8 ml or breast development < B2 not randomised) 
Exclusion criteria for study entry: HV ≥ 75th 
centile, dialysis therapy, any form of 
malignancy or treatment with GH during 
past 12 months 
 
Characteristics of participants 
Mean ± SD 1 IU/kg/week GH No treatment p-value 
Boys/girls 71/35 72/25  
Age (years) 12.6 ± 3.4 12.1 ± 3.1  
Proportion prepubertal (%) 53 63  
Years since transplantation 3.6 ± 2.3 3.2 ± 2.4  
Proportion cadaver donors (%) 81 86  
HtSDS –3.2 ± 1.4 –3.1 ± 1.1  
GV before treatment (cm/year) 3.6 ± 2.2 4.0 ± 2.1  
GFR (insulin)(ml/min/1.73 m2) 48 ± 27 48 ± 26  
GF (Morris) (ml/min/1.73 m2) 51 ± 21 51 ± 2.1  
Rejection episodes prior to study (n)    
0–1 episode 69 63  
2–4 episodes 30 32  
5–8 episodes 7 1  
Comments    
N not clear for patient groups at baseline.   
Results    
Mean ± SD change from baseline 1 IU/kg/week GH (n = 28) No treatment (n = 30) p-value 
Change in GV (cm/year) 3.7 ± 1.6 0.3 ± 1.6 < 0.0001 
Change in HtSDS +0.6 ± 0.3 +0.1 ± 0.3 < 0.0001 
Comments 
Primary outcome (GFR) and other outcomes not data extracted as not reportedly separately for prepubertal children. 
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Methodological comments 
Allocation to treatment groups: Randomised centrally, but no further details given. 
Blinding: Open label. 
Comparability of treatment groups: No p-values given. Appear to be similar, although control group contained 10% more 
prepubertal patients than treatment group and no. of patients with a high no. of acute rejections was higher in the GH- 
treated patients (seven vs one). 
Method of data analysis: No information given. 
Sample size/power calculation: Not stated. 
Attrition/dropout: 23 excluded from analysis of renal function (treatment occurred without randomisation, GFR < 20 ml/ 
min/1.73 m2; transplantation < 12 months before study entry; non-compliance); 49 excluded from analysis of growth 
[abnormal thyroid function, growing too well (or not being short enough) before the study, previous growth not 
documented]. 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
Fine et al. 1. GH 0.05 mg/kg/day s.c. Target population: prepubertal Primary outcomes: not stated 
1994108 2. Placebo in equivalent growth-retarded children with CRF Secondary outcomes: GV, HtSDS 
Country: USA volume. Number of participants: Total: n = 125 height age, BA, Cumulative 
Study design: Dose adjusted every 3 1. n = 82 ∆HA – ∆BA, weight gain, triceps 
RCT months for change in weight 2. n = 43 skinfold thickness, mid-arm 
muscle circumference 
Number of Duration of treatment: 2 years’   Sample attrition/dropout: group 1 – 13 
centres: 17 treatment was discontinued in year 1, 13 in year 2; group 2 – 12 in   Method of assessing outcomes: 
Funding: at renal transplantation, year 1, 3 in year 
anthropometric measurements 
Genentech significant adverse event, or Inclusion criteria for study entry: 
made by same observer every 3
 
when BA > 15 years for boys months; radiological evaluation 
and > 14 years for girls and irreversible renal insufficiency, of BA every 6 months. HSDS 
growth rate was < 2 cm/year. creatinine clearance > 5 and < 75 ml/ calculated using age- and sex- 
Treatment was paused if a min/1.73 m
2, height < 3rd percentile specific norms from the NCHS 
patient’s height percentile for CA, BA < 10 years for girls and Length of follow-up: 2 years 
exceeded the Tanner target < 11 years for boys, prepubertal 
percentile for mid-parental status (Tanner stage 1) 
height (4/82 group 1, 11/42 Exclusion criteria for study entry: 
group 2)                           evidence of a specific cause for 
Other interventions used:            growth failure other than CRF 
dialysis was permitted as inability to obtain accurate 
required; multivitamins, height measurements, use of 
vitamin D analogue and corticosteroids or other medications 
various other therapies were   that influence growth, diabetes 
permitted as required mellitus, active malignant disease 
or treatment of a malignant disease 
within past year, use of any other 
investigational drug therapy within 2 
months of randomisation 
 
Characteristics of participants 
              Age (years) 6.0 ± 3.9 5.7 ± 3.6 
Sex (f/m) 21/61 14/28 
Height age 4.0 ± 2.9 3.8 ± 2.8 
BA 4.2 ± 3.0 4.2 ± 2.9 
HtSDS –2.9 ± 0.9 –2.9 ± 1.0 
Standardised height –2.94 ± 0.86 (n = 55) –2.82 ± 0.97 (n = 27) 
IGF-1 (µg/ml) 121 ± 73 (n = 55) 141 ± 94 (n = 20) 
Fasting insulin (pmol/l) 70.3 ± 43.6 (n = 40) 87.8 ± 71.1 (n = 21) 
Postprandial insulin 25.8 ± 26.8 (n = 43) 30.1 ± 14.6 (n = 19) 
(pmol/l) 
Fasting glucose (mmol/l) 5.1 ± 1.1 (n = 49) 5.0 ± 0.7 (n = 24) 
Postprandial glucose 5.3 ± 1.8 (n = 37) 6.0 ± 1.7 (n = 21) 
(mmol/l) 
HbA1c (%) 5.1 ± 0.9 (n = 48) 5.4 ± 1.0 (n = 24) 
Creatinine (µmol/l) 174 ± 111 (n = 48) 173 ± 97 (n = 24) 
Creatinine (mg/dl) 2.3 ± 1.5 (n = 48) 2.3 ± 1.3 (n = 24) 
Creatinine clearance (ml/   0.55 ± 0.33 (n = 48) 0.52 ± 0.31 (n = 24) 
sec/1.73 m2) 
 
Creatinine clearance (ml/   32.8 ± 19.5 (n = 48) 31.1 ± 18.3 (n = 24) 
min/1.73 m2) 
Blood urea nitrogen 15.6 ± 6.6 (n = 48) 16.0 ± 7.3 (n = 24) 
(mmol/l) 
Blood urea nitrogen (mg/   43.6 ± 18.5 (n = 48) 44.9 ± 20.5 (n = 24) 
dl) 
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Results 
Mean ± SD GH 0.05 mg/kg/day (n = 82) Placebo (n = 43) p-value 
GV year 1 (cm/year) 10.7 ± 3.1 (n = 55) 6.5 ± 2.6 (n = 27) < 0.00005 
GV year 2 (cm/year) 7.8 ± 2.1 (n = 55) 5.5 ± 1.9 (n = 27) < 0.00005 
HtSDS at year 2 –1.6, p < 0.00005 compared with baseline –2.9, p = 0.52 compared with 
baseline 
Roche–Wainer–Thissen 
predicted AH at 2 years 
(cm) 
Weight gain after 2 years 
(kg) 
Triceps skinfold thickness 
(mm) 
Mid-arm muscle 
circumference (cm) 
Change in BA at 2 years 
(years) 
Standardised height (1 
year) 
Cumulative change in HA 
– change in BA, year 1 
Cumulative change in HA 
– change in BA, year 2) 
Standardised height (2 
year) 
5.4 –0.4 < 0.00005 
 
 
 
6.7 ± 2.2 4.6 ± 2.7 0.0004 
 
–1.6 ± 2.6 0.6 ± 3.8 0.006 
 
2.1 ± 1.1 1.3 ± 1.2 0.007 
 
2.3 ± 0.7 1.6 ± 0.5 0.0001 
 
–1.93 ± 1.01 (n = 55) –2.90 ± 0.95 (n = 27) 
 
0.28 ± 0.45 (n = 43) –0.04 ± 0.36 (n = 21) 
0.15 ± 0.62 (n = 43) –0.12 ± 0.43 (n = 21) 0.08 
–1.55 ± 1.16 (n = 55) –2.91 ± 1.04 (n = 27) < 0.00005 
Height age (1 year) 4.5 ± 2.7 (n = 43) 5.0 ± 3.2 (n = 21) 
Height age (2 year) 5.6 ± 2.9 (n = 43) 5.7 ± 3.3 (n = 21) < 0.00005 
BA (1 year) 4.6 ± 2.6 (n = 43) 5.2 ± 3.1 (n = 21) 
BA (2 year) 5.8 ± 2.8 (n = 43) 6.0 ± 3.2 (n = 21) 0.0001 
IGF-1 (µg/l), year 1 286 ± 158 (n = 47) 167 ± 97 (n = 20) 0.0004 
IGF-1 (µg/l), year 2 244 ± 128 (n = 47) 135 ± 80 (n = 20) 0.0001 
Fasting insulin (pmol/l) 
year 1 
Fasting insulin (pmol/l) 
year 2 
Postprandial insulin 
(pmol/l), year 1 
Postprandial insulin 
(pmol/l), year 2 
Fasting glucose (mmol/l), 
year 1 
Fasting glucose (mmol/l), 
year 2 
Postprandial glucose 
(mmol/l), year 1 
Postprandial glucose 
(mmol/l), year 2 
104.9 ± 54.5 (n = 40) 76.9 ± 28.4 (n = 21) 
80.9 ± 42.8 (n = 40) 59.1 ± 34.6 (n = 21) 0.03 
36.6 ± 29.0 (n = 43) 27.7 ± 17.2 (n = 19) 
29.0± 20.7 (n = 43) 27.2 ± 16.9 (n = 19) 0.32 
5.2 ± 0.6 (n = 49) 5.2 ± 1.0 (n = 24) 
5.0 ± 0.6 (n = 49) 5.1 ± 0.7 (n = 24) 0.70 
5.4 ± 1.1 (n = 37) 5.1 ± 1.2 (n = 21) 
5.4 ± 1.1 (n = 37) 5.5 ± 1.1 (n = 21) 0.28 
HbA 
HbA 
(%), year 1 5.0 ± 0.8 (n = 48) 5.0 ± 0.8 (n = 24) 
(%), year 2 4.9 ± 0.7 (n = 48) 5.0 ± 0.8 (n = 24) 0.33 
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Creatinine (µmol/l), 
year 1 
Creatinine (µmol/l), 
year 2 
218 ± 163 (n = 48) 192 ± 96 (n = 24) 
269 ± 205 (n = 48) 219 ± 114 (n = 24) 0.08 
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1c 
 
 
 
 
 
 
Creatinine (mg/dl), year 1   2.9 ± 2.1 (n = 48) 2.5 ± 1.3 (n = 24) 
Creatinine (mg/dl), year 2   3.5 ± 2.7 (n = 48) 2.9       ±       1.5       (n   =   24) 0.08 
Creatinine clearance (ml/ 
sec/1.73 m2), year 1 
Creatinine clearance (ml/ 
sec/1.73 m2), year 2 
Creatinine clearance (ml/ 
min/1.73 m2), year 1 
Creatinine clearance (ml/ 
min/1.73 m2), year 2 
Blood urea nitrogen 
(mmol/l), year 1 
Blood urea nitrogen 
(mmol/l), year 2 
Blood urea nitrogen (mg/ 
dl), year 1 
Blood urea nitrogen (mg/ 
dl), year 2 
Serum alkaline 
phosphatase level change 
from baseline (IU/l), 
year 1 
Serum alkaline 
phosphatase level change 
from baseline (IU/l), 
year 2 
Comments 
0.55 ± 0.42 (n = 48) 0.51 ± 0.33 (n = 24) 
0.49 ± 0.35 (n = 48) 0.48   ±   0.34   (n = 24) 0.63 
32.8 ± 25.2 (n = 48) 30.7 ± 19.9 (n = 24) 
29.3 ± 21.3 (n = 48) 28.9       ±        20.4       (n   =   24) 0.63 
16.1 ± 8.8 (n = 48) 17.7 ± 8.7 (n = 24) 
17.2 ± 8.7 (n = 48) 15.9       ±        7.1       (n   =   24) 0.26 
45.0 ± 24.5 (n = 48) 49.7 ± 24.4 (n = 24) 
48.2 ± 24.5 (n = 48) 44.5   ±   20.0   (n = 24) 0.26 
120.1 ± 130.1 (n = 48) 45.6   ±    90.0   (n = 24) 0.014 
nr ns 
Mean fasting insulin levels changed significantly in patients with GH between baseline and 12 months (p = 0.0005) but not 
between baseline and 24 months. Changes in placebo group were not significant. Postprandial insulin levels also significant 
for GH group between baseline and year 1 (p = 0.0089) but not significant between baseline and 24 months. Changes from 
baseline in placebo group were not significant. No significant change in HbA or thyroxine or TSH in either group at either 
time period. 
Biochemical measurements: There was no significant difference in the variation in the serum calcium, phosphorous, 
triglyceride or cholesterol levels between the two groups during the first 2 years of treatment. 
Adverse effects 
No differences between groups in year 1. Year 2 asthma or wheezing in 8 out f 55 GH patients and none of placebo. All 
episodes preceded by upper respiratory tract infections. ‘No clinically significant side effects were associated with rhGH 
treatment.’ During the 1st 12 months, 19 out of 82 patients had low titre GH antibodies (i.e. anti-GH antibody serum 
binding by radioimmunoassay at least twice background values after 10-fold dilution), but over 2 years there was no 
significant difference in growth rate between patients who acquired anti-GH antibodies and those who did not. 
Methodological comments 
Allocation to treatment groups: No information on randomisation except performed to place 2/3 in treatment and 1/3 in 
placebo and to maintain balance in age, sex, standardised height, degree of renal function and primary renal disease. 
Blinding: Placebo used in equivalent volume, but no further detail given. 
Comparability of treatment groups: IGF-1 and fasting insulin levels were higher in the placebo group, but were not reported 
to have been significantly different. 
Method of data analysis: Between- and within-group comparisons were made with two-tailed t-tests; p < 0.05 was 
considered statistically significant. Many outcome measures are only presented for patients who completed both years of 
the study. Not ITT. 
Sample size/power calculation: Not reported. 
Attrition/dropout: GH: 13 in year 1, 13 in year 2; placebo: 12 in year 1, 3 in year 2. 41% of total withdrawals were due to 
renal transplant, 24% requested removal, 15% non-compliance. 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Adequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
Hokken- 1. 4 IU/m2 biosynthetic Target population: prepubertal children Primary outcomes: not stated 
Koelega et al. human GH daily s.c.i., with CRF and severe growth retardation   Secondary outcomes: GV, GV SDS, 
1991104 followed by crossover to   Number of participants: total 20 BA (years), IGF-1 and IFG-II 
Country: placebo 1. 8 plasma concentrations 
international 2. Placebo followed 
2. 8 Method of assessing outcomes:
 
Study design: by crossover to  height measured with a 
crossover RCT biosynthetic human GH Original assignment not stated Harpenden stadiometer; BA 
Number 
daily s.c.i. Sample attrition/dropout: Four left due to calculated from radiographs 
of centres: Duration of treatment: 6 kidney transplantation at start of study and every 
multicentre months in each arm of Inclusion/exclusion criteria for study entry: 6 months. Baseline height 
Funding: Novo 
the study CRF ≥ 1 year, creatinine clearance expressed as SDS for CA 
Nordisk Other interventions used: below 20 ml/min/1.73 m
2, HtSDS for age compared with Dutch reference 
A/S Denmark phosphate-binding < –1.88 and HV for age < 25th percentile,   
data. GV expressed as SDS for 
medication, calcium prepubertal (Tanner stage I), BA < 10 CA compared with references 
supplements and years for girls and 12 years for boys, derived from Infant–Childhood– 
1,25-dihydroxy vitamin no evidence of growth retardation Puberty Model. 
D cause other than CRF, normal thyroid Length of follow-up:12 months 
function, no osteodystrophy, no 
previous treatment with anabolic 
steroids, sex steroids or recombinant 
human erythropoietin 
 
Characteristics of participants (median, range) 
  2      2      Age (years) 8.7 (4.4 to 11.3) 8.6 (4.4 to 16.0) 
Sex (m/f) 6/2 4/4 
BA (years) 7.4 (3.7 to 10.2) 7.5 (3.7 to 10.6) 
HtSDS –2.3 (–3.9 to –1.8) –2.7 (–5.6 to –2.0) 
GV (cm/6 months) 1.6 (0 to 3.0) 1.4 (0.2 to 2.6) 
Weight for height (%) 98.2 (86.7 to 113.5) 101.5 (90.3 to 116.5) 
Mean (SD) GV (cm/6 months) 6 1.5 (0.7) 1.5 (0.5) 
months pre-study 
Mean (SD) HV SDS 6 months –3.2 (1.4) –2.9 (2.0) 
prestudy 
Mean (SD) BA (years) 6 months 6.9 (2.3) 7.7 (2.6) 
prestudy 
Mean (SD) IGF-1 (ng/ml) 173 (135) 197 (94) 
SDS for BA 
0.8 (2.7) 1.4 (1.6) 
 
Mean (SD) IGF-II (ng/ml) 1160 (485) 1178 (483) 
SDS for BA 2.5 (3.0) 3.4 (4.0) 
Mean (SD) IGFBP-3 (ng/ml) 5429 (1352) 6559 (2552) 
SDS for BA 3.2 (1.1) 4.2 (2.1) 
Mean (SD) IGFBP-1 (ng/ml) 195 (126) 190 (115) 
SDS for BA 30 (20) 29 (17) 
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Outcomes 
 
 
After 6 
months’ GH 
 
After 6 
months’ 
placebo 
 
After 6 
months’ 
placebo 
 
 
After 6 months’ 
GH 
Overall mean 
effect of GH 
minus effect 
of placebo 
Mean (SD) GV (cm/6 
months) 
5.2 (1.2) 1.5 (0.4) 2.4 (1.0) 4.4 (1.6) 2.9 (95% CI 
2.3 to 3.5) 
(p < 0.0001) 
Mean (SD) HV SDS 6.9 (2.4) –3.0 (1.6) –0.5 (3.2) 5.0 (4.5) 7.7 (p < 0.0001) 
Mean (SD) BA (years) 7.0 (1.9) 7.6 (1.7) 8.0 (2.6) 8.4 (2.8) –0.01 
Mean (SD) IGF-1 (ng/ml) 264 (168) 160 (104) 160 (95) 268 (120) 106 
SDS for BA 2.6 (2.0) –0.2 (1.5) 0.3 (1.6) 2.9 (2.0) 2.7 (p < 0.0001) 
Mean (SD) IGF-2 (ng/ml) 1174 (361) 983 (336) 1192 (340) 1346 (492) 172 
SDS for BA 2.8 (2.8) 0.9 (2.2) 3.4 (2.4) 4.6 (3.4) 1.6 
Mean (SD) IGFBP-3 
(ng/ml) 
SDS for BA 
7708 (2323) 
 
5.0 (1.3) 
6102 (1892) 
 
3.7 (1.3) 
6501 (1988) 
 
3.9 (1.4) 
8706 (2275) 
 
5.2 (1.4) 
1906 
 
1.3 (p < 0.0001) 
Mean (SD) IGFBP-1 
(ng/ml) 
SDS for BA 
119 (95) 
 
16.4 (16.8) 
185 (119) 
 
27.1 (22.4) 
215 (106) 
 
32 (19.5) 
140 (90) 
 
20 (16.6) 
–70 (p < 0.0001) 
 
–11.2 
     (p < 0.0001) 
 
 
 
 
 
 
 
Results   
4 IU/m2 hGH/placebo (n = 8) Placebo/4 IU/m2 hGH (n = 8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments 
For GV, there was no significant carry-over effect (–0.04 cm/6 months, p = 0.94). Period check was –0.9 cm/6 months 
(p < 0.06). 
Adverse effects 
Serum alkaline phosphate was significantly increased during GH treatment, but returned to pretreatment levels when 
GH therapy was replaced by placebo (p < 0.0001). There was no significant change in parathyroid hormone concentration 
during either treatment schedule. Thyroid function was normal. 
Methodological comments 
Allocation to treatment groups: States randomly and blindly assigned, but no further details given. 
Blinding: Stated to be double blind. 
Comparability of treatment groups: Similar at baseline, although IGF-1 and IGFBP-3 were higher in group 2 at baseline. 
Method of data analysis: Not ITT. Paper states that statistical methods appropriate for crossover trials were used but no 
further details were given. Treatment effects were calculated and tested after taking into account any period effect. 
Sample size/power calculation: No information in paper. 
Attrition/dropout: Four children left the study to have kidney transplants; 3 at 6 months and 1 at 7 months. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Unknown 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
Hokken- 1. 4 IU/m2 GH/placebo Target population: prepubertal children Primary outcomes: not stated 
Koelega et al. daily s.c.i. after renal transplant Secondary outcomes: HV, GVSDS, 
1996105 2. Placebo/4 IU/m2 GH Number of participants: total n = 11 BA, GFR, ERPF, IGF-1 measures, 
Country: daily s.c.i. 1. n = 6 insulin and other biochemical 
international Duration of treatment: 6 2. n = 5 
markers 
Study design: months in each arm  Method of assessing outcomes: 
crossover RCT Other interventions used: 
Sample attrition/dropout: none same investigator examined 
Number immunosuppressive Inclusion criteria for study entry: postrenal children at enrolment and every 
of centres: therapy transplant (≥ 12 months), stable condition  3 months; height measured 
multicentre  without rejection episodes (≥ 12 months),  with a Harpenden stadiometer HtSDS for age < –1.88 and HV for age until three consecutive readings Funding: Novo < 50th percentile OR HtSDS above –1.88   within 0.2 cm; GV references 
Nordisk A/S with HV < 25th percentile, prepubertal derived from Infant–Childhood– 
(Tanner stage I), BA < 10 years for girls Puberty Model; Dutch reference 
and 12 years for boys, prednisone dose data used for baseline HtSDS; 
≤ 0.25 mg/kg/day ≥ 6 months, no evidence     BA determined from wrist 
of growth retardation cause other radiographs 
than following renal transplant, normal Length of follow-up: 12 months 
thyroid function and acid–base balance, 
no previous treatment with sex steroids 
 
Characteristics of participants 
Median, range 4 IU/m2 GH/placebo (n = 6) Placebo/4 IU/m2 GH (n = 5) p-value 
Age (years) 12.1 (9.1 to 18.7) 11.1 (8.3 to 14.9) 
Sex (m/f) 5/1 4/1 
HtSDS –3.0 (–7.6 to –1.2) –2.6 (–3.6 to –2.1) 
GV (6 months) 1.4 (0.5 to 2.6) 0.8 (0.6 to 1.8) 
BMI SDS 3.1 (–1.1 to 4.2) 1.3 (–0.2 to 3.7) 
GFR (ml/min/1.73 m2) 62 (56 to 81) 38 (19 to 74) 
BA (years) 9.5 (7.9 to 11.5) 7.5 (5.2 to 10.5) 
 
Results (mean, SD) 
4 IU/m2 GH/placebo (n = 6) Placebo/4 IU/m2 GH (n = 5) 
Overall mean 
After 6 After 6 After 6 After 6 effect of GH 
months’ months’  months’ months’   minus effect 
Outcomes Prestudy GH placebo Prestudy   placebo GH of placebo 
HV (cm/6 months) 1.5 (0.7) 5.3 (1.0) 1.5 (0.9) 1.0 (0.5) 1.9 (0.7) 3.9 (1.3) 2.9 (95% CI 
1.9 to 3.9) 
(p < 0.0001) 
GVSDS –1.7 (1.8) 9.1 (2.9) –1.3 (2.9) –3.3 (0.9) –0.4 (1.7) 5.3 (4.0) 8.0 (p < 0.0001) 
BA (years) 9.5 (1.7) 9.7 (1.4) 10.5 (2.2) 7.7 (2.2) 8.0 (2.1) 8.1 (1.2) –0.5 
GFR (ml/min/1.73 m2) 66 (13) 80 (30) 64 (1) 44 (22) 49 (22) 47 (38) 5.5 
ERPF (ml/min/1.73 m2) 261 (75) 254 (87) 264 (77) 173 (79) 191 (62) 184 (86) –15.6 
IGF-1 (ng/ml) 280 (121) 594 (180) 240 (143) 274 (89) 321 (94) 488 (237) 228 
SDSBA 0.9 (1.6) 5.4 (2.8) 1.0 (2.5) 2.8 (1.8) 3.4 (0.5) 6.4 (1.9) 3.7 (p < 0.0001) 
IGF-2 (ng/ml) 759 (114) 799 (186) 689 (31) 728 (349) 898 (56) 900 (63) 73 
SDSBA 0.5 (0.9) 1.1 (1.7) 0.0 (0.4) 0.9 (3.2) 2.2 (1.2) 2.3 (1.0) 0.5 
IGFBP-3 (ng/ml) 4902 7457 5681 5787 6228 8495 1698 
(1099) (2088) (1588) (1037) (2193) (2921) 
SDSBA 2.8 (1.8) 4.5 (1.5) 3.7 (2.9) 3.8 (0.7) 3.9 (1.5) 5.3 (1.5) 0.9 
IGFBP-1 (ng/ml) 52 (32) 52 (23) 71 (43) 83 (40) 62 (28) 43 (35) 19 
SDSBA 4.7 (4.6) 4.6 (3.5) 7.5 (6.3) 9.7 (6.8) 6.7 (4.9) 5.1 (5.2) –2.1 
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Cholesterol (mM/l) 
LDL mM/l 
6.4 (1.1)a 
4.0 (1.4) 
6.0 (1.0)a 
3.2 (0.6) 
6.5 (1.8)a 
4.0 (2.3) 
6.3 (0.7)a 
3.7 (1.0) 
6.5 (0.7)a 
4.1 (0.9) 
6.2 (0.6)a 
3.7 (0.7) 
–0.3 
–0.5 
Apolipoprotein A1 (mg/ 
dl) 
155 (22) 163 (29) 130 (45) 171 (52) 151 (18) 141 (25) 10 
Apolipoprotein B (mg/dl) 110 (33) 91 (18) 113 (40) 111 (28) 112 (20) 115 (27) –9 
Fructosamine (mM/l) 282 (40) 296 (16) 277 (36) 338 (59) 313 (62) 312 (37) 8 
OGTT – glucose (mM/l)        
Fasting 4.7 (1.2) 5.3 (0.9) 5.1 (1.1) 5.2 (0.3) 4.5 (0.5) 4.8 (0.3) 0.3 
Integrated 738 (163) 784 (165) 691 (79) 943 (249) 846 (143) 854 (168) 55 
OGTT – insulin ( μU/m        
Fasting 20 (14) 38 (12) 22 (14) 12 (5) 19 (15) 17 (8) 7 
Integrated 2481 4582 3648 2319 2349 4267 1532 (p < 0.05 
 (1006) (3042) (1643) (1019) (444) (1092) GH vs placebo) 
Comments 
ERPF, effective renal plasma flow; GVSDS, chronological age; SDSBA, SDS for BA. 
a  p < 0.05 GH vs placebo. 
For HV, there was no significant carry-over effect (0.5 cm/6 months, p = 0.30). Period effect was 0.9 cm/6 months (p = 0.06). 
Cholesterol and other outcomes above were compared against controls. Not data extracted as not part of randomised 
study. 
Adverse effects 
None of the patients had an acute rejection episode during the study. No SAEs. 
Methodological comments 
Allocation to treatment groups: States randomly and blindly assigned to groups, but no further details given. 
Blinding: No details provided. 
Comparability of treatment groups: Similar at baseline (although BA 2 years higher in group 1). 
Method of data analysis: Paper states that statistical methods appropriate for crossover trials were used. Reference cited, 
but no further details given. Treatment effects were calculated and tested after taking into account any period effect. 
ANOVA used to test influence of baseline variables. Correlations were tested by Spearman non-parametric test. ITT 
analysis performed. 
Sample size/power calculation: Not stated. 
Attrition/dropout: All children completed the study. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Adequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Adequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
Powell et al. 1. 0.05 mg/kg/day Target population: prepubertal children with Primary outcomes: not specified 
1997106 s.c. rhGH chronic renal failure Secondary outcomes: height gain; 
Country: USA 2. No treatment Number of participants: total 69 entered, 44 HtSDS; BA; mid-arm muscle 
Study design: Duration of analysed circumference; triceps skinfold 
multicentre, treatment: 1 year 1. n = 30 thickness; weight gain; various 
open-label RCT Other interventions 2. n = 14 
IGF measures; insulin; ALS; 
GHBP Number of used: Sample attrition/dropout: 20 left (12 ESRF, six 
centres: 26 entered puberty, one allergic to rhGH, one 
Method of assessing outcomes:
 
Funding: drowned); four group 1 and one group 2 
anthropometric measurements
 
Genentech Inc.; completed study but were excluded as they 
taken at 0, 3 and 12 months;
 
government had insufficient serum for the 0- and 12-month 
height measured using wall-
 
grants protein assays 
mounted stadiometer; BA 
determined by a left hand and 
Inclusion criteria for study entry: irreversible renal wrist radiograph at 0 and 12 
insufficiency (GFR > 10 and < 40 ml/min/1.73 m2),   months 
height < fifth percentile for age, age > 2.5 years, Length of follow-up: 1 year 
ability to stand for height measurement, BA 
< 10 for girls and 11 for boys, Tanner stage I 
Exclusion criteria for study entry: serum albumin 
< 2.5 g/dl, receiving medications that influence 
growth, presence of illness affecting growth, 
diabetes mellitus, presence or past history of 
malignancy 
 
Characteristics of participants (mean ± SD) 
Characteristic 0.05 mg/kg/day rhGH (n = 30) No treatment (n = 14) p-value 
Sex (% male) 83  86 
GFR (ml/min/1.73 m2) 27.5 ± 8.9 27.6 ± 8.8 
Age (years) 5.6 ± 2.0 5.7 ± 2.6 
BA (years) 4.0 ± 1.5 (n = 27) 4.2 ± 1.8 
HtSDS –2.7 ± 0.7 –2.7 ± 0.8 
Weight for HtSDS 0.0 ± 1.3 –0.2 ± 1.5 
MAMC (cm) 14.1 ± 1.6 (n = 29) 14.4 ± 2.8 
TSF (mm) 7.9 ± 3.2 (n = 29) 8.5 ± 3.2 
IGF-1 (nM) 15 ± 10 10 ± 5 
IGF-1 SDS –0.7 ± 1.3 –1.2 ± 1.0 
Free IGF-1 (pM) 71 ± 41 (n = 17) 141 ± 94 (n = 9) 0.029 
IGF-2 (nM) 100 ± 29 101 ± 41 
IGF-2 SDS 1.2 ± 1.2 1.1 ± 1.3 
Insulin pM b 19 ± 14 52 ± 66 0.021 
Total IGF (nM) 115 ± 34 111 ± 45 
IGFBP-1 (nM) 18 ± 9 17 ± 21 
IGFBP-1 SDS 2.4 ± 0.6 2.1 ± 1.4 
IGFBP-2 (nM)a 50 ± 17 51 ± 26 
IGFBP-3 (nM)b 130 ± 50 109 ± 25 
IGFBP-3 SDSc 1.7 ± 2.0 0.7 ± 1.1 
ALS (nM) 207 ± 81 179 ± 40 
GHBP (pM) 183 ± 104 144 ± 104 (n = 12) 
GHBP SDS 0.4 ± 1.7 0.0 ± 1.3 (n = 12) 
a Values > normal range (22 ± 11), p < 0.001. 
b Values not different from normal range (98 ± 17). 
c  Values > normal range (–0.2 ± 0.7), p = 0.013. 
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Results (mean ± SD change from 0–12 months) 
Outcome 0.05 mg/kg/day rhGH (n = 30) No treatment (n = 14) p-value 
BA (years) 1.0 ± 0.3 (n = 27) 0.9 ± 0.4 (n = 13) 0.5282 
Height gain (cm) 9.1 ± 2.8 5.5 ± 1.9 < .0001 
Weight gain (kg) 3.5 ± 1.5 2.2 ± 1.0 0.007 
HtSDS 0.8 ± 0.5 0.0 ± 0.3 < 0.0001 
Weight for HtSDS 0.4 ± 0.7 0.4 ± 0.5 0.8703 
MAMC (cm) 1.2 ± 0.9 (n = 29) –0.2 ± 1.7 (n = 13) 0.0015 
TSF (mm) –1.9 ± 2.5 (n = 29) 0.9 ± 1.2 (n = 13) 0.0003 
IGF-1 (nM) No actual values presented – only small diagram, which is hard to read 
accurately. Not data extracted 
IGF-1 (SDS) 0.2 ± 1.0 No change from baseline – no values 
reported 
< 0.006 
< 0.006 
IGF-2 (nM) 
accurately. Not data extracted 
< 0.006 
Free IGF-1 (pM) No actual values presented – only small diagram, which is hard to read < 0.0464 
IGF-2 SDS 2.1 ± 1.3 No change from baseline – no values 
reported 
< 0.006 
Insulin (pM) } No actual values presented – only small diagram which is hard to read < 0.017 Total IGF (nM) accurately. Not data extracted < 0.011 IGFBP-1 (nM) < 0.017 IGFBP-1 SDS < 0.017 IGFBP-2 (nM) ns IGFBP-3 (nM) < 0.011 
IGFBP-3 SDS 4.0 ± 3.2 No change from baseline – no values 
reported 
< 0.011 
GHBP (pM) }  
accurately. Not data extracted ns 
ALS (nM) No actual values presented – only small diagram, which is hard to read < 0.011 
GHBP SDS ns 
Comments 
10 healthy children (80% male; mean age 7.4 ± 2.7 years) provided serum samples for control values for IGFBP-2 and 
IGFBP-3 measurements. 
Adverse effects 
Not reported. 
Methodological comments 
Allocation to treatment groups: Randomised 1 : 2, no information on method of randomisation. Groups balanced for age, 
gender, height, GFR at baseline and nature of primary renal disease 
Blinding: Open label. 
Comparability of treatment groups: Free IGF-1 and insulin were statistically significantly higher in control group, otherwise 
groups were similar. 10 healthy children (80% male; mean age 7.4 ± 2.7 years) provided serum samples for control values 
for IGFBP-2 and IGFBP-3 measurements. Mean age for control children was approximately 2 years older than for the 
randomised children. 
Method of data analysis: Not ITT. Data presented as mean ± SD but converted to log10 values for statistical analysis. 
ANCOVA used to test differences between groups; p ≤ 0.05 considered significant. Multiple regression analysis used to 
analyse effect of multiple variables on change in HtSDS, but not data extracted here. 
Sample size/power calculation: Not reported, and primary outcome not clearly defined. 
Attrition/dropout: 20 left (12 ESRF; six entered puberty; one allergic to rhGH; one drowned); four group 1 and one group 2 
completed study but were excluded as they had insufficient serum for the 0- and 12-month protein assays. 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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SGA data extraction forms 
 
Reference and 
design Intervention Participants 
 
Outcome measures 
Lagrou et al. 1. GH 0.066 mg/kg/day Target population: prepubertal children Primary outcomes: GV 
2008110 2. Untreated (did born SGA Secondary outcomes: HtSDS, 
Countries: not receive placebo Number of participants: total: 40 WtSDS, BMI SDS, head 
Belgium and injections) 1.    20 circumference SDS, perception 
Luxembourg Duration of treatment: 2 2. 20 of short stature (not data 
Study design: years extracted), perception of 
RCT Other inter entions sed: 
Sample attrition/dropout: One treated changes in height and physical 
patient dropped out due to family appearance (not data extracted), 
Number of none stated problems perceptions of changes in centres: 11 
Inclusion/exclusion criteria for study entry: psychosocial functioning (not 
Funding: Belgian birth weight and or length below –2 SD data extracted) 
Study Group for gestational age, CA between 3 and 8 Method of assessing outcomes: 
for Paediatric years, current height below –2.5 SD, GV standard auxological assessment 
Endocrinology/ SDS below +1.0 SD during the last 6–18 of height, weight and head 
GH provided by months circumference measurements Pfizer 
Exclusion criteria for study entry: gestational every 6 months, SDS calculated 
age < 34 weeks; endocrine disease, using British references, 
including GH deficiency; severe chronic psychological assessments 
disease; Turner, Noonan or Down performed at start of study and 
Syndrome or other genetically confirmed after 2 years of follow-up (not 
syndromes; chromosomal abnormalities, data extracted) 
bone disease, current or previous Length of follow-up: 2 years 
irradiation therapy, current or previous  
(up to 18 months before inclusion)  
treatment with glucocorticoids, severe  
mental retardation (IQ ≤ 50)  
Characteristics of participants  
Characteristic GH 0.066 mg/kg/day (n = 20) Untreated (n = 20) p-value 
Birth WtSDS –2.7 ± 0.9 –2.6 ± 0.8 ns 
Gestational age 37.3 ± 2.1 38.2 ± 1.6 ns 
Age (years) 5.5 ± 1.6 5.1 ± 1.3 ns 
HtSDS –3.3 ± 0.6 –3.2 ± 0.9 ns 
WtSDS –3.8 ± 1.3 –3.9 ± 1.4 ns 
BMI (SDS) –1.7 ± 1.1 –2.0 ± 1.5 ns 
Head circumference –2.7 ± 1.4 –2.8 ± 1.6 ns 
(SDS)  
Results (mean ± SD)  
Outcomes GH 0.066 mg/kg/day (n = 20) Untreated (n = 19) p-value 
HtSDS –1.9 ± 0.7 –3.1 ± 0.9 < 0.001 
WtSDS –2.3 ± 1.2 –3.7 ± 1.5 < 0.01 
BMI (SDS) –1.5 ± 1.1 –2.0 ± 1.5 ns 
Head circumference –2.0 ± 1.4 –2.8 ± 1.5 < 0.05 
(SDS)  
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Adverse effects 
Tolerance only discussed in terms of perceptions of the injection by parents and children. No AEs reported or discussed. 
Methodological comments 
Allocation to treatment groups: States randomised taking into account: gender, chronological age, WtSDS and study centre, 
no further details. 
Blinding: No details given, untreated participants not given placebo injections. 
Comparability of treatment groups: Authors report no differences in the auxological parameters between groups at baseline. 
Method of data analysis: Differences of continuous variables between subgroups were evaluated by Students unpaired t-test 
or by the Mann–Whitney U-test as appropriate. The level of significance of difference was set at p < 0.05. 
Sample size/power calculation: Based on 0.8 power to detect a significant difference (p = 0.05). 20 subjects in each group 
were required, assuming a difference of 2 cm/year in GV and a SD of 2.2 cm/year. 
Attrition/dropout: One treated patient dropped out due to family problems. Data for untreated group is for 19 after 2 years, 
no explanation of this. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
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Reference and 
design Intervention Participants Outcome measures 
Carel et al. 1. Daily GH injections: Target population: children born SGA Primary outcomes: AH SDS 
2003111 0.2 IU/kg/day (0.067 mg/ Number of participants: total 168 Secondary outcomes: gain in SD units 
Country: France kg/day) 1. 112 between height at inclusion and AH 
Study design: 2. No treatment 2. 56 Method of assessing outcomes: follow- 
RCT Duration of treatment:  up visits were every 3 months for 
Number of Until reached AH. 
Sample attrition/dropout: the treated group, and every 6 
centres: not The mean duration of For treatment: group 1, n = 21; group months for the control group and 
stated treatment was 2.7 ± 0.6 2, n = 23 the following data recorded: height, 
Funding: Sanofi– 
years For analysis: group 1, n = 10; group weight, CA, pubertal stage, dose and 
Synthélabo Other interventions used: 2, n = 9 
tolerance. BA analysed yearly. SDS 
none stated Inclusion criteria for study entry: birth calculation appears to be based on 
length < –2 SDS for gestational French registry study 
age and term > 30 weeks; at study Length of follow-up: criteria for 
inclusion, height ≤ –2.5 for age or stopping treatment/follow-up 
less; CA > 10.5 years for girls and were < 1 cm growth over the last 
> 12.5 years for boys; BA ≥ 9 years 6 months, and a BA of ≥ 15 years 
for girls and ≥ 10 years for boys; for girls, and ≥ 16 years for boys. 
peak plasma GH concentration after Only 4% of patients met this criteria 
pharmacological stimulation at least when treatment was stopped, so   
10 µg/l to exclude GH deficiency; authors considered treatments to 
Tanner stage I or II, with testicular be almost complete for analytical 
volume < 8 ml or uterus length purposes if GV was 2 cm or less over 
< 50 mm the last 6 months, or BA was ≥ 13 
Exclusion criteria for study entry: years for girls, and ≥ 15 years for 
chromosomal abnormalities in girls; boys. Patients who had discontinued 
constitutional bone diseases, any follow-up before reaching AH 
chronic disease interfering with were contacted later for a final AH 
growth; steroid or sex steroid measurement. Those who had not 
treatment; dysmorphic syndromes reached AH were maintained in the 
other than Russell–Silver; no catch- analysis without correction 
up growth criteria were specified 
 
Characteristics of participants 
Daily GH injections: 0.2 IU/ 
   
         Target height –1.2 ± 0.9 –0.9 ± 1.0 
Duration of pregnancy (weeks) 39 ± 2 39 ± 2 
Birth length (SDS) –2.8 ± 0.8 –3.1 ± 1.0 < 0.05 
Birth WtSDS –1.8 ± 0.8 –1.9 ± 0.8 
Age (years) 12.7 ± 1.4 12.8 ± 1.6 
Height (cm) 
HtSDS –3.2 ± 0.7 –3.2 ± 0.6 
WtSDS –1.9 ± 0.7 –2.2 ± 0.6 
GV (cm/year) 
BA (years) 10.6 ± 1.4 10.8 ± 1.6 
Pubertal (Tanner stage II) (%) 22  21 
Comments 
Four patients had Russell–Silver syndrome. GV and height (cm) were not detailed for the groups as a whole, but for boys 
and girls within the group separately. 
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Results 
 
 
 
Outcomes 
 
 
Daily GH injections: 0.2 IU/ 
kg/day (0.067 mg/kg/day) 
(n = 91) Untreated (n = 33) p-value 
At inclusion: age (years) 12.6 ± 1.5 12.9 ± 1.4 
At inclusion: HtSDS –3.2 ± 0.6 –3.2 ± 0.6 
At inclusion: height (cm) nr for whole group nr for whole group 
At end of treatment: age (years) 15.7 ± 1.5 nr 
At end of treatment: HtSDS –2.1 ± 1.0 nr 
At end of treatment: height (cm) nr for whole group nr 
At AH measurement: age (years) nr nr 
At AH measurement: HtSDS –2.1 ± 1.0 –2.7 ± 1.0  0.005 
At AH measurement: height (cm) nr for whole group nr for whole group 
At AH measurement: total height 
gain (cm) 
At AH measurement: total height 
gain (SDS) 
At AH measurement: difference from 
target HtSDS 
Comments 
26 ± 7 22 ± 6 0.005 
 
1.1 ± 0.9 0.5 ± 0.8 0.002 
 
–0.9 ± 1.2 –1.7 ± 1.2 0.005 
A difference of 0.6 SDS was observed in FH between the control and treated groups (95% CI 0.2 to 0.9). (A difference of 
1.4 was observed at baseline, unclear if this is accounted for in finding the 0.6 result significant.) The measurements above 
that have not been reported for the whole group are reported in the paper separately for boys and girls. 
Adverse effects 
Overall, 44% of treated patients reported AEs, 10% having 4 or more events. The most frequently reported events 
involved the respiratory system (19%), osteomuscular system (14%), central nervous system (9%), and digestive tract (8%). 
Authors state that all of these were mild, reversible, benign conditions that were unlikely to be related to GH treatment. 
16 AEs recorded in 14 treated patients were considered severe: trauma, psychiatric symptoms, abdominal symptoms, 
otitis, asthma, varicocele, striae, and migraine. Again, authors state that these are unlikely to be related to GH treatment 
– two were causally related to treatment: one slipped capital epiphysis after 1.5 years of treatment and had one single 
seizure episode 10 minutes after first injection. 
Methodological comments 
Allocation to treatment groups: Allocation sequence generated centrally and faxed to participants. 
Blinding: Group assignment was not masked, and the treated group was twice as large as the control group. 
Comparability of treatment groups: There is a significant difference in birth length between the treated and untreated groups, 
with the treated group being longer than the untreated group (p = 0.04). On other characteristics the groups appear to be 
broadly similar. 
Method of data analysis: Means and SD values are presented. Mann–Whitney U-test to compare groups. An α risk of 5% 
was set as the significance threshold. Not ITT. 
Sample size/power calculation: Not reported. 
Attrition/dropout: Four patients in the treatment group were excluded from analysis due to severe diseases interfering with 
growth (sickle cell anaemia, pulmonary hypertension, type 1 neurofibromatosis and severe prematurity). Five patients 
assigned to the treatment group refused GH treatment but remained in the study and were analysed as part of the control 
group; 15 patients left the study early (14 in control and one in the treated group). Treatment was completed in 4/102 
patients and almost complete in 64/102. The reasons for interrupting treatment early were: growth rates considered 
insufficient by patient/physician (n = 12), weariness with the treatment (n = 10), loss to follow-up (n = 5), satisfaction with 
height (n = 2), local intolerance (n = 1), and striae attributed to the treatment by the patient (n = 1). In addition, some of 
the investigators wrongly considered that the treatment duration was limited to 3 years and stopped the treatment early 
(n = unclear). 102 treated and 47 control patients are included in the analysis. Authors state that group reassignments or 
protocol deviations concerned 12 and 5 patients followed to AH in the treated and control groups respectively. Appear 
to have been significant problems with attrition for various reasons, appears to be fully described. Group assignment was 
not blinded and, despite the study being randomised and centrally allocated, the treatment group is twice as large as the 
control: either this was 2 : 1 randomisation (this is not reported) or large numbers of the control group dropped out after 
randomisation, or possibly swapped to the treatment group: this is unclear. 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Inadequate 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
De Schepper 1. High-dose GH: Target population: children born SGA Primary outcomes: none clearly 
et al. 2007109 66 ± 3 µg/kg s.c. once Number of participants: total: 40 (25) stated 
Country: Belgium daily, adjusted every 6 1. 11 Secondary outcomes: HtSDS and 
Study design: 
months to body weight 
2. 14 
WtSDS, anthropometric and 
RCT 2. Untreated (did  absorptiometric characteristics 
Number of 
not receive placebo Sample attrition/dropout: The trial cohort Method of assessing outcomes: 
centres: eight 
injections) was reduced from 40 to 25 based on the study participants seen every 3 
Duration of treatment: 2 availability of the same absorptiometry months, height measured with 
Funding: Belgian years apparatus to assess body composition Harpenden stadiometer, and 
Study Group  in a homogeneous fashion across eight 
for Paediatric Other interventions used: centres. No anthropometric differences 
weight with electronic scale.
 
Endocrinology/ none stated were detectable between the study 
Mid-upper arm circumference
 
and four skinfolds were 
Pfizer population and the non-included measured at study start and 
subcohort (authors state, no data after 1 and 2 years 
reported) 
Length of follow-up: 2 years 
Inclusion criteria for study entry: birth 
weight, length or both < –2 SD for 
gestational age, current height < –2.5 
SDGV < +1 SD in the last 6–18 months, 
age between 3 and 8 years at study start 
Exclusion criteria for study entry: premature 
birth (gestational age < 34 weeks); 
evidence for endocrine or bone disease; 
severe chronic disease; Turner, Noonan, 
Down or other genetic syndrome; 
irradiation treatment; current or 
previous glucocorticoid treatment; 
severe cognitive dysfunction (est. IQ < 50) 
 
Characteristics of participants 
Ch t i ti  Hi h d  GH (GH) (  = 11)a U t t d (  = 14) p l  
Age (years) 5.1 ± 1.6 5.1 ± 1.4 
Gestational age (weeks) 37 ± 3 38 ± 2 
Birth WtSDS –2.4 ± 0.8 –2.5 ± 0.8 
Birth length (SDS) –3.1 ± 0.6 –2.9 ± 0.7 
Mid-parental heightb –0.9 ± 0.8 –0.8 ± 0.7 
HtSDS –3.3 ± 0.7 –3.2 ± 1 
WtSDS –3.5 ± 1.2 –3.6 ± 1.5 
Subscapular skinfold (mm) 5.4 ± 1.1 6.4 ± 2.1 
Triceps skinfold (mm) 7.9 ± 1.4 8.3 ± 2.1 
Subscapular/triceps 0.7 ± 0.2 0.8 ± 0.2 
Sum skinfolds (mm) 22.1 ± 3 24.3 ± 6 
Body fat fraction (%) 12.9 ± 2.1 14.1 ± 3.6 
MUAMA (cm) 12.8 ± 2.5 14.1 ± 3.5 
MUAFA (cm) 5.5 ± 1.1 5.7 ± 1.7 
Lean mass (kg) 10 ± 3 9.9 ± 2.2 
FM (kg) 2.3 ± 0.5 2.5 ± 0.9 
Lean mass (%) 78 ± 4 77 ± 5 
FM (%) 15 ± 3 20 ± 5 
Trunk fat (kg) 0.7 ± 0.3 0.8 ± 0.4 
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Limb fat (kg) 1.1 ± 0.3 1.2 ± 0.5 
Trunk fat/limb fat 0.6 ± 0.2 0.6 ± 0.2 
Trunk fat/leg fat 0.8 ± 0.3 0.8 ± 0.3 
MUAFA, mid upper arm fat area; MUAMA, mid upper arm muscle area. 
a  Not significant for baseline comparisons between groups. 
b  [Father’s HtSDS + mother’s HtSDS]/2. 
 
Results   
High-dose GH (GH) (n = 11)a Untreated (n = 14) 
 
Outcomes 1 year 2 years  1 year 2 years p-valuea 
HtSDS –2.1 ± 0.7b –1.7 ± 0.7b,e  –3.1 ± 1c –3 ± 1c < 0.0001 
WtSDS –2.4 ± 1.3b –1.8 ± 1b,e  –3.5 ± 1.4 –3.4 ± 1.6c < 0.0001 
Subscapular skinfold 
(mm) 
4.7 ± 0.8c 5.1 ± 1  5.7 ± 1.8c 6 ± 2.1 ns 
Triceps skinfold (mm) 4.9 ± 1.5b 5.5 ± 2.1b  8.2 ± 2.3 7.9 ± 2.4 < 0.001 
Subscapular/triceps 1 ± 0.3d 1 ± 0.3b,f  0.7 ± 0.2 0.8 ± 0.2i 0.001 
Sum skinfolds (mm) 16.6 ± 3.4b 18.1 ± 5d  22.4 ± 5.8c 22.9 ± 6.8 < 0.005 
Body fat fraction (%) 9.1 ± 2.1b 10.1 ± 3d  13.3 ± 3.5 13.4 ± 3.5 < 0.005 
MUAMA (cm) 15.2 ± 2.9b 17 ± 2.7b,g  13.3 ± 2.3d 14.1 ± 2.9b,h < 0.005 
MUAFA (cm) 3.6 ± 1.2b 4.3 ± 1.9d,h  5.8 ± 2 5.7 ± 1.9 0.001 
Lean mass (kg) 13.2 ± 3.4b 15.5 ± 3.4b,e  10.9 ± 2.4b 12.2 ± 2.5b,e < 0.0001 
FM (kg) 2.4 ± 0.7 2.9 ± 1c,g  2.8 ± 1.1c 3.1 ± 1.1b,h ns 
Lean mass (%) 82 ± 3d 82 ± 3c  77 ± 6 77 ± 5 < 0.05 
FM (%) 15 ± 3d 15 ± 2c  20 ± 6 20 ± 5 < 0.05 
Trunk fat (kg) 0.9 ± 0.3 1 ± 0.3c  0.9 ± 0.5 1 ± 0.6b ns 
Limb fat (kg) 0.9 ± 0.5 1.3 ± 0.7g  1.4 ± 0.6c 1.5 ± 0.6 < 0.05 
Trunk fat/limb fat 1 ± 0.5d 0.9 ± 0.3d,f  0.6 ± 0.2 0.7 ± 0.2i < 0.0001 
Trunk fat/leg fat 1.5 ± 0.7d 1.3 ± 0.4d,f  0.8 ± 0.3 0.9 ± 0.3i < 0.0001 
Comments       
a Difference between untreated and treated group (analysis of variance) unclear if this is totals over the 2 years of the 
study, including baseline measurements. 
b p < 0.0005 paired t-test or Wilcoxon rank test@ baseline – year 1, baseline – year 2. 
c  p < 0.05. 
d  p < 0.005. 
e  p < 0.0005 paired t-test or Wilcoxon rank test: year 1 – year 2. 
f   Elevated for age. 
g  p < 0.005. 
h  p < 0.5. 
i   Normal for age. 
GH treatment was accompanied by a gain of lean mass (p < 0.0001) and by a centripetal redistribution of FM (p < 0.0001) 
but not by an overall gain or loss of FM. The effects of high dose GH on adiposity are not readily detectable in the trunk 
and are essentially limited to the limbs. 
Adverse effects 
Authors state that ‘none had a noteworthy adverse event during the 2 years of study’. 
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Methodological comments 
Allocation to treatment groups: States randomised, no information reported on allocation to groups. Original trial cohort 
was 40, this was reduced to 25 due to availability of equipment. 
Blinding: No information on blinding reported, untreated group did not receive placebo injections. 
Comparability of treatment groups: Groups appear comparable at baseline – authors state there were no detectable baseline 
differences in the subgroups. 
Method of data analysis: Results are expressed as mean ± SD. Repeated measures analysis of variance was used to test for 
differences between subgroups. The level of statistical significance was set at p < 0.05. 
Sample size/power calculation: None reported. 
Attrition/dropout: 15 children from the original cohort were withdrawn due to issues with availability of measuring 
equipment – unclear at what stage this happened. No dropouts are reported from the 25 included in the study, apart from 
this. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
de Zegher et 1. High-dose GH Target population: short children born   Primary outcomes: not clearly stated 
al. 2002113 (100 µg/kg/day) SGA Secondary outcomes: growth response 
Countries: UK 2. No treatment Number of participants: total 13 and its relationship to pretreatment 
and Belgium Duration of treatment: 2 1. 9 GH secretion (not data extracted) 
Study design: years 2. 4 
HtSDS, WtSDS, BMI SDS, GV (cm/ 
RCT Other interventions used: 
year)
 Sample attrition/dropout: nr 
Number of None stated  Method of assessing outcomes: 
centres: two  Inclusion criteria for study entry: birth Overnight GH profiles and GH weight/length < –2 SD for gestational   stimulation tests at baseline (not Funding: age, current height < –3.0 SD, GV data extracted), intravenous glucose 
Pharmacia Ltd below 0.0 SD, age between 2 and 8 tolerance tests were performed at 
years                                          baseline, yearly on GH treatment 
Exclusion criteria for study entry:   and 3 months post GH treatment. 
identified syndrome other than            Height, weights and BMI converted 
Silver–Russell to age- and sex- adjusted SDS using 
current UK reference data 
Length of follow-up: 2 years 
 
Characteristics of participants 
High-dose GH (100 µg/kg/day) 
Characteristic (n = 9) No treatment (n = 4) p-value 
Age (years) 6.3 (4.0 to 8.0) 4.7 (2.3 to 6.3) 
HtSDS –3.6 (–5.5 to –2.8) –3.1 (–3.4 to –2.8) 
WtSDS –4.5 (–7.2 to –2.6) –3.8 (–5.5 to –2.7) 
BMI SDS –2.3 (–5.0 to –0.7) –2.0 (–4.2 to –0.1) 
GV (cm/year) 5.1 (4.0 to 6.8) 6.4 (5.3 to 7.5) 
 
Results (means and ranges) 
High-dose GH 
Outcomes (100 µg/kg/day) (n = 9) No treatment (n = 4) p-value 
Age (years) (year 1) 7.2 (5.0 to 8.8) 5.7 (3.3 to 7.3) 
Age (years) (year 2) 8.2 (6.0 to 9.9) 6.5 (4.3 to 8.3) 
HtSDS (year 1) –2.4 (–4.6 to –1.4)a –3.0 (–3.3 to –2.7) 
HtSDS (year 2) –1.8 (–3.9 to –0.5)a –3.0 (–3.3 to –2.5) 
WtSDS (year 1) –2.9 (–4.7 to –1.7)a –4.0 (–5.4 to –3.2) 
WtSDS (year 2) –2.1 (–3.6 to –0.9)a –3.8 (–4.8 to –3.2) 
BMI SDS (year 1) –1.6 (–3.8 to –0.8)a –2.3 (–3.9 to –1.3) 
BMI SDS (year 2) –1.2 (–3.4 to –0.4)a –2.1 (–2.9 to –1.4) 
GV (cm/year) (year 1) 11.0 (7.4 to 13.3) nr 
GV (cm/year) (year 2) 8.5 (6.3 to 10.2) 5.6 (4.4 to 6.8) 
Comments 
a  p < 0.0001 from baseline. 
Authors state that GH-treated children showed significant increments in HtSDS, WtSDS and BMI SDS over 2 years (all 
p < 0.0001). Untreated SGA children remained on their height, weight and BMI SD levels. 
Glucose and insulin metabolism markers not data extracted as reported for the treated group, no results reported for 
controls. Authors state that compared to baseline levels, children in the treated group showed significant increases in 
fasting levels of insulin (year 1, p = 0.003; year 2, p = 0.0002) and decreases in insulin sensitivity (year 1, p = 0.003; year 2, 
p = 0.0002). 
Adverse effects 
Not reported/discussed. No child showed impaired glucose tolerance. 
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Methodological comments 
Allocation to treatment groups: Randomised on a 2 : 1 basis, no further details. 
Blinding: No details given. No placebo used. 
Comparability of treatment groups: Groups appear similar. 
Method of data analysis: Means and ranges are presented. Changes in height/weight, glucose and insulin parameters analysed 
using paired t-tests. ITT. 
Sample size/power calculation: Not reported. 
Attrition/dropout: Not reported. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Adequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants Outcome measures 
de Zegher et 1. GH 0.2 IU/kg/day s.c. Target population: children born SGA Primary outcomes: not clearly 
al. 1996112 2. GH 0.3 IU/kg/day s.c. Number of participants: total 54 stated 
Country: Belgium 3. Untreated 1. 20 Secondary outcomes: height, 
Study design: Duration of treatment: 2 2. 21 
HtSDS, GV, GV SDS, WtSDS,
 
open-label RCT years 
weight gain, BMI and BMI SDS, 3. 13                                                          serum IGF-1, IGF-II, IGFBP-3, Number Other interventions used: Sample attrition/dropout: group 1, n = 2; osteocalcin 
of centres: None stated group 2, n = 1; group 3, n = 1 Method of assessing outcomes: 
multicentre 
Funding: support Inclusion/exclusion criteria for study 
study visits including history, 
from Pharmacia entry: birth weight/length < –2 SD for 
auxological evaluation, BA 
Peptide gestational age, HtSDS for age < –2.5, 
determination, and dose 
Hormones GV SDS for age < +1, CA between 2 
adjustment were scheduled 
and 8 years, serum GH concentration every 6 months. Biochemical 
> 10 µg/l after exercise, glucagon or examinations were performed 
insulin tolerance test, available growth yearly. All BAs were read 
data concerning the period preceding the   according to Tanner– 
start of the study                            Whitehouse II method, HtSDS 
Exclusion criteria for study entry: endocrine for BA was used as an index of 
disorders, Turner or Downs syndrome,      FH prognosis 
previous or concomitant irradiation or Length of follow-up: 2 years 
anabolic steroid therapy, severe chronic 
disease, severe mental retardation 
 
Characteristics of participants 
GH 0.2 IU/kg/day GH 0.3 IU/kg/day 
Ch t i ti  (   20) (   19) U t t d (   13) l  
Birth weight (g)                 2082.0 ± 139.0                  1842.0 ± 115.0               1996.0 ± 136.0                   ns 
Birth length (cm)               42.3 ± 1.1                   42.5 ± 0.9                    42.1 ± 1.1                    ns 
Chronological age (years)   5.4 ± 0.5                           5.1 ± 0.4                        4.9 ± 0.5                                 ns 
BA (years)                         4.5 ± 0.5                         3.7 ± 0.5                       3.7 ± 0.5                          ns 
HtSDS                               –3.5 ± 0.2                         –3.7 ± 0.2                      –3.4 ± 0.3                                ns 
GV (cm/year)                     6.6 ± 0.4                           7.0 ± 0.5                        6.7 ± 0.7                             ns 
GV SDS                             –0.9 ± 0.2                         –0.7 ± 0.3                     –0.6 ± 0.3                               ns 
Weight (kg)                       13.2 ± 0.9                       12.3 ± 0.7                      12.0 ± 0.8                        ns 
WtSDS                            –2.5 ± 0.2                         –2.9 ± 0.2                      –2.8 ± 0.2                            ns 
BMI                               14.0 ± 0.4                         13.8 ± 0.4                      13.5 ± 0.4                               ns 
BMI SDS                         –1.8 ± 0.4                         –1.8 ± 0.3                      –2.0 ± 0.4                          ns 
Serum IGF-1 (µg/l)             107.0 ± 15.0                     108.0 ± 14.0                  108.0 ± 21.0                     ns 
Serum IGF-2 (µg/l)             557.0 ± 44.0                    748.0 ± 60.0                  699.0 ± 103.0                    ns 
Serum IGFBP-3 (mg/l)        3.34 ± 0.33                       3.36 ± 0.38                    3.35 ± 0.38                              ns 
Serum osteocalcin (µg/l)    69.0 ± 3.0                         69.0 ± 2.0                      63.0 ± 3.0                               ns 
Results are mean ± SEM. The 52 participating children were considered to have no specific syndrome (n = 33), Silver–Russell 
syndrome (n = 10), fetal alcohol syndrome (n = 4), Dubowitz syndrome (n = 3), 4p- syndrome (n = 1) or lacrimo-auriculo- 
dento-digital syndrome (n = 1). 
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Results 
Outcomes at 2 years, 
   
unless otherwise GH 0.2 IU/kg/day GH 0.3 IU/kg/day 
stated (n = 20) (n = 19) Untreated (n = 13) p-value 
Gain in BA (years) 1.35 ± 0.16 1.33 ± 0.24 0.84 ± 0.07 < 0.001 treated vs 
untreated 
GV (cm/year) (year 1) 11.5 ± 0.4 12.0 ± 0.4 nr  
GV (cm/year) 10.2 ± 0.2 11.0 ± 0.4 5.7 ± 0.3 < 0.001 untreated 
vs treated; < 0.05 
    group 1 vs group 2 
GV SDS (year 1) 5.3 ± 0.3 5.8 ± 0.4. nr  
GV SDS 4.3 ± 0.3 5.2 ± 0.4 –0.9 ± 0.3 < 0.001 untreated 
vs treated 
Gain in HtSDS 2.1 ± 0.1 2.5 ± 0.1 0.2 ± 0.1 < 0.001 untreated 
vs treated 
Gain in HtSDS for BA 1.0 ± 0.2 1.2 ± 0.4 0.0 ± 0.3 < 0.05 untreated vs 
treated 
Weight gain (kg) 6.9 ± 0.6 7.8 ± 0.5 3.6 ± 0.4 < 0.001 untreated 
vs treated 
Gain in WtSDS 1.3 ± 0.1 1.8 ± 0.1 0.4 ± 0.1 < 0.001 untreated 
vs group 1; < 0.01 
    group 1 vs group 2 
Serum IGF-1 (µg/l) (year 
1) 
274 ± 30 392 ± 43 145 ± 23 < 0.01 group 1 vs 
untreated; < 0.05 
    group 1 vs group 2 
Serum IGF-1 (µg/l) 332 ± 29 655 ± 69 168 ± 46 < 0.0001 group 
1 vs group 2; 
    < 0.01 group 1 vs 
    untreated 
Serum IGF-II (µg/l) (year 
1) 
745 ± 72 944 ± 101 756 ± 108  
Serum IGF-II (µg/l) 834 ± 53 966 ± 56 881 ± 125 ns 
Serum IGFBP-3 (mg/l) 
(year 1) 
5.37 ± 0.42 6.35 ± 0.44 3.88 ± 0.48  
Serum IGFBP-3 (mg/l) 6.10 ± 0.35 6.50 ± 0.52 4.00 ± 0.58 ns for group 1 vs 2; 
< 0.001 untreated 
    vs group 1 
Serum osteocalcin (µg/l) 
(year 1) 
89.4 ± 5.9 93.6 ± 9.9 59.9 ± 1.9  
Serum osteocalcin (µg/l) 100.0 ± 8.6 102.7 ± 9.8 72.5 ± 7.3 < 0.05 untreated vs 
group 1, ns group 1 
    vs group 2 
Comments 
Results are mean ± SEM. Compliance: Over 2 years less than 10 injections were said to be missed in 36/38 children. In 
two children, respectively, 3% and 8% of the injections were reportedly omitted. Children with and without specified 
syndromes appeared to present similar growth responses. The GV during the first year was higher than during the 
second year, both in group 1 (11.5 ± 0.4 vs 8.8 ± 0.2 cm/year) and group 2 (12.0 ± 0.4 vs 10.0 ± 0.3 cm/year). After 2 years all 
untreated children still had a HtSDS < –2.2, whereas this was no longer the case for 35/38 treated children. BMI and BMI 
SDS remained similar in the three groups after 1 and 2 years. BMI of the study population is reported, not separately for 
the groups, or treated vs untreated. Fasting serum insulin concentrations were twice as high (p = 0.01) in treated children 
compared with untreated children both after 1 year (20.3 ± 2.2 mU/l vs 10.6 ± 2.4 mU/l) and 2 years (18.9 ± 3.0 mU/l vs 
9.4 ± 1.3 mU/l) with no difference between the treated groups. 
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Adverse effects 
Four SAEs, which authors state conceivably not related to GH. One treated child received antibiotics for possible 
osteomyelitis of the distal tibia. Three children hospitalised in relation to viral diseases: one untreated and two treated. 
Treatment was not interrupted. Cutaneous eczema was aggravated in one child in group 1, no treatment interruption. 
Three treated children reported a possible increase in size or number of pigmented naevi, treatment was not interrupted. 
After 2 years, all HbA values were normal. 
Methodological comments 
Allocation to treatment groups: Stated to be weighted randomisation, no further details. 
Blinding: Open label. Assessor for BA blinded to chronological age and treatment randomisation. 
Comparability of treatment groups: No significant differences at baseline. 
Method of data analysis: Wilcoxon rank-sum test used for differences between groups for growth variables, and Student’s 
t-test for biochemical markers. Statistically significant differences were considered to be obtained at p < 0.05. Results are 
mean ± SEM. Not ITT. Paper does not mention if there were any adjustments for multiple comparisons. 
Sample size/power calculation: None reported. 
Attrition/dropout: Two children allocated to 0.3 IU/kg did not start. Two children dropped out of the study for psychosocial 
reasons, one control after the start visit and one child from group 1 after 19 months. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Partial 
6. Was the care provider blinded? Unknown 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Adequate 
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Reference and 
design Intervention Participants 
 
Outcome measures 
Phillip et al. 1. rhGH 0.033 mg/kg/day Target population: 3- to 8-year-olds Primary outcomes: measurement of 
2009114 2. rhGH 0.1 mg/kg/day with persistent short stature, born height during 2 years. Treatment 
multinational  Number of participants: total n = 15 compared with untreated children 
Study design: 2 years, but data only 1. n = 51 
Secondary outcomes: HtSDS, IGF-1, 
Number control group received 3. n = 47 
Method of assessing outcomes: 
multicentre Other interventions used: 
Sample attrition/dropout: n = 2 adjusted target height calculated 
Nordisk  entry: birth weight/length ≤ –2 SDS; 
assessed using radiograph; HtSDS 
during last 3 months; parental height population references by country 
≥ –2 SDS; normal response to GH Length of follow-up: 1 year 
test 
Characteristics of participants 
rhGH 0.033 mg/kg/ rhGH 0.1 mg/kg/day No treatment 
Mean ± SD day (n = 51) (n = 51) (n = 47) p-value 
Sex (m/f) (%) 55/45 47/53 51/49 nr 
Birth length (cm) 44.3 ± 5.3 44.6 ± 4.3 43.9 ± 5.0 nr 
Birth weight (kg) 1.9 ± 0.6 2.0 ± 0.6 2.0 ± 0.6 nr 
Gestational age (weeks) 36.9 ± 3.6 37.6 ± 3.3 37.5 ± 3.2 nr 
Target HtSDS –0.9 ± 0.6 –0.8 ± 0.6 –0.9 ± 0.8 nr 
Height (cm) 99.0 ± 9.3 98.9 ± 9.0 99.2 ± 7.9 nr 
HtSDS –3.1 ± 0.5 –3.2 ± 0.7 –3.1 ± 0.5 nr 
Age (years) 5.5 ± 1.5 5.5 ± 1.4 5.6 ± 1.4 nr 
BA (years) 4.7 ± 1.8 4.9 ± 1.8 5.0 ± 1.9 nr 
BA–CA 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 nr 
IGF-1 (ng/ml) 116.7 ± 59.4 145.9 ± 92.3 130.0 ± 84.1 nr 
IGFBP-3 (µg/l) 3.2 ± 0.9 3.5 ± 0.9 3.4 ± 1.1 nr 
IGF-1 SDS –1.4 ± 0.6 –1.1 ± 0.9 –1.2 ± 1.0 nr 
Fasting glucose (mmol/l) 4.6 ± 0.6 4.7 ± 0.6 4.6 ± 0.4 nr 
Fasting insulin (µIU/ml) 3.1 ± 2.8 2.7 ± 1.9 2.8 ± 3.3 nr 
HbA  (%) 5.2 ± 0.4 5.2 ± 0.3 5.1 ± 0.4 nr 
Results at year 1 (mean ± SD)    
rhGH 0.033 mg/kg/ rhGH 0.1 mg/kg/day No treatment  
day (n = 51) (n = 51) (n = 45) p-value 
HtSDS –2.3 ± 0.6 –1.8 ± 0.8 –3.0 ± 0.6 nr 
Change in HtSDS 0.8 ± 0.3 1.4 ± 0.4 0.1 ± 0.3 nr 
Additional height gain 3.3 ± 0.2 (95% CI 2.9 6.5 ± 0.2 (95% CI 6.0 n/a nr 
(cm) to 3.7) to 6.9)  
IGF-1 (ng/ml) 345.6 ± 177 594.3 ± 221 176.3 ± 107 nr 
IGFBP-3 (µg/l) 4.8 ± 1.1 6.1 ± 1.4 3.9 ± 1.1 nr 
IGF-1 SDS 0.9 ± 1.9 3.3 ± 2.1 –0.9 ± 1.2 nr 
Fasting glucose (mmol/l) 4.8 ± 0.5 5.0 ± 0.5 4.8 ± 0.6 nr 
Fasting insulin (µ IU/ml) 5.3 ± 3.5 8.9 ± 5.0 4.1 ± 6.3 nr 
HbA  (%) 5.3 ± 0.4 5.3 ± 0.2 5.2 ± 0.4 nr 
 
 
 
 
 
 
Data extraction form for primary studies 
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Adverse events 
Only reported for overall 2-year study, so treatment arms are different (no control arm). The majority (349/358, 73.5%) 
of AEs were mild to moderate in severity, and the most common events (57%) were childhood infections. 16 SAEs were 
reported, three of which were likely to be related to rhGH (convulsions, epilepsy, papilloedema – all stabilised/resolved 
after rhGH discontinued). 
Methodological comments 
Allocation to treatment groups: Randomised 1 : 1 to double-blind treatment in the two rhGH groups or to a control group 
that was untreated in the first year and received rhGH in the second. A computer-controlled, centralised system was used 
to assign treatment. 
Blinding: BA assessed centrally by clinicians blinded to subject’s characteristics (other than gender) and treatment. 
Comparability of treatment groups: Similar at baseline, but no p-values reported. 
Method of data analysis: Mixed-effects model (ANCOVA) used where effects of age, sex and treatment duration were 
included. Tests were two-sided F-tests, performed at the 5% significance level. 
Sample size/power calculation: At least 50 patients per group were required to detect a difference in height gain of 0.75 cm 
between the two rhGH groups with a power of 90% and a significance level of 0.05. To allow for comparison with the third 
group, and allowing for a dropout rate of 20%, 180 patients were required to be enrolled. 
Attrition/dropout: Two randomised patients missing from analysis. Reasons not given. 
 
 
Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Adequate 
2. Was the treatment allocation concealed? Unclear 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Partial 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
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SHOX deficiency data extraction forms 
 
Reference and 
design Intervention Participants Outcome measures 
Blum et al. 1. Daily s.c.i. of 50 µg GH   Target population: prepubertal children Primary outcomes: First year GV 
200749 2. No treatment with SHOX-D Secondary outcomes: comparison 
Countries: 3. Daily s.c.i. of 50 µg Number of participants: total 68 patients between treatment effects in 
international GH had SHOX gene deletions or mutations, SHOX-D and patients with TS 
(14) of which 52 with SHOX-D enrolled. (not data extracted as not per Duration of treatment: 2 
Study design: years 
A further 26 (group 3) with TS were protocol); AEs 
RCT  enrolled as an additional GH arm Method of assessing outcomes: 
Other interventions used: 
Number of 1. n = 27 height, IGF-1 and IGFBP-3 
centres: 33 2. n = 25 measured at baseline, 3 months, 
6 months, then at 6-month 
Funding: Eli Lilly 3. n = 26 (not data extracted as not per intervals for remainder of the & Co. protocol) 2 years; left hand and wrist 
Sample attrition/dropout: one radiographs for BA performed 
Inclusion criteria for study entry: confirmed at baseline, 1 year and 2 year – 
SHOX-D; age ≥ 3 years; prepubertal assessed centrally using Greulich 
(Tanner stage 1); height < 3rd percentile and Pyle method; glucose 
or < 10th percentile with HV < 25th and routine blood analysis at 
percentile; BA < 10 years (boys) or baseline and first year. HtSDS 
< 8 years (girls); < 9 years (TS girls); calculated using a central 
no GH deficiency or resistance; no European reference 
chronic disease; no growth-influencing Length of follow-up: 2 years 
medications 
 
Characteristics of participants (mean ± SD, unless otherwise stated) 
SHOX-D 
p-value, 
Group 1: 50 µg GH Group 2: no treatment group 1 vs 
Characteristic (n = 27) (n = 25) group 2 
Complete deletion of SHOX gene (n) 18 16 
Partial gene deletions (n) 2 2 
Point mutations (n) 7 7 
Female/male (%) 52/48 56/44 
LWS/ISS phenotype (%) 56/40 44/56 0.689 
Chronological age (years) 7.5 ± 2.7 7.3 ± 2.1 0.914 
BA (years) 6.6 ± 2.8 6.5 ± 2.0 0.928 
BA–CA –1.0 ± 0.9 –0.8 ± 0.8 0.809 
BA SDS –1.2 ± 1.1 –1.0 ± 1.0 0.641 
HtSDS –3.3 ± 1.0 –3.3 ± 0.8 0.111 
Target HtSDS –1.3 ± 1.0 –1.5 ± 0.9 0.013 
BMI SDS 0.2 ± 0.9 0.6 ± 0.9 0.147 
IGF-1 SDS –0.8 ± 1.0 –0.9 ± 1.0 0.521 
IGFBP-3 SDS 0.6 ± 1.3 0.1 ± 1.1 0.058 
ISS, idiopathic short stature; LWS, Léri–Weill syndrome. 
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Results (mean ± SD, unless otherwise stated) 
SHOX-D p-value 
group 1 vs 
Outcome Group 1: 50 µg GH Group 2: no treatment group 2 
Baseline HV (cm/year) 
Baseline HV SDS 
Baseline HtSDS 
1st-year HV (cm/year) 
1st-year HV SDS 
1st-year HtSDS 
2nd-year HV (cm/year) 2nd-
year HV SDS 
2nd-year HtSDS 
2nd-year height gain (cm) 
Catch-up of BA 
AEs 
4.8 ± 0.3 (n = 18) 5.0 ± 0.5 (n = 14) 0.721 
–1.2 ± 0.3 (n = 12) –1.0 ± 0.6 (n = 10) 0.605 
–3.3 ± 0.2 (n = 27) –3.2 ± 0.2 (n = 24) 0.822 
8.7 ± 0.3 (n = 27) 5.2 ± 0.2 (n = 24) < 0.001 
3.0 ± 0.3 (n = 25) –0.7 ± 0.2 (n = 22) < 0.001 
–2.6 ± 0.2 (n = 27) –3.1 ± 0.2 (n = 24) < 0.001 
7.3 ± 0.2 (n = 27) 5.4 ± 0.2 (n = 24) < 0.001 
2.3 ± 0.3 (n = 27) –0.4 ± 0.1 (n = 22) < 0.001 
–2.1 ± 0.2 (n = 27) –3.0 ± 0.2 (n = 24) < 0.001 
16.4 ± 0.4 (n = 27) 10.5 ± 0.4 (n = 24) < 0.001 
1.34 ± 0.07 1.1 ± 0.09 0.161 
 
 
 
SHOX-D 
p-value 
Group 1: 50 µg GH Group 2: no treatment group 1 vs 
(n = 27) (n = 25) group 2 
At least 1 treatment-emergent AE 85 68 
(mostly common childhood illnesses) 
(%) 
Arthralgia 3 2 
Gynecomastia (males) 1 (n = 12 males) 0 (n = 12 males) 
Increased number of cutaneous naevi 2 0 
Recurrent otitis media 1 1 
Scoliosis 1 0 
Diabetes 0 0 
Comments 
Overall, 41% of GH-treated patients with SHOX-D reached a height within the normal range for age and gender (> –2.0 
SDS), compared with only one patient in the control group. For the GH-treated patients with SHOX-D, 1st year GV was 
somewhat greater for males (9.3 ± 0.5 cm/year) than for females (8.4 ± 0.5 cm/year), the baseline to second-year change 
in GV was very similar. Subgroup analysis for ISS phenotype vs LWS phenotype presented but not data extracted as not 
per protocol. IGF-1 SDS were in the low-normal range in each of the study groups at baseline and remained there for the 
untreated group. In the GH-treated group, values increased to the upper-normal range. IGF-1 concentrations exceeded 
two SDS at least once during GH treatment in 10 (37%) of patients and no untreated patients. IGFBP-3 SDS at baseline 
were closer to the normal mean than the corresponding IGF-1 SDS in both study groups and increased to the upper- 
normal range in the treated group. There was a strong relationship between IGF-1 SDS and IGFBP-3 SDS values during 
GH treatment, such that no subject had an IGF-1 SDS in the upper tertile with an IGFBP-3 SDS in the lower tertile. No 
significant changes in thyroid function. No SAEs were reported for subjects with SHOX-D. 
Methodological comments 
Allocation to treatment groups: After stratification by sex and according to presence or absence of LWS, patients were 
randomised on a 1 : 1 basis. No further details given. 
Blinding: Blood analyses were carried out in a central facility. Open label. 
Comparability of treatment groups: Similar at baseline, although target HtSDS is statistically significantly lower in the rhGH 
group. 
Method of data analysis: HtSDS calculated using a central European reference. 
Sample size/power calculation: Not reported. 
Attrition/dropout: One subject who discontinued with no postbaseline height data was excluded from the efficacy analyses; 
all patients were included in the safety analyses. ANOVA used for between-group differences. 
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Quality criteria for assessment of experimental studies 
 
1. Was the assignment to the treatment groups really random? Unknown 
2. Was the treatment allocation concealed? Unknown 
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Adequate 
5. Were outcome assessors blinded to the treatment allocation? Partial 
6. Was the care provider blinded? Inadequate 
7. Was the patient blinded? Inadequate 
8. Were the point estimates and measure of variability presented for the primary 
outcome measure? 
Adequate 
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
181 
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved. 
 
  
 
Health Technology Assessment 2010; Vol. 14: No. 42 DOI: 10.3310/hta14420 
 
 
 
 
 
 
 
Appendix 5 
List of excluded studies 
 
 
Excluded due to wrong patient 
group (n = 40) 
Arends NJ, Boonstra VH, Mulder PG, Odink RJ, 
Stokvis-Brantsma WH, Rongen-Westerlaken C, et al. GH 
treatment and its effect on bone mineral density, bone 
maturation and growth in short children born small 
for gestational age: 3-year results of a randomised, 
controlled GH trial. Clin Endocrinol 2003;59:779–87. 
 
Arends NJ, Boonstra VH, Hokken-Koelega AC. Head 
circumference and body proportions before and 
during growth hormone treatment in short children 
who were born small for gestational age. Pediatrics 
2004;114:683–90. 
 
Argente J, Gracia R, Ibanez L, Oliver A, Borrajo E, 
Vela A, et al. Improvement in growth after two years of 
growth hormone therapy in very young children born 
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catch-up growth: results of a multicenter, controlled, 
randomized, open clinical trial. J Clin Endocrinol Metab 
2007;92:3095–101. 
 
Arwert LI, Deijen JB, Witlox J, Drent ML. The influence 
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deficient patients: a meta-analysis. Growth Horm IGF Res 
2005;15:47–54. 
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complete somatic development in childhood- 
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Attanasio AF, Shavrikova EP, Blum WF, Shalet SM. 
Quality of life in childhood onset growth hormone- 
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children with short stature born small for gestational 
age before and during a randomized GH trial. Horm Res 
2006;65:23–30. 
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Neyzi O. Growth hormone treatment in short children 
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growth hormone (GH) receptor polymorphism does 
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per day) or the spontaneous growth in short non-GH- 
deficient small-for-gestational-age children: results from 
a two-year controlled prospective study in 170 Spanish 
patients. J Clin Endocrinol Metab 2006;91:3281–6. 
 
Carroll PV, Littlewood R, Weissberger AJ, Bogalho P, 
McGauley G, Sonksen PH, et al. The effects of two doses 
of replacement growth hormone on the biochemical, 
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growth hormone-deficient adults. Eur J Endocrinol 
1997;137:146–53. 
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Sagnard L, et al. Dose-dependent catch-up growth after 
2 years of growth hormone treatment in intrauterine 
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Appendix 6 
List of eligible abstracts 
 
 
he following conference abstracts were 
identified in searches and were of relevance 
to the review, but did not contain sufficient 
information to be included. 
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Appendix 7 
List of ongoing studies 
 
 
Searches identified two relevant 
RCTs, which are ongoing 
Study NCT00190658 aims to compare the mean 
first-year GV of somatropin-treated prepubertal 
patients with SHOX-D with the GV of a control 
group of untreated prepubertal patients with 
SHOX-D. Both groups will be compared to a 
somatropin-treated group of girls with TS. 
 
• Sponsor: Eli Lilly & Co. 
• Estimated end date: December 2010. 
Study NCT00625872 focuses on the effect of a 
1-year somatropin treatment (0.035 mg/kg/day 
or 0.067 mg/kg/day) on neuromuscular function 
and cognitive performance in short children 
born SGA. Height gain and GV are included as 
secondary outcome measures. Inclusion criteria are 
birth length- and/or birth weight-SDS adjusted to 
gestational age < –2.0, current HtSDS < –2.5 and 
parental adjusted HtSDS below –1, GV SDS < 0 
during the last year before inclusion. 
 
• Sponsor: Pfizer. 
• End date: not reported. 
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Appendix 8 
Critique of industry submissions 
(clinical effectiveness) 
 
 
ix of the seven manufacturers submitted reports 
to NICE, and these are briefly appraised below. 
Please see Chapter 4 (Review of the manufacturers’ 
submissions) for a discussion of the economic 
models and results included in the MSs. 
 
SHTAC review of clinical 
effectiveness in Eli Lilly’s 
submission 
Comprehensiveness of ascertainment of 
published studies 
• The MS uses the Novo Nordisk systematic 
review, which did not include SHOX. The 
MS states (p. 13) that the evidence for SHOX 
came from Lilly’s databases, i.e. there was 
no systematic review for this. The conditions 
listed as inclusion criteria for SGA include 
IUGR, which was not in the NICE scope. 
The comparator was clearly stated to be ‘no 
treatment’. However, the inclusion criteria also 
state that active-controlled RCTs were included. 
This is then contradicted by the exclusion 
criteria, which state that studies comparing 
somatropin with other treatments known or 
presumed to affect growth would be excluded. 
• The MS clearly reports search dates, search 
strategies and databases searched. 
• Enough detail was provided for the searches to 
be reproducible. 
• The MS does not present information on 
searches for ongoing studies. 
• Conference proceedings were excluded from 
the review. 
• The MS includes a separate search for QoL 
data in adolescents and adults. 
by SHTAC as mean age = 23.8), Drake 2003, 
Shalet 2003 and Mauras 2005 (all excluded  
by SHTAC as patients had completed linear 
growth). The manufacturer included six other 
studies that were either dosing studies or 
compared two different versions of somatropin. 
• TS  Nine RCTs (three placebo controlled: 
Gravholt 2002, 2005; Quigley 2002; all 
included by SHTAC) and six other studies 
[Bannick 2006, van Pareren 2003, Sas 2001 
(all excluded by SHTAC as dose studies), 
Davenport 2007, Johnston 2001, CGHAC 2005 
(all included by SHTAC)]. 
• CRI  Four CTs: de Graaf 2003 (SHTAC 
excluded as this is analysis of body proportions 
in an RCT that we have already included for 
height and body composition outcomes – 
Hokken Koelega 1991), Hertel 2002 (SHTAC 
excluded as compares two doses, no placebo 
arm), Sanchez 2002 (included by SHTAC), Fine 
2002 (SHTAC excluded as includes pubertal 
children, with no separate data analysis). 
• SGA Twenty RCTs identified, of which six 
had placebo or no treatment as control arm 
[Boguszweski 1998, Butenadt 1997, Arends 
2003 2004, Boonstra 2006 (SHTAC excluded 
these as patient group did not meet our 
criteria), van Pareren 2003 (SHTAC excluded 
as this is a follow-up of a dose–response study)]. 
• PWS not relevant for this drug. 
• SHOX not included in systematic review. 
Reported data comes from the GDFN study 
(n = 78), Blum et al. 2007 (SHTAC included 
this). 
• None of the additional studies met SHTAC’s 
inclusion criteria. 
 
Searches identified Clinical analysis  
The MS contains a summary of the included trials, • The MS also reports observational studies, in  
but there is no tabulation of details such as study particular data from the KIGS database.  
type, treatment arms, etc. The review included the • Given that the manufacturer included a range  
following RCTs: of studies that did not meet SHTAC’s inclusion  
 criteria, it is not possible to compare their  
• GHD Five placebo/no treatment-controlled conclusions with those of SHTAC.  
RCTs (mostly during transition phase): • The MS did not include a meta-analysis or  
Jorgensen 2002 (excluded by SHTAC as indirect comparison.  
mean age = 20), Underwood 2003 (excluded   
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• The MS includes a short narrative summary 
of the included trials for each disease, but 
there is no overall tabulation of the included 
studies’ characteristics or results and no quality 
assessment of the trials. 
• The MS uses the same outcome measures as 
the SHTAC review. 
• The MS reports more detail on AEs from 
observational studies in addition to the limited 
information available in the RCTs. 
 
Interpretation 
• The MS does not present any tabulated data 
from the studies included in the systematic 
review; there is simply a short narrative 
summary of each disease. It is therefore 
not possible to assess whether or not the 
manufacturer’s analysis is supported by data in 
the included trials. 
 
Key issues 
• The manufacturer’s systematic review included 
a broad range of studies, for example dosage 
studies, which did not meet their own inclusion 
criteria. 
• Very little detail is presented for the 
included studies (e.g. patient characteristics, 
treatment arms, length of study) and there 
is no tabulation of data. The manufacturer’s 
conclusions seem to be based on both trials 
that met their inclusion criteria and those that 
clearly did not (e.g. dosage studies). 
 
SHTAC review of clinical 
effectiveness in Novo Nordisk’s 
submission 
Comprehensiveness of ascertainment of 
published studies 
• Databases searched and the dates of searches 
are specified. Searches were conducted from 
the date of the original NICE appraisal – w/c 
28 August 2008, and from 1996 to w/c 28 
August 2008 for SGA (not included in the last 
review). 
• Search strategies are supplied in the 
appendices. 
• Search strategies are detailed and appear 
reproducible. 
• Novo Nordisk does not appear to have 
searched for other ongoing studies, but do 
report on two ongoing studies, specifically of 
Norditropin – NESGAS and NordiNet IOS. 
• Conference proceedings were not searched for 
and are listed in the exclusion criteria. 
Clinical analysis 
• Novo Nordisk did not include PWS or SHOX. 
Uncontrolled trials were included. For long- 
term effects of rhGH treatment, i.e. FH/AH/ 
near adult height, open-label extension studies 
were ‘deemed to be appropriate as the length 
of the RCTs was likely to be too short to capture 
the long term treatment effect’. Dose–response 
trials have been included. In the case of SGA, 
these form the majority of the submission. 
• SGA Novo Nordisk have included 21 studies. 
None of these was included in SHTAC’s 
MTA. Exclusions in the SHTAC MTA were 
on the basis of patient group not meeting the 
inclusion criteria or on design, as 14 of the 21 
were dose–response studies. The five studies 
included in our MTA were not included in the 
Novo Nordisk submission. Novo Nordisk also 
included open-label extension studies. 
• GHD Novo Nordisk have included 13 studies. 
One of these is the GHD study included in 
SHTAC’s MTA. Eight are transition-phase 
studies – these are not included in SHTAC’s 
systematic review. Four are dose–response 
studies and therefore are excluded from the 
MTA. Two are biosimilars compared with their 
reference product. 
• TS  Novo Nordisk discuss the Turner Cochrane 
Review. A total of 23 studies were included, 
including the six included in SHTAC’s MTA. 
The remaining studies were dose response, 
with the exception of one, which compared 
once-daily versus twice-daily injections. 
• CRI Novo Nordisk have included nine studies, 
five of which were included in SHTAC’s MTA. 
Of the four excluded from the MTA, two were 
dose–response studies, one was excluded on 
patient group. 
• Nothing in the excluded reasons indicates 
why all of SHTAC’s included SGA papers are 
excluded. 
 
Conclusions 
• SGA  It is not possible to compare the 
conclusions as the studies included in the two 
reviews are so different. 
• GHD Again the conclusions are difficult to 
compare as Novo Nordisk include transition 
phase studies, which SHTAC excluded from 
the main systematic review as patients had 
completed linear growth; dose–response 
studies; and studies comparing biosimilars 
to their reference drug. Novo Nordisk’s 
conclusions tend to be based on dose–response 
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studies, and how far an outcome/result is dose 
dependent. 
• TS Novo Nordisk concludes that height is 
improved in a ‘dose-dependent’ manner: The 
SHTAC MTA does not include dose–response 
studies or consider dose issues. SHTAC has 
concluded that there is evidence of improved 
body composition and height outcomes in girls 
with TS; this needs to be weighed against issues 
of quality of reporting and size of trials. 
• CRI Height conclusions are dose related, 
and body composition ‘does not appear to be 
negatively influenced by rhGH therapy’. 
• Outcome measures are broadly similar. 
• Additional AE rates from KIGS and NCGS 
databases are included in an appendix. 
 
Interpretation 
• SGA Conclusions do not appear to fully reflect 
Novo Nordisk’s analyses, although the analysis 
contains few results and is a broad summary 
in itself. Very few of the points discussed in 
the analyses compare treated and untreated 
groups, predominantly focusing on dose– 
response or differences in the treated group 
from baseline. 
• TS Apart from height outcomes, few results 
are reported and, again, the focus is often on 
dose-related effects. The summary somewhat 
overstates the evidence presented. 
• CRI Conclusions do appear to match analyses, 
although again few detailed results are 
presented. Novo Nordisk does not comment 
on the quantity/quality of research available to 
support their conclusions. 
• GHD Novo Nordisk considered transition- 
phase studies alongside non-transition phase 
studies for height and other outcomes, but 
separately for biochemical/body composition 
markers. The authors then summarise that 
the transition phase studies may lead to an 
underestimation of growth in children with 
GHD. Other conclusions appear to match the 
analyses. 
• Quality is discussed to a degree in the results 
sections – it is mentioned, for example, if trials 
are short, or low in patient numbers. However, 
this, or its possible effects on conclusions/ 
findings, is not referred to in the summary. 
 
Key issues 
• The submission does not include the SGA 
papers included in SHTAC’s review, but does 
include studies whose patients do not meet 
the birth length/WtSDS criteria and/or current 
HtSDS criteria included. 
• Dose–response studies are included for all 
conditions. 
 
SHTAC review of clinical 
effectiveness in Pfizer’s 
submission 
Comprehensiveness of ascertainment of 
published studies 
• The manufacturer supplied full details of 
the systematic review, specifying dates and 
databases searched. 
• Search strategies were supplied. 
• Enough detail was provided for the searches to 
be reproducible. 
• Inclusion criteria differed from that used by 
SHTAC in that cohort, observational, and 
retrospective studies were included. The 
manufacturer’s inclusion criteria defined 
children as being < 16 years old, whereas 
SHTAC included those up to 18 since they 
may still be growing and thus able to benefit 
from rhGH treatment. The manufacturer did 
not specify what the comparator should be 
(NICE’s final scope indicates that this should 
be treatment without somatropin). 
• The manufacturer restricted the review to 
only those studies which used Genotropin, 
or were sponsored by Pfizer. They excluded 
studies which used a competitor’s brand of 
somatropin. However, they also report the 
results of the Novo Nordisk full systematic 
review – see SHTAC assessment of the Novo 
Nordisk MS for more details. 
• The MS does not report ongoing studies. 
• The MS does not state whether or not they 
searched for conference proceedings. 
 
Searches identified (studies for 
Genotropin) 
• GHD  Three RCTs and 17 observational 
studies. None of the three RCTs met our 
inclusion criteria. Coelho et al. (2008) 
compared two doses of Genotropin; Romer 
et al. (2007) compared omnitrope with 
Genotropin; Dorr et al. (2003) compared 
Genotropin delivered via two different devices. 
• TS One RCT and eight observational studies: 
the single RCT by Johnston (2001) was also 
included in the SHTAC review. 
• PWS Twelve RCTs (three from previous 
appraisal) and six observational studies. 
One of these (Festen 2007) is not included 
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in our review as it is not a fully randomised 
study (children were stratified by age, and  
only the under-12s were randomized – older 
children were all given rhGH, but results were 
not reported separately for the randomised 
patients). Two of the studies included by the 
manufacturer have been combined by SHTAC, 
as they report data from the same RCT [Festen 
et al. 2008 and de Lind van Wijngaarden 2009 
(cited as Roderick et al. 2009 in the MS)]. 
• CRI No new RCTs, three observational studies. 
The submission discusses only the Broyer 
study from the previous review, and not the 
others that SHTAC included as these were not 
observing Genotropin. 
• SGA   Thirteen RCTs, 10 observational studies. 
Of the 13 RCTs, only five reported treatment 
versus no treatment/placebo. SHTAC excluded 
the review by Lagrou (2007) as its outcomes 
did not meet our inclusion criteria. We also 
excluded the reviews by Bundak (2001) and 
Carracosa (2006) as their patient groups did 
not match our criteria. We included the De 
Schepper (2008) study and the de Zegher 
(2002)  studies. 
• None of the manufacturer’s included studies 
reported QoL as an outcome measure. 
• The MS also includes a summary of the Novo 
Nordisk systematic review. Please see SHTAC’s 
appraisal of that submission for further details. 
 
Clinical analysis 
• The manufacturer has only included RCTs 
of its own brand of somatropin, so it is not 
possible to compare their findings directly with 
those of SHTAC. 
• GH and SGA RCTs  The MS and SHTAC 
reviews included different RCTs, so it is not 
possible to compare the evidence reported. 
The RCTs included for GHD were not placebo/ 
no treatment controlled. 
• PWS The MS includes two studies (Roderick et 
al. 2009 and Festen et al. 2008), which appear 
to be the same RCT – SHTAC has treated these 
as one RCT to avoid double-counting. 
• Given that the manufacturer included a range 
of studies that did not meet SHTAC’s inclusion 
criteria, and focused only on studies of their 
own product, it is not possible to compare their 
conclusions directly with those of SHTAC. 
• The MS did not include a meta-analysis or 
indirect comparison. Results are presented  
in tables and there is a narrative synthesis for 
each disease area. 
• The MS uses the same outcome measures as 
the SHTAC review. 
• The MS includes data from the KIGS database, 
which is not included in the SHTAC review of 
clinical effectiveness as it is observational data. 
Additional adverse event data from the KIGS 
database is presented on p. 97 of the MS. 
 
Interpretation 
• The manufacturer’s interpretation of the 
clinical data in the RCTs matches their 
analyses. 
• There are separate sections discussing the 
results of RCTs and of observational studies. 
• Data from observational studies have not been 
checked by SHTAC. 
 
Key issues 
• The manufacturer’s systematic review included 
dose comparison studies for GHD, which 
SHTAC excluded. 
• Many of the studies included for the 
manufacturer’s review of SGA studies were 
excluded by SHTAC, as their patients did not 
meet our inclusion criteria. 
 
SHTAC review of clinical 
effectiveness in Merck Serono’s 
submission 
Comprehensiveness of ascertainment of 
published studies 
• The MS uses the SHTAC review conducted in 
20026 and the systematic review conducted by 
Novo Nordisk for studies published since then 
(see Novo Nordisk critique) for the licensed 
indications for Saizen (GHD, TS, CRI and 
SGA). 
 
Searches identified 
• Studies identified and reported are all those 
from the previous SHTAC report (RCTs and 
non-RCTs reporting FH) plus RCTs published 
since then identified by the Novo Nordisk 
review. 
• GHD No additional RCTs were reported for 
GHD although an additional one is included in 
the SHTAC MTA (Mauras 2005). 
• TS  4 RCTs (Johnston 2001; CGHAC 2005; 
Quigley 2002; Davenport 2007). However, the 
MS did not identify two RCTs included in the 
SHTAC MTA (both Gravholt 2005). 
• CRI  Three RCTs (de Graaf 2003; Fine 2002; 
Sanchez 2002). Two of these (de Graaf and 
Fine) are not included in the SHTAC MTA 
review because they do not meet our inclusion 
criteria. One RCT (Fine 2004) is not included 
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in the MS but meets the SHTAC MTA inclusion 
criteria and is therefore included in that. 
• SGA  Four RCTs (Buttenandt 1997; 
Boguszewski 1998; Arends 2004; Van Pareren 
2003). These do not match the studies 
identified in the SHTAC MTA (from which they 
are excluded on the basis of patient group and 
study design). 
• The MS does not identify any RCTs that meet 
the inclusion criteria of the SHTAC MTA that 
are not already included. 
 
Clinical analysis 
• Evidence reported is broadly similar to the 
SHTAC MTA in that it uses RCTs in the 
original SHTAC report; there are some 
discrepancies on RCTs since that time and on 
the extra indication SGA. 
• Narrative synthesis is somewhat selective. All 
included studies are tabulated, but only height 
results are reported. 
• Manufacturer’s submission also includes some 
non-systematic review data on psychological 
outcomes and body composition, and long- 
term data from the KIGS observational 
database. 
• Conclusions are generally similar to the 
SHTAC MTA. 
• GHD  The MS has used the previous SHTAC 
review so conclusions on growth are similar but 
no data on LBM/biochemical markers. 
• TS Conclusions are broadly similar to the 
SHTAC MTA in terms of growth and LBM. 
• CRI Conclusions broadly similar to the SHTAC 
MTA in terms of growth; no statement on other 
outcomes. 
• SGA Conclusions broadly similar to the 
SHTAC MTA in terms of growth; no statement 
on other outcomes. 
• Growth outcomes measures are same as the 
SHTAC MTA. 
 
Interpretation 
• Overall MS interpretation of the clinical data 
matches the MS analyses, although the MS 
relies heavily on the previous SHTAC report. 
The new evidence is not really synthesised 
except for SGA, which includes studies that are 
not in the SHTAC MTA. Conclusions are based 
on selective statements and focus on height 
outcomes. 
• Manufacturer’s submission states that new data 
has ‘not materially changed the understanding 
of the efficacy of GH in children’. 
Questions 
• The major areas of discrepancy compared with 
the SHTAC MTA relate to studies omitted from 
the MS (GHD 1, TS 2, CRI 1 and SGA 5). 
 
SHTAC review of clinical 
effectiveness in Ipsen Ltd’s 
submission 
Comprehensiveness of ascertainment of 
published studies 
• The databases and dates searched are specified. 
• Search strategies were supplied and appear 
comprehensive enough to be reproducible. 
• Ongoing studies were not searched for or 
reported in this submission. 
• Conference proceedings were excluded. 
• This review includes CRI, GHD and TS, 
and ‘somatropin’ as intervention, including 
products from other manufacturers, and 
published and available in full studies in the 
English language. Exclusion criteria given but 
reasons for individual studies’ exclusions not 
stated. 
• Assessment of article quality looks at 
allocation concealment, patient blinding, 
investigator blinding, baseline differences of 
the experimental groups and ‘completeness  
of follow-up’. The MS did not appear to assess 
if there was an ITT analysis, or care-provider 
blinding. 
 
Clinical analysis 
• For the results of the systematic review, we are 
referred to the submission prepared by Novo 
Nordisk. Studies are not referenced in the text. 
No conclusions in this submission, apart from 
on the limitations of RCTs for FH data, and 
the subsequent need to rely on observational 
studies (i.e. KIGS database) for this. The 
number of studies for each condition reporting 
certain outcomes is given, but the results are in 
the Novo Nordisk submission and not detailed 
in the Ipsen submission. 
• Manufacturer has included 11 GHD studies; 
most appear to be transition-phase studies. 
• MS states that nine TS studies were found. 
• MS states that four CRI studies were found. 
• Limited new data on FH from RCTs, so appear 
to have included observational studies for this 
outcome. However, no references are given in 
the text so cannot check. 
• The MS states that ‘there are limited data 
available on the effect of GH on height in 
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RCTs [therefore] use of observational data from 
… KIGS was appropriate.’ This appears to 
have been used to inform the economic model. 
• A ‘rapid appraisal of the literature’ was 
undertaken by Eli Lilly for QoL ‘impact of 
short stature in adults’ due to lack of data on 
children and QoL. 
• No conclusions stated here: referred to Novo 
Nordisk submission. 
• There are no indirect comparisons included 
here. 
• No outcome results are reported here, but 
those outcomes reported in the included 
studies reflect those in the SHTAC review. 
• GHD  Four out of eight studies reporting AE 
‘found that a higher dose was associated with  
a greater incidence of AEs and/or serious AEs’. 
The remaining studies reported no differences 
between groups. Only one study in the SHTAC 
review reported AEs, with a slightly higher 
percentage in the GH group experiencing 
these. Only one event in each group was 
thought to be study drug related: oedema in 
GH and sluggishness in placebo. MS reports 
AEs that are thought to be related to study 
drug. 
• CRI  Three studies in the MS report AEs: 
one study reported a higher number of SAEs 
related to GH therapy compared with no 
treatment; another study reported SAEs that 
were ‘therapy-related’. SAEs related to therapy 
reported here include diabetes mellitus, 
hypertension and injection pain. This is not 
reflected in the studies included in SHTAC 
review. Difficulty with comparisons as there are 
no references in the text. 
• TS A greater incidence of AE in the GH 
group was reported in two out of four studies 
reporting AEs in the SHTAC review. In the MS, 
one study showed GH to be associated with 
‘greater incidence of treatment emergent AEs’. 
No major differences between the groups were 
found in the other studies in the MS. 
• No references are given for these studies and 
AEs, and no proportions/means are reported – 
just these general results. 
 
Interpretation 
• No interpretation included here – referred to 
the Novo Nordisk submission. 
 
Key issues 
• Inclusion of observational data to inform FH 
differs from SHTAC review. 
• Studies not referenced here – cannot cross- 
check with SHTAC review. See Novo Nordisk 
submission for further details. 
 
SHTAC review of clinical 
effectiveness in Sandoz’s 
submission 
Comprehensiveness of ascertainment of 
published studies 
• The submission did not include a systematic 
review, so there were no details of search 
strategies, databases or dates searched. 
 
Searches identified 
• The MS includes details of two phase III 
studies: AQ-study and LYO-study. Neither 
meets SHTAC’s inclusion criteria; AQ-study 
compares different doses of omnitrope with 
a reference product and LYO-study is a non- 
comparative trial. 
 
Clinical analysis 
• The evidence reported in the Sandoz 
submission is from trials specific to their 
biosimilar product. The submission does not 
include any trials of rhGH versus no treatment. 
It is therefore not possible to compare their 
submission with the evidence presented in the 
SHTAC systematic review. 
• The submission uses the same outcome 
measures as the SHTAC review. 
• The submission includes a summary of AEs 
from the AQ-study and the LYO-study, neither 
of which was included in the SHTAC review. 
The manufacturer stated that the safety 
profiles of omnitrope and Genotropin were 
comparable. 
 
Interpretation 
• The manufacturer’s interpretation of the 
clinical data matches their analyses. 
 
Key issues 
• The manufacturer presents evidence for 
the use of omnitrope compared with other 
somatropin formulations, but does not present 
any information for its effectiveness compared 
with no treatment. The included studies did 
not meet SHTAC’s inclusion criteria. 
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Appendix 9 
Critical appraisal of manufacturers’ 
economic evaluation 
 
TABLE 61 Critical appraisal checklist of economic evaluation (questions in this checklist based on Drummond and Jefferson, the NICE 
reference case, and the ISPOR checklist) 
 
Item MSa 
1 Is there a well-defined question? Yes 
2 Is the patient group in the study similar to those of interest in UK NHS? Yes 
3 Is the correct comparator used that is routinely used in NHS? Yes 
4 Is the study type and modelling methodology reasonable? Yes 
5 Is an appropriate perspective used for the analysis? Yes 
6 Is the health-care system or setting comparable to UK? Yes 
7 Is the effectiveness of the intervention established based on a systematic review? No 
8 Is the model structure appropriate and does it fit with the clinical theory of the disease Yes 
process?  
9 Are assumptions reasonable and appropriate? Yes 
10 Are health benefits measured in QALYs using a standardised and validated generic instrument Yes 
from a representative sample of the public?  
11 Are the resource costs used reasonable and appropriate for the NHS? Yes 
12 Are the health states and parameters used in the model described clearly and are they ? 
reasonable and appropriate for the NHS?  
13 Is an appropriate discount rate used? Yes 
14 Has the model been validated appropriately? ? 
15 Is sensitivity analysis undertaken and presented clearly? Yes 
a  Yes/no/? (unclear or partially true). 
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Appendix 10 
Critical appraisal of Sandoz 
MS (cost-effectiveness) 
 
 
his appendix describes a critical appraisal of 
the cost-effectiveness section of the Sandoz 
Summary of general concerns 
The MS did not comply with NICE’s recommended 
138 
MS. The submission attempts a cost-minimisation structure and did not estimate QALYs or present 
analysis comparing omnitrope with Genotropin 
(which was defined as the reference product) in 
patients with GHD and TS, rather than a cost- 
effectiveness analysis. There is no indication 
that a systematic review of clinical evidence has 
been undertaken. The cost-effectiveness analysis 
according to NICE guidance138 was not presented. 
 
Appraisal of the manufacturer cost-
effectiveness analysis 
A summary of the MS compared with the NICE 
reference case requirements is given in Table 62. 
cost-effectiveness analysis. The MS attempted a 
cost-minimisation analysis, implicitly suggesting 
that treatment with omnitrope is equally effective as 
treatment with Genotropin (in terms of additional 
height in children with GHD and TS), but is 
associated with less cost to the NHS. Due to the 
number of uncertainties it is not clear whether this 
assertion is justified. In particular, there was limited 
clinical efficacy data to support the non-inferiority 
of omnitrope compared with Genotropin. The only 
head-to-head RCT comparing omnitrope with 
Genotropin was of insufficient duration and might 
not have been designed as a non-inferiority trial. 
 
 
 
 
 
TABLE 62 Assessment of Sandoz submission against NICE reference case requirements 
 
NICE reference case requirements Included in submission 
Decision problem: as per the scope developed by NICE ×a 
Comparator: no treatment alternative ×a 
Perspective on costs: NHS and PSS b 
Perspective on outcomes: all health effects on individuals ×c 
Type of economic evaluation: cost-effectiveness analysis × 
Synthesis of evidence on outcomes: based on a systematic review No evidence synthesis 
Measure of health benefits: QALYs × 
Description of health states for QALY calculations: use of a standardised and validated × 
generic instrument 
Method of preference elicitation for health state values: choice based method (e.g. TTO, × 
SG, not rating scale) 
Source of preference data: representative sample of the public × 
Discount rate: 3.5% p.a. for costs and health effects × 
, yes; ×, no. 
a Scope states that rhGH (somatropin) be compared with no treatment alternative. The cost comparison includes only 
omnitrope and Genotropin. 
b Only costs of pharmaceuticals omnitrope and Genotropin are included in cost comparison. 
c The MS does not include an economic evaluation according to the NICE guidance. Patient outcomes (either observed 
or the final outcomes) are not included in the health economics part of the MS. 
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The MS did not include any clinical evidence in 
relation to licensed indications other than GHD. 
Without clinical evidence that unequivocally 
demonstrated the non-inferiority of omnitrope in 
comparison with Genotropin, the results of a cost- 
minimisation analysis cannot be confirmed. 
 
The results of the cost comparison reported in the 
MS were not comparable with the results of cost- 
effectiveness analysis reported in the submissions 
by Pfizer, Eli Lilly, Ipsen, Novo Nordisk and Merck 
Serono because Sandoz have not presented results 
either as an estimated incremental cost per QALY 
or as an incremental cost per extra centimetre 
gained, and the reported cost was neither a lifetime 
cost nor the cost per duration of treatment (until 
near-adult height is achieved). 
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Appendix 11 
Quality of life from HSE 2003 
 
 
he Health Survey for England database was 
reanalysed in a similar way to Christensen and 
 
 
(estht) and EQ-5D (eqmean). Incomplete records 
were omitted. For those with complete records 
(n = 13,321), the HSE 2003 data had mean AH for 
males of 175 cm (SD 7.2) and mean AH for females 
of 161 cm (6.8). There were 50 observations less 
than –3 SDS or greater than 3 SDS (i.e. 0.4%) and 
617 observations less than –2 SDS or greater than 2 
SDS (4.6%). 
 
An analysis was completed to see the effect of 
different ages on QoL scores using a subset of 
people of age 18–49 years and over 50 years old. 
QoL score for all ages was 0.86; age 18–49 years 
QoL had mean 0.91 (SD = 0.18); and age 50+ 
years QoL had mean 0.8 (SD = 0.26). The QoL 
in the younger category was significantly better 
than for the older category and so it is logical to 
estimate the EQ-5D for each of these age groups. 
 
There were few individuals in the SDS < –3 group 
and the estimates are highly variable. In addition, 
the majority of these individuals are in the older 
age group (mean age 72 years). It is therefore more 
logical to fit the distribution to all data and use this 
in the model. 
TABLE 63 Frequency of individuals at different ages and HtSDS 
in HSE 2003 
 
 
Age 18–49 years Age 50+ years 
 
SDS n Eqmean n Eqmean 
< –3.0 5 0.85 24 0.63 
–3 to < –2.5 6 0.75 62 0.70 
–2.5 to < –2.0 42 0.88 161 0.73 
–2 to < –1.5 140 0.85 397 0.78 
–1.5 to < –1.0 475 0.91 798 0.79 
–1.0 to <–0.5 845 0.90 1133 0.78 
–0.5 to < 0 1331 0.90 1288 0.82 
0 to < 0.5 1485 0.91 1029 0.81 
0.5 to < 1.0 1288 0.91 707 0.83 
1.0 to < 1.5 837 0.91 368 0.84 
1.5 to < 2.0 431 0.91 152 0.85 
2.0 to < 2.5 201 0.92 41 0.84 
2.5 to < 3.0 42 0.89 12 0.83 
> 3.0 20 0.98 1 0.90 
 
TABLE 64 Quality of life from fitted values 
 
Age Fitted QoL score 
18–49 years –0.0024x2 + 0.0177x + 0.9017 
> 50 years –0.0054x2 + 0.0297x + 0.817 
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FIGURE 9 Relationship between height (HtSDS) and EQ-5D score for adults aged 18 –50 years in HSE 2003. 
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FIGURE 10 Relationship between height (HtSDS) and EQ-5D score for adults aged older than 50 years in HSE 2003. 
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Appendix 12 
Input parameters for probabilistic 
sensitivity analysis 
 
 
he distribution assigned to each variable 
included in the PSA and the parameters of the 
distribution are reported in this appendix. 
 
Health-state utility 
The utility increments for HtSDS below –2.0, 
between –2.0 and 0, and above 0 were sampled 
using estimated standard errors. These were 
derived from an assumption that a variation of 
plus or minus 20% was an appropriate CI for the 
average utility gain. No other summary statistic 
was available. These were sampled using a normal 
distribution. 
 
Compliance 
The compliance of the model was based on the 
range of 69% to 95% compliance estimated in the 
compliance review conducted by Merck Serono. 
The estimated ‘standard errors’ for compliance 
was derived from this range, as this was thought to 
provide the best estimate of variability due to lack 
of other summary data. 
 
Height standard deviations 
The reported mean HtSDSs were taken from  
the applicable RCTs and KIGS data for both the 
treated and untreated groups consistent with 
the base-case analysis. The standard errors were 
calculated for each mean HtSDS, except for PWS, 
for which there was no mean reported; in this 
case a median value was assumed to adequately 
represent the mean. A SD of 1 was used to estimate 
the standard error for PWS. This is consistent 
with the level of dispersion reported for the other 
conditions. The HtSDS were simulated using the 
normal distributions. See Table 67 for mean and 
standard errors for each condition: 
 
Starting age and treatment 
length 
The starting age and treatment length were 
sampled using estimated ‘standard errors’. These 
were derived from CIs placed 2 years either side 
of the mean starting age and treatment length. 
This method was used instead of calculating the 
standard errors from the KIGS database. It was felt 
that the very small standard errors from KIGS did 
not reflect the possible variability in starting age 
and treatment length. These were sampled using 
normal distributions. 
 
Childhood drug dose 
The means for the childhood drug dose for all the 
conditions were the same as used in the base-case 
analysis. The estimated ‘standard errors’ attempted 
 
 
TABLE 65 Health-state utility parameters and distribution 
 
95% CI 
Health-state utility Mean ‘Standard error’ Lower Upper Distribution 
Below –2 HtSDS 0.061 0.0061 0.049 0.730 Normal 
Between –2 and 0 HtSDS 0.010 0.0010 0.008  0.120 
Above 0 HtSDS 0.002 0.0002 0.0016  0.0024 
TABLE 66 Compliance parameters and distribution 
Mean ‘Standard error’ Alpha Beta Distribution 
Compliance 0.85 0.085 14.150 2.497 Beta 
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TABLE 67 HtSDS parameters and distribution 
 
Condition HtSDS Mean Standard error Distribution 
GHD Treated baseline –2.99 0.0134 Normal 
 Treated end –1.17 0.0216  
 Untreated baseline –2.99 0.0134  
 Untreated end –2.99 0.0216  
TS Treated baseline –3.40 0.1152  
 Treated end –1.80 0.0206  
 Untreated baseline –3.40 0.1220  
 Untreated end –3.10 0.2294  
PWS Treated baseline –2.00 0.2000  
 Treated end –0.50 0.2085  
 Untreated baseline –2.50 0.2132  
 Untreated end –2.60 0.2182  
CRI Treated baseline –2.90 0.1214  
 Treated end –1.60 0.1925  
 Untreated baseline –2.90 0.0994  
 Untreated end –2.90 0.1525  
SGA Treated baseline –3.10 0.0700  
 Treated end –2.30 0.0840  
 Untreated baseline –3.10 0.0729  
 Untreated end –3.00 0.0894  
SHOX-D Treated baseline –3.30 0.1925  
 Treated end –2.10 0.0385  
 Untreated baseline –3.30 0.1600  
 Untreated end –3.00 0.0408  
 
TABLE 68 Starting age and treatment length parameters and distribution 
 
 95% CI  
 Mean ‘Standard error’ Lower Upper Distribution 
Starting age 
GHD 
 
 
9.0 
 
 
1.020 
 
 
7.0 
 
 
11.0 
 
 
Normal 
TS 10.0 1.020 8.0 12.0  
PWS 7.0 1.020 5.0 9.0  
CRI 9.0 1.020 7.0 11.0  
SGA 8.0 1.020 6.0 10.0  
SHOX-D 8.0 1.020 6.0 10.0  
Treatment length 
GHD 
 
 
7.0 
 
 
1.0200 
 
 
5.0 
 
 
9.0 
 
 
Normal 
TS 6.0 1.0200 4.0 8.0  
PWS 8.0 1.0200 6.0 10.0  
CRI 5.0 1.0200 3.0 7.0  
SGA 6.0 1.0200 4.0 8.0  
SHOX-D 7.0 1.0200 5.0 9.0  
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Item Mean ‘Standard error’ Alpha Beta Distribution 
Outpatient (first) 206.28 24.57 126.07 1.64 Gamma 
Outpatient (subsequent) 127.97 11.40 126.07 1.02  
Specialist nurse 73.00 6.50 126.07 0.58  
District nurse 64.00 5.70 126.07 0.51  
Blood test 51.00 4.54 126.07 0.40  
X-ray 28.64 2.55 126.07 0.23  
Pituitary function test 246.50 21.95 126.07 1.96  
 
 
 
 
 
 
TABLE 69 Childhood drug dose parameters and distribution 
 
 95% CI  
Childhood dose Mean ‘Standard error’ Lower Upper Distribution 
GHD 0.025 0.00255 0.020 0.030 Normal 
TS 0.045 0.00255 0.040 0.050  
PWS 0.035 0.00255 0.030 0.040  
CRI 0.045 0.00255 0.040 0.050  
SGA 0.035 0.00255 0.030 0.040  
SHOX-D 0.040 0.00255 0.040 0.050  
 
to express the appropriate variability of doses used 
in the KIGS database and also the maximum doses 
suggested in the BNF. These were sampled using 
normal distributions. 
 
Proportion of males 
The reported mean proportion of males for each 
condition was taken from the KIGS database for 
both the treated and untreated groups. This was 
consistent with the base-case analysis. The standard 
errors were calculated for each mean proportion of 
males and sampled using a normal distribution. 
Costs 
Costs included in the PSA were those related  
to outpatient visits, nurse visits and monitoring 
tests. Drug costs were not varied in the PSA, but 
were included at values quoted in the BNF. Costs 
derived from NHS Reference Costs were sampled 
using estimated ‘standard errors’. These assumed 
that a variation of plus or minus 25% was an 
appropriate CI for the average reference costs. The 
estimated standard errors are shown in column 3  
of the Table 71. Parameters for gamma distributions 
(shown in columns 4 and 5) were derived using 
the means and estimated ‘standard errors’. The 
simulated values were inflated to 2008–9 prices 
using appropriate inflation indices, as for the base- 
case and deterministic sensitivity analyses. 
 
 
TABLE 70 Proportion of males parameters and distribution 
 
Proportion of males Mean Standard error Distribution 
GHD 0.70 0.0100 Normal 
TS 0.00 0.0000  
PWS 0.50 0.0045  
CRI 0.71 0.0040  
SGA 0.596 0.0032  
SHOX-D 0.48 0.0019  
 
TABLE 71 Costs parameters and distribution 
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Appendix 13 
Weight tables for males and females 
by age (Western Europe KIGS) 
 
 
 
Weight (kg) 
 
 
Age 
SGA  GHD  PWS  CRI  TS 
(years) Male Female Male Female Male Female Male Female Female 
0 4.00 3.0 6.01 5.63 4.00 3.00 4.00 3.00 3.00 
1 6.00 5.7 8.40 7.96 9.41 8.37 8.14 6.60 7.03 
2 8.07 8.48 10.18 9.81 10.96 10.15 10.42 9.60 10.19 
3 10.10 10.04 12.18 11.98 14.48 12.08 12.39 11.77 11.91 
4 11.13 11.39 13.97 13.63 17.67 15.92 14.26 13.13 13.80 
5 13.63 13.62 15.72 15.41 20.55 20.00 16.24 15.22 15.56 
6 15.58 15.79 17.79 17.49 23.37 23.18 17.98 18.15 17.67 
7 17.96 17.86 20.15 19.76 26.96 26.64 20.14 19.33 20.20 
8 20.06 19.86 22.76 22.41 31.48 29.42 22.42 21.47 23.14 
9 22.27 22.45 25.4 25.42 35.82 33.94 24.92 23.41 26.57 
10 24.93 24.83 28.5 28.79 40.95 41.24 27.49 26.42 30.04 
11 27.73 28.52 31.74 32.02 44.46 44.29 30.49 30.17 34.05 
12 31.08 31.71 35.00 35.99 51.70 47.49 34.08 34.78 38.47 
13 34.53 35.36 39.28 40.26 57.96 52.80 37.43 37.27 42.33 
14 38.89 38.22 44.40 44.19 63.80 56.84 41.15 39.80 46.00 
15 44.33 40.27 49.91 47.72 69.02 59.07 44.84 41.03 49.05 
16 49.04 43.05 54.47 49.97 74.43 56.32 48.70 41.15 51.47 
17 53.50 47.03 58.5 53.38 74.14 61.15 50.4 42.66 52.53 
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